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ABSTRACT 
 
Brionna Y. Hair: Body Mass Index, Breast Tissue, and the Epigenome 
(Under the direction of Melissa Troester) 
 
             Purpose: Obesity is a known risk factor for breast cancer. Though the mechanisms 
underlying the relationship remain to be elucidated, biologic pathways involving hormones, 
inflammation, and insulin resistance have been implicated. The goal of this dissertation was to 
explore the relationships between body mass index (BMI), gene methylation, and gene 
expression in breast tissue to better understand how BMI influences breast tissue. Methods: 
Methylation values were calculated in two study populations. Patients from the Normal Breast 
Study (NBS) contributed non-diseased tissue, while patients from the Carolina Breast Cancer 
Study (CBCS) contributed tumor tissue. Multivariable linear regression was used to identify 
which probes were associated with BMI and, of those, which were correlated with gene 
expression. Pathway analyses were conducted to determine which biologic pathways were 
enriched among BMI-associated methylation sites. Results: Of the 431,568 sites analyzed for the 
non-diseased tissue sampled from participants of the NBS, BMI was associated with 2,573 
probes (false discovery rate q-value <0.05). Inflammatory and insulin signaling pathways were 
enriched among the 2,573 probes. Of the 1,251 BMI-associated sites that had linked gene 
expression data, 226 were correlated with gene expression. Of the 935 probes analyzed for the 
tumor tissue sampled from participants of the CBCS, 2 were associated with BMI in the full 
dataset and 21 were associated with BMI among estrogen-receptor positive tumors (false 
discovery rate q-value <0.05). There were no pathways enriched among the 21 BMI-associated 
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methylation sites identified in the estrogen-receptor positive tumors. Conclusions: BMI is 
associated with the methylation of genes and biologic pathways involved in inflammatory 
processes and insulin resistance. This research provides insight into the carcinogenic processes 
through which obesity may affect breast cancer risk and can inform research investigating 
actionable biomarkers of the obesity-breast cancer association.  
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Chapter 1: Background 
 
1.1 Breast Cancer Epidemiology 
1.1.1 Significance 
Breast cancer is a major public health burden both worldwide and in the US, where it is 
the second most diagnosed cancer and the second leading cause of cancer death among women 
(1). In 2012, it was estimated that 226,870 cases of breast cancer would be diagnosed in the U.S. 
and that 39,510 women would die from the disease (2). Breast cancer incidence decreased 
between 1995 and 2005 before stabilizing between 2005 and 2008, while mortality from the 
disease has continually declined (2). Survival for those with breast cancer varies by stage, with 
those diagnosed with local disease experiencing five-year relative survival upwards of 95%, 
compared to survival rates between 80 and 87% for those with regional disease and survival rates 
between 24 and 30% for those with distant disease (3). 
Despite the substantial amount of research dedicated to breast cancer, approximately 1 in 
8 women will be diagnosed with the disease and 1 in 36 will die from it (1). Most of the decline 
in breast cancer mortality has been attributed to better detection and treatment, instead of 
prevention, of the disease (1). The aim of this dissertation was to study how a common risk 
factor, obesity, may influence the development of breast cancer in hopes of informing research 
that could lead to both better prevention and treatment of the disease. The next sections describe 
the current knowledge of breast cancer and its known risk factors before discussing the focal 
point of this dissertation, the relationships between obesity, gene methylation, and gene 
expression. 
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1.1.2 Breast Cancer Heterogeneity 
Histopathology. The majority of in situ and invasive carcinomas arise in the terminal 
duct-lobular units of the breast (4). Based on histological features, the two most common 
classifications of breast tumors are ductal, which accounts for 50-80% of breast tumors globally, 
and lobular, which accounts for 5-15% of breast tumors globally (4, 5).   
To understand the mechanisms underlying breast cancer incidence, it is helpful to 
describe the histological stages of the disease. Different models of the progression from normal 
to cancerous breast tissue have been posited for the histological types. For ductal carcinomas, 
possible, but not necessary, precursors include atypical lesions such as atypical ductal 
hyperplasia (ADH), flat epithelial atypia (FEA) microglandular adenosis lesions, and atypical 
cystic lobules, which may progress to low or high grade ductal carcinoma in situ (DCIS) (5).  
DCIS can, in turn, progress into low or high grade invasive ductal carcinomas (IDCs) (5, 6).   
For lobular carcinomas, the progression has been posited to begin with atypical lobular 
hyperplasia (ALH), followed by lobular carcinoma in situ, which is a potential, but not 
necessary, precursor to invasive lobular carcinoma (5). Though lobular carcinoma in situ was 
previously thought to be unable to progress to invasive cancer, recent evidence supports their 
invasive potential (5). 
Gene expression studies have confirmed the distinctness of the different histological 
classifications of breast tumors, with invasive ductal carcinomas displaying different 
transcriptional profiles than invasive lobular carcinomas (7) and with DCIS expressing different 
genes than invasive ductal carcinomas (8). There is also evidence that most low-grade invasive 
ductal tumors do not progress to high-grade tumors, but are distinct subtypes exhibiting different 
transcriptional profiles (5). Low-grade DCIS, which tends to feature loss of 16q, generally 
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progress to low-grade invasive tumors; similarly, high grade DCIS tend to progress to high-grade 
IDC (5).   
Molecular Subtypes. Gene expression studies not only shed light on the underlying 
differences that distinguish features of established histological types, but they also were used to 
further subtype breast tumors into molecular subtypes and bolster the current scientific 
understanding of the disease. Differences in gene expression of tumors correspond to differences 
in “growth rate, in the activity of specific signaling pathways, and in the cellular composition of 
the tumors” (9).   
The Perou ‘intrinsic’ breast tumor subtypes are based on gene expression studies (9).  
Tumors can generally be divided based on the level of expression of the estrogen receptor, with 
tumors that are estrogen receptor positive (ER+) being further classified as either luminal A or 
luminal B.  Luminal A and B tumors tend to be low- or intermediate-grade, express genes of 
ductal epithelial cells, and are thought to represent a continuum based on ER expression, HER2 
overexpression, and cell proliferation (5, 10).  Luminal A tumors tend to have better prognosis 
than luminal B tumors (4). 
The tumors that are estrogen receptor negative (ER-) include human epidermal growth 
factor receptor-2 (Her2) and basal-like tumors, both of which tend to be high-grade (5). The 
Her2 subtype overexpresses HER2, a member of the epidermal growth factor receptor family 
that functions in signal transduction (11). Her2 overexpression, which has been found in 10 – 
34% of breast tumors, is particularly potent in the activation of signaling pathways (11).  Breast 
tumors that overexpress Her2 have been associated with poor prognosis, but the use of 
trastuzumab therapy has led to improvements in survival in those with this tumor subtype (11). 
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Basal-like tumors express cytokeratins associated with myoepithelial cells (5), exhibit 
necrosis and immune cell infiltration (5), and are similar to tumors found in those with BRCA1 
mutations (4). The prevalence of the basal-like subtype differs by age and race, with 
approximately 27% of breast tumors found in young African-American women classified as 
basal-like, compared to 16% for older African-American women, 15% for young white women, 
and 9% for older white women (12, 13).  
Unlike luminal A tumors, which are the most commonly diagnosed tumor subtype and 
are associated with good prognosis, basal-like tumors are associated with an aggressive 
presentation (13, 14), poor prognosis (13, 14), and lacks targeted therapy (15).   
Other subtypes have been identified by gene expression studies, including: molecular 
apocrine tumors, which have androgen receptors but no estrogen receptors (5), a subtype 
associated with expression of genes regulated by interferon (4), and claudin-low tumors, which 
have expression profiles with cancer stem cell properties (16), though the clinical relevance of 
these subtypes remain to be determined.  
Though limited by examining tissue after cancer has been diagnosed, gene expression 
studies and the emergence of molecular subtypes provide clues as to what pathways are involved 
in the emergence of breast cancer and help generate hypotheses regarding breast cancer etiology. 
Hormonal Receptor Status. One of the most reliable predictors of breast cancer outcome 
is the hormonal receptor status of the tumor.  Though it has long been known that steroid 
hormones are important in breast cancer, it is their receptors that mediate the effect of hormones 
(17, 18). The two receptors that are clinically assessed in breast tumors are the estrogen receptor 
(ER) and the progesterone receptor (PR) (17), though the presence of ER is more predictive of 
response to hormonal therapy (19). In genetic expression studies, breast tumors tend to cluster by 
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ER status (20).  The expression of receptors, which act as transcription factors, are elevated in 
both premalignant breast lesions and in malignant breast tumors (17, 21).    
The ER has two forms: ERα and the more recently discovered ERβ (19).  In normal 
breast tissue, between 7 and 17% of epithelial cells express ERα, but expression of the receptor 
tends to be higher in pre-malignant breast lesions and in DCIS (19, 22). In normal cells, the 
expression of ERα increases with age, but plateaus after menopause (22). ERα was thought to 
exist solely in the luminal epithelial cells of breast ducts and lobules (19), but ERα has also been 
detected in small amounts in fibroblasts and adipocytes of breast tissue in teenage girls and in 
pregnant women (22). In normal tissue ERα expression is not associated with cell proliferation 
(19), but it is in breast cancer cells (22). ERβ is more commonly expressed in normal breast cells 
than ERα, having been detected in cells of the luminal epithelium, the myoepithelium, and of the 
stroma (19), but tends to be less expressed in tumor tissue than ERα (22). The contributions of 
ERβ to breast cancer are less understood (17), though it may down-regulate the activities of ERα 
(22).   
There remains much to be understood about how ER expression in normal, non-
malignant tissue relates to the risk of breast cancer. Though generally the transcription activities 
mediated by receptors are induced when they are bound by the appropriate ligand, the extent of 
transcription is complicated by the presence of co-activators and co-repressors that may further 
stimulate or repress gene activation, respectively (17). ER can also be activated independent of 
binding by a ligand through pathways that involve the insulin-like growth factor receptor, the 
insulin receptor, and Her2 (17). It has been posited that hypoxia in early breast lesions may 
influence the expression of ER (22). 
6 
 
PR is only detected in small quantities in normal breast epithelial tissue (22). Animal 
studies have shown that estrogen can induce expression of PR, but it is not clear if PR expression 
is elevated in premalignant breast lesions as ERα is, though PR is expressed in 50 to 70% of 
invasive breast tumors (22).  
The hormone receptor status of breast tumors is associated with breast cancer outcome: 
women with tumors that are ER+/PR+ are at reduced risk of mortality than those with either one 
or both tumors negative for ER or PR (23). Breast tumors that are negative for both ER and PR 
tend to be higher stage, grade, and larger in size at diagnosis, but even within grade, tumors that 
are ER+/PR+ have less mortality (23). 
1.1.3 Breast Cancer Risk Factors 
The association between breast cancer and various risk factors have been well-studied, 
with several exposures consistently found to be associated with incidence while others are less 
established. As will be discussed, the relationship of some risk factors to disease incidence may 
differ by breast tumor subtype. 
Reproductive Risk Factors. Several reproductive factors are well-established risk factors 
for breast cancer. In a meta-analysis of 12 studies, younger age at menarche, nulliparity, and 
increased age at first birth were associated with increased cancer risk in ER+ tumors (24); in ER- 
tumors, the association between incidence and age at menarche may be limited to those who 
began menarche at 12 years or younger (instead of a dose response relationship), and nulliparity 
and age at first birth were not associated with incidence (24). In the Women’s Health Initiative, 
for women with triple-negative tumors ([TNTs], which include  basal-like tumors), nulliparity 
was associated with lower risk while increasing number of births was associated with higher risk; 
the opposite relationships were found for ER+ tumors (25). Though in that study, breastfeeding 
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was not significantly associated with either ER+ tumors or TNTs (25), other studies have found 
lack of breastfeeding to be associated with both luminal A tumors and TNTs, though the effect 
may be of higher magnitude in TNTs (26).   
Reproductive factors may contribute to the incidence of breast cancer through length of 
exposure to estrogen, with those experiencing earlier ages of menarche and later ages at 
menopause exposed to estrogen for longer times (27), though the relationships are thought to be 
more complex than a linear relationship between estrogen exposure and breast cancer incidence 
(28). Women who have experienced pregnancy and breastfeeding are also thought to have more 
differentiated breast tissue, which has been posited to lower breast cancer risk (12, 29). 
Exogenous Hormone Use. The association of oral contraceptive use with breast cancer 
risk may be time-sensitive, with an increased risk found for current users that diminishes with 
time after exposure is ended (30). Oral contraceptive use was not associated with TNTs, though 
long duration of use was associated with reduced risk for ER+ tumors in the Women’s Health 
Initiative (25).  
Hormone replacement therapy (HRT) has been associated with breast cancer risk, 
increasing the incidence of disease in postmenopausal women in relation to the amount of 
estrogen in the formulation (31). The use of combination estrogen and progesterone HRT 
increased the risk of breast cancer, showing a higher effect than estrogen alone (31, 32).  Studies 
have produced conflicting results on whether the effect of HRT is limited to ER+ tumors, or if it 
also increases risk of ER- tumors (33). Similar to oral contraceptive use, the effect of HRT 
appears to diminish after termination of use (30, 34). 
Physical Activity. Physical activity has consistently been found to reduce the incidence of 
breast cancer (35-37). The trend of decreasing incidence with increasing physical activity 
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appears to be generally consistent regardless of estrogen receptor status (38), though one study 
did find heterogeneity by hormonal receptor status (36). It is not clear how physical activity 
exerts its influence on breast cancer incidence, though it may be related to immune function (38). 
Others have hypothesized that physical activity may act through alterations in body composition, 
however, the effect appears to go beyond a reduction in BMI (38). 
Diet. There is not strong epidemiological evidence that dietary components influence 
breast cancer risk. The interest in studying dietary factors is partially rooted in the difference in 
breast cancer incidence and mortality between countries with different dietary habits, especially 
with regard to fat intake (39). Meta-analyses tend to show no association between dietary intake 
of fat and risk of breast cancer (39, 40). However, when examining subtypes of fat, one meta-
analysis found that saturated and polyunsaturated fats were associated with higher breast cancer 
incidence, while monounsaturated fats were not associated with incidence (41). 
Other components of the diet that have been examined in relation to breast cancer 
incidence include fruit and vegetable intake and intake of soy (42). The association of breast 
cancer risk with fruit and vegetable intake has been inconsistent, while a meta-analysis found 
that high soy intake may slightly reduce incidence (41). 
Alcohol Consumption. Alcohol has shown a dose-response relationship with breast 
cancer incidence (43). In a cohort of Swedish women, the incidence of invasive tumors was 
associated with daily alcohol intake, with those consuming the equivalent of at least one cup of 
ethanol  a day having a RR of 1.4 (95% CI: 1.0, 1.8) compared to non-drinkers, but the effect 
was limited to those with ER+ tumors (44). A meta-analysis found that compared to those with 
the lowest levels of alcohol drinking, those in the highest category of alcohol consumption had a 
27% increased risk for ER+ tumors and a 14% increased risk for ER- tumors (45). 
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Family History. A family history of breast cancer, defined in various ways, has been 
associated with increased risk of the disease, with the highest relative risk found in those who 
have both a mother and sister affected (RR: 3.6), and a lower relative risk for those who only 
have a second degree relative affected (RR: 1.5) (46). Meta-analyses have reported that an 
increased risk of developing breast cancer occurred in those with family members diagnosed at 
younger ages (46, 47). The recognized relationships between breast cancer incidence and 
common risk factors appear to hold among women with a family history of breast cancer, 
including inverse risk with parity, breastfeeding, and physical activity and increased risk with 
alcohol consumption and postmenopausal weight gain (48).   
Family history of breast cancer is associated with mutations in the BRCA1 and BRCA2 
genes, though mutations in these genes do not explain all of the increased risk of breast cancer in 
those with a family history of the disease and who are over 50 (46) (shared environment may 
also lead to an increase in breast cancer in those with family history (49)).  The BRCA1 and 
BRCA2 genes appear to function in tumor suppression and genome integrity (50); mutations in 
these genes tend to result in truncation of their corresponding protein and may result in breast 
cancer in up to 85% of mutation carriers (50), though penetrance estimates may be influenced by 
selection bias (51).  In one study of mutations among families with breast cancer, BRCA1 
mutations were associated with about 50% of the families, BRCA2 mutations were associated 
with 32% of families, and the remaining 16% of breast cancer families had neither mutation (52). 
In a population-based study of young women diagnosed with breast cancer, approximately 9% of 
those diagnosed before age 35 carried a germline mutation of either BRCA1 or BRCA2 as did 
12% of those diagnosed before age 45 (53). Overall, about 5% of breast tumors are associated 
with mutations in BRCA1 or BRCA2 (51). There appear to be histologic differences between the 
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breast tumors of those with BRCA1 mutation, with BRCA2 mutation, and with no family history 
of disease (sporadic), with those having a BRCA1 mutation displaying higher grade, mitotic 
counts, and lymphocyte infiltration than sporadic tumors and those with BRCA2 mutations 
displaying lower mitotic counts than sporadic tumors (54, 55). 
Mammographic Density. Mammographic density has consistently been found to be 
associated with breast cancer risk (56).  An estimate of mammographic density has been defined 
as the percent of mammographic images made up of epithelial or fibrous tissue, as opposed to fat 
tissue. It has been posited that high density due to increased epithelial cells may be associated 
with a larger number of ductal stem cells while high density due to increased connective stromal 
tissues may be associated with factors affecting the growth of epithelial cells (57); the increased 
cellular proliferation associated with this density may result in an environment conducive to 
breast carcinogenesis (58).  Mammographic density is inversely associated with weight and BMI 
(56, 57).    
Menopausal Status. The incidence of breast cancer has been shown to have two distinct 
linear trends when assessed on log-log plots (log of age and log of incidence): an increasing 
trend from aged 30 to about 50 years, then a brief decline around the age of menopause (known 
as Clemmesen’s hook), followed by a slower increase until about age 80 (31, 59, 60).  The 
timing of menopause correlates with breast cancer risk, with a decreased incidence among those 
experiencing menopause at earlier ages, though the association attenuates when adjusting for 
current BMI and age at first birth (28). When matched on age, women who are premenopausal 
have higher risk of breast cancer than those who are postmenopausal (28). The effects of certain 
breast cancer risk factors appear to differ by menopausal status, with the number of full-term 
pregnancies not significantly associated with premenopausal breast cancer incidence and age at 
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menarche more strongly associated with risk in premenopausal compared to postmenopausal 
breast cancer (61).   
Race and Ethnicity. There is variation in both incidence and mortality of breast cancer 
by race. African-American women tend to have lower incidence rates than white women (116.1 
versus 122.3 per 100,000 population, respectively) and both of those groups have much higher 
rates than women of other ethnicities (84.9 per 100,000 population for Asian Americans, 89.2 for 
American Indians, and 92.3 for Hispanics) (2). African-American women, however, have the 
highest mortality rates (32.0 per 100,000 population), followed by white women (22.8), 
American Indians (17.2), Hispanics (15.1), and Asian Americans (12.2).  For all racial groups 
except for American Indians, breast cancer mortality has been declining (3). 
There are many factors that may contribute to the racial differences in incidence and 
mortality, including likelihood of presenting with aggressive tumor subtypes (13), distribution of 
risk factors (12), stage at diagnosis (62), and access to healthcare (62).   
African-American women are more likely to be diagnosed with basal-like tumors than 
white women, and are less likely to be diagnosed with luminal A tumors (13). African-American 
women tend to have higher fertility rates than white women (63), which may lead to relatively 
lower incidence of the common luminal A tumors, but are less likely to breastfeed after 
pregnancy and have higher waist-to-hip ratios, both of which have been found to be risk factors 
for basal-like breast tumors (12).  This differential distribution of risk factors (64) may result in 
African-American being less likely to develop the more common luminal A breast tumors than 
white women, but more likely to develop basal-like tumors, and therefore have poorer survival.   
African-American women are also more likely to present with higher stage of disease, 
with one study finding that 16% of African-American diagnosed at stage III or IV breast cancer, 
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compared to 8.1% of white women (62), which may be related to having more aggressive 
tumors, having higher levels of obesity, and having poorer access to medical care (65). 
1.1.4 Summary 
Breast cancer places a large burden on the public health. Though mortality from the 
disease has been declining due to improved detection and treatment, and our understanding of 
the molecular biology of the disease continues to grow, reducing incidence of the disease 
through prevention remains difficult. The relationships of the established risk factors to the more 
recent molecular subtypes of breast cancer are not clear due to conflicting results in published 
data and in many cases are hard to modify given societal trends. The following section will focus 
on obesity, a modifiable risk factor that is currently receiving a large amount of attention.  
Understanding the biological mechanisms linking obesity to breast cancer can help bolster 
interventions aimed at reducing obesity in the US and may also provide new targets for the 
treatment and chemoprevention of breast tumors. 
1.2 Adiposity and Breast Cancer 
The relationship between adiposity and breast cancer reflects local interactions between 
the breast parenchyma and breast adipose tissue (in fact, the majority of human breast tissue 
consists of adipose cells (66)), but is likely also influenced by the systemic effects of adiposity, 
evidenced by the association of obesity with multiple cancers (67). In breast tissue, when a tumor 
becomes invasive, infiltrating the basement membrane and fibrous connective tissue, it comes 
into close contact with adipocytes (66). Systemically, adiposity influences the levels of hormones 
in circulation and immune responses (68, 69), both of which can lead to processes that influence 
breast carcinogenesis.  
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1.2.1 Biological Mechanisms Involving Adiposity 
The majority of adipose tissue in humans consists of white adipose tissue, which can be 
subcutaneous (under the skin) or visceral (surrounding internal organs); an excess of the latter 
tissue type is associated with metabolic abnormalities (70). Adipose tissue, the site of energy 
storage in the human body, is primarily made up of adipocytes (71) which produce proteins that 
function in the regulation of appetite, lipid metabolism, immune function, insulin sensitivity, 
angiogenesis, and blood pressure (71-73).   
There are several mechanisms by which adiposity may influence the development of 
breast cancer, including the association of adiposity with hormone levels (68, 69, 74-76), insulin 
resistance (66, 77, 78), and inflammatory and immune response pathways (69, 79-81).  
Hormone-Related Mechanisms. Estrogens play a role in normal breast development 
(75), but elevated levels of the endogenous hormone are associated with increased risk of breast 
cancer (74). In premenopausal women, the ovaries produce estradiol and progesterone cyclically, 
leading to different serum concentrations of the hormones depending on the day of the menstrual 
cycle (31). In postmenopausal women, the levels of estradiol produced by the ovaries are greatly 
reduced (31), but androgens such as testosterone can be converted to estrogens via aromatization 
in breast adipose tissue (74, 82, 83). 
There are several mechanisms through which estrogens may influence carcinogenesis, 
including pathways associated with DNA damage and pathways associated with increased cell 
proliferation. Animal studies provide evidence for the genotoxic properties of estrogens and its 
metabolites (74, 75). Estrogen metabolism is associated with formation of unstable DNA adducts 
and production of reactive oxygen species which can lead to DNA damage and mutations (74, 
76).  
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Exposure to estrogen is also thought to promote carcinogenesis through increasing the 
cell division rate leading to proliferation of breast epithelial cells (69) and through inhibiting 
apoptosis (74). Estrogens can induce resting cells to enter the growth phase, in a process 
mediated by the transcription factor c-Myc (66) and can also bind directly to nuclear ERs and 
ultimately influence the expression of genes with relevance to proliferation (74). Specifically, 
estrogens can influence cell proliferation and apoptosis by binding with membrane ERs which 
can lead to activation of kinases (including mitogen-activated protein kinases) and by invoking 
signaling pathways involving epidermal growth factor receptors and insulin-like growth factor-1 
receptors (74). 
In postmenopausal women, androgen precursors are converted to estrogen in peripheral 
adipose tissue through the aromatase enzyme in a process known as peripheral aromatization (66, 
69, 82). Both estrogen production, which can occur in the breast and abdomen, and aromatase 
levels are higher in those with greater adipose tissue (66, 69). The high levels of estrogen found 
in breast tumors may be related to increased aromatase production that occurs when adipocytes, 
interacting with tumor cells, secrete chemicals such as tumor necrosis factor alpha (TNF-α) and 
interleukin-6 (IL-6) (66).  Both TNF-α and IL-6 have been shown to stimulate aromatase activity 
(84, 85). 
Obesity may also lead to an increase in the bioavailability of estrogen and androgens 
because it is inversely associated with sex hormone binding globulins (SHBG) (68). In addition 
to removing estrogen from circulation, SHBG further protects against tumorigenesis by binding 
to a site on breast cancer cells that inhibits estradiol-associated cell proliferation (66, 86). 
Research has found that high blood concentrations of SHBG are associated with lower breast 
cancer risk (66, 86). 
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Insulin Resistance and Insulin Mediated Pathways. Another posited mechanism for the 
association between adiposity and breast cancer involves insulin and insulin resistance.  The 
normal function of adipocytes is highly regulated by insulin, which promotes uptake of glucose 
and the synthesis and storage of triglycerides by adipose tissue (78, 87). When insulin resistance 
occurs, the ability of adipocytes to respond to insulin-related signals to transport and metabolize 
glucose is hindered (78). Obesity may be associated with insulin resistance because of 
differential expression of molecules that are part of the insulin signaling pathway (78). When 
adipose tissue is unable to efficiently store or metabolize glucose (a feature of metabolic 
syndrome), the higher concentrations of glucose lead to increased secretion of insulin by the 
pancreas (66). Consequently, higher BMI is associated with higher levels of circulating insulin 
and insulin-like growth factor-1 (IGF-1) (77). Obesity may also influence the development of 
insulin resistance through its association with increased levels of free fatty acids, TNFα, and 
resistin, all of which result in hyperinsulinemia and insulin resistance (77).   
Insulin is known to stimulate DNA synthesis, and hyperinsulinemia is correlated with 
increased production of IGF-1, a ligand that is associated with cell growth, cell differentiation, 
and, in concert with other growth factors, can have mitogenic effects (66, 88, 89). When IGF-1 
binds to the receptor IGF-1R, it can activate many pathways, including MAPK, the mitogen-
activated protein kinase pathway, which has been shown to increase proliferation of breast cells 
(66, 90).   
In addition to higher concentrations of insulin-like growth factor (IGF-1), insulin 
resistance also results in less production of insulin-like growth factor binding protein (66, 77, 91, 
92) and  increased concentration of leptin (68), a protein that can stimulate breast epithelial cell 
growth and can work with estrogen to promote transcription factors and angiogenesis (68, 69).   
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Though the link between BMI and IGF-1 may not be linear (93), with research showing 
the highest levels of IGF-1 in those with BMI between 24 and 27 (66), there is some 
epidemiological evidence that insulin and IGF-1 are associated with breast cancer.  About 50% 
of breast tumors overexpress IGF-1R compared to normal tissue (66). When examining breast 
cancer risk by menopausal status, postmenopausal women with diabetes have a slightly higher 
risk of breast cancer, and in women undergoing biopsies for benign breast disease or invasive 
breast cancer, those with the highest insulin levels had higher breast cancer risk (66, 94).  Studies 
among premenopausal women have found increased risk of breast cancer or DCIS with increased 
levels of IGF-1, but not in postmenopausal women (66, 95).   
In postmenopausal women, the interaction between estrogen and IGF pathways may be 
of more importance than IGF alone (66). Insulin resistance and ER-mediated pathways may 
interact to increase breast cancer risk. When the ER is activated, its activity can increase cell 
proliferation (22, 66). There is evidence that insulin and IGFs can induce ER-α activation in 
breast cancer cells without estradiol, and when both IGF-1 and estradiol are present, they interact 
to activate ER more than would be expected based on their independent effects on the receptor 
(66, 96).   
Adipokines and Adipose-Derived Ligands. There is evidence that components of adipose 
tissue itself can promote tumorigenesis. In animal studies, mice developed tumors when they 
were given both mammary cancer cell lines and adipose tissue but not when the cancer cell lines 
were injected far from adipose tissue (66). In vitro, it was found that media enriched with 
adipose cells up-regulated genes involved in proliferation, invasion and metastasis, but down-
regulated genes involved in cell-cycle checkpoints and tumor suppression (66). 
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There are a few components of adipose tissue that may influence carcinogenesis.  Leptin 
is a ligand produced by adipose tissue. Though it was previously thought that leptin 
concentrations increased as a response to prevent obesity, there is evidence that leptin levels rise 
with obesity, and may in some circumstances lead to obesity (66, 97). Leptin levels may be 
influenced by both BMI and physical activity, with obese women having higher levels of leptin 
than normal weight women; physical activity is associated with decreased leptin among obese 
women (68). 
Though leptin has been found to be expressed in normal breast tissue, when comparing 
breast cancer tissue to non-diseased tissue, leptin receptors have been found to be overexpressed 
in up to 90% of breast tumors and in none of normal tissue (98). Leptin has been shown to 
stimulate breast cell proliferation via activation of the MAPK pathway (99). It has also been 
associated with tumor invasion and angiogenesis (68, 77); while expression of its receptor is 
associated with metastasis and poor survival (66, 98). Leptin is thought to influence breast 
carcinogenesis by promoting the transcription of aromatase (100, 101), which could lead to 
higher estrogen production, and may also lead to activation of ER-α.   
Adiponectin is another ligand produced in adipocytes that may potentially affect breast 
carcinogenesis. Adiponectin, which is inversely correlated with waist circumference, has been 
found to inhibit proliferation and regulate angiogenesis (66, 100, 101). Binding of adiponectin to 
its receptors may activate other pathways that result in the differentiation of breast cells and 
increase BRCA1 expression (66). 
Inflammation/Immune Response. Adipose tissue is correlated with the presence of 
immune cells and inflammatory markers that may influence carcinogenesis. White adipose tissue 
consists of a small percentage of macrophages, the amount of which increases with adiposity 
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(102). Other immune components that are associated with adiposity include the cytokines TNF-α 
and IL-6, both of which have local and systemic inflammation effects (69, 102-104). An 
inflammatory response, with its associated infiltration of inflammatory cells, increase in 
cytokines, and tissue remodeling, could lead to tumor promotion through lowered immunity, 
increased angiogenesis, and tumor invasiveness (79, 80).    
Macrophages found in the infiltrate of tumors are known as tumor-associated 
macrophages (TAMs) (81) and are associated with both obesity (102) and poor prognosis (105). 
Although macrophages can have anti-angiogenic properties and can kill tumor cells (81), they 
have several properties that are tumorigenic. They can produce angiogenic molecules like 
vascular endothelial growth factor (VEGF), platelet-derived endothelial cell growth factor, and 
thymidine phosphorylates, which are associated with tumor neovascularization (105); they are 
associated with increased presence of chemokines, which may regulate angiogenesis (105); they 
express proinflammatory cytokines that aid in tumorigenesis by activating nuclear factor (NF)-kβ 
in tumor cells, the activation of which can lead to “self-sufficiency in growth signals, 
insensitivity to growth inhibition, resistance to apoptotic signals, immortalization, angiogenesis, 
tissue invasion, and metastatsis” (105); and they tend to accumulate in hypoxic regions of 
tumors, where they adapt to this environment by promoting angiogenesis (105). Macrophages 
also produce enzymes that can degrade the extra-cellular matrix, such as matrix-metalloproteases 
(MMPs), which have been implicated in the epithelial-mesenchymal transition of breast cells and 
tumorigenesis (105, 106).  
Tumor necrosis factor-alpha (TNF-α) is an inflammatory cytokine that may be associated 
with obesity (66) and is active in several different biologic pathways, including promotion of 
insulin resistance, the induction of apoptosis, regulation of IL-6 synthesis and estrogen synthesis 
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in adipose tissue (66). Though the cytokine has functions that promote the death of damaged 
cells, it also has tumorigenic effects (81). Mice studies have shown that when deficient in TNF-
α, mice did not develop skin cancer (105). Even though TNF-α has anti-angiogenic properties, in 
certain contexts, including chronic inflammation, it can promote angiogenesis and lead to 
stromal changes that enable tumor proliferation and invasion (81). TNF-α may also result in 
DNA damage by inducing the formation of reactive oxygen (81). In breast tumors specifically 
TAMs are thought to produce TNF-α (81). 
Similar to TNF-alpha, interleukin-6 (IL-6) is a cytokine that is associated with obesity 
(specifically, visceral adiposity), is produced as a result of chronic inflammation, and has both 
cancer-promoting and anti-cancer functions (71, 72, 107). There is evidence indicating that IL-6 
prevents early stage breast cancer, but the cytokine is also correlated with cell migration via 
MAPK, antiapoptosis, stimulation of aromatase, and poor prognosis among those with metastatic 
disease (66). 
1.2.2 Exposure Assessment: Validity of Using Body Mass Index to Measure Adiposity 
Although the risks associated with adiposity are not fully understood, as the previous 
section highlights there are many possible pathways through which it could affect breast cancer. 
However, because adiposity is difficult to measure in epidemiologic studies, investigators often 
use body mass index (BMI) as a proxy for adiposity when exploring the relationship between 
obesity and breast cancer risk. 
In women, the percentage of normal body fat varies from about 14 to 28%, but can reach 
to as high as 70% in those who are morbidly obese (66). Though obesity is defined as an 
individual who has excess body fat, in many studies obesity is generally characterized as excess 
body weight due to the difficulty of measuring body fat (108). BMI is commonly used in studies 
20 
 
to categorize individuals, though there are several limitations to the use of standardized 
categories of BMI as a measure of body fat.  For instance, women and older individuals tend to 
have higher percentage of body fat than men and younger individuals at the same BMI (108). 
There is also debate over whether the same cut-offs for overweight and obesity should be used in 
different ethnic groups (109); evidence suggests that the relationship between visceral adipose 
tissue and BMI differs by race, with whites having higher visceral fat than African-Americans at 
certain BMI levels (70, 110). However, in a study comparing percentage fat to measures of BMI 
and waist circumference, BMI showed the highest correlation with body fat in women and was 
also well-correlated with waist circumference (111).  
1.2.3 Epidemiology of Obesity and Breast Cancer: Importance of Effect Modifiers 
The prevalence of obesity and overweight as measured by BMI has been increasing over 
time in the US (108). In 2009-2010, 33% of female adolescents were in the 85
th
 percentile of the 
BMI range and 17% were in the 95
th
 percentile (112); in adult women, 65% were classified as 
overweight or obese and 36% were classified as obese (113). There is ethnic variation in the 
prevalence, with 82% of adult African-American women, 74% of Hispanics, and 61% of non-
Hispanic whites categorized as overweight or obese, and 59% of African-Americans, 41% of 
Hispanics, and 33% of non-Hispanic whites considered obese (113). 
Though the prevalence of overweight and obesity is commonly reported using BMI, 
different measures of obesity have been associated with breast cancer incidence. Gaining weight 
as an adult increases the risk of diagnosis, with a risk ratio (RR) of 1.05 associated with every 5 
kg increase in weight; the RR becomes 1.75 with weight gain over 22 kg (68). A high waist-to-
hip ratio (WHR) is associated with both premenopausal and postmenopausal breast cancer 
incidence while a high percentage of body fat is linked to incidence of postmenopausal breast 
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cancer (68). However, since BMI is highly correlated with other measures of obesity (section 
1.2.2), the relationship between BMI and breast cancer will be the focus of the majority of this 
dissertation. 
The association between BMI and breast cancer differs with menopausal status.  
Observational studies have found an increased risk of breast cancer in postmenopausal women 
who are overweight or obese compared to those who are of normal weight (114), with odds 
ratios ranging from 1.1 to 2.5 (69) and an estimated 3% increase in the risk of breast cancer with 
a one point gain in BMI (68). Women who gained weight as an adult are also at an increased risk 
of postmenopausal breast cancer when compared to those who maintained their weight (114, 
115), and the association is more pronounced among those who did not use hormone 
replacement therapy (69, 114, 115). It has been estimated that 20% of postmenopausal breast 
cancer can be attributed to obesity and that 18,000 deaths in women over age 50 could be 
avoided if women in the US had a BMI <25 (68). 
An inverse association between weight and breast cancer incidence has generally been 
found among premenopausal women (69, 116), with odds ratios of approximately 0.6 estimated 
when comparing women with BMIs ≥ 27 to women with BMIs ≤ 22 (69).  The association is 
most pronounced among women less than 35 years of age and holds after adjustment for 
previous weight (69). The excess breast tumors found among leaner women are generally smaller 
tumors (< 2.0 cm), well-differentiated, and are not associated with lymph node involvement, 
suggesting that these tumors are less aggressive (69). Though it is not clear why obesity is 
associated with reduced risk of breast cancer among premenopausal women, hypotheses include 
reduced ovulatory cycles associated with obesity lowering the lifetime exposure to estrogen (69) 
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and confounding by mammographic density (the relationship between BMI and obesity became 
positive when mammographic density was controlled for in the Nurses’ Health Study) (117). 
Obesity has been associated with worse prognosis and outcome in both pre- and 
postmenopausal women, including advanced stage at diagnosis (114), an association that is 
stronger among women < 50 (69); larger tumor size (69); nodal involvement (69); higher grade 
(68); higher mitotic cell count (68); recurrence (118); metastases (69); and mortality (118), with 
premenopausal women who have the highest BMI levels experiencing over twice the mortality 
within 5 years when compared to women with the lowest BMI levels (68). The poorer prognosis 
associated with obesity is not entirely due to being diagnosed at later stage of disease, with 
research finding that worse outcomes can occur among those diagnosed with early stage of 
disease (68). 
In addition to postmenopausal breast cancer, obesity has also been correlated with both 
hormone receptor positive (24, 119) and negative tumors (69, 119-121), though in one study the 
association was stronger (though not statistically significant) when examining waist-hip ratio 
instead of BMI (122). 
When examining BMI by age and ER status, one study found that among women 50 
years of age or younger, obesity (BMI ≥ 30) is associated with reduced incidence for ER+ 
tumors, but may not be related to incidence of ER- tumors (OR: 1.10; 95% CI: 0.92, 1.30) (24). 
Another study that combined two case-control studies, in postmenopausal women with ER+/PR+ 
tumors, increasing BMI was associated with increased risk, but no consistent pattern was found 
in ER-/PR- tumors (38); in premenopausal women, there were no significant trends between 
BMI and breast cancer incidence, though women with BMI between 22 and 24 had an increased 
odds of ER+/PR+ tumors (38).  
23 
 
1.2.4 Summary 
There is a substantial body of epidemiologic literature supporting an association between 
BMI and breast cancer, though the relationship varies by menopausal status and perhaps by 
tumor subtype. The purpose of this research was to delve deeper into the potential mechanisms 
underlying the association by exploring whether adiposity influences gene methylation in breast 
tissue.  
1.3 Body Mass Index, Breast Cancer, and the Epigenome 
The hypotheses suggesting various mechanisms for how obesity influences breast cancer 
risk align with the results of gene expression studies that compare breast tissue from normal, 
overweight and obese patients. This study aimed to determine whether the same genes that are 
differentially expressed in normal and overweight women are also differentially methylated. 
Sections 1.3.1-1.3.3 provide an overview of gene expression differences found by BMI status in 
breast tissue, detail how gene expression is correlated with gene methylation, and discuss how 
gene methylation might influence carcinogenesis and be influenced by BMI. 
1.3.1 Gene Expression and Body Mass Index 
There is evidence that BMI may influence gene expression in breast cancer patients. In a 
study of gene expression by BMI status in 103 breast tumors, supervised analyses using ANOVA 
revealed 545 genes differentially expressed by BMI status (p-value <0.01) with tissue from 
normal and overweight patients exhibiting similar profiles that were different from the profile of 
tissue from obese women; racial differences in BMI did not explain the differences (20). Genes 
that were down-regulated in the obese group included genes that functioned in transcription 
regulation; when the obesity signature was applied to other datasets, the signature correlated with 
higher rates of metastasis, suggestive of a tumor progression effect (20). The authors concluded 
that their obesity signature was distinct from other oncogenic pathways such as ones mediated 
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through IGF-1, estrogen, and MAPK, even though their signature was correlated with these 
pathways (20), suggesting that there may be an additional pathway for the relationship between 
obesity and breast carcinogenesis. Molecules that induced the obesity signature included 
estrogenic compounds (alpha-estradiol, levonorgestrel, and hexestrol); testosterone and drugs 
that stimulate dopamine or inhibit acetylcholine pathways repressed the signature (20). 
BMI also correlates with gene expression in non-tumor tissue. A study that examined 
BMI (categorized into tertiles: <21, 21-24, >24) and gene expression in both histologically 
normal tissue distant from tumors and in tumor tissue found that high BMI was associated with 
mRNA expression of IGF-1I and IGF-1R in post-menopausal but not pre-menopausal women in 
histologically normal tissue and was associated with IGF-1R in post-menopausal women in 
tumor tissue (92), bolstering the epidemiologic evidence that the effect of BMI on breast cancer 
differs by menopausal status. The expression of IGF-1R was associated with expression of cyclin 
D1 and bcl-2, which act in cell cycle regulation and apoptosis (92). Another study examining 
women undergoing reduction mammoplasty found 760 genes differentially expressed when 
comparing obese to normal weight women, with 203 genes up-regulated and 557 genes down-
regulated (overweight women had a heterogeneous profile); the gene signature showed 
enrichment for monocytes, macrophages, and pathways that may act in macrophage 
infiltration/action in obese women, which was confirmed by a higher number of macrophages 
found in IHC staining (123). However, one study of women undergoing biopsies for irregular 
mammography findings did not find any differences in gene expression by BMI when treated as 
a continuous variable; this study was limited by a small percentage of obese women (6%) in their 
study population (16). 
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Gene Expression and Methylation. The aforementioned studies provide evidence that 
BMI may influence gene expression in breast cancer. There is also evidence that gene 
methylation may affect gene expression in cancer. In a study of colorectal cancer cell lines, 
methylation in the CpG sites of hMLH1 was correlated with silencing of the gene (124).  
Methylation has also been associated with gene expression in breast tumor tissue, with 
hypomethylation of certain genes correlating strongly with reduced presence of that same gene 
(125), and in breast cancer cell lines (126). A goal of this research was to further explore the link 
between gene methylation and gene expression in breast cancer. 
1.3.2 Gene Methylation as a Mechanistic Link 
Overview of gene methylation. Gene methylation is a mechanism that controls the 
expression of genes (127). DNA methylation occurs when a methyl group is covalently added to 
cytosine via DNA cytosine methyltransferase (128) and is frequently observed in regions of a 
gene where there are clusters of cytosines next to guanosine (CpG islands) (127). About 70% of 
CpG dinucleotides are methylated in the human genome (though CpG islands tend to be 
unmethylated), and CpG nucleotides are located near transcription sites of about half of all 
human genes (128). 
Gene methylation can be measured by using global methylation values, which 
characterize the amount of methylation genome-wide in repetitive DNA elements like Alu and 
LINE-1 (129), and by using gene-specific methylation, which examines the amount of 
methylation on a certain gene or region of a gene (130). 
DNA methylation, depending on the gene examined, appears to be 1) influenced by 
environmental factors within an individual’s lifetime (128, 131, 132), 2) stable over an 
individual’s lifetime  (133), or 3) inherited by daughter cells (128, 134). Studies show that 
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differences in global methylation increases with age in twins (131, 132) and that for specific 
genes, methylation changes with age (128). In one study of blood samples from an Icelandic 
population, genes that were variably methylated among individuals were classified into genes 
that showed intra-individual variability over time and ones that were stable over time (133). 
There is also evidence that suggests that methylation is heritable and is controlled by genes 
(134), and specifically, by genes coding for maintenance methyltransferase (128). These studies 
support the idea that gene methylation may be influenced by environmental factors for some, but 
not all genes, and that depending on the gene, methylation may change over time. It has been 
posited that methylation does not silence active genes, but maintains the silence of genes already 
silenced by, for example, histone modification (another mechanism that controls gene expression 
and is correlated with DNA methylation) (128, 135); suggesting that DNA methylation may be a 
marker of another mechanism influencing gene expression (74, 75). 
Role of Methylation in Carcinogenesis. Gene methylation has the potential to influence 
the carcinogenic process in different ways. In normal tissues, methylation plays a role in whether 
cells are growing or senescent and how cells differentiate; if these patterns become abnormal, 
cancer may result (136). Both hypomethylation (relatively lower methylation of a gene site) and 
hypermethylation (relatively higher methylation of a gene site) have been associated with cancer 
(136). CpG dinucleotides are normally methylated in many somatic tissues; hypomethylation 
may lead to activation of oncogenes and is also linked to chromosomal instability (137), 
especially when hypomethylation occurs in “pericentromeric satellite sequences”, which occurs 
in breast cancers and may be related to recombination of the sequences (136).   
There is evidence that genes that are usually unmethylated in normal breast tissue are 
methylated in breast cancers and that overexpression of methyltransferase is associated with 
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breast tumors (128). Methylation of CpG islands is thought to inactivate genes that act in DNA 
repair, tumor suppression, cell cycle regulation, and transcription (138). 
Widschwendter et al (128) examined how methylation of genes implicated in breast 
cancer could influence each of the six characteristics of cancer cells reviewed by Hanahan and 
Weinberg (139). By comparing tumor and normal breast tissue, the paper discusses how 
methylation may influence: genes that act in the replicative potential of cells via 
hypermethylation of their CpG island promoter regions (examples include p16ink4a, a tumor 
suppressor gene, cyclin D2, 14-3-3 sigma, GSTP1); genes that may be involved in self-
sufficiency of growth signals via inactivation of estrogen receptor-α, estrogen receptor-β, 
progesterone receptor, RASSF1A, and SYK; genes involved in insensitivity to anti-growth signals 
such as transforming growth factor β (TGF β) and High in normal-1 (HIN-1); genes that 
influence evasion of apoptosis, including genes involved in p53 stability (DAP kinase, TWIST) 
and other apoptotic genes (TMS1, ZAC, GPC3, and FHIT); and genes that are involved in 
invasion and metastasis such as E-cadherin and h-cadherin (which suppress invasion), APC 
(which functions in cytoskeleton stabilization) and prostasin and breast cancer specific gene1 
(BCSG1); according to the paper there is not much evidence of methylation influencing genes 
involved in angiogenesis (128). 
In examining whether methylation influences the progression of tumor tissue from ductal 
carcinoma in situ to invasive ductal carcinoma by comparing methylation of specific genes in 
these two neoplasm types, one study found no significant differences in either the number of 
tumor suppressor genes methylated between DCIS and IDC neoplasms (with at least 50% of both 
neoplasm types having methylation in PAX6, PAX5, WT1 BRCA2, CDH13, and MSH6) or in the 
methylation percentages of individual genes, though there was non-significantly lower 
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methylation of GSTP1, TP53, and CDH13 in IDC compared to DCIS (140). From this data, the 
authors concluded that changes found in IDC already existed in DCIS tumors (140), though this 
data does not rule out the possibility that additional methylation changes can occur with 
progression to invasive cancer; other studies have also found that methylation may act early in 
the carcinogenic process, including promoter hypermethylation of the tumor suppressor gene, 
p16ink4 in pre-invasive breast lesions (141-143), increased ER-α hypermethylation in the 
continuum from DCIS to metastatic tumors (144), and more RARβ methylation in benign breast 
tissue from cancer patients than in non-diseased women (145). These findings have implications 
for the timing of methylation changes in the carcinogenic process. 
Gene Methylation and Tissue from Women without Breast Cancer. There is evidence 
that some of the genes reported to be differentially methylated between tumor and normal breast 
tissue above by Widshwendter et al (128) are also differentially methylated in histologically 
normal cells and tissue (143, 146).  Among human mammary epithelial cells (HMECs) examined 
in vitro, a variant type was found that proliferates beyond the point when most of the cells arrest; 
these variant HMECs tend to be hypermethylated in the promoter region of the tumor suppressor 
gene, p16 (143). In vivo, 47% of 15 women undergoing reduction mammoplasty displayed 
promoter methylation of p16; methylation of this gene was found in both ductal and lobular 
tissue, but not in myoepithelial or stromal cells (143), supporting the idea that methylation differs 
in the various tissue types. In another study of women undergoing reduction mammoplasty, there 
was promoter hypermethylation in 31% of the women for p16, 17% for BRCA1, 9% for ER-α, 
and 0% for RAR-β; 7% of women had both ER-α and BRCA1 hypermethylated (146). 
Importantly, there was some evidence that breast cancer risk factors were associated with gene 
methylation, with African-American women exhibiting less hypermethylation of p16 (OR: .4; 
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95% CI: .2,.9) and higher methylation of ER-α and BRCA1, (though not significant) (146), 
supporting the hypothesis that risk factors may influence methylation of genes that have 
relevance in carcinogenesis.   
1.3.3 Body Mass Index and Methylation  
It is not clear how BMI would mechanistically influence DNA methylation, though some 
evidence comes from animal studies and epidemiological research of diseases other than cancer. 
One animal study found that obesity induced by high-fat diets changed methylation levels of the 
leptin promoter region in adipocytes (147). It has also been posited that obesity is associated with 
elevated levels of pro-inflammatory cytokines like IL-6 and TNF-α (148) and that, in those with 
chronic kidney disease, DNA methylation of WBCs is associated with inflammation (149). 
Taken together, this evidence supports the possibility that BMI may be associated with 
methylation changes that could influence the carcinogenic process. 
There is a dearth of epidemiological research on the potential association between BMI 
and methylation in general and in breast tissue specifically. Several studies have examined 
methylation in white blood cells (WBCs) in lieu of organ-specific tissues, suggesting that 
methylation in WBCs may be biomarkers for tissue methylation in general (150), for different 
cancers (150-152), and for breast cancer-related methylation (153).  
In a study of global methylation in WBCs from 85 women without cancer, those whose 
current BMI was 25 or higher had non-statistically significant higher levels of methylation than 
those with BMI less than 25 after adjustment for variables including childhood smoking 
exposure, nulliparity, and age at 1
st
 birth (154). It was also found that exposures that occurred 
earlier in life, such as exposure to prenatal smoke, later age at menarche, nulliparity and age at 1
st
 
birth, were significantly associated with higher methylation (154), highlighting the importance of 
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timing of exposure assessment when assessing methylation. When methylation of the repetitive 
element, LINE-1, was measured in the peripheral blood of men and women, those with BMI less 
than 25 had the lowest mean methylation percentage and those with BMI greater than or equal to 
30 had the highest methylation percentages, though the results were not statistically significant in 
crude analyses and 90% of the study population was overweight or obese (155); however, when 
different measures of adiposity were used, such as central obesity, the differences in percentage 
methylation persisted, even after adjustment for age and race (but not gender) (155). Other 
studies reviewed in Terry et al (156) have not found significant correlations between methylation 
values in the repetitive elements, LINE-1 and Alu, and BMI (157, 158), but one study examining 
BMI in women of childbearing age reported less LINE-1 methylation in those with higher BMI 
(159). 
There is also evidence that methylation is higher in those with higher BMI when 
examining specific genes in WBCs: methylation was increased in those with higher BMI for 
three of four differentially methylated CpG sites (MMP9, PM20D1, and PRKG1) (133). 
When methylation was measured in breast tissue from women undergoing reduction 
mammoplasty, there were no significant associations, but those with higher BMI (≥ 31) had less 
methylation of p16 (OR: 0.6; 95% CI: 0.29, 1.36), more BRCA1 methylation (OR: 1.7; 95% CI: 
0.24, 11.48) and more ER-α methylation (OR: 2.4; 95% CI: 0.43, 12.92) (146); the results from 
this study were limited by very small strata (146). 
When gene-specific methylation was measured by BMI in breast tumor tissue, there was 
no statistically significant differences in percentage methylation by BMI or waist-to-hip ratio for 
E-cadherin, p16, or RAR-β(2) (160). 
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1.3.4 Summary 
The present body of literature focusing on BMI, the epigenome and breast cancer is 
suggestive of a mechanistic link between obesity and cancer-associated gene expression through 
gene methylation, but there are several gaps in the literature that need to be addressed.  There are 
several pathways through which obesity may influence breast cancer, including pathways that act 
through hormones (66, 74, 75), insulin resistance (66, 68, 69), and immune responses (79, 80, 
102).  Gene expression studies provide evidence of these pathways, with obese women showing 
differential expression of genes on these pathways in both tumor and non-tumor tissue in some 
studies (20, 92, 123), but not in other research (16). More research is needed to validate these 
findings and to explore whether there are additional pathways through which adiposity may 
influence breast cancer. There is also evidence that gene methylation is correlated with gene 
expression in breast cancer (125, 126), though to date, no study has examined the correlation 
between gene expression and gene methylation in the same dataset in the context of BMI and 
breast cancer. 
Research has found differential methylation of genes known to be involved in 
carcinogenic processes when comparing tumor to non-tumor breast tissue (128), but it is not 
clear at what point during the transformation of cells from normal to malignant do these 
methylation changes occur, warranting further exploration of gene methylation in non-diseased 
women. The studies that have examined gene methylation in breast cells and tissue have shown 
that there may be differences in methylation by some breast cancer risk factors (143, 146). There 
is limited research regarding the link between BMI and gene methylation with studies in white 
blood cells finding non-significant differences in global methylation (154, 155) and in specific 
genes (133). Similarly, non-significant differences were found in gene methylation by BMI 
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status in a study that examined the association in non-tumor breast tissue in specific genes (146). 
To date, no study has explored the link between BMI and gene methylation in non-tumor breast 
tissue in a comprehensive gene-specific panel. 
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 Chapter 2: Methods 
 
2.1 Study Design 
2.1.1 Normal Breast Study 
The Normal Breast Study (NBS) is an ongoing study of non-diseased breast tissue. The 
study contacted 526 English-speaking women undergoing breast surgery at the University of 
North Carolina Hospitals between 2009 and 2013. Eligible surgery included prophylactic surgery 
for women at high risk of breast cancer; total mastectomy, partial mastectomy, and excisional 
biopsy for women with breast cancer; and reduction mammoplasty. Of the 526 patients contacted 
for participation, 19 declined to participate, 4 requested removal from the study after providing 
written consent, and 29 did not have adequate levels of breast tissue.  The final total study 
population consisted of 474 patients. All participants agreed to provide snap frozen breast tissue 
and blood samples; a computer-assisted telephone interview was conducted to assess 
demographics and risk factors. Medical record abstraction was performed to obtain 
anthropometric data at time of surgery. 
For this investigation, tissue samples of approximately 96 women were selected from 
women undergoing prophylactic surgery, reduction mammoplasty (RM), lumpectomy or 
mastectomy.  For participants who had either a lumpectomy or mastectomy, the tissue was 
sampled at least 4 cm from the tumor. For the participants with breast cancer, only tumors that 
were classified as invasive ductal carcinoma were included. In order to attain a study population 
of 96 women, patients who were classified with IDC but also had DCIS or another abnormal 
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growth were included in the sample because the prevalence of IDC with synchronous DCIS was 
high in the NBS population, and there were not enough patients with IDC alone.  
2.1.2 Carolina Breast Cancer Study 
The Carolina Breast Cancer Study (CBCS) is a population-based case-control study 
conducted in North Carolina. During phase I of the study, cases of invasive breast cancer were 
randomly recruited from the North Carolina Central Cancer Registry between 1993 and 1996. 
Facilities are required to send abstracts of medical records to the Central Cancer Registry for 
reportable diseases, including invasive and in situ breast cancer. The registry categorized the 
cancer by morphology and topography using the International Classification of Diseases for 
Oncology 2
nd
 Edition (codes: C500-C509 for invasive and in situ breast cancer) (161). Medical 
record abstraction was used to confirm case diagnosis by CBCS staff. The study participants 
were restricted to English-speaking women aged 20 to 74 years. Participation in this study 
included in-person interviews with trained nurses to collect demographic and risk factor data, 
donation of tumor blocks from pathologists, and medical record abstraction. Tumor blocks were 
requested from the pathologists of consenting cases. Pathologists associated with CBCS verified 
the diagnosis of cancer for all of the cases. Immunohistochemical markers were used to subtype 
the tumors into luminal A and basal-like, based on the detection of estrogen receptor (ER), 
progesterone receptor (PR), human epidermal growth hormone 1 and 2 (HER1 and HER2), and 
cytokeratins 5 and 6. Luminal A tumors were those that were positive for ER, PR, and HER2; 
basal-like tumors were negative for ER, PR, HER2 and were positive for cytokeratins 5/6 or 
HER1.  
The CBCS oversampled women under age 50 and African-American women to ensure 
evaluation of these previously understudied patient groups. The oversampling of African-
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American women enables stratification by race and by subtype, as African-American women 
present more frequently with basal-like cancers, and examination of whether BMI-associated 
gene methylation or expression differs within these strata. Breast tumor methylation values were 
obtained on 517 of the cases. 
2.1.3 Exposure Assessment 
BMI was used as a proxy for adiposity for this research. Although BMI is not a perfect 
surrogate for adiposity, BMI is highly correlated with adiposity (111) and with risk of 
postmenopausal breast cancer (68). 
For the NBS, BMI was assessed at time of surgery and was abstracted from medical 
records. Using data from medical records should limit potential for information bias since most 
studies have found that when compared to direct measurement, women tend to underreport 
weight, with larger discrepancies among those with higher BMI, but to slightly overestimate 
height (162). BMI was treated as a continuous variable based on the results of exploratory 
analyses.  
For the CBCS, study eligibility was restricted to patients whose pre-diagnosis BMI was 
available. BMI was self-reported (participants were asked to recall their weight one year prior to 
interview) and was categorized as normal weight (18.5 kg/m
2 ≤ BMI < 25 kg/m2), overweight 
(25 kg/m
2 ≤ BMI <  30 kg/m2), or obese (BMI ≥ 30 kg/m2). The results of exploratory analyses 
suggested that regression analyses should be restricted to those of obese or normal weight.  
2.1.4 Covariate Assessment and Confounding 
Age and race were treated as confounders in all analyses. Other variables that were 
assessed for confounding included alcohol intake, menopausal status, smoking, diet, age at first 
birth, parity, education, income, and physical activity. Though it was not feasible to consider 
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how covariates may confound the association between BMI and gene methylation or gene 
expression for every gene site available on the array platforms, there is evidence that there are 
differences in methylation by age (128, 131, 132), race (146), socioeconomic status (154), parity 
(154), smoking (150), physical activity (163), and age at first birth (154). Dietary composition, 
which has been associated with obesity (164-168), may also act as a confounder in these 
analyses. Various components of the diet have been associated with methylation, both genome-
wide (169) and in specific genes (170-172). Specifically, components of green tea and fruits and 
vegetables are associated with methylation (173, 174). Since all of these variables may also be 
associated with body fat distribution or BMI (112, 113, 175-179), they were included in 
modeling to determine whether they act as confounders in this data. 
There were some variations in how some of these covariates were collected in NBS and 
CBCS. In the NBS, age was abstracted from medical record at the time of surgery; in the CBCS 
age was self-reported at time of diagnosis. In both datasets, self-reported race will be used. In the 
NBS, alcohol intake was captured for the year prior to the survey and was categorized as ever (≥ 
12 drinks) versus never (< 12 drinks); in the CBCS, alcohol intake is dichotomized as ever vs. 
never consumption of beer, wine, liquor or mixed drinks. In the NBS data, physical activity 
included information on whether the participant exercised moderately in the 6 months prior to 
their abnormal mammogram; in the CBCS data, physical activity was dichotomized as yes or no 
for the three months prior to interview. In the NBS, smoking was categorized based on current 
smoking status and ever versus never smoking status; in the CBCS, smoking was categorized as 
never, former, or current at the time of diagnosis. In both the NBS and CBCS, menopausal status 
was categorized as either premenopausal, peri-menopausal, or postmenopausal based on self-
reported data. Components of the diet were also assessed for confounding, including 
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consumption of fruits and vegetables, which were captured in the NBS and CBCS data, and 
consumption of green tea and coffee, which was captured in the NBS. The NBS had self-
reported data on age at first pregnancy; CBCS had self-reported data on age at first full-term 
birth. Both the NBS and the CBCS had data on parity, but only CBCS had data on household 
income and education.  
To assess for confounding, covariates that were associated with BMI status at an alpha 
level of 0.05 and were differentially methylated at a false-discovery rate of ≤ 0.05 were included 
as potential confounders. The false-discovery rate was used to control for multiple testing (123). 
2.2 Laboratory Procedures 
2.2.1 Methylation Assessment 
DNA for the NBS samples was isolated using the DNeasy Blood and Tissue Kit from 
Qiagen by following the manufacturer’s spin-column protocol. Sodium bisulfite modification of 
the DNA was conducted using EZ DNA Methylation Gold Kit (Zymo Research, Orange, CA), 
after which the quantity and concentration of the DNA was assessed using Nanodrop 
spectrophotometers to ensure that 500 ng of DNA at a concentration of 50 ng/ul in nuclease free 
water were available for use for the Illumina Infinium HumanMethylation450 BeadChip 
platform. 
To assay the methylation values for NBS, the Illumina Infinium HumanMethylation450 
BeadChip array was used. This array can assess over 450,000 methylation sites, including CpG 
sites, non-CpG sites, sites within CpG islands in promoter and in non-coding gene regions, and 
sites on miRNA promoter regions (180). The Conway-Dorsey lab has successfully evaluated 
frozen breast tumor core biopsies using the 450k platform. 
The array was analyzed by the Mammalian Genotyping Core, as described by Sandoval 
et al. (180). The methylation value (β-value) of each site was determined by comparing the 
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fluorescent signal ratio of the methylated allele to the sum of the signals from the methylated and 
unmethylated alleles. The β-values range from 0 to 1, representing the fraction of DNA 
methylated (with 0 indicating CpG sites that were completely unmethylated and 1 indicating 
sites that were fully methylated). A positive and negative control was used on each bead array. 
To reduce bias from batch effects, all of the samples from the NBS patients were run on one 
array. 
 The methylation values were assayed for the CBCS tumor samples using the Illumina 
GoldenGate Methylation Cancer Panel I array which assesses methylation on 1,505 CpG 
promoter sites of 807 genes indicated in the carcinogenic process (31). The tissue was processed 
as formalin-fixed paraffin embedded tissue blocks, which has been shown to give similar results 
as fresh tissue (181). 
2.2.2 Gene Expression Assessment 
 To isolate RNA from normal breast tissues for the gene expression microarray, RNA was 
isolated using RNeasy kits. Nanodrop spectrophotometers and an Agilent 2100 Bioanalyzer was 
used to assess RNA concentration and quality, respectively. 4x44 K Agilent whole genome 
arrays were run using Cy3-labeled references (123). The data was normalized and probes with 
<10 dpi in any channel and probes missing over 20% of data across all samples will be excluded 
(123).  Individuals missing more than 30% of probe data were also excluded. Additionally, 
probes that do not have an ENTREZ ID or do not exhibit variable expression across individuals 
(an interquartile range below the median) were excluded (123). 
2.3 Specific Aims and Hypotheses 
Specific Aim 1. Objective: Examine whether BMI is associated with gene methylation in 
histologically normal tissue, identify which of those sites are most significantly associated with 
BMI status, determine if those sites’ methylation values correlate with gene expression, and 
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identify the biologic pathways represented by those sites. Hypotheses: There will be a difference 
in gene methylation profile by BMI status and this methylation profile will reflect etiologically 
relevant action of adiposity on the target cells for carcinogenesis. Biologically relevant gene 
methylation changes will be correlated with gene expression. Pathways enriched for 
inflammatory response, insulin resistance and estrogenic activity will be identified through 
pathway analysis. Approach: Tissue from patients undergoing breast surgery and recruited into 
the Normal Breast Study (NBS) were assayed for gene methylation using the Illumina Infinium 
HumanMethylation450 BeadChip array (180). Generalized linear regression was used to identify 
which genes are significantly associated with BMI. Regression coefficients were calculated to 
assess the relationship between gene methylation and expression. Pathway analysis was 
performed to identify gene functionality. 
Specific Aim 2. Objective: Examine BMI-associated gene methylation changes in tumor 
tissue and identify functions of these genes. Hypotheses: The methylation profiles of tumor 
tissue will differ by BMI status; enriched pathways will include genes on inflammatory and 
insulin resistance pathways. Approach: Gene methylation has been assayed on cases of the 
Carolina Breast Cancer study using the Illumina GoldenGate Methylation Cancer Panel I array 
(182). Generalized linear regression was used to identify genes that are most differentially 
methylated by BMI status and gene ontology tools were used to identify which biologic 
pathways these genes function in. 
2.4 Statistical Analyses 
2.4.1 Linear Regression 
In the NBS, robust linear regression was used to assess the relationship between BMI 
and gene methylation (183).  Only ever alcohol use (≥ 12 lifetime drinks) met the criteria for 
confounding (associated with BMI at p-value <0.05 and associated with gene methylation at 
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false discovery rate (FDR) q-value <0.05). The final adjustment set consisted of alcohol use, 
age, and race. Linear regression, using limma with an empiric Bayes approach (184), was also 
conducted to examine the association between BMI and gene expression in the tissue samples 
that were adjacent to the samples used for the methylation analyses.  
In the CBCS data, linear regression using limma with an empirical Bayes approach (184) 
was conducted to assess which CpG sites were associated with pre-diagnosis body mass index 
(BMI). The R statistical package (www.r-project.org/) was used to conduct all regression 
analyses. BMI was treated as a 2-category variable (obese versus normal weight, with 
overweight women excluded) for regression modeling, to enhance our power to detect obesity-
associated methylation, the heterogeneous overweight group was excluded. After assessing for 
confounding, the final adjustment set consisted of age, race, and menopausal status. 
In the CBCS data, exploratory analyses indicated that in addition to testing the 
association between BMI and gene methylation in breast tumor tissue overall, the relationship 
should also be assessed among ER-positive tumors.  
2.4.2 Correlation between Gene Methylation and Expression 
 Linear regression was used to determine which of the CpG sites that were differentially 
methylated by BMI were also associated with gene expression in the NBS data. A regression 
coefficient was calculated to identify the BMI-associated CpG sites that were either inversely or 
directly associated with gene expression values using tissue sampled from the same individual. A 
correlation coefficient of ≤ -0.3 or ≥ 0.3 was used as the cut-off. 
 Though there was no linked gene expression data for the CBCS patients, the correlation 
between methylation and expression in breast tumors that were collected through The Cancer 
Genome Atlas (http://cancergenome.nih.gov/) was assessed for the exact CpG sites that were 
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significantly associated with BMI in the CBCS analyses or that were located within 200 base 
pairs from these sites.   
2.4.3 Pathway Analysis 
 QIAGEN’s Ingenuity Systems Pathway Analysis (IPA, QIAGEN Redwood City, 
www.qiagen.com/ingenuity) was used to perform pathway analysis for genes associated with 
differentially methylated probes. While limited by the calculation of p-values using a gene-
sampling rather than subject-sampling framework (185), this method allowed for interactive 
pathway analysis of complex methylation data. 
2.4.4 Predictive Accuracy 
 To assess the predictive accuracy of the CpG sites and gene expression probes associated 
with BMI in the NBS data, leave-one-out cross validation and k-Nearest Neighbors classification 
was used (186). This classification tool allowed examination of how accurate the BMI-associated 
sites were at predicting known obese or normal weight. 
2.5 Strengths and Limitations 
2.5.1 Study Design 
Strengths of the NBS include assaying both gene methylation and gene expression in 
nearby tissue samples, which allowed examination of how correlated methylation changes are 
with changes in expression. The use of histologically normal tissue was also an advantage 
because it is difficult to determine whether epigenetic anomalies observed in tumor tissue are due 
to etiologically relevant changes or co-occur with the carcinogenic process. The majority of 
tissue sampled from the NBS was cancer-adjacent. Studies have found that tissue adjacent to 
tumors harbor more genetic aberrations than tissue more distal from the same tumors, possibly 
reflecting a field cancerization effect (187-189). For this study, only tissue sampled >4 cm from 
an invasive tumor were analyzed with the intent of minimizing the effect of field cancerization. 
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However, women diagnosed with breast cancer are at increased risk of experiencing both 
recurrence and second breast primaries (190, 191) and breast cancer survivors who are 
overweight are at even higher risk of experiencing these adverse outcomes (190, 191). This 
complicates the interpretation of our results of histologically normal cancer-adjacent breast 
tissue.  
 Advantages of using cases from the CBCS included the oversampling of women under 
age 50 and of African-American women, resulting in a relatively large number of both African-
American women and basal-like tumors in this study population. Also, because the cases are 
population-based as opposed to hospital-based, it is easier to determine the source population 
from which the cases arise and to generalize the results of this study. A limitation of the CBCS 
data was use of the Illumina Cancer I Panel, which is limited to probes that are of known 
carcinogenic relevance and may not include probes that are associated with BMI. 
2.5.2 Exposure Assessment 
 As discussed in section 1.2.2, BMI is not a perfect proxy for adiposity, but it is an 
acceptable surrogate. In the NBS, the use of BMI abstracted from medical records prevented 
information bias that can occur when women inaccurately report their weight. In the CBCS data, 
self-reported data was used to ensure that pre-diagnosis BMI could be assessed. There is 
evidence that that women tend to underestimate their weight (162), which could bias the results 
as will be discussed in section 5.3. 
2.5.3 Summary 
The overall goal of this research was to explore how BMI influences the epigenome in 
breast carcinogenesis. It sought to understand 1) whether gene methylation is an intermediate 
step between BMI status and gene expression in breast tissue and 2) how genes that are 
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differentially methylated and expressed by BMI status may influence pathways towards breast 
cancer. Two datasets, one from the NBS and one from the CBCS, were used to assess these 
relationships in non-diseased and tumor tissue, respectively. Linear regression was used to 
identify BMI-associated methylation sites and to identify methylation sites that were correlated 
with gene expression. Pathway analyses were conducted to determine the functions of BMI-
associated methylation sites. 
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Chapter 3: Body Mass Index and Gene Methylation in Normal Breast Tissue 
 
3.1 Introduction 
Breast cancer is a heterogeneous disease comprised of at least five subtypes based on 
gene expression patterns (9, 17).The incidence of these breast tumor subtypes varies by risk 
factors such as age, race, body size, and breastfeeding history (12, 13), suggesting that risk factor 
status may differentially influence subtype-specific carcinogenic pathways. Obesity, in 
particular, is a modifiable breast cancer risk factor that has well-established and complex 
relationships with breast cancer subtypes (68, 69). For example, though body mass index (BMI) 
is associated with subtypes that are both positive and negative for hormone receptors (24, 69, 
119-121), high BMI is more strongly associated with hormone receptor positive tumors (38). 
Gene expression studies suggest several mechanisms through which BMI might influence 
breast carcinogenesis. In studies of non-diseased breast tissue, differences in expression by BMI 
were found for genes that code for insulin-like growth factor 2 (IGF-2), for the insulin-like 
growth factor 1 receptor (IGF-1R), and for genes involved in inflammation (92, 123). When 
IGF-1R is triggered, it can activate many pathways that increase the proliferation of breast cells 
(66, 90) while an inflammatory response could contribute to tumor invasiveness through 
increased angiogenesis and tissue remodeling (79, 80). 
 The goal of this study was to explore BMI-associated epigenetic changes in non-diseased 
breast tissue using data from the Normal Breast Study. Methylation sites (CpG loci) for which 
there was a significant (q-value <0.05) association with BMI are termed BMI-associated 
methylation sites. Specifically, we investigated whether BMI was associated with the 
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methylation of genes involved in insulin-like growth factor, immune response, and other cancer-
related pathways. Further, because gene methylation is a mechanism for controlling gene 
expression (127), we assessed which of the BMI-associated methylation sites were also 
correlated with gene expression. Identifying which epigenetic changes are associated with BMI 
can provide insight into how BMI influences breast carcinogenesis and may direct research of 
molecular targets for the prevention of breast cancer. 
3.2 Methods 
3.2.1 Study Population 
Study subjects were from the Normal Breast Study. The study contacted 526 English-
speaking women, at least 18 years of age, undergoing breast surgery at University of North 
Carolina Hospitals between 2009 and 2013 for participation. Qualifying surgery types included 
total mastectomy, partial mastectomy, and excisional biopsy for women with breast tumors; 
prophylactic mastectomy for women at high risk of breast cancer; and reduction mammoplasty.  
Of the 526 patients contacted for participation, 19 declined to participate, 4 requested removal 
from the study after providing written consent, and breast tissue was not available for 29 
patients at the time of surgery, resulting in a final study population of 474 patients. Study 
participants provided breast tissue at the time of surgery. Samples with sufficient quantities 
were preserved by being snap frozen and embedded in paraffin. Demographic and risk factor 
data were collected through a telephone interview conducted by the University of North 
Carolina’s Survey Research Unit. Medical abstraction was conducted to obtain anthropometric 
data. 
Methylation values were determined for 96 of the women participating in the Normal 
Breast Study. Cancer-adjacent, histologically-normal samples were collected from 70 women 
with invasive ductal carcinoma; the remaining tissue samples were collected from women 
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undergoing reduction mammoplasty (n=18) or prophylactic surgery (n=8).  For the women 
undergoing surgery for tumor removal, tissue samples included in this study were taken ≥ 4 cm 
from the tumor margin. The University of North Carolina at Chapel Hill Institutional Review 
Board approved this study. 
3.2.2 Gene Methylation Assessment 
The Illumina HumanMethylation450 BeadChip array (180) was used to assay 
methylation levels in the tissue samples. The array assesses methylation in 485,577 cytosine-
guanine dinucleotide (CpG) sites and has a coverage of 99% of RefSeq genes, with an average 
of 17 CpG sites per gene. DNA was isolated using the DNeasy Blood and Tissue Kit from 
Qiagen (Valencia, CA) by following the manufacturer’s spin-column protocol. Sodium bisulfite 
modification of the DNA was conducted using EZ DNA Methylation Gold Kit (Zymo Research, 
Orange, CA), after which the quantity and concentration of the DNA was assessed using a 
Nanodrop spectrophotometer to ensure that 500 ng of DNA was available for use for the 
HumanMethylation450 BeadChip platform. 
Methylation levels (beta values) were calculated based on the intensity measures of two 
probes corresponding to unmethylated (U) or methylated (M) CpGs. Probe raw intensity values 
were extracted with the Illumina GenomeStudio® software (version 2011.1). To correct dye bias 
and normalize the methylation data, the M and U intensity values were pre-processed separately 
for the Infinium I and II CpG probes as follows: 1) for Infinium I probes, the red and green 
channel probes  were separately background corrected (using the Robust Multichip Average 
(RMA) method (192)) and quantile normalized; 2) for Infinium II probes, dye bias between U 
and M intensity values were first corrected using the normalizeMethyLumiSet method in the R 
package “methylumi” (193), and then RMA background correction and quantile normalization 
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were performed separately for U and M intensity values; 3) the beta value for each CpG site was 
recalculated as the ratio of normalized fluorescent intensities between methylated and 
unmethylated alleles β=M/(M+U+100); a beta value of 0 indicates no methylation while a value 
of 1 indicates complete methylation. Batch effects and bisulfite conversion intensities were 
adjusted for and, to minimize the effect of outlier methylation values in regression modeling, any 
beta values that were more than 3 standard deviations from the mean were excluded for each 
CpG probe. A sensitivity analysis was conducted, in which the outlier values were retained, to 
determine the impact of removing outlier methylation on the results. In the sensitivity analysis, 
712 CpG sites were associated with BMI, and 80 pathways were enriched among those BMI-
associated sites. There was considerable overlap between the biologic pathways enriched in the 
sensitivity analysis and the main results presented in this paper, with 47 of the 80 pathways 
enriched among the BMI-associated sites in the sensitivity analysis also enriched in the main 
results. Because outlier values were influential in the linear regression analysis, outliers were 
excluded for the results presented henceforth. Low performance CpG probes were also filtered 
by: 1) excluding 13,449 CpG probes located at sites with common SNPs (minor allele frequency 
≥ 0.05 in Europeans or Africans based on the 1000 Genomes Project data (194)); and 2) 
excluding  41,937 CpGs with probes mapped to multiple genomic locations (195). After 
applying these exclusion criteria, 431,568 CpGs remained. 
3.2.3 Gene Expression Assessment 
Gene expression was assessed in tissue samples adjacent to the tissue sampled for the 
methylation assay. RNA was isolated using Qiagen RNeasy kits (Valencia, CA). A Nanodrop 
spectrophotometer  and an Agilent 2100 Bioanalyzer were used to assess RNA concentration 
and quality, respectively. Gene expression analysis was performed using Agilent Low Input 
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Quick Amp labeling, 2-color (5190-2306) and Human Gene Expression 4x44k v2 Microarray 
kits (G4845A; Santa Clara, Ca) as per the manufacturer’s instruction. The data were normalized 
and probes with <10 dpi in any channel were excluded (123).  Probes missing over 20% of data 
across all samples, probes that did not map to an ENTREZ ID, or individuals missing more than 
30% of probe data were also excluded.  
3.2.4 Statistical Analysis 
Robust linear regression, in which parameter estimates are less influenced by outliers, 
was used to assess the relationship between BMI and gene methylation (183). BMI at the time 
of surgery was treated as a continuous linear variable for regression modeling. The study 
sample was restricted to those of white or African-American race; current smokers were 
excluded from the dataset because only 3 individuals identified as such, as were two 
underweight individuals and 4 individuals missing data on alcohol use. The resulting final study 
population was 81. Age at first pregnancy, parity, menopausal status, alcohol use, physical 
activity, and fruit and vegetable intake were assessed for confounding. Only ever alcohol use (≥ 
12 lifetime drinks) met our empirical criteria for confounding (association with BMI at p-value 
<0.05 and association with gene methylation at false discovery rate (FDR) q-value <0.05 (196)). 
The final adjustment set consisted of alcohol use, along with age and race which were 
determined to be confounders a priori. Linear regression was also used to determine which of 
the BMI-associated CpG sites were correlated with gene expression. All statistical analyses 
were performed using R software package (version 2.15.3). An FDR q-value of <0.05 was used 
as the significance cut-off for regression analyses; a Pearson correlation cut-off of ≤ -0.30 or ≥ 
0.30 was used as the cut-off for determining correlation with gene expression. 
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Gene set enrichment analysis was conducted to determine what pathways were enriched 
among the BMI-associated methylation sites. Using data from the National Center for 
Biotechnology Information (NCBI) Human Genome Build 37 Gene Annotation Database (197), 
each CpG was mapped to the nearest gene based on distance between the CpG and a nearby gene 
transcription start site (TSS). A total of 392,910 CpGs on the array are within 5kb of the nearest 
TSS of 22,810 NCBI reference genes. CpGs located farther than 5kb from the nearest TSS were 
excluded from the gene set enrichment analysis. To test for enrichment of gene pathways in 
BMI-associated CpG sites, Ingenuity Systems Pathway Analysis (IPA, Ingenuity
®
 Systems, 
www.ingenuity.com) was used, though it is limited by the calculation of p-values using a gene-
sampling rather than subject-sampling framework (185). For the analysis, all 640 canonical 
pathways that included at least one of the 22,810 genes on the array were extracted, then the 
binomial test was performed to test whether genes significant at a FDR threshold of 0.05 were 
enriched in any of these pathways. Enrichment test p-values were derived from 5,000 rounds of 
permutation tests. At each permutation test, association test p-values were randomly shuffled for 
all 392,910 CpGs and then repeated for each corresponding enrichment test. A permutation p-
value of <0.05 was used as a significance cut-off. IPA analyses were conducted on the BMI-
associated sites identified in this study and in two studies (20, 123) that examined the association 
between BMI and gene expression in non-diseased breast tissue.  
Linear regression, using limma with an empiric Bayes approach (184), was conducted to 
examine the association between BMI and gene expression in the tissue samples. Probes that 
did not exhibit variable expression across individuals (an interquartile range below the median) 
were excluded (123). 
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The accuracy in predicting the obese (BMI ≥ 30 kg/m2) and normal weight (18.5 kg/m2 ≥ 
BMI > 25 kg/m
2
) status of the BMI-associated methylation sites, the BMI-associated gene 
expression-correlated methylation sites, and the BMI-associated gene expression sites was 
conducted using leave-one-out cross validation and k-Nearest Neighbor classification (186).  
3.3 Results 
3.3.1 Methylation Sites Associated with BMI 
The 81 study participants ranged in age from 19 to 84 years, with a median age of 53. 
Approximately 27% of the study participants were normal weight (18.5 kg/m
2 ≤ BMI < 25 
kg/m
2
), 33% were overweight (25 kg/m
2 ≤ BMI < 30 kg/m2), and 40% were obese (BMI ≥ 30 
kg/m
2
) (Table 3.1). 
Linear regression analyses revealed that 2,573 CpG sites were significantly associated 
with BMI after adjustment for age, race, and alcohol use (Table A1). BMI-associated 
methylation sites were found on all chromosomes as illustrated by a Manhattan Plot (Figure 3.1), 
and approximately 57% of the sites were inversely associated with BMI. Figure 3.2 displays 
scatterplots of methylation values by BMI for CpG sites selected among those with FDR q-
values ≤ 0.05. Of the 2,573 BMI-associated probes, 10% were located on CpG islands (which 
tend to be near promoter regions (198)), 24% were located on shores (which are up- or 
downstream of islands (199)), and 11% were located on shelves (which are up- or downstream of 
shores (199)); the remaining 54% were not located in or near CpG islands. The BMI-associated 
probes were less likely to be located on CpG islands than would be predicted by the 
representation of CpG island probes available on the 450k platform (10% vs 31%; chi-square p-
value <0.001).   
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3.3.2 Pathway Analysis 
Based on gene set enrichment analysis using the IPA database, many of the BMI-
associated methylation sites were involved in inflammatory or immune response pathways, 
including genes indicated in the signaling of several interleukins, natural killer cells, B cells, T 
cells, and NF-kB (Table A2). BMI-associated CpG sites were also enriched in metabolic 
pathways involving insulin receptor and leptin signaling and in pathways that influence 
carcinogenesis, such as human epidermal growth factor 2 (HER-2), angiopoietin, and hepatocyte 
growth factor (HGF) signaling. The pathways identified from our BMI-associated sites were 
confirmed in two previously reported studies and listed in Table 3.2. Many of the common 
pathways were related to inflammatory processes, though there were also pathways indicative of 
cardiovascular pathogenesis, such as the aldosterone signaling in epithelial cells pathway and the 
endothelin-1 signaling pathway. One gene, C-terminal binding protein 2 (CTBP2), was 
associated with BMI in all three studies (Supplemental Table 6); the association between BMI 
and methylation percentage for the CTBP2 probe identified in this study is shown in Figure 2B. 
Pathway analyses were also conducted on the BMI-associated probes by genomic location. 
Pathways involved in inflammation and immune response were represented in all of the location 
types (data not shown). 
3.3.3 Correlation with Gene Expression 
We were able to evaluate the correlation between gene methylation and expression in 61 
of the 81 study participants and for 1,251 of the 2,573 BMI-associated probes that mapped to the 
microarray dataset. Of those, 226 unique BMI-associated CpG sites were correlated with gene 
expression at a Pearson correlation coefficient equal to or greater than the absolute value of .30 
(Table A3). Approximately 68% of the 226 were inversely correlated with gene expression. Of 
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those 226, 28% were located on shores, 14% were located on shelves, and 8% were located on 
islands. 
3.3.4 Predictive Accuracy 
Methylation markers, relative to gene expression markers, had greater predictive 
accuracy in distinguishing between obese and normal weight individuals. The predictive 
accuracy of the probes identified as significantly associated with BMI using the gene expression 
data alone was 60% (n=48; 9 probes identified as significant; Table A4), compared to a 
predictive accuracy of 69% for the 226 BMI-associated, expression-correlated CpG sites, and 
72% for the 2,573 BMI-associated methylation sites.   
3.3.5 Exploratory Analyses  
Two exploratory analyses were conducted to examine the effect of tissue type (reduction 
mammoplasty, prophylactic surgery, or invasive ductal carcinoma) on percent methylation. In 
the first sensitivity analysis, tissue source was treated as the main exposure variable and age was 
a covariate. No methylation sites were significantly associated with tissue source in this analysis, 
indicating that the three tissue sources could be analyzed together. In the second sensitivity 
analysis, tissue source was treated as an adjustment factor in a regression model of BMI as the 
main exposure variable and age, race, and alcohol use as covariates to determine if tissue source 
affected the identification of BMI-associated methylation sites. The methylation values for 174 
sites were associated with BMI in this exploratory analysis; all but two of the 174 sites were also 
identified in the main regression analysis reported in this study (Table A5).  
3.4 Discussion 
 This is the first study to examine the association between BMI and genome-wide 
methylation and gene expression in histologically non-diseased breast tissue. Approximately 
18% (226/1,251) of the BMI-associated methylation sites were significantly associated with gene 
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expression, suggesting that BMI-associated methylation may help control the expression of some 
genes. Similar to other research, we found that correlation with expression was higher for probes 
located on CpG shores than ones located on CpG islands (199, 200), suggesting that BMI-
associated methylation sites that are up- or downstream of promoter regions are more influential 
in expression. The 2,573 methylation sites identified as associated with BMI were better at 
distinguishing between obese versus normal BMI status when compared to the probes based on 
gene expression data alone (72% predictive accuracy versus 60%, respectively). These predictive 
accuracy values are comparable to values reported in other studies using molecular markers to 
predict various phenotypes (201-203) and underscore the heterogeneity in BMI with regard to 
methylation status.  
 Our findings indicate that BMI may influence breast carcinogenesis through multiple 
mechanisms. Pathways enriched among BMI-associated methylation sites in our data included 
ones involved in the inflammatory response (e.g. interleukin-6 and NF-kB signaling), in energy 
metabolism (insulin receptor and leptin signaling), and in epithelial-stromal interactions 
(hepatocyte growth factor signaling). All of these pathways have been implicated in various 
aspects of the carcinogenic process. Interleukin-6 (IL-6), a product of chronic inflammation, is 
associated with obesity and has both cancer-promoting and anti-cancer functions (71, 72, 107). 
Though IL-6 has been shown to prevent early stage breast cancer, the cytokine is also correlated 
with cell migration, antiapoptosis, stimulation of aromatase activity, and poor prognosis among 
those with metastatic disease (66, 84, 85). The activation of NF-kappaB signaling is associated 
with angiogenesis, tumor invasiveness, and antiapoptosis in tumor cells (105) while a pathway 
involving the signaling of leptin, a ligand produced by adipose tissue, could influence breast 
carcinogenesis through increased estrogen production via aromatase transcription (100, 101) and 
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also through the promotion of angiogenesis and tumor invasion (68, 77).  Insulin-like growth 
factor receptor signaling involves activation of pathways shown to increase proliferation of 
breast cells (66, 90) while hepatocyte growth factor (HGF) has been shown to be associated with 
obesity in murine models (204), to promote cell migration in vitro (204), and to influence the 
invasive potential of premalignant breast cells (205). 
 Our results are consistent with studies finding that BMI is associated with epigenetic 
changes in breast tissue. Creighton et al. reported that 799 probes representing 662 genes were 
differentially expressed when comparing the breast tumor tissue of obese patients to that of 
normal and overweight patients (20); we were able to examine the overlap between 439 of those 
genes and found that 42 of them were differentially methylated by BMI in the present study. 
Similarly, in our previous work examining the tissue from women undergoing reduction 
mammoplasty from a different population, we found 760 genes were differentially expressed 
when comparing the non-diseased tissue of obese and normal weight women (123); we were able 
to examine the overlap between 547 of those 760 genes and found that 68 of them were 
differentially methylated by BMI in the present study (Supplemental Table 6). As in our present 
study, we previously reported enrichment for pathways involved in inflammation and immune 
response, including pathways that may act in macrophage infiltration. Furthermore, one gene, 
CTBP2, which encodes for a transcriptional repressor, was identified as associated with BMI in 
our present methylation-based analysis, in our previous gene expression results (123), and in the 
gene expression results of Creighton et al (20). Expression of members of the CtBP family, 
which has been shown to promote the epithelial to mesenchymal transition and genomic 
instability in breast cancer cells (206), has been implicated in breast carcinogenesis (206, 207).  
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Several previous studies examined the relationship between BMI and methylation of 
specific candidate genes in either non-diseased or tumor breast tissue, but did not find any 
significant associations (146, 160). However, these studies were limited by small strata (146) and 
did not use a genome-wide approach (146, 160). One of the gene sites examined by Tao et al., E-
cadherin or CDH1, had a methylation site that was associated with BMI in our analysis. 
 This work was strengthened by studying epigenetic changes in benign breast tissue, 
which has more genomic stability than tumor tissue (208). Methylation patterns may change after 
cancer initiation in tumor tissue, so studying the benign tissue allows assessment of pathways 
more proximal to exposure.  However, it is important to recognize that while the cancer-adjacent 
tissue assayed for this study was sampled >4 cm from an invasive tumor to minimize the effect 
of field cancerization (187-189), it is possible that these tissues harbor some changes related to 
the disease status of the patients, limiting the generalizability of our results. However, the 
inclusion of reduction mammoplasty patients with no disease and the observation in an 
exploratory analysis that methylation patterns were not different by tissue source in this 
population mitigate this concern. This study was also strengthened by studying both methylation 
and expression in the same patients, allowing us to examine the extent to which differences in 
methylation were associated with differences in gene expression.  
 This research identified numerous BMI-associated changes in normal breast tissue. Our 
results underscore the profound epigenetic effects of adiposity on breast tissue. The findings 
suggest that epigenetic reprogramming of tissue is an important consequence of differences in 
BMI and that BMI may affect the cellular microenvironment through several different cancer-
associated pathways.  It is unknown whether these epigenetic changes are reversible with weight 
loss. Future research should evaluate methylation in these same pathways following weight loss 
56 
 
and gain.  Having specific molecular markers of obesity’s effects on breast tissue could facilitate 
intervention studies by identifying biomarkers to serve as surrogate endpoints between obesity 
and early carcinogenic changes and could elucidate biologic pathways important in the 
prevention and treatment of breast cancer.   
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Table 3.1 Selected population characteristics in 
the Normal Breast Study  
 
N % 
Total 81 100 
   
Body Mass Index (BMI) 
       Obese (BMI ≥ 30) 32 40 
     Overweight (25 ≤ BMI < 30) 27 33 
     Normal (18.5 ≤ BMI < 25) 22 27 
   Race 
       White 55 68 
     African-American 26 32 
   Age 
       Age < 50 31 38 
     Age ≥ 50 50 62 
   Menopausal Status 
       Premenopausal 27 33 
     Postmenopausal 50 62 
     Missing 4 5 
   Ever Consumed Alcohol 
       Yes 66 81 
     No 15 19 
   Tissue Source 
       Prophylactic Surgery 6 7 
     Reduction Mammoplasty 17 21 
     Mastectomy/Lumpectomy 58 72 
 
 
 
 
 
Table 3.2 Pathways Enriched in BMI-Associated Methylation Sites in the Normal Breast Studya, Ingenuity Systems Pathway Analysis 
Ingenuity Systems 
Pathway Analysis ID Countb Sizec p-valued Gene Symbol 
Natural Killer Cell 
Signaling 
18 68 <0.0001 PRKCE,PRKCB,SH3BP2,LCP2,VAV3,SYNJ2,PAK1,PTPN6,PIK3CD,VAV2,MAP2K1,PRKCZ,PRK
CQ,FCGR3B,PIK3R3,INPP5D,FCER1G,GRB2 
Chronic Myeloid Leukemia 
Signaling 
21 88 0.0002 HDAC4,CDKN1B,TGFB3,CHUK,CTBP1,CDK6,E2F5,SMAD3,CTBP2,HDAC10,HDAC1,PIK3CG, 
STAT5A,PIK3CD,TGFB1,MAP2K1,TFDP1,PIK3R2,CRK,PIK3R3,GRB2 
IL-8 Signaling 30 177 0.0004 PLD4,PRKCE,ARRB2,DIRAS3,ITGB2,NCF2,FLT1,PLCB2,PIK3CD,GNA12,PRKCZ,TRAF6, 
PIK3R2,MPO,PLD6,PRKCQ,CCND2,BRAF,PRKCB,EIF4EBP1,CHUK,CCND3,PIK3CG,GNAS,MA
P2K1,LIMK2,GNG7,GNB1,FNBP1,PIK3R3 
Production of Nitric Oxide 
and Reactive Oxygen 
Species in Macrophages 
29 172 0.0006 PRKCE,DIRAS3,NCF4,PPP1R10,TNFRSF11B,APOA1,RAP1A,NCF2,PIK3CD,NGFR,PRKCZ, 
TNFRSF1B,PIK3R2,MPO,PRKCQ,LYZ,HOXA10,PRKCB,CHUK,PPP2R5C,SERPINA1,SPI1,PIK3C
G,APOC2,PTPN6,MAP2K1,IRF8,FNBP1,PIK3R3 
Role of NFAT in 
Regulation of the Immune 
Response 
27 158 0.0012 CD79B,MEF2D,LCP2,XPO1,CSNK1D,HLA-
DMA,PLCB2,PIK3CD,GNA12,PIK3R2,PRKCQ,FCGR3B,PPP3CB,HLA-DMB,NFATC4, 
CHUK,CD247,PIK3CG,GNAS,MAP2K1,GNAT2,GNG7,GNB1,CD79A,PIK3R3,FCER1G,GRB2 
Phospholipase C Signaling 37 216 0.0014 PRKCE,PLD4,CD79B,MEF2D,LCP2,PLA2G4E,DIRAS3,ADCY7,RAP1A,PLCB2,PRKCZ,ADCY5, 
ITGB1,ARHGEF17,PLD6,PRKCQ,PPP3CB,ARHGEF10,HDAC4,PRKCB,ADCY9,NFATC4,ADCY4
,CD247,ARHGEF12,HDAC10,HDAC1,GNAS,MAP2K1,GNG7,GNB1,FNBP1,CD79A,CREB5, 
FCER1G,GRB2,ITGA4 
Fc Epsilon RI Signaling 19 105 0.0016 PRKCE,IL13,PRKCB,LCP2,VAV3,PLA2G4E,SYNJ2,PIK3CG,PIK3CD,VAV2,MAP2K1,PRKCZ, 
PIK3R2,PRKCQ,GAB1,PIK3R3,INPP5D,FCER1G,GRB2 
Endothelin-1 Signaling 28 165 0.0026 ECE1,PLD4,PRKCE,PLA2G4E,PLCD4,ADCY7,PLCL2,PLA2G2C,PLCB2,PIK3CD,GNA12,CASP2, 
PRKCZ,ADCY5,PIK3R2,PLD6,PRKCQ,GAB1,MAPK4,BRAF,PRKCB,ADCY9,ADCY4,PIK3CG,G
NAS,GNAT2,PIK3R3,GRB2 
IL-6 Signaling 17 110 0.0028 CHUK,CYP19A1,TNFRSF11B,COL1A1,SOCS1,SRF,PIK3CG,PIK3CD,NGFR,MAP2K1,IL1A, 
TRAF6,TNFRSF1B,PIK3R2,IL1RN,PIK3R3,GRB2 
Fcγ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 
18 90 0.0034 PLD4,PRKCE,ACTA2,PRKCB,LCP2,VAV3,PAK1,PXN,PIK3CG,VAV2,PRKCZ,NCK2,PIK3R2, 
CRK,PRKCQ,PLD6,PIK3R3,INPP5D 
Renal Cell Carcinoma 
Signaling 
13 68 0.0046 ETS1,PAK1,RAP1A,PIK3CG,PIK3CD,TGFB1,MAP2K1,MET,PIK3R2,CRK,GAB1,PIK3R3,GRB2 
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Table 3.2 Continued 
Ingenuity Systems 
Pathway Analysis ID Countb Sizec p-valued Gene Symbol 
Leukocyte Extravasation 
Signaling 
28 181 0.0054 CD44,PRKCE,ACTA2,CXCR4,NCF4,ACTN1,ITGB2,RAP1A,NCF2,PXN,PIK3CD,CLDN15,VAV2, 
PRKCZ,SPN,ITGB1,PIK3R2,CRK,PRKCQ,ARHGAP9,PRKCB,VAV3,CTTN,MMP17,PIK3CG, 
CLDN19,PIK3R3,ITGA4 
Aldosterone Signaling in 
Epithelial Cells 
23 147 0.0066 PRKCE,DNAJB13,CRYAB,ASIC2,PLCD4,PLCL2,DNAJC11,PLCB2,PIK3CD,DNAJB6,PRKCZ, 
PIK3R2,SGK1,DNAJC27,PRKCQ,SLC9A1,SCNN1A,ASIC1,PRKCB,PIK3CG,MAP2K1,DNAJC15, 
PIK3R3 
Integrin Signaling 30 188 0.0066 TSPAN4,ACTA2,DIRAS3,ARHGAP26,PAK1,ACTN1,ITGB2,RAP1A,PXN,PARVB,ASAP1,CAPN3,
PIK3CD,ITGB1,PIK3R2,CRK,NEDD9,ITGA2B,BRAF,CTTN,PIK3CG,MAP2K1,ITGB4,MYLK,NCK
2,FNBP1,PIK3R3,ITGB7,ITGA4,GRB2 
Paxillin Signaling 17 96 0.0114 ACTA2,PAK1,ACTN1,ITGB2,PXN,PIK3CG,PIK3CD,ITGB4,ITGB1,NCK2,PIK3R2,CRK,PIK3R3, 
ITGB7,ITGA2B,GRB2,ITGA4 
LPS/IL-1 Mediated 
Inhibition of RXR Function 
23 196 0.0130 ALDH4A1,XPO1,ALDH3B1,CYP3A5,TNFRSF11B,HS6ST1,ALDH1A3,NGFR,IL1A,ACOX2, 
TRAF6,ACSL1,TNFRSF1B,HS3ST2,MGMT,ACSL6,SULT1C2,NR1H3,APOC2,CHST3,ACOX3,IL1
RN,ABCB9 
Phospholipases 8 55 0.0140 PLD4,PLCB2,PLA2G4E,PLCD4,PLA2G2C,PLCL2,PLD6,CCR1 
Erythropoietin Signaling 13 66 0.0144 PRKCE,PRKCB,SOCS1,PIK3CG,STAT5A,PTPN6,PIK3CD,MAP2K1,PRKCZ,PIK3R2,PRKCQ, 
PIK3R3,GRB2 
Fcγ RIIB Signaling in B 
Lymphocytes 
8 40 0.0154 PIK3CG,PIK3CD,CD79B,CD79A,PIK3R2,PIK3R3,INPP5D,GRB2 
FAK Signaling 16 82 0.0164 ACTA2,TNS1,ARHGAP26,PAK1,PXN,PIK3CG,ASAP1,PIK3CD,CAPN3,MAP2K1,ITGB1,PIK3R2, 
CRK,PIK3R3,GRB2,ITGA4 
Acute Myeloid Leukemia 
Signaling 
14 73 0.0176 BRAF,EIF4EBP1,SPI1,PIK3CG,STAT5A,PIK3CD,MAP2K1,CSF1R,PIK3R2,TCF7L2,PIK3R3,CSF3R
,TCF7,GRB2 
HGF Signaling 17 96 0.0188 PRKCE,ETS1,PRKCB,PAK1,RAP1A,PXN,PIK3CG,PIK3CD,MAP2K1,ELF1,PRKCZ,MET,PIK3R2, 
PRKCQ,GAB1,PIK3R3,GRB2 
Melanocyte Development 
and Pigmentation Signaling 
16 82 0.0196 ADCY9,ADCY4,ADCY7,SH2B2,MITF,PIK3CG,GNAS,PTPN6,PIK3CD,MAP2K1,ADCY5,CREB5, 
PIK3R2,CRK,PIK3R3,GRB2 
Prolactin Signaling 14 73 0.0212 PRKCE,PRKCB,SOCS1,PIK3CG,STAT5A,PIK3CD,MAP2K1,PRKCZ,SOCS7,PIK3R2,PRKCQ, 
PIK3R3,TCF7,GRB2 
Thrombopoietin Signaling 11 55 0.0234 PIK3CG,STAT5A,PRKCE,PIK3CD,MAP2K1,PRKCB,PRKCZ,PIK3R2,PRKCQ,PIK3R3,GRB2 
Gap Junction Signaling 24 149 0.0256 PRKCE,ACTA2,PLCD4,CSNK1D,ADCY7,PLCL2,PRKG2,PLCB2,PIK3CD,BGLAP,PRKCZ,ADCY5,
PIK3R2,PRKCQ,PPP3CB,TUBB2B,PRKCB,ADCY9,ADCY4,PIK3CG,GNAS,MAP2K1,PIK3R3, 
GRB2 
HER-2 Signaling in Breast 
Cancer 
15 75 0.0296 CDKN1B,PRKCE,PRKCB,CDK6,ITGB2,PIK3CG,PIK3CD,ITGB4,PRKCZ,ITGB1,PIK3R2,PRKCQ, 
PIK3R3,ITGB7,GRB2 
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Table 3.2 Continued 
Ingenuity Systems 
Pathway Analysis ID Countb Sizec p-valued Gene Symbol 
Signaling by Rho Family 
GTPases 
33 219 0.0304 ACTA2,DIAPH3,CDC42EP4,DIRAS3,PAK1,NCF2,CDH18,PIK3CD,GNA12,PRKCZ,ITGB1,PIK3R2,
ARHGEF17,SLC9A1,CDH2,ARHGEF10,ARHGEF12,CDH8,CDH9,SEPT9,PIK3CG,GNAS,MAP2K1,
LIMK2,GNAT2,PKN1,MYLK,GNG7,GNB1,FNBP1,CYFIP1,PIK3R3,ITGA4 
Role of NFAT in Cardiac 
Hypertrophy 
29 174 0.0332 PRKCE,MEF2D,PLCD4,ADCY7,PLCL2,PLCB2,PIK3CD,TGFB1,IGF1R,PRKCZ,ADCY5,PIK3R2, 
PRKCQ,PPP3CB,HDAC4,TGFB3,PRKCB,NFATC4,ADCY9,ADCY4,HDAC10,HDAC1,PIK3CG,GN
AS,MAP2K1,GNG7,GNB1,PIK3R3,GRB2 
Angiopoietin Signaling 10 63 0.0338 PIK3CG,STAT5A,PIK3CD,DOK2,CHUK,PIK3R2,PAK1,CRK,PIK3R3,GRB2 
IL-2 Signaling 8 51 0.0382 PIK3CG,STAT5A,PIK3CD,MAP2K1,PIK3R2,SOCS1,PIK3R3,GRB2 
B Cell Receptor Signaling 22 149 0.0402 CD79B,PIK3CD,VAV2,PIK3R2,PRKCQ,GAB1,PPP3CB,ETS1,PRKCB,NFATC4,CHUK,VAV3, 
SYNJ2,CD22,PIK3CG,PTPN6,MAP2K1,CD79A,CREB5,PIK3R3,INPP5D,GRB2 
Insulin Receptor Signaling 21 122 0.0408 SCNN1A,RPTOR,ASIC1,EIF4EBP1,ASIC2,SYNJ2,PPP1R10,TRIP10,SH2B2,PIK3CG,PIK3CD, 
PTPRF,MAP2K1,PRKCZ,PIK3R2,SGK1,CRK,GAB1,PIK3R3,INPP5D,GRB2 
JAK/Stat Signaling 10 67 0.0448 SOCS1,PIK3CG,STAT5A,PTPN6,PIK3CD,MAP2K1,SOCS7,PIK3R2,PIK3R3,GRB2 
     
a
Includes pathways enriched in BMI-associated probes in the present study and overlapping with pathways identified as enriched for BMI-associated expression 
in two published studies (References 13 and 49) 
b
# of BMI-associated genes in the pathway 
c
# of total gene in the pathway 
d
Permutation p-value for BMI-associated genes 
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Chapter 4: Body Mass Index and Gene Methylation in Breast Tumor Tissue 
 
4.1 Introduction 
 Larger body size, including the body mass index (BMI) defined categories of overweight 
and obese, are associated with both the incidence and prognosis of breast cancer, though the risk 
varies by menopausal status and tumor subtype. In premenopausal women, an inverse association 
has generally been found between BMI and breast cancer incidence (69, 116) while increased 
BMI has been shown to increase the risk among postmenopausal women (114), with an 
estimated 3% increase in risk with each one unit gain in BMI (68). There is also evidence that 
obesity may increase incidence of estrogen receptor (ER)-positive but not ER-negative tumors, 
though these relationships differ by age and menopausal status (24, 38).  
  Beyond associations between BMI and breast cancer incidence, obesity is also associated 
with worse prognosis and outcome in both pre- and postmenopausal women (68). Obese breast 
cancer patients are more likely to be diagnosed with advanced stage at diagnosis (114), larger 
tumor size (69), nodal involvement (69), higher grade (68), and higher mitotic cell count (68). 
They are also at higher risk of experiencing recurrence (118), metastasis (69), and mortality 
(118).  
The biological mechanisms underlying obesity’s effects on carcinogenesis are poorly 
understood. Gene methylation, a mechanism for controlling the expression of genes (127), has 
the potential to influence the carcinogenic process during both tumor formation and progression. 
In normal tissues, methylation plays a role in whether cells are growing or senescent and how 
64 
 
cells differentiate; if these patterns become abnormal, cancer may result (136). Abnormal 
methylation can also influence tumor invasiveness and metastasis (128).  
Though obesity has been associated with increased methylation in several cancer-related 
genes (133, 209), previous research has been limited by the use of white blood cells instead of 
breast tissue (133, 209) or by focusing on only candidate genes (160). We sought to test whether 
obesity is associated with methylation in a panel of cancer-related genes in the tumor tissue of 
women diagnosed with breast cancer. Identifying genes that are differentially methylated by 
BMI can provide evidence for the underlying biological processes through which obesity 
influences breast carcinogenesis and may facilitate the development of chemoprevention and 
treatment targets.  
4.2 Methods 
4.2.1 Study Participants 
Data from Phase I of the Carolina Breast Cancer Study (CBCS) was used to assess gene 
methylation in tumor tissue collected from women with breast cancer. The CBCS study design 
data collection methods have been previously described (210). Briefly, women diagnosed with 
breast cancer were recruited with randomized sampling between 1993 and 1996 from the North 
Carolina Central Cancer Registry. African-American women and women younger than 50 years 
of age were oversampled to comprise approximately 50% of the study population. Participation 
in the study was limited to English-speaking women aged 20 to 74 years. CBCS pathologists 
verified the cancer diagnosis of all participants. Only participants with sufficient tumor block 
material for methylation analyses were included in the current study. Participants were 
interviewed in-person by trained nurses to collect demographic and breast cancer risk factor data. 
The University of North Carolina at Chapel Hill Institutional Review Board approved this study.   
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4.2.2 Gene Methylation Assessment 
The Illumina Cancer Panel I platform (Illumina Inc., San Diego, CA), which consists of 
1,505 gene sites with known relevance to cancer (182), measures DNA methylation at cytosine-
guanine dinucleotide (CpG) sites. The methylation level of each CpG site on the panel was 
measured as a beta value, which was calculated by comparing the fluorescent signal ratio of the 
methylated allele to the sum of the signals from the methylated and unmethylated alleles. The 
beta values range from 0 to 1, representing the fraction of methylated DNA, with 0 indicating no 
methylation and 1 indicating complete methylation. Of the 1,505 CpG sites on the platform, 570 
were removed from the analysis due to poor performance or because the sites overlapped regions 
with SNPs or copy number variation, which may render them unreliable (211). The remaining 
935 CpG sites (212) were assessed for association with BMI.  
4.2.3 Statistical Analyses 
Linear regression, using limma with an empirical Bayes approach (184), was conducted 
to assess which CpG sites were associated with pre-diagnosis body mass index (BMI). The R 
statistical package (www.r-project.org/) was used to conduct all regression analyses. Pre-
diagnosis BMI was self-reported at the time of interview and was categorized as normal weight 
(18.5 ≤ BMI < 25), overweight (25 ≤ BMI < 30) or obese (BMI ≥ 30). Use of a categorical rather 
than continuous coding for BMI was chosen to minimize potential bias due to underestimation of 
weight (162). Comparisons were 2-category contrasts (obese versus normal weight, with 
overweight women excluded) for regression modeling based on previous studies that showed that 
the overweight class was highly heterogeneous with regard to obesity-dependent gene expression 
(123). To enhance our power to detect obesity-associated methylation, the intermediate 
overweight phenotype group was excluded. 
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Statistical analyses were restricted to those of African-American or white race. Race and 
age (treated as a continuous variable) were considered confounders a priori and were included as 
covariates in all analyses. Other variables assessed for confounding included menopausal status, 
age at first full-term birth, parity, alcohol use, smoking status, physical activity, fruit and 
vegetable intake, income, and education status. Among these variables, only menopausal status 
was associated with both BMI (p-value <0.05) and gene methylation (false discovery rate (FDR) 
q-value <0.05), resulting in a final adjustment set that included age, race, and menopausal status. 
Clinical stage was not included as a confounder in these analyses because it is likely on the 
causal pathway between BMI and methylation status. In addition to testing the association 
between BMI and gene methylation in breast tumor tissue overall, the relationship was also 
assessed among ER-positive tumors because prior research has shown that this subgroup of 
tumors may be more stable genomically than other tumor subtypes (213, 214). In comparison to 
ER-positive tumors, the etiologically relevant methylation changes occurring in ER-negative 
tumors may be harder to detect due to genomic instability. In a sensitivity analysis restricted to 
ER-negative tumors, there were no CpG sites associated with obesity in a regression model 
adjusting for age, race, and menopausal status. 
 An FDR q-value of <0.05 was used as the statistical significance cut-off for identifying 
differentially methylated genes. QIAGEN’s Ingenuity Systems Pathway Analysis (IPA, 
QIAGEN Redwood City, www.qiagen.com/ingenuity) was used to perform pathway analysis for 
differentially methylated genes.  While limited by the calculation of p-values using a gene-
sampling rather than subject-sampling framework (185), this method allows interactive pathway 
analysis of complex methylation data. 
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 Though we did not have data on gene expression for the tissue analyzed in this study, we 
assessed the correlation between methylation and expression in breast tumors collected through 
The Cancer Genome Atlas (http://cancergenome.nih.gov/) for the methylation sites that were 
significantly associated with BMI in our study or that were close by. 
4.3 Results 
4.3.1 Methylation Sites Associated with Obesity 
 Of the 517 patients eligible for study participation, 492 had both pre-diagnosis BMI data 
and methylation data; of these, 345 were either obese or of normal weight (Table 4.1). The 
median age for the 492 study participants was 47 years. In unadjusted analyses, 30 CpG sites 
were differentially methylated by BMI status (obese vs. normal) at a q-value < 0.05; after 
adjustment for age, race, and menopausal status, two CpG sites remained significantly 
differentially methylated: SH3BP2_P771_R on the promoter region of the SH3BP2 gene, which 
regulates transcriptional activity in immune cells, and Xist_seq_80_S95_R on the non-protein 
coding XIST gene. For both sites, the average methylation beta values were higher in the tissue of 
obese patients, when compared to those of normal weight. 
4.3.2 Methylation in Estrogen-Receptor Positive Tumors  
In analyses restricted to ER-positive tumors (n=208), 21 probes were significantly associated 
with BMI (obese vs. normal) after adjustment for age, race, and menopausal status (Table 4.2). 
Twelve of the 21 significant sites were located in CpG islands. Three CpG sites mapped to 
chromosome 4 (SH3BP2_P771_R, SH3BP2_E18_F, and PKD2_P336_R), three mapped to the 
X chromosome (Xist_seq_80_S95_R, MCF2_P1024_R, and BTK_P105_F), and two each 
mapped to chromosome 10 (ERCC6_P698_R, BMPR1A_E88_F), chromosome 11 
(TSG101_P257_R, SPI1_E205_F), and chromosome 12 (IGFBP6_E47_F, ARHGDIB_P148_R). 
Figure 4.1 displays a volcano plot, a visual representation of the regression analysis wherein each 
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circle represents a methylation site; circles with positive coefficients signify higher average beta 
values in the obese compared to those of normal weight, while circles with negative coefficients 
signify lower beta values in the obese. The majority of the sites were hypermethylated in the 
obese group, as were all of the probes that were significantly associated with obesity (circles 
above the horizontal line).  
The methylation sites that showed the most significant changes in the beta values 
between obese vs. normal BMI patients were on the DNMT3B gene, which codes for a DNA 
methyltransferase; the IGFBP6 gene, which codes for an insulin-like growth factor binding 
protein; the ERCC6 gene, which codes for a protein that functions in excision repair; and the 
SH3BP2 gene. In the IPA analysis testing for whether any biological pathways were enriched 
among the 21 differentially methylated CpG sites, no pathways were significant after correcting 
for multiple comparisons at the p-value < 0.05 level. 
4.3.3 Correlation with Gene Expression 
The 21 methylation sites that were associated with BMI in the overall or ER-positive 
analyses were mapped to breast tumors collected by The Cancer Genome Atlas (TCGA) to 
assess the correlation between gene methylation and expression. Of the 21 sites, 19 matched to 
probes that were at least within 200 base pairs of the probe used in the TCGA data, and three 
sites matched to more than one probe (Table A7). Approximately 63% of the 19 BMI-associated 
methylation sites were significantly and inversely associated with gene expression (correlation 
coefficient ≤ -0.20). 
4.4 Discussion 
Because methylation is a mechanism for controlling gene expression (127), exploring the 
relationship between obesity and methylation can provide insight on BMI-associated expression 
of cancer-related genes. Our regression analyses suggest that BMI is associated with gene 
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methylation in cancer-related genes overall and especially among ER-positive breast tumors. 
When assessing the correlation between methylation and expression for our BMI-associated 
methylation sites (from both our overall and ER-positive analyses) in breast tumors collected 
through The Cancer Genome Atlas, about 63% showed a significant inverse correlation between 
methylation and expression.  
Previous research in breast tissue has demonstrated that BMI is associated with the 
differential expression of genes involved in pathways related to immune response and insulin-
like growth factor availability (92, 123). In our study, BMI was associated with methylation of 
genes involved not only in immune response and insulin-like growth factor pathways, but also in 
DNA methylation and DNA repair. This suggests that gene methylation may be an intermediate 
step between obesity and gene expression in carcinogenic processes. Notably, SH3BP2 was the 
most significant BMI-associated site in our overall analysis, while SH3BP2, IGFBP6, DNMT3, 
and ERCC6 were the most statistically significant BMI-associated sites among ER-positive 
tumors. All four of these genes were hypermethylated with obesity. The SH3BP2 gene codes for 
a protein that acts in the signal transduction of various immune response pathways (215). It has 
been implicated in responses involving neutrophils (216), B cells (217-219), and T cells (215), 
and it may function as a tumor suppressor gene (215). Our finding that SH3BP2 is 
hypermethylated in the tumor tissue of obese breast cancer patients suggests that obesity may 
confer an abnormal immune response in breast tissue. This is interesting in light of previous 
research also showing increased infiltration of macrophages in the breast tissue of obese women 
(123, 220). The IGFBP6 gene codes for a protein that binds with high affinity to insulin-like 
growth factor-2 (IGF-II) (221), which plays a role in cellular proliferation, differentiation, and 
migration, and is regulated by the IGFBP6 protein (221). Expression of IGFBP6 may be 
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associated with cancer incidence (221), with studies finding lower expression of the protein in 
the serum of breast cancer patients when compared to the serum of those with benign breast 
disease (222, 223). Our finding of hypermethylation of IGFBP6 in obese patients suggests that 
obesity may lead to reduced expression in breast tissue via gene methylation. BMI may also 
impact broader mechanisms controlling methylation. For example, DNMT3 is a member of a 
family of DNA methyltransferases that code for enzymes involved in the methylation of 
promoter regions of genes (224), and DNMT3 mRNA has been shown to be overexpressed in 
breast tumor tissue (224, 225) and cell lines (226). Finally, the ERCC6 protein, also known as 
the Cockayne syndrome complementation group B (CSB) protein, is involved in transcription-
coupled nucleotide excision DNA repair (227). 
Our study was strengthened by examining the association between BMI and methylation 
in breast tumor tissue rather than white blood cells (WBCs), as in most previous studies. 
Nonetheless, prior research has shown that differences in methylation between those with and 
without cancer may be driven by changes in the distribution of WBC populations (228). Obesity 
may also be associated with changes in the distribution of WBC populations, resulting in 
methylation differences by BMI status. In one study of WBCs, methylation was increased in 
those with higher BMI for three of four differentially methylated CpG sites (MMP9, PM20D1, 
and PRKG1) (133). Of those sites, only MMP9 was included in the methylation panel used in 
this study, and it was not associated with obesity either overall or among ER-positive tumors. In 
another study of methylation in WBCs, BMI was associated with increased methylation of 
several sites on HIF3A, a gene that encodes for a protein involved in responses to hypoxia (209). 
However, in the latter study, the magnitude of change was not replicated when the HIF3A loci 
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were examined in adipose tissue, underscoring the importance of tissue specific methylation. 
There were no CpG sites on the HIF3A gene in the methylation panel used for this study.  
Given previous reports of differentially methylated genes associated with BMI in both 
genome wide and candidate loci studies (133, 209), it is interesting that studies examining global 
methylation in WBCs are inconclusive regarding the direction of methylation in response to 
increasing BMI. In a study of global methylation in 85 women, overweight and obese patients 
had non-statistically significant higher levels of methylation than those with a normal BMI after 
adjustment for variables including childhood smoking exposure, nulliparity, and age at 1
st
 birth 
(154). When methylation of the repetitive element, LINE-1, was measured in the peripheral 
blood of men and women, those with a normal BMI had the lowest mean methylation percentage 
and those who were obese had the highest methylation percentages, though the results were not 
statistically significant in crude analyses (155). Other studies reviewed in Terry et al (156) did 
not find significant correlations between methylation values in the LINE-1 and ALU repetitive 
elements and BMI (157, 158), and one study examining BMI in women of childbearing age 
reported less LINE-1 methylation in those with higher BMI (159).  
These aforementioned studies suggest that obesity may be weakly associated with an 
increase in methylation in WBCs, but do not address whether BMI may affect methylation in 
breast tissue. Given our emphasis on the tumor tissue, the most relevant previous research for our 
purposes are studies of breast tumor methylation and BMI (160, 229). In one study, Tao et al. 
examined the association between obesity and methylation in three candidate genes, E-cadherin, 
p16, and RAR-β(2), in breast tumor tissue, and showed no statistically significant differences in 
percentage methylation by BMI status in their study population; regression analyses stratified by 
ER status were not reported (160). The three genes examined by Tao et al. (160) were 
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represented on our methylation panel, and none of them met the criteria for differential 
methylation in this research. However, we were unable to ascertain the exact CpG loci on which 
methylation values were measured. Given that DNA methylation levels can vary greatly within 
short base pair distances (230), it may not be appropriate to compare our gene methylation 
results with those of Tao et al. In another study, Naudshad et al. examined the association 
between BMI and methylation in Ec-SOD, RASSF1, BRCA1, and BNIP3; all of the gene loci 
except for BNIP3 were significantly, increasingly methylated with higher BMI while BNIP3 was 
significantly, inversely associated with BMI (229). All but the BNIP3 gene examined by 
Naushad et al. (229) were represented on our methylation panel, and none of them were 
associated with BMI in this research. However, there were no exact loci matches between the 
probes available on our methylation panel and the Ec-SOD and BRCA1 sites examined by 
Naushad et al. and we were unable to determine the location of the RASSF1 probe. As stated 
above, because gene methylation is loci-specific (230), it may not be appropriate to compare 
their reported methylation results to our findings. 
Our study is novel in that it assesses the relationship between BMI and methylation in 
breast tumor tissue using a panel of cancer-associated genes. This enabled us to discern 
relationships between obesity and methylation that might not be apparent in WBCs or that might 
be overlooked by focusing on a small number of candidate genes. Our analysis was also 
strengthened by analyzing ER-positive tumors, which have been shown to feature fewer 
chromosomal aberrations than other tumor subtypes (213, 214). However, there were some 
limitations associated with our analysis. Although tissue from ER-positive tumors may be more 
stable than that from other tumor subtypes, in the analysis of any tumor tissue, it is difficult to 
determine which methylation changes influence the carcinogenic process and which occur as a 
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result of it (208). Furthermore, there may be heterogeneity within ER-positive tumors (i.e. some 
tumors are luminal A and others luminal B) that may have influenced the reported associations 
between methylation and obesity. For example, among the obese patients, 77% of the ER-
positive tumors were luminal A, while for the normal weight patients, 70% of the ER-positive 
tumors were luminal A. It is possible that the reported associations between BMI and 
methylation in this study were influenced by differences in the proportion of luminal A versus 
luminal B tumors by BMI status. However, there is not strong epidemiological evidence that 
obesity is associated with luminal A versus luminal B status (231). Finally, we were unable to 
validate our results in an independent dataset because we were not able to identify public data 
sources where both methylation and BMI were measured and reported. Our study, however, 
contributes data on both BMI and methylation status to the public domain, and future studies will 
be able to validate findings using these data. 
In summary, our study provides evidence that obesity may be associated with increased 
gene methylation in breast tumor tissue and may play a role in the expression of genes associated 
with immune response, insulin-like growth factor availability, and other pathways involved in 
carcinogenesis. If obesity does act through methylation to control expression of carcinogenesis-
related genes, differentially methylated sites could serve as targets for the chemoprevention and 
treatment of breast cancer in women with obesity as a risk factor.  
 
 
  
Table 4.1: Selected population characteristics of eligible breast cancer cases in the Carolina Breast Cancer 
Study, Phase 1 
 
Total
a 
 
Normal
b
 
 
Overweight
b
 
 
Obese
b
 
 
N % 
 
N % 
 
N % 
 
N % 
Total 492 100% 
 
195 100% 
 
147 100% 
 
150 100% 
          
  
Race         
   African-American 200 40.7% 
 
37 19.0% 
 
61 41.5% 
 
102 68.0% 
   White 282 57.3% 
 
152 77.9% 
 
83 56.5% 
 
47 31.3% 
   Other 10 2.0% 
 
6 3.1% 
 
3 2.0% 
 
1 0.7% 
           
Menopausal Status 
         
  
   Premenopausal 262 53.3% 
 
108 55.4% 
 
78 53.1% 
 
76 50.7% 
   Postmenopausal 230 46.7% 
 
87 44.6% 
 
69 46.9% 
 
74 49.3% 
          
  
Alcohol Use 
         
  
   Never 141 28.7% 
 
41 21.0% 
 
45 30.6% 
 
55 36.7% 
   Ever 351 71.3% 
 
154 79.0% 
 
102 69.4% 
 
95 63.3% 
 
         
  
Smoking Status 
         
  
   Never 251 51.0% 
 
93 47.7% 
 
79 53.7% 
 
79 52.7% 
   Former 146 29.7% 
 
57 29.2% 
 
42 28.6% 
 
47 31.3% 
   Current 95 19.3% 
 
45 23.1% 
 
26 17.7% 
 
24 16.0% 
          
  
Income, $ 
         
  
   <15,000 119 24.2% 
 
31 17.2% 
 
30 22.6% 
 
58 40.3% 
   15,000 – 30,000 99 20.1% 
 
38 21.1% 
 
27 20.3% 
 
34 23.6% 
   30,000 – 50,000 113 23.0% 
 
50 27.8% 
 
33 24.8% 
 
30 20.8% 
   ≥50,000 126 25.6% 
 
61 33.9% 
 
43 32.3% 
 
22 15.3% 
            Education
c
 
              <High School 90 18.3% 
 
18 9.2% 
 
26 17.7% 
 
46 30.7% 
   High School 269 54.7% 
 
107 54.9% 
 
87 59.2% 
 
75 50.0% 
   College 133 27.0% 
 
70 35.9% 
 
34 23.1% 
 
29 19.3% 
a
Columns may not sum to total due to missing data
 
bNormal weight: 18.5 ≤ BMI < 25; overweight: 25 ≤ BMI < 30; obese: BMI ≥ 30 
c
High School: high school completion (or equivalent), technical or business school, and some college; College: college 
completion and post-graduate school or professional degree 
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Table 4.2 Methylation sites associated with BMI (FDR <.05) in the Carolina Breast Cancer Study among patients with estrogen receptor-positive tumors 
Probe ID Gene Gene Description CHRa Islandb Coefficient p-value q-value Normalc Overweightc,d Obesec 
DNMT3B_P352_R DNMT3B DNA cytosine-5 methyltransferase 3 beta  
   isoform 2 
20q11 N 0.0230 0.00017 0.03818 15.5% 17.3% 17.6% 
IGFBP6_E47_F IGFBP6 Insulin-like growth factor binding protein  6 12q13 N 0.0447 0.00032 0.03818 37.5% 40.5% 43.3% 
ERCC6_P698_R ERCC6 Excision repair cross-complementing  rodent 
repair deficiency,  complementation group 6 
10q11 Y 0.0480 0.00037 0.03818 43.1% 46.8% 47.3% 
SH3BP2_P771_Re SH3BP2 SH3-domain binding protein 2 4p16 Y 0.0324 0.00048 0.03818 17.4% 20.8% 22.7% 
PLAGL1_E68_R PLAGL1 Pleiomorphic adenoma gene-like 1  isoform 1 6q24-25 Y 0.0422 0.00049 0.03818 69.8% 72.5% 75.4% 
FZD9_E458_F FZD9 Frizzled 9 7q11 Y 0.0535 0.00096 0.04640 49.2% 50.0% 55.4% 
BMPR1A_E88_F BMPR1A Bone morphogenetic protein receptor,  type IA 
precursor 
10q22 Y 0.0320 0.00101 0.04640 65.0% 66.7% 69.2% 
TSG101_P257_R TSG101 Tumor susceptibility gene 101 11p15 Y 0.0400 0.00132 0.04640 25.4% 29.0% 29.8% 
RIPK4_E166_F RIPK4 receptor-interacting serine-threonine kinase 4  21q22 Y 0.0171 0.00133 0.04640 7.2% 9.6% 10.1% 
Xist_seq_80_S95_Re XIST X inactive specific transcript (non-protein 
coding) 
Xq13 N 0.0299 0.00143 0.04640 74.3% 76.3% 78.9% 
TDGF1_P428_R TDGF1 Teratocarcinoma-derived growth factor 1 3p21 N 0.0412 0.00147 0.04640 40.7% 41.8% 44.6% 
MCF2_P1024_R MCF2 MCF.2 cell line derived transforming    
sequence 
Xq27 N 0.0393 0.00151 0.04640 77.6% 80.6% 82.3% 
SPI1_E205_F SPI1 Spleen focus forming virus (SFFV)  proviral 
integration oncogene spi1 
11p11 Y 0.0372 0.00154 0.04640 54.1% 57.8% 58.8% 
SH3BP2_E18_F SH3BP2 SH3-domain binding protein 2 4p16 N 0.0284 0.00208 0.04934 25.3% 28.6% 29.9% 
ABO_E110_F ABO ABO blood group (transferase A, alpha 1- 
 3-N-acetylgalactosaminyltransferase;  
 transferase B, alpha 1-3-galactosyltransferase) 
9q34 Y 0.0373 0.00225 0.04934 15.8% 18.0% 20.6% 
CHI3L2_P226_F CHI3L2 Chitinase 3-like 2 isoform c 1p13 N 0.0352 0.00227 0.04934 74.8% 75.2% 74.6% 
BTK_P105_F BTK Bruton agammaglobulinemia tyrosine  kinase Xq21-22 N 0.0363 0.00240 0.04934 39.6% 42.4% 44.8% 
SNURF_P78_F SNURF SNRPN upstream reading frame protein 15q11-12 Y 0.0381 0.00254 0.04934 69.5% 71.0% 74.3% 
ARHGDIB_P148_R ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 12p12 N 0.0340 0.00255 0.04934 44.5% 45.5% 47.0% 
SEZ6L_P299_F SEZ6L Seizure related 6 homolog (mouse)-like    
precursor 
22q12 Y 0.0482 0.00255 0.04934 17.5% 18.0% 21.3% 
PKD2_P336_R PKD2 Polycystin 2 4q22 Y 0.0260 0.00265 0.04934 13.1% 14.6% 16.5% 
aCHR = Chromsome.  bIsland indicates whether the probe is located in a CpG Island; N = no; Y = yes.  cUnadjusted % Methylation; Normal weight: 18.5 ≤ BMI < 25; overweight: 25 
≤ BMI < 30; obese BMI ≥ 30).  dOverweight individuals were not included in the regression analysis, but are included here for descriptive purposes. eAssociated with BMI in overall 
breast tumor tissue regression analysis 
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Chapter 5: Discussion 
 
5.1 Summary 
 The goal of this dissertation was to explore how BMI might influence methylation of 
breast tissue. Specifically, it sought to determine what pathways were enriched among the 
identified BMI-associated methylation sites and whether incorporation of gene expression data 
could identify the methylation sites with the greatest biological relevance to the obesity-breast 
cancer association. Tissue was sampled from two study populations to assess these relationships: 
patients in the Normal Breast Study (NBS) contributed non-diseased tissue, while patients in the 
Carolina Breast Cancer Study (CBCS) contributed tumor tissue.  
In the non-diseased tissue, methylation values were calculated using a genome-wide 
panel of 431,568 methylation sites. Of those, 2,573 sites were associated with continuous BMI, 
57% of which showed an inverse association with BMI. As hypothesized based on previous 
studies (92, 123), pathways involved in inflammation and insulin receptor signaling were 
enriched among the BMI-associated probes. Of the 1,251 BMI-associated probes that had linked 
gene expression data, 18% were correlated with gene expression (correlation coefficient ≤ -0.3 or 
≥ 0.3). Subsetting the BMI-associated methylation sites to those that were correlated with gene 
expression yielded a similar  predictive accuracy to that of the 2,573 BMI-associated methylation 
sites. This has implications for future research, as it suggests that biomarkers of the influence of 
BMI on breast tissue can potentially be obtained from methylation data alone or from the 
combination of gene expression and methylation data.  
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In the tumor data, 935 methylation sites were analyzed. The association between obesity 
(BMI ≥ 30 kg/m2) and methylation was more pronounced in estrogen receptor-positive (ER-
positive) tumors than in the full dataset. In contrast to findings in the non-diseased tissue where 
BMI was associated with both increased and decreased methylation, in the tumor tissue, 
methylation values increased with obesity in the significant BMI-associated probes (false 
discovery rate q-value < 0.05). Though there were no pathways significantly enriched among the 
BMI-associated probes identified in the tumor data, obesity was associated with the methylation 
of genes that function in immune response and insulin-like growth factor availability. 
 While methylation is often studied to gain insights on cancer etiology, these results 
showing distinct patterns for tumor versus normal tissue suggest that methylation may be a 
dynamic process, with changes potentially occurring during disease progression. The findings 
that methylation was primarily associated with BMI in ER-positive tumors is also interesting in 
light of the epidemiologic evidence that associations between BMI and risk are most consistent 
for hormone receptor positive disease (38). The finding of altered methylation in inflammatory 
genes and pathways in both non-diseased and tumor tissue is consistent with expectation based 
on previous gene expression studies and shows that the effects of BMI on inflammation may be 
regulated by semi-stable methylation at the cellular level, rather than simply representing a 
transient tissue-level state. This latter point is important because it remains unknown whether 
weight loss can reduce breast cancer risk.  
The results were aligned with study hypotheses that methylation would be associated with 
BMI, that pathways enriched for inflammatory and insulin resistance pathways would be 
enriched among BMI-associated methylation sites, and that there would be some correlation 
between gene methylation and expression among the BMI-associated methylation sites. 
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However, there were no biologic pathways enriched among the tumor methylation profiles, 
precluding a comparison between non-diseased and tumor tissue. The next sections discuss the 
limitations influencing the interpretation of the findings. 
5.2 Generalizability and Selection Bias 
While DNA from blood is widely available for research studies, tissue specimens are 
typically scarce, both in their availability and in the quantity of DNA that can be obtained. 
Therefore, the focus on breast tissue for this study necessitated work with specific populations of 
tissue donors. It is important to consider how the selection of these study populations may have 
influenced the findings. The NBS participants were drawn from women undergoing different 
types of surgery. As a result, their probability of participating in the study depended upon disease 
status. Likewise, for the CBCS, only cases were included, and cases were more likely to be 
assayed for methylation if their tumors were larger, which would allow for sufficient DNA to be 
obtained for the arrays. Thus, both studies are subject to possible selection bias and/or 
generalizability limitations.   
Participants for the NBS were recruited from women undergoing surgery for reduction 
mammoplasty, prophylactic surgery, or breast tumor removal. Women undergoing reduction 
mammoplasty are at higher risk of breast cancer than the general population (146), and women 
undergoing prophylactic surgery are at much higher risk. Further, there is evidence that 
histologic abnormalities and signs of proliferative disease may be more common in tissue 
derived from women undergoing reduction mammoplasty or with benign breast disease, relative 
to women volunteering for biopsy without other indications for surgery (232). Therefore, some 
characteristics of the tissue sampled for this study may differ from the characteristics of breast 
tissue of women in the general population. However, the reported differences in frequency of 
abnormalities may have been influenced by tissue sampling methods (when extracting breast 
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tissue from reduction mammoplasty patients, surgeons may target areas with abnormalities) 
instead of, or in addition to, differences in the underlying patient populations’ tissue 
characteristics (232). Tissue specimens displaying morphological abnormalities were excluded 
from the NBS. However, it is not clear whether using tissue from the NBS participants, with the 
potential for higher frequency of abnormalities compared to tissue from women not indicated for 
surgery, would affect the BMI-associated methylation changes identified in this work. 
Suggestions for addressing breast tissue sampling for future research will be discussed in section 
5.5. 
In addition to concerns about generalizability, selection bias may also have affected the 
BMI-associated probes identified in this study. Because the NBS is not a population-based study 
and has selection criteria that are associated with BMI, spurious associations may have been 
induced by selection of study participants, as can be illustrated with a directed acyclic graph 
(DAG; see Appendix A for further discussion of selection bias by study design). However, in 
exploratory analyses, there were no significant associations between gene methylation and tissue 
source (false discovery rate q-value <0.05), at least partially mitigating concerns that the 
selection of study participants was correlated with gene methylation. In another exploratory 
analysis, tissue source was included as a confounder in a regression model with methylation as 
the outcome, BMI as the main exposure variable, and age, race and alcohol use as covariates. 
Though there were considerably fewer significant probes associated with BMI (174 versus 
2,573), all but two of the probes in this exploratory analysis were also identified as associated 
with BMI in the primary regression analysis. 
In the CBCS, African-American women and younger women were oversampled, 
resulting in an unweighted case population that is different from a general breast cancer cohort.  
81 
 
However, age and race were controlled for in the analyses, providing appropriate adjustment for 
the sampling design and increasing the generalizability. The response rate for the CBCS was 
77%, and, based on an abbreviated interview with women who refused to participate, there were 
no significant differences between participants and non-participants with regard to breast cancer 
risk factors (210). Of the 861 patients who enrolled in the CBCS Phase I, 684 had sufficient 
tissue available for the methylation assay, and methylation values were successfully calculated 
on 517. When comparing the risk factor distribution for the 517 individuals with methylation 
values to the 165 who were not successfully assayed, only age was significantly different: those 
with methylation values were more likely to be less than 50 years of age (unpublished data from 
Kathy Conway Dorsey). Because larger tumors were more likely to be included in the study 
since they have more methylation data available, selection bias could have resulted if the 
relationship between BMI and gene methylation differs by tumor size. However, the use of both 
normal and tumor tissue in this research should also help to circumvent the limitations of each 
individual study. Also, finding genes involved in inflammatory pathways in both studies further 
reduces concern about spurious associations resulting from selection bias. 
5.3 Information Bias 
 There are several ways in which information bias could have influenced the results of this 
dissertation, including use of BMI as a surrogate for obesity, the timeframe for which BMI was 
collected, and, in the CBCS, the reliance on distant self-report of BMI.  
In both the NBS and CBCS, BMI was used as a surrogate for obesity. Assuming non-
differential misclassification, more precise measurement of adiposity could strengthen the 
magnitude of some of the BMI-associated coefficients reported in this work. However, as 
discussed in section 1.2.2, BMI is highly correlated with body fat in women (111) and with risk 
of postmenopausal breast cancer (68).  
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Information bias could also have resulted from the timeframe during which BMI was 
collected in the study populations. BMI was collected at time of surgery in the NBS and within a 
year before diagnosis in the CBCS. However, it is unclear that these timeframes overlap with the 
etiologic window for the carcinogenic effect of adiposity on gene methylation in breast tissue. 
BMI earlier in the lifecycle might influence methylation in breast tissue. However, because 
postmenopausal breast cancer is influenced by postmenopausal BMI, it is plausible that BMI 
assessed at the time of surgery (NBS) or within a year of diagnosis (CBCS), is within the 
etiologic window. Further, since previous weight is generally correlated with current weight, 
with the majority of people remaining within 15 pounds of prior weight within 10 year intervals 
(233), the BMI timeframes assessed in this dissertation may serve as a useful proxy for earlier 
BMI. 
Finally, self-reported pre-diagnosis BMI was used as the main exposure variable in the 
CBCS analyses. At the time of interview, participants were asked to recall their weight one year 
prior to interview. Information bias may have resulted from the use of self-reported BMI and 
from the distant recall. Studies have found that when compared to direct measurement, women 
tend to underreport weight, with larger discrepancies among those with higher BMI, but to 
slightly overestimate height (162). If women with higher BMI tended to underreport their weight 
more than women with lower BMI, this may have biased the reported associations between BMI 
and gene methylation. There may also be some misclassification of BMI due to participant recall 
of prior weight. However, several studies have shown high correlation between recall of previous 
weight with the corresponding recorded weight (234-236).  
5.4 Study Limitations 
 Though there were considerable strengths in the design of this dissertation, including the 
sampling of breast tissue instead of blood, the pairing of methylation data with gene expression 
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data, and the use of non-diseased tissue to explore how obesity might induce a carcinogenic 
microenvironment, there were several limitations that warrant discussion. 
 One of the aims of the dissertation was to compare BMI-associated methylation changes 
between non-diseased and tumor tissue. However, the use of different platforms in the NBS and 
CBCS data was a significant barrier to comparing BMI-associated probes between the two study 
populations as there was limited overlap in probes between the GoldenGate Cancer I panel used 
for the CBCS and the HumanMethylation450 panel used for the NBS (there were 249 probes in 
common between the two methylation panels used for this dissertation). The overlap in biologic 
pathways enriched among the BMI-associated probes could also not be explored with statistical 
methods because there were no significant pathways enriched in the CBCS data after adjusting 
for multiple comparisons. 
 Comparing the results from the two datasets was also complicated by likely 
compositional differences between the tumor tissue and the non-diseased tissue collected for this 
work. Tumor tissue is largely derived from epithelial cells (237), while the non-diseased tissue 
used in this study was a mixture of adipose, epithelial, and stromal cells. Generally, epithelial 
cells were the lowest percentage of the three cell types in the non-diseased tissue. This difference 
in composition type may help explain the difference in directionality found for the BMI-
associated probes by tissue type, where BMI was associated with increasing methylation values 
in the tumor tissue, but with mostly decreasing methylation values in the non-diseased tissue. 
 This research was also limited by the focus on gene methylation. In the NBS population, 
only 18% of the BMI-associated methylation sites were correlated with expression. Even after 
restricting to CpG loci located on CpG islands, which tend to be in promoter regions, only 12% 
of the BMI-associated methylation sites (17/138) were correlated with gene expression. This is in 
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contrast to 18% of CpG loci on shores showing a correlation with gene expression. This finding 
of a correlation between shores and gene expression is consistent with other work (200). The 
lower correlation between methylation and expression in islands relative to shores may be 
because methylation acts to repress gene expression through promotion of histone modification 
more than through interference with transcription binding on promoter regions (238). Alternative 
mechanisms of gene expression, including histone phosphorylation (239), histone acetylation 
(240), and microRNA-based regulation (241), were not considered in this study. Further, it was 
assumed that methylation of a gene site would influence expression of that same gene. The 
possibilities that methylation could influence alternative splicing or expression of groups of 
genes were not explored. 
 A further limitation of the study design was the lack of power to adequately assess the 
association between BMI and gene methylation within strata of breast cancer risk factors or 
tumor characteristics. Given the variability in the obesity-breast cancer association by 
menopausal status (69, 116) and tumor subtype (69, 119-121), it is possible that different or 
additional biologic pathways would be enriched within strata when compared to the non-
stratified results.     
 Finally, in this study, disease had already developed in the majority of the participants.  
In any biomarker study of breast cancer cases, it is always possible that reverse causation could 
bias the results. That is, the disease itself could induce changes in methylation that depend upon 
BMI and therefore induce a spurious association between BMI and methylation. Previous 
research has shown that while field effects (methylation changes that are shared in tumor and 
adjacent normal tissue) occurred in distant tissues, they were much reduced at distances greater 
than 4 cm from a tumor, when compared to distance nearer a tumor (187-189). Sampling of 
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tissue distant (>4 cm) from the site of tumor in the NBS, therefore, reduces the biological 
plausibility of this alternative explanation for study findings.  
5.5 Future Directions 
 In this research, BMI was associated with methylation of genes and biologic pathways 
known to increase the risk of cancer, including pathways relevant to inflammation and insulin 
resistance. Because of the novelty of this study, the most important next step is validation of 
these findings in independent datasets. Beyond validation, the results of this dissertation have 
several implications for future research directions.  
This work suggests that there is some correlation between BMI-associated probes and 
gene expression in both non-diseased and tumor tissue. Future research should explore other 
mechanisms of gene expression, such as histone modification and miRNA-based regulation, to 
gain a more comprehensive picture of how BMI influences epigenetic changes in breast tissue. 
Further, this study only assessed BMI at one point in time. Future research should examine the 
impact of weight change and of BMI collected at different timepoints on methylation status. 
Another important area for future research concerns determining the appropriate study 
populations and tissue sources for epigenetic research. This dissertation focused primarily on 
women who were already diagnosed with cancer or who were at higher risk of disease, which 
may limit generalizability. Efforts have been undertaken by the National Cancer Institute and the 
Susan G. Komen Foundation to collect breast tissue samples from healthy volunteers (242). As 
discussed in section 5.2, there may be differences in tissue characteristics and sampling methods 
for tissue drawn from healthy volunteers when compared to tissue drawn from women 
undergoing reduction mammoplasty (232). Future research should explore this issue by 
collecting random breast tissue samples from reduction mammoplasty patients, in addition to the 
standard practice of extracting tissue from areas with grossly visible parenchyma that may be 
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enriched for histologic abnormalities. These random tissue samples can then be compared to 
samples collected from healthy volunteers. If there are no differences between the tissues from 
reduction mammoplasty patients and healthy volunteers, the need to ask volunteers to donate 
breast tissue could be reduced. 
5.6 Significance 
 The findings of this dissertation suggest that BMI might influence the epigenetics of 
breast tissue. Specifically, it suggests that BMI is associated with methylation of CpG loci in 
genes that act in inflammation and immune response (69, 79-81) and in insulin resistance (66, 
77, 78), all of which have been associated with cancer risk and progression (66, 79, 80, 88, 89). 
This work is novel in examining the association between BMI, methylation, and gene expression 
in non-diseased breast tissue using a genome-wide panel and contributes the resulting data to the 
public domain, providing the basis for future replication work. 
The results of this dissertation can be used to inform innovative biologic, translational, 
and public health research that addresses the impact of obesity on breast cancer. Obesity is a very 
complex phenomenon, representing a collection of multiple dysfunctional biological phenotypes. 
These findings can help lead to the better identification of the specific biological characteristics 
that mediate the obesity-breast cancer association. This may enable research that more directly 
addresses the biologically relevant phenotypes of obesity and lead to better estimation of the 
direct effect of obesity on risk. The BMI-associated genes and pathways identified in this work 
may also inform research that addresses how methylation varies with diet, weight loss, and 
pharmacologic interventions that could eventually be applied to breast cancer patients.  
5.7 Conclusions 
 The goal of this dissertation was to explore the effect of BMI on gene methylation to 
better understand how obesity influences breast cancer risk and progression. This study was 
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novel in examining the relationship between BMI and gene methylation in breast tissue instead 
of blood and in using panels of methylation sites instead of candidate genes. The results suggest 
that BMI influences the methylation of genes involved in inflammation and insulin resistance, 
processes that have been linked to carcinogenesis. It also suggests that BMI-associated 
methylation changes are also correlated with gene expression for a subset of probes, indicating 
that BMI may exert some influence on the expression of cancer-related processes. With 
validation, this work can lead to a better understanding of the biological impact of obesity and, 
potentially, more refined risk stratification of women based on knowledge of their epigenetic 
data.  
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APPENDIX A. TABLES 
 
Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg01044662 2 75938360 S_Shore GCFC2 64.0 1.58E-08 0.004 
cg05612654 6 2375895 
 
LOC100508120 -93.4 5.19E-08 0.005 
cg12924510 18 514363 N_Shore NA -78.0 5.81E-08 0.005 
cg15028995 19 46628119 
 
IGFL3 -124.5 1.88E-07 0.012 
cg02609279 2 182325952 S_Shelf ITGA4 -54.3 3.22E-07 0.012 
cg14724298 4 54424764 
 
LNX1 -44.9 3.44E-07 0.012 
cg20810975 17 42467199 S_Shelf ITGA2B -81.7 3.48E-07 0.012 
cg22727965 7 25898770 Island NA -75.0 3.49E-07 0.012 
cg16551670 5 106637856 
 
NA -42.0 4.30E-07 0.012 
cg22216196 19 15564105 Island WIZ 52.2 4.54E-07 0.012 
cg22573003 X 15402648 
 
FIGF 60.3 5.15E-07 0.012 
cg18445108 17 5138259 
 
SCIMP -78.8 5.23E-07 0.012 
cg26050975 5 179231109 N_Shore MGAT4B -85.7 5.73E-07 0.012 
cg13673563 14 21738473 S_Shore HNRNPC -75.2 7.41E-07 0.014 
cg09667606 6 158507930 Island SYNJ2 -45.8 7.70E-07 0.014 
cg13674705 1 184829177 
 
FAM129A -101.3 8.33E-07 0.014 
cg10767045 10 89264128 N_Shore MINPP1 41.1 8.51E-07 0.014 
cg26972389 5 169407753 
 
FAM196B 70.9 1.04E-06 0.016 
cg26894297 1 23754550 S_Shelf TCEA3 -130.6 1.29E-06 0.018 
cg22190361 2 174886880 N_Shelf NA -33.8 1.32E-06 0.018 
cg23252243 2 26987820 S_Shore SLC35F6 46.2 1.45E-06 0.018 
cg02382221 4 86682649 
 
ARHGAP24 -119.1 1.50E-06 0.018 
cg14575356 6 130013903 
 
ARHGAP18 -55.9 1.51E-06 0.018 
cg01440934 1 47051752 
 
MKNK1 -94.3 1.61E-06 0.018 
cg03089651 1 161039695 
 
ARHGAP30 -59.1 1.79E-06 0.018 
cg08468577 11 2973342 
 
NAP1L4 -81.9 1.81E-06 0.018 
cg00667525 19 18699118 N_Shore C19orf60 49.1 1.89E-06 0.018 
cg22595920 1 9716050 S_Shelf C1orf200 -82.5 1.92E-06 0.018 
cg20487608 6 15288126 
 
JARID2 -68.6 1.99E-06 0.018 
cg23159337 3 193272778 
 
ATP13A4 78.0 2.10E-06 0.018 
cg24165086 11 64705980 
 
GPHA2 -117.4 2.27E-06 0.018 
cg04090347 21 44061597 
 
NA 41.7 2.28E-06 0.018 
cg16298927 6 170191076 S_Shore LINC00574 29.7 2.30E-06 0.018 
cg05287480 7 27176127 N_Shelf HOXA-AS3 64.4 2.35E-06 0.018 
cg03874653 3 123380206 
 
MYLK 38.8 2.38E-06 0.018 
cg09250458 16 1139916 Island C1QTNF8 47.3 2.43E-06 0.018 
cg17969683 8 24151514 
 
ADAM28 -50.0 2.58E-06 0.018 
cg24546683 1 242097870 N_Shelf NA 31.8 2.66E-06 0.018 
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Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg21218183 1 92760687 
 
RPAP2 -31.1 2.66E-06 0.018 
cg01652190 22 50026171 Island C22orf34 33.7 2.78E-06 0.018 
cg06107293 15 22915986 
 
CYFIP1 -50.5 2.80E-06 0.018 
cg19502671 13 114129004 
 
DCUN1D2 -63.0 2.85E-06 0.018 
cg08486903 7 98739496 N_Shore SMURF1 69.4 2.90E-06 0.018 
cg24833674 1 166914191 N_Shelf ILDR2 -62.0 2.95E-06 0.018 
cg06110286 8 145728587 N_Shore GPT 70.9 3.01E-06 0.018 
cg03198066 2 159311068 N_Shelf CCDC148 -64.6 3.04E-06 0.018 
cg16515974 6 31695064 N_Shore DDAH2 -96.2 3.13E-06 0.018 
cg06034527 15 96912955 S_Shore NA -43.8 3.25E-06 0.018 
cg12405520 11 126030310 
 
NA 50.3 3.26E-06 0.018 
cg18857467 1 32787489 
 
HDAC1 -37.0 3.28E-06 0.018 
cg00027232 2 85547231 
 
TGOLN2 -80.3 3.38E-06 0.018 
cg00407944 9 139424152 N_Shore NOTCH1 -53.8 3.38E-06 0.018 
cg24640390 10 71336969 N_Shore NEUROG3 55.7 3.48E-06 0.018 
cg11967765 7 2774195 N_Shore GNA12 -57.1 3.51E-06 0.018 
cg03458695 10 78163703 
 
C10orf11 -87.0 3.52E-06 0.018 
cg19228647 6 6901002 
 
NA -36.7 3.54E-06 0.018 
cg21500909 19 41870640 S_Shore B9D2 -47.4 3.56E-06 0.018 
cg02737379 3 119379530 
 
POPDC2 30.0 3.81E-06 0.018 
cg01825818 2 131554018 N_Shore NA -71.1 3.83E-06 0.018 
cg17852032 6 158066811 
 
ZDHHC14 -62.9 3.83E-06 0.018 
cg17658002 19 11689997 S_Shore ACP5 -59.9 4.04E-06 0.018 
cg21988461 4 88008667 
 
AFF1 -62.2 4.19E-06 0.018 
cg08840913 2 24139933 Island ATAD2B -61.8 4.21E-06 0.018 
cg03814063 22 50025915 
 
C22orf34 49.5 4.21E-06 0.018 
cg12967050 19 36233297 S_Shore IGFLR1 -85.4 4.38E-06 0.018 
cg05587400 10 5817943 
 
GDI2 -53.5 4.42E-06 0.018 
cg13071208 8 145686887 N_Shore CYHR1 44.7 4.44E-06 0.018 
cg00451054 8 77913321 S_Shore PEX2 50.8 4.46E-06 0.018 
cg26272443 19 41083341 Island SHKBP1 110.2 4.49E-06 0.018 
cg10499974 3 46244099 
 
CCR1 -59.5 4.57E-06 0.018 
cg08202836 3 196373751 
 
NRROS -37.9 4.57E-06 0.018 
cg15694146 1 27823372 
 
NA 54.9 4.67E-06 0.018 
cg00045118 8 93076177 
 
RUNX1T1 50.8 4.70E-06 0.018 
cg24527008 5 177870233 
 
COL23A1 -52.6 4.73E-06 0.018 
cg27621997 11 60608634 N_Shore CCDC86 31.9 4.87E-06 0.018 
cg23357708 19 8580509 S_Shore ZNF414 -71.1 4.89E-06 0.018 
cg27571769 4 185704063 
 
ACSL1 -42.3 5.07E-06 0.018 
cg14007090 20 60915009 S_Shelf LAMA5 -83.8 5.13E-06 0.018 
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Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg22717593 19 45647012 N_Shore PPP1R37 -91.4 5.23E-06 0.018 
cg20609803 1 161184305 
 
FCER1G -69.0 5.26E-06 0.018 
cg25346117 1 116923256 
 
ATP1A1 -95.4 5.35E-06 0.018 
cg01052699 4 171030995 
 
NA 51.2 5.39E-06 0.018 
cg24637417 12 51636921 S_Shelf DAZAP2 -73.7 5.53E-06 0.018 
cg04188920 10 3138534 
 
PFKP -50.5 5.60E-06 0.018 
cg21241317 6 32122736 S_Shore LOC100507547 146.3 5.69E-06 0.018 
cg06427816 17 1090326 
 
ABR 36.6 5.70E-06 0.018 
cg00753676 4 38662991 N_Shore KLF3 -70.5 5.77E-06 0.018 
cg18993949 4 15481269 
 
CC2D2A 36.3 5.79E-06 0.018 
cg13067714 14 69091453 N_Shelf NA -92.8 5.87E-06 0.018 
cg26787020 1 174968089 N_Shore CACYBP 41.2 6.05E-06 0.019 
cg24870729 1 62102363 
 
NA -51.9 6.17E-06 0.019 
cg14841540 1 90427858 
 
NA -35.8 6.27E-06 0.019 
cg01033299 12 53601015 
 
ITGB7 -46.0 6.33E-06 0.019 
cg20107346 12 88803163 
 
NA -112.2 6.51E-06 0.019 
cg06928741 6 31691430 Island C6orf25 -73.9 6.53E-06 0.019 
cg24013213 13 51640142 
 
GUCY1B2 -42.3 6.91E-06 0.020 
cg18418051 5 32734970 
 
NPR3 -57.9 6.96E-06 0.020 
cg10145584 11 117860269 
 
IL10RA -75.5 7.00E-06 0.020 
cg10021122 1 117610620 S_Shelf TTF2 81.6 7.00E-06 0.020 
cg19971655 1 55464927 Island BSND -74.2 7.08E-06 0.020 
cg13580767 12 50135122 S_Shore TMBIM6 779.9 7.08E-06 0.020 
cg08526959 2 25149334 
 
NA -92.2 7.28E-06 0.020 
cg11751101 12 7244660 
 
C1R 44.7 7.30E-06 0.020 
cg01893100 3 167799377 
 
GOLIM4 -38.4 7.58E-06 0.020 
cg09167779 5 112566614 
 
MCC 38.4 7.64E-06 0.020 
cg01816936 12 123518888 
 
PITPNM2 -56.4 7.65E-06 0.020 
cg25992874 7 142997642 
 
CASP2 -89.8 7.69E-06 0.020 
cg15998505 1 153479701 
 
NA 76.8 7.73E-06 0.020 
cg01354046 5 171057339 Island NA 74.8 7.74E-06 0.020 
cg21870038 17 33390736 
 
RFFL -30.4 7.80E-06 0.020 
cg02455383 22 27014116 
 
CRYBB1 -67.3 7.93E-06 0.020 
cg26504421 17 71339361 
 
SDK2 64.5 8.07E-06 0.020 
cg04147906 17 26373775 
 
NLK -67.4 8.08E-06 0.020 
cg06261052 10 13545875 
 
BEND7 -82.6 8.15E-06 0.020 
cg24428218 10 126303795 Island NA -29.7 8.20E-06 0.020 
cg16077055 2 106428750 
 
NCK2 29.3 8.26E-06 0.020 
cg10274453 13 43378116 
 
NA -34.6 8.34E-06 0.020 
cg08254266 8 36641818 
 
KCNU1 -122.5 8.35E-06 0.020 
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Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg00309582 20 55841925 S_Shore BMP7 450.9 8.43E-06 0.020 
cg26923863 4 1221838 Island CTBP1 -53.1 8.52E-06 0.020 
cg00057966 17 56408694 
 
MIR142 -50.8 8.62E-06 0.020 
cg02492873 2 25193821 N_Shore DNAJC27 41.5 8.64E-06 0.020 
cg05949640 4 2627057 
 
FAM193A 30.9 8.90E-06 0.020 
cg07788061 19 13207239 N_Shore NFIX -92.6 8.92E-06 0.020 
cg23962746 1 209105888 
 
NA 69.9 8.98E-06 0.020 
cg00201196 16 8738469 
 
METTL22 -80.6 9.07E-06 0.020 
cg10227830 4 144332828 
 
GAB1 49.2 9.19E-06 0.020 
cg17207512 6 11382553 
 
NEDD9 -54.5 9.27E-06 0.020 
cg10666916 6 33872206 S_Shore NA -76.6 9.44E-06 0.020 
cg08813888 2 662396 
 
NA -53.8 9.44E-06 0.020 
cg26732720 11 64392533 
 
NRXN2 -64.5 9.53E-06 0.020 
cg11494437 3 15678564 
 
BTD -50.2 9.66E-06 0.020 
cg18637901 4 3247372 N_Shelf MSANTD1 -120.5 9.68E-06 0.020 
cg10324998 1 92338262 
 
TGFBR3 66.5 9.87E-06 0.021 
cg16250868 7 3710628 
 
SDK1 -23.0 9.88E-06 0.021 
cg16721359 8 98610787 
 
NA -69.9 1.04E-05 0.021 
cg11649821 1 1859438 Island NA -60.2 1.06E-05 0.021 
cg25037841 22 20237341 
 
MIR1286 46.4 1.07E-05 0.021 
cg03069267 9 134699490 Island NA 53.4 1.08E-05 0.021 
cg14855124 1 9180023 
 
GPR157 -69.9 1.08E-05 0.021 
cg15818008 11 112126170 
 
C11orf34 -41.8 1.08E-05 0.021 
cg02154345 12 115104983 Island NA -55.2 1.09E-05 0.021 
cg23343486 17 75449911 
 
SEPT9 -67.8 1.10E-05 0.021 
cg14080050 9 33159025 S_Shelf B4GALT1 -48.7 1.10E-05 0.021 
cg24020157 10 43697521 
 
RASGEF1A -60.5 1.11E-05 0.021 
cg18966495 6 22222737 N_Shore NA 58.5 1.11E-05 0.021 
cg18638581 2 75059602 N_Shore HK2 -47.7 1.14E-05 0.021 
cg14146966 2 61757674 S_Shore XPO1 43.2 1.15E-05 0.021 
cg08486269 6 154677972 
 
IPCEF1 -42.3 1.15E-05 0.021 
cg03310874 7 4850260 
 
RADIL -50.3 1.15E-05 0.021 
cg02320083 5 171057072 Island NA 651.7 1.16E-05 0.021 
cg17042715 13 75814730 
 
CTAGE11P -141.2 1.16E-05 0.021 
cg26681847 11 120208749 S_Shore ARHGEF12 63.4 1.17E-05 0.021 
cg26274090 19 40195028 
 
LGALS14 44.3 1.18E-05 0.021 
cg20382493 13 114829170 
 
RASA3 48.5 1.20E-05 0.021 
cg02596994 12 122296950 
 
HPD 51.2 1.21E-05 0.021 
cg03886558 12 57869490 Island ARHGAP9 48.7 1.21E-05 0.021 
cg04042106 11 65628736 S_Shore MUS81 266.5 1.22E-05 0.021 
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Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg16323359 6 41913381 S_Shelf CCND3 -156.1 1.22E-05 0.021 
cg24254842 1 42193353 
 
HIVEP3 -31.2 1.22E-05 0.021 
cg23238058 6 7042879 
 
NA -40.6 1.23E-05 0.021 
cg06048102 13 51575027 
 
GUCY1B2 43.5 1.23E-05 0.021 
cg17952939 1 9154250 
 
NA -69.6 1.26E-05 0.021 
cg02544658 21 44876604 Island NA -51.2 1.26E-05 0.021 
cg01034993 15 68992751 Island CORO2B -48.6 1.26E-05 0.021 
cg09568217 17 7311868 
 
NLGN2 -60.6 1.26E-05 0.021 
cg01062269 X 100603843 
 
TIMM8A -58.2 1.27E-05 0.021 
cg00471696 2 173955214 Island ZAK 46.5 1.27E-05 0.021 
cg23595451 4 1035462 
 
NA 65.8 1.28E-05 0.021 
cg08685085 12 57114435 
 
NACA -58.4 1.29E-05 0.021 
cg24226371 15 75945038 
 
SNX33 49.0 1.32E-05 0.021 
cg22022821 11 102750873 
 
NA -70.7 1.33E-05 0.021 
cg07113653 6 13428657 
 
GFOD1 -47.9 1.33E-05 0.021 
cg04079215 1 95095221 
 
NA -57.4 1.33E-05 0.021 
cg25789721 3 10370264 S_Shore ATP2B2 64.0 1.34E-05 0.021 
cg06955979 14 101162556 
 
NA 60.4 1.34E-05 0.021 
cg00348762 16 56228114 N_Shore DKFZP434H168 66.2 1.34E-05 0.021 
cg27574973 7 78218446 
 
MAGI2 -108.7 1.35E-05 0.021 
cg14225168 9 139403827 N_Shore NOTCH1 -56.9 1.39E-05 0.022 
cg09275408 10 44500491 N_Shore NA -60.4 1.40E-05 0.022 
cg09120934 11 120187999 
 
POU2F3 56.5 1.41E-05 0.022 
cg25337513 17 78800631 
 
RPTOR -69.1 1.42E-05 0.022 
cg09679746 16 61960656 
 
CDH8 68.8 1.42E-05 0.022 
cg06150803 13 24144257 S_Shore TNFRSF19 44.8 1.42E-05 0.022 
cg07353685 1 153536278 
 
S100A2 -63.0 1.43E-05 0.022 
cg03984209 3 55920018 
 
ERC2 -37.6 1.44E-05 0.022 
cg02460419 12 124198876 S_Shore ATP6V0A2 -61.0 1.44E-05 0.022 
cg20120371 17 41956344 
 
MPP2 33.2 1.46E-05 0.022 
cg18334681 6 132066129 
 
ENPP3 -30.1 1.47E-05 0.022 
cg16496462 12 124854282 N_Shelf NCOR2 41.6 1.47E-05 0.022 
cg26918808 1 67950349 
 
NA 43.2 1.49E-05 0.022 
cg11297046 19 49657000 S_Shore HRC -57.8 1.51E-05 0.022 
cg01209566 8 125954151 
 
LINC00964 55.9 1.52E-05 0.022 
cg20049422 15 26044289 
 
ATP10A -42.0 1.54E-05 0.022 
cg11010552 5 131338478 
 
ACSL6 -94.1 1.55E-05 0.022 
cg27050111 16 8738240 
 
METTL22 -51.4 1.56E-05 0.022 
cg05120113 3 33140160 S_Shore GLB1 -131.5 1.57E-05 0.022 
cg22480742 7 134576386 
 
CALD1 47.9 1.58E-05 0.022 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg11534596 1 17574720 
 
PADI3 -60.9 1.62E-05 0.023 
cg21005416 1 21606617 
 
ECE1 -31.2 1.62E-05 0.023 
cg19323703 2 46498015 
 
NA -73.2 1.64E-05 0.023 
cg12105382 12 4390091 
 
CCND2 49.8 1.66E-05 0.023 
cg17626734 6 130182551 
 
TMEM244 28.7 1.67E-05 0.023 
cg17920246 10 14116424 
 
FRMD4A 37.3 1.67E-05 0.023 
cg19262637 1 240783328 
 
NA 34.0 1.70E-05 0.023 
cg13549277 12 6659520 S_Shore IFFO1 -57.0 1.73E-05 0.023 
cg17210664 10 61297420 
 
NA 43.3 1.73E-05 0.023 
cg16530881 17 38708399 
 
NA 37.1 1.74E-05 0.023 
cg16903174 2 9468351 
 
ASAP2 -44.6 1.77E-05 0.024 
cg10058766 1 12186079 
 
TNFRSF8 -38.6 1.78E-05 0.024 
cg23854567 12 120694893 
 
PXN 43.3 1.79E-05 0.024 
cg15757292 11 119994008 
 
TRIM29 -61.9 1.80E-05 0.024 
cg02894226 20 3190561 Island ITPA 425.2 1.82E-05 0.024 
cg13866093 6 28502727 
 
GPX5 39.4 1.83E-05 0.024 
cg12006375 13 51640315 
 
GUCY1B2 -70.6 1.86E-05 0.024 
cg02609337 8 134559320 
 
ST3GAL1 -45.9 1.86E-05 0.024 
cg16593865 8 126082720 
 
KIAA0196 45.1 1.89E-05 0.024 
cg25724895 20 58630390 
 
C20orf197 -52.3 1.90E-05 0.024 
cg22485921 5 131557716 
 
P4HA2 60.7 1.91E-05 0.024 
cg02365539 7 2136919 
 
MAD1L1 -70.6 1.92E-05 0.024 
cg06688763 7 92238207 
 
CDK6 51.1 1.92E-05 0.024 
cg15847685 4 62129666 
 
NA -32.9 1.94E-05 0.024 
cg11547696 8 142288508 
 
NA -100.0 1.95E-05 0.024 
cg15408360 14 102432104 
 
DYNC1H1 39.3 1.95E-05 0.024 
cg07892449 17 4835627 S_Shore GP1BA -54.0 1.95E-05 0.024 
cg01048752 8 10001523 
 
MSRA -110.9 2.01E-05 0.025 
cg02338840 2 207931932 
 
NA -86.0 2.04E-05 0.025 
cg22718308 15 42308160 
 
PLA2G4E -176.5 2.08E-05 0.025 
cg06682445 7 43915791 
 
URGCP-MRPS24 -64.9 2.08E-05 0.025 
cg12656272 3 100328186 
 
GPR128 -56.8 2.09E-05 0.025 
cg00423487 19 4455957 N_Shore UBXN6 74.4 2.10E-05 0.025 
cg21459713 8 623688 Island ERICH1 -41.5 2.10E-05 0.025 
cg10576992 4 119662530 
 
SEC24D 35.6 2.11E-05 0.025 
cg01456691 6 11382556 
 
NEDD9 -67.8 2.12E-05 0.025 
cg11574092 2 241394528 N_Shore MIR149 -59.6 2.13E-05 0.025 
cg13688889 9 100608707 N_Shore NA -44.3 2.15E-05 0.025 
cg24413778 13 110977981 
 
COL4A2 -45.8 2.15E-05 0.025 
cg12332776 10 71336241 N_Shore NEUROG3 65.1 2.16E-05 0.025 
94 
 
Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
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cg20103124 13 31309625 S_Shore ALOX5AP -65.5 2.17E-05 0.025 
cg17478749 6 31589365 
 
PRRC2A 132.9 2.17E-05 0.025 
cg00791321 2 239999938 
 
HDAC4 66.4 2.18E-05 0.025 
cg14162552 9 139744532 Island PHPT1 50.3 2.18E-05 0.025 
cg08329473 10 116133852 
 
AFAP1L2 63.3 2.19E-05 0.025 
cg03919657 17 48502312 N_Shore ACSF2 -55.6 2.20E-05 0.025 
cg08643131 19 1356150 S_Shore MUM1 72.3 2.20E-05 0.025 
cg01374870 6 32905127 
 
HLA-DMB -47.7 2.21E-05 0.025 
cg26075966 7 44999021 N_Shelf NA -29.6 2.21E-05 0.025 
cg09916174 7 134576049 
 
CALD1 41.0 2.22E-05 0.025 
cg21188533 3 53700263 
 
CACNA1D -46.8 2.23E-05 0.025 
cg16982073 13 112507984 
 
NA 28.6 2.25E-05 0.025 
cg00373763 13 50908713 
 
NA -82.3 2.25E-05 0.025 
cg13011604 3 46950416 
 
NA 53.1 2.25E-05 0.025 
cg19960420 10 101282185 N_Shore NA 36.0 2.26E-05 0.025 
cg16119522 20 37433745 N_Shore PPP1R16B -53.5 2.26E-05 0.025 
cg07035442 17 81028481 
 
NA -59.0 2.28E-05 0.025 
cg16377679 5 58388744 
 
PDE4D 34.9 2.29E-05 0.025 
cg24598993 6 4923095 
 
CDYL -55.9 2.29E-05 0.025 
cg12196406 19 35629576 N_Shelf FXYD1 55.3 2.30E-05 0.025 
cg08892455 17 1231715 
 
NA -55.9 2.31E-05 0.025 
cg00017461 22 30663316 S_Shelf OSM -57.6 2.31E-05 0.025 
cg19585100 14 73703023 N_Shore PAPLN -62.0 2.37E-05 0.026 
cg02475834 10 13628849 Island PRPF18 678.1 2.39E-05 0.026 
cg02185666 2 206549667 Island NRP2 -29.2 2.42E-05 0.026 
cg00045607 1 161039690 
 
ARHGAP30 -65.6 2.43E-05 0.026 
cg06943912 19 10715612 S_Shelf SLC44A2 -43.8 2.44E-05 0.026 
cg23093580 1 39491322 
 
NDUFS5 52.9 2.46E-05 0.026 
cg23301925 14 91294322 
 
NA 61.3 2.46E-05 0.026 
cg13423554 1 42317463 
 
HIVEP3 -31.0 2.48E-05 0.026 
cg14431165 6 44160222 
 
NA -48.3 2.52E-05 0.026 
cg08579540 2 175652652 
 
NA 41.1 2.53E-05 0.026 
cg19619756 5 1219499 S_Shore SLC6A19 78.2 2.56E-05 0.026 
cg17171407 8 119960777 N_Shelf TNFRSF11B -27.1 2.58E-05 0.027 
cg18033335 19 11034897 S_Shelf YIPF2 79.1 2.60E-05 0.027 
cg24365867 11 10715595 
 
MRVI1 45.3 2.61E-05 0.027 
cg25576997 14 56257750 
 
LINC00520 -22.5 2.61E-05 0.027 
cg13912573 9 92293297 S_Shore UNQ6494 61.3 2.62E-05 0.027 
cg02023973 16 1519973 
 
CLCN7 -50.6 2.63E-05 0.027 
cg06112654 10 35505599 S_Shore NA -44.9 2.66E-05 0.027 
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cg23433345 12 77059628 
 
NA -66.5 2.68E-05 0.027 
cg00431968 8 92528313 
 
NA -45.7 2.69E-05 0.027 
cg20317872 1 111743202 N_Shelf DENND2D -63.8 2.69E-05 0.027 
cg15401418 17 75316383 
 
9-Sep 45.7 2.71E-05 0.027 
cg22438522 4 646293 N_Shore PDE6B -125.2 2.72E-05 0.027 
cg09248380 4 111397190 N_Shore ENPEP 41.1 2.73E-05 0.027 
cg14485633 9 136783440 
 
VAV2 -36.9 2.73E-05 0.027 
cg26639479 16 30363681 
 
CD2BP2 47.7 2.73E-05 0.027 
cg22057874 2 179184866 N_Shelf OSBPL6 -43.8 2.73E-05 0.027 
cg11844079 1 160001979 Island PIGM 432.3 2.74E-05 0.027 
cg15335334 17 73642547 
 
SMIM6 -45.0 2.75E-05 0.027 
cg09743596 16 89180843 
 
ACSF3 -80.5 2.79E-05 0.027 
cg02129017 6 168983500 
 
SMOC2 -105.5 2.79E-05 0.027 
cg16259171 11 73660510 
 
DNAJB13 -56.9 2.79E-05 0.027 
cg23845168 17 31271015 
 
NA 38.7 2.80E-05 0.027 
cg14155193 9 129148742 
 
MVB12B -58.4 2.86E-05 0.027 
cg18887230 7 98739627 N_Shore SMURF1 64.8 2.86E-05 0.027 
cg17209284 2 231235574 
 
SP140L -75.9 2.90E-05 0.027 
cg12097896 8 26471364 N_Shore DPYSL2 -84.5 2.91E-05 0.027 
cg03173570 21 33031392 
 
SOD1 54.6 2.91E-05 0.027 
cg12104698 7 139529130 
 
TBXAS1 -76.4 2.92E-05 0.027 
cg01900371 2 27256120 Island TMEM214 537.4 2.97E-05 0.028 
cg09423875 6 32014663 
 
TNXB 85.5 2.98E-05 0.028 
cg11869499 15 89872984 N_Shelf POLG -68.0 2.99E-05 0.028 
cg04177826 22 50985681 Island KLHDC7B 43.2 3.01E-05 0.028 
cg02933639 4 8207325 
 
SH3TC1 -60.3 3.03E-05 0.028 
cg00259404 6 28885568 
 
TRIM27 -53.0 3.06E-05 0.028 
cg22501604 4 187647344 S_Shelf FAT1 91.5 3.07E-05 0.028 
cg02322889 4 25101274 
 
NA 39.2 3.07E-05 0.028 
cg15744333 6 32372310 Island BTNL2 39.4 3.07E-05 0.028 
cg18887096 2 219472410 
 
PLCD4 48.0 3.08E-05 0.028 
cg20635370 10 80666318 
 
NA -39.8 3.08E-05 0.028 
cg19232382 10 134953542 N_Shore NA 26.9 3.11E-05 0.028 
cg03046611 3 55340399 
 
NA 23.5 3.12E-05 0.028 
cg12297590 6 158080750 
 
ZDHHC14 -23.1 3.12E-05 0.028 
cg20652759 10 409280 Island DIP2C -127.6 3.13E-05 0.028 
cg25652701 7 105348517 
 
ATXN7L1 -52.6 3.16E-05 0.028 
cg25527547 7 100862300 S_Shore PLOD3 33.7 3.18E-05 0.028 
cg06787669 7 45018789 
 
MYO1G -49.8 3.20E-05 0.028 
cg21190644 6 2659375 
 
NA -68.4 3.21E-05 0.028 
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cg21412215 8 39973292 
 
NA 50.2 3.22E-05 0.028 
cg03373714 2 147632094 
 
NA -28.8 3.24E-05 0.028 
cg04229928 11 119303807 
 
USP2-AS1 60.4 3.24E-05 0.028 
cg26011014 1 40783003 Island COL9A2 319.2 3.25E-05 0.028 
cg08981041 4 117624191 N_Shelf NA 61.9 3.26E-05 0.028 
cg14669515 1 9386821 
 
SPSB1 47.1 3.29E-05 0.028 
cg09996284 1 156211851 N_Shelf BGLAP -58.8 3.30E-05 0.028 
cg18512930 4 1496880 S_Shelf NA 46.3 3.30E-05 0.028 
cg25505880 11 62574338 S_Shore NXF1 -63.7 3.32E-05 0.028 
cg24751773 2 107192564 
 
NA 67.1 3.33E-05 0.028 
cg00035969 1 112159097 N_Shelf RAP1A -34.5 3.35E-05 0.029 
cg04217515 21 46325853 S_Shore ITGB2 -50.8 3.38E-05 0.029 
cg15244101 12 49627624 N_Shore NA -47.8 3.39E-05 0.029 
cg01457077 2 239228573 N_Shore TRAF3IP1 80.9 3.39E-05 0.029 
cg11234339 11 10907448 
 
NA 58.4 3.42E-05 0.029 
cg06385449 11 63974123 N_Shore FERMT3 -64.5 3.43E-05 0.029 
cg27563126 9 132438028 Island PRRX2 62.6 3.44E-05 0.029 
cg06645778 2 64680425 
 
LGALSL 37.6 3.49E-05 0.029 
cg04568981 1 53125850 N_Shore NA 58.9 3.49E-05 0.029 
cg19502709 5 169816214 
 
KCNMB1 -30.1 3.50E-05 0.029 
cg08114852 11 13461802 
 
BTBD10 95.7 3.50E-05 0.029 
cg00639635 6 143837891 
 
FUCA2 -57.4 3.50E-05 0.029 
cg16262559 4 1535729 S_Shore NA 35.8 3.52E-05 0.029 
cg09781650 16 66285054 
 
NA 30.7 3.53E-05 0.029 
cg19268453 6 32905114 
 
HLA-DMB -59.6 3.54E-05 0.029 
cg00770372 8 37237473 
 
NA 32.0 3.55E-05 0.029 
cg08284638 2 86255154 
 
LOC90784 -55.8 3.55E-05 0.029 
cg04454664 5 71748552 
 
ZNF366 51.5 3.55E-05 0.029 
cg18174678 1 42801761 S_Shore FOXJ3 31.4 3.56E-05 0.029 
cg14105566 2 121107846 N_Shore INHBB -64.9 3.57E-05 0.029 
cg13357416 17 707032 S_Shore NXN 35.3 3.57E-05 0.029 
cg10271819 7 139426030 
 
HIPK2 -51.7 3.58E-05 0.029 
cg08094206 6 30122523 
 
TRIM10 30.4 3.60E-05 0.029 
cg00566997 17 9675101 Island DHRS7C -109.5 3.62E-05 0.029 
cg00974579 16 88990188 N_Shelf CBFA2T3 69.7 3.62E-05 0.029 
cg07830160 1 159880327 
 
NA -39.6 3.63E-05 0.029 
cg13135609 8 125123369 
 
FER1L6 -72.1 3.65E-05 0.029 
cg18057548 19 3617614 S_Shelf CACTIN -40.9 3.66E-05 0.029 
cg17627898 12 118782453 
 
TAOK3 -48.6 3.68E-05 0.029 
cg16261114 15 99551997 
 
PGPEP1L -71.5 3.69E-05 0.029 
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cg13603551 7 150549406 
 
AOC1 -64.3 3.70E-05 0.029 
cg00294149 16 75604552 S_Shelf GABARAPL2 -38.9 3.72E-05 0.029 
cg10881242 5 171057282 Island NA 84.4 3.73E-05 0.029 
cg10103528 1 22979739 
 
C1QB -49.8 3.75E-05 0.029 
cg23360388 5 94726774 S_Shore FAM81B -32.9 3.78E-05 0.029 
cg20069688 6 31941049 
 
DOM3Z 83.9 3.78E-05 0.029 
cg03409108 6 34489785 
 
PACSIN1 -65.0 3.80E-05 0.029 
cg02144258 2 220391374 S_Shelf ASIC4 -54.7 3.81E-05 0.029 
cg16823610 4 40856529 N_Shelf APBB2 -109.7 3.82E-05 0.029 
cg06942450 20 57583520 S_Shore CTSZ -78.9 3.83E-05 0.029 
cg23051299 2 75938289 S_Shore GCFC2 98.0 3.84E-05 0.029 
cg09259534 1 218472841 
 
RRP15 38.2 3.85E-05 0.029 
cg22460123 12 52638294 N_Shore KRT7 -35.7 3.85E-05 0.029 
cg04325187 X 149930807 Island MTMR1 67.3 3.88E-05 0.029 
cg09801824 10 74076930 N_Shelf NA -65.0 3.89E-05 0.029 
cg26078407 2 240225062 
 
MIR4269 -43.7 3.92E-05 0.029 
cg22751954 6 143023932 
 
NA -63.6 3.92E-05 0.029 
cg00828556 3 196351986 
 
NA -42.5 3.92E-05 0.029 
cg09821400 10 33654419 
 
NA -78.3 3.93E-05 0.029 
cg24641737 1 111743271 N_Shelf DENND2D -46.6 3.93E-05 0.029 
cg03179542 7 2647333 S_Shore IQCE -38.9 3.96E-05 0.029 
cg24889694 8 101522535 
 
ANKRD46 35.2 3.99E-05 0.029 
cg04516672 10 126411663 
 
FAM53B -28.9 3.99E-05 0.029 
cg09941581 4 124220074 
 
SPATA5 36.4 3.99E-05 0.029 
cg17190781 6 40387783 
 
LRFN2 -120.3 4.02E-05 0.029 
cg21871338 14 87262857 
 
NA 40.2 4.02E-05 0.029 
cg02824983 15 38659681 
 
NA -38.1 4.05E-05 0.029 
cg14886850 14 75122289 
 
NA 25.7 4.05E-05 0.029 
cg00836101 15 39876248 S_Shelf THBS1 37.3 4.06E-05 0.029 
cg16384774 14 89626932 
 
FOXN3 -314.7 4.07E-05 0.029 
cg02073763 2 46064034 N_Shore PRKCE -67.0 4.07E-05 0.029 
cg19201009 10 99475406 S_Shore MARVELD1 45.1 4.07E-05 0.029 
cg13856674 15 93722590 
 
NA -44.5 4.09E-05 0.029 
cg03479209 3 58020999 
 
FLNB -40.6 4.11E-05 0.029 
cg25035489 1 6036550 
 
NPHP4 -76.7 4.14E-05 0.029 
cg26124526 5 60618932 
 
NA -43.1 4.15E-05 0.029 
cg25953692 6 31695415 
 
DDAH2 -63.0 4.16E-05 0.029 
cg08688659 11 35249965 N_Shore CD44 -71.3 4.16E-05 0.029 
cg23753351 4 40860327 S_Shore APBB2 -28.2 4.17E-05 0.029 
cg03190219 7 25898688 Island NA -48.0 4.18E-05 0.029 
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cg19230025 19 35488496 N_Shelf GRAMD1A -23.6 4.18E-05 0.029 
cg00651488 16 85236465 
 
NA 58.9 4.19E-05 0.029 
cg11110759 14 101282683 
 
MIR2392 -73.8 4.20E-05 0.029 
cg17184477 15 67360705 S_Shore SMAD3 51.3 4.22E-05 0.029 
cg10166664 5 60624229 N_Shelf ZSWIM6 -29.9 4.25E-05 0.029 
cg15326297 2 235464680 
 
NA 49.4 4.27E-05 0.029 
cg26783127 17 79128918 N_Shelf AATK -80.1 4.27E-05 0.029 
cg04120400 2 133425064 N_Shore LYPD1 -55.3 4.28E-05 0.029 
cg13795831 20 57582706 S_Shore CTSZ -45.4 4.29E-05 0.029 
cg06830360 8 142413013 
 
NA -42.6 4.31E-05 0.029 
cg21271945 1 2080081 N_Shelf PRKCZ -39.5 4.31E-05 0.029 
cg05964212 3 48936979 S_Shore SLC25A20 -65.5 4.34E-05 0.029 
cg25282976 17 79005047 N_Shore BAIAP2-AS1 -35.1 4.35E-05 0.029 
cg24718773 2 138739074 
 
HNMT -60.2 4.36E-05 0.029 
cg01534527 3 38003247 
 
CTDSPL -45.6 4.37E-05 0.029 
cg15755265 15 63673502 N_Shore CA12 125.6 4.39E-05 0.029 
cg02555923 3 14319984 
 
NA -70.0 4.40E-05 0.029 
cg20418394 10 72254335 S_Shore PALD1 -50.0 4.40E-05 0.029 
cg10001720 1 31231363 
 
LAPTM5 -37.2 4.40E-05 0.029 
cg05596664 3 171179040 
 
TNIK 389.9 4.40E-05 0.029 
cg25452067 10 101281603 
 
NA 50.3 4.41E-05 0.029 
cg18589102 10 132683444 
 
NA 44.0 4.41E-05 0.029 
cg05061769 15 59700360 Island NA -27.8 4.41E-05 0.029 
cg21880476 6 885298 N_Shelf NA -29.9 4.43E-05 0.029 
cg24882673 8 40625224 
 
ZMAT4 -19.6 4.45E-05 0.030 
cg25360761 19 35819943 
 
CD22 -36.1 4.48E-05 0.030 
cg03750478 16 29757375 
 
C16orf54 -58.6 4.52E-05 0.030 
cg16097772 12 69742232 
 
LYZ -65.0 4.53E-05 0.030 
cg04405704 6 31369119 N_Shore MICA -28.6 4.55E-05 0.030 
cg20610950 17 75096202 
 
SEC14L1 -44.4 4.56E-05 0.030 
cg06481431 19 6745321 N_Shore TRIP10 36.0 4.57E-05 0.030 
cg01185640 6 158053980 
 
ZDHHC14 28.3 4.59E-05 0.030 
cg19139589 2 25149093 
 
NA -87.6 4.60E-05 0.030 
cg25414209 13 36785834 N_Shore SOHLH2 -93.1 4.61E-05 0.030 
cg03549705 16 29674618 N_Shelf SPN -82.7 4.61E-05 0.030 
cg04010915 12 110547053 
 
NA 35.3 4.62E-05 0.030 
cg25907743 10 90519680 
 
LIPN -49.1 4.62E-05 0.030 
cg21284779 1 155910526 
 
RXFP4 -50.9 4.62E-05 0.030 
cg26907302 10 127464488 S_Shore MMP21 -159.2 4.64E-05 0.030 
cg04217082 8 37889752 S_Shore EIF4EBP1 31.5 4.64E-05 0.030 
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cg06305891 3 195897904 
 
NA -56.7 4.65E-05 0.030 
cg21129729 2 42719678 N_Shore KCNG3 -99.2 4.65E-05 0.030 
cg03807883 11 36535685 S_Shelf TRAF6 40.9 4.67E-05 0.030 
cg10655236 17 753974 
 
NXN 29.5 4.68E-05 0.030 
cg03125531 8 1906418 
 
ARHGEF10 27.1 4.69E-05 0.030 
cg01833890 12 2564063 
 
CACNA1C -46.8 4.71E-05 0.030 
cg21390363 17 18171734 S_Shelf NA 47.5 4.71E-05 0.030 
cg23886165 13 76209457 N_Shore LMO7 31.6 4.72E-05 0.030 
cg12446613 5 159072916 N_Shore NA -66.7 4.74E-05 0.030 
cg11825501 7 4168039 
 
SDK1 -92.8 4.74E-05 0.030 
cg15860924 1 33612977 Island TRIM62 59.1 4.75E-05 0.030 
cg26441979 8 79143895 
 
NA -53.9 4.76E-05 0.030 
cg03672272 22 46470191 S_Shore NA 42.0 4.79E-05 0.030 
cg03997039 16 29703361 N_Shelf QPRT -69.9 4.81E-05 0.030 
cg10109731 16 88472541 
 
NA 36.1 4.83E-05 0.030 
cg13593887 9 138159326 S_Shelf NA -86.7 4.83E-05 0.030 
cg00539174 20 57583434 S_Shore CTSZ -66.2 4.86E-05 0.030 
cg11067407 11 113599852 
 
NA -44.8 4.86E-05 0.030 
cg25299676 7 116312739 S_Shore MET 110.2 4.87E-05 0.030 
cg10855531 2 62702472 
 
NA -77.2 4.89E-05 0.030 
cg05300378 17 74128731 
 
NA 55.0 4.90E-05 0.030 
cg17342469 22 46473074 
 
NA 35.3 4.90E-05 0.030 
cg01721313 3 169751609 N_Shelf GPR160 -86.7 4.92E-05 0.030 
cg11433866 12 115126908 S_Shore TBX3 -67.2 4.94E-05 0.030 
cg19701213 19 42817154 
 
TMEM145 52.9 4.97E-05 0.030 
cg04790874 19 42381950 N_Shore CD79A -62.4 4.97E-05 0.030 
cg21513254 6 30624502 
 
DHX16 -73.6 4.98E-05 0.030 
cg02016065 3 157290927 
 
C3orf55 -64.5 4.99E-05 0.030 
cg00250645 8 72534391 
 
NA -52.2 4.99E-05 0.030 
cg20306863 1 3593812 
 
TP73 -63.2 5.01E-05 0.030 
cg07104557 7 1036653 N_Shelf C7orf50 -87.5 5.02E-05 0.030 
cg08884752 1 2162001 S_Shore SKI 39.8 5.03E-05 0.030 
cg15454698 3 14473580 
 
SLC6A6 -43.1 5.03E-05 0.030 
cg18133072 1 28287782 S_Shore XKR8 73.1 5.04E-05 0.030 
cg20682563 5 133460874 
 
TCF7 36.9 5.06E-05 0.030 
cg19252956 9 273072 
 
DOCK8 -44.1 5.07E-05 0.030 
cg25426302 6 32120826 
 
PPT2 27.8 5.08E-05 0.030 
cg20283498 10 73387917 N_Shore CDH23 -59.2 5.08E-05 0.030 
cg10712687 11 92714801 
 
MTNR1B -442.0 5.09E-05 0.030 
cg23671196 15 50405520 
 
ATP8B4 -56.1 5.09E-05 0.030 
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Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg16527057 1 157069242 
 
ETV3L -88.6 5.10E-05 0.030 
cg16413842 6 170191082 S_Shore LINC00574 23.2 5.13E-05 0.030 
cg04919519 14 103524989 S_Shore CDC42BPB 128.7 5.17E-05 0.030 
cg14789659 10 63809073 
 
ARID5B 50.2 5.18E-05 0.030 
cg12405048 12 112074086 
 
NA 43.0 5.18E-05 0.030 
cg01809797 22 31796612 S_Shore DRG1 31.7 5.19E-05 0.030 
cg09798061 16 1482603 Island NA -61.1 5.20E-05 0.030 
cg04207142 8 86089106 N_Shore E2F5 45.3 5.24E-05 0.030 
cg12073251 8 141568652 
 
AGO2 -50.0 5.25E-05 0.030 
cg02889973 1 234977572 
 
NA -36.4 5.25E-05 0.030 
cg19909613 8 109487153 
 
EMC2 -43.1 5.26E-05 0.030 
cg14512326 9 86240166 N_Shelf IDNK -72.3 5.29E-05 0.030 
cg12207930 3 151048337 
 
P2RY13 -56.4 5.29E-05 0.030 
cg15849098 7 150211761 S_Shore GIMAP7 -24.2 5.29E-05 0.030 
cg11982525 7 106505688 
 
PIK3CG -25.8 5.29E-05 0.030 
cg19744173 2 112913178 N_Shelf FBLN7 -61.8 5.32E-05 0.030 
cg18315380 7 1095666 
 
GPR146 -42.6 5.37E-05 0.030 
cg11578064 12 112074044 N_Shore NA 30.8 5.37E-05 0.030 
cg06462065 19 55885168 N_Shelf TMEM190 -58.4 5.43E-05 0.030 
cg09723979 11 19736248 S_Shore LOC100126784 127.2 5.44E-05 0.030 
cg15776617 2 9324111 
 
NA -31.7 5.45E-05 0.030 
cg26215003 X 20431166 
 
NA -80.6 5.45E-05 0.030 
cg23445003 7 101535821 
 
CUX1 -44.4 5.46E-05 0.030 
cg06626655 1 38099916 Island RSPO1 127.7 5.48E-05 0.030 
cg11802899 14 52867870 
 
NA -57.1 5.48E-05 0.030 
cg02670637 1 56184693 
 
NA 46.8 5.49E-05 0.030 
cg09337852 7 134464288 
 
CALD1 72.0 5.49E-05 0.030 
cg27151122 12 50447407 S_Shore ASIC1 -64.4 5.50E-05 0.030 
cg12127196 1 50489240 N_Shore AGBL4 46.8 5.50E-05 0.030 
cg02592062 19 19043788 N_Shelf HOMER3 -55.5 5.50E-05 0.030 
cg03254137 17 17661258 
 
RAI1 -79.2 5.51E-05 0.030 
cg02586212 1 192544902 
 
RGS1 -70.0 5.61E-05 0.031 
cg22771161 19 4788146 N_Shelf FEM1A 30.8 5.62E-05 0.031 
cg06579738 11 111165311 N_Shelf C11orf93 28.5 5.63E-05 0.031 
cg18569141 15 90727995 S_Shelf SEMA4B 74.1 5.64E-05 0.031 
cg17013990 1 161091682 Island NIT1 -51.7 5.64E-05 0.031 
cg14619064 17 56355331 Island MPO -81.4 5.65E-05 0.031 
cg10163050 X 153637650 N_Shelf DNASE1L1 -71.8 5.66E-05 0.031 
cg20100768 13 80706924 
 
NA 89.1 5.67E-05 0.031 
cg25744957 4 7106195 
 
FLJ36777 -88.3 5.68E-05 0.031 
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Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg19039313 2 136634366 S_Shore MCM6 -30.8 5.69E-05 0.031 
cg23590660 12 8205602 
 
FOXJ2 -36.4 5.70E-05 0.031 
cg23165541 15 64338164 Island DAPK2 40.0 5.71E-05 0.031 
cg18186672 2 71679841 N_Shore DYSF -31.9 5.72E-05 0.031 
cg01945913 5 1469001 S_Shore LPCAT1 -95.2 5.73E-05 0.031 
cg18121946 17 12697550 S_Shelf ARHGAP44 -91.7 5.74E-05 0.031 
cg26688315 2 218027591 
 
NA 63.3 5.75E-05 0.031 
cg24126180 7 128580582 S_Shore IRF5 -59.0 5.77E-05 0.031 
cg21067465 11 86304288 
 
ME3 -44.2 5.78E-05 0.031 
cg24259363 3 8525217 
 
LMCD1-AS1 34.1 5.80E-05 0.031 
cg02794695 8 134072611 
 
SLA -56.4 5.80E-05 0.031 
cg27560796 6 33864689 
 
LOC100507584 32.3 5.81E-05 0.031 
cg15722438 19 8552601 S_Shore HNRNPM -59.3 5.84E-05 0.031 
cg05117638 6 113952661 
 
NA -36.1 5.85E-05 0.031 
cg02342791 15 31508943 S_Shore NA -42.7 5.87E-05 0.031 
cg05711445 7 139528855 
 
TBXAS1 -37.4 5.87E-05 0.031 
cg26413855 6 30796199 
 
NA 34.5 5.88E-05 0.031 
cg17146738 7 98739698 
 
SMURF1 69.0 5.89E-05 0.031 
cg24778004 2 121461039 N_Shore NA -44.6 5.89E-05 0.031 
cg16771652 16 50730385 
 
NOD2 -55.9 5.89E-05 0.031 
cg04055490 17 8059012 N_Shore PER1 44.4 5.91E-05 0.031 
cg07721872 16 87735256 N_Shore NA -159.2 5.91E-05 0.031 
cg16911810 2 119596346 N_Shelf NA -49.3 5.94E-05 0.031 
cg09676376 12 54779077 
 
ZNF385A -68.9 5.96E-05 0.031 
cg17918556 2 169372300 
 
CERS6 32.8 6.01E-05 0.031 
cg07224067 17 48555565 N_Shore RSAD1 53.0 6.04E-05 0.031 
cg18759732 2 65889827 
 
NA 45.3 6.06E-05 0.031 
cg00520380 22 31643997 
 
LIMK2 64.9 6.08E-05 0.031 
cg02647408 11 88241594 N_Shore GRM5-AS1 -54.3 6.09E-05 0.031 
cg14745748 11 45717986 
 
NA -106.5 6.10E-05 0.031 
cg27214856 22 46473343 
 
NA 44.0 6.11E-05 0.031 
cg02780988 17 39646994 
 
KRT36 -60.9 6.11E-05 0.031 
cg15275312 3 50363059 
 
TUSC2 -75.4 6.14E-05 0.031 
cg01578632 16 69958298 
 
WWP2 27.3 6.14E-05 0.031 
cg14495916 3 171800301 N_Shelf FNDC3B 30.6 6.14E-05 0.031 
cg22720761 1 159769263 
 
FCRL6 -93.9 6.16E-05 0.031 
cg07868561 5 148434089 
 
SH3TC2 32.1 6.18E-05 0.031 
cg04602992 17 62009628 
 
CD79B -42.0 6.18E-05 0.031 
cg09783905 6 30294179 N_Shelf HCG17 1209.7 6.22E-05 0.031 
cg16785938 4 10022984 Island SLC2A9 -68.5 6.22E-05 0.031 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg01986263 20 58659848 S_Shore NA -59.7 6.22E-05 0.031 
cg14565465 9 74298933 
 
TMEM2 -36.5 6.25E-05 0.031 
cg00667937 2 168572563 Island NA -62.2 6.26E-05 0.031 
cg14386312 19 58740861 S_Shore ZNF544 57.2 6.29E-05 0.031 
cg04078115 22 33278114 
 
SYN3 -54.5 6.30E-05 0.031 
cg17000076 10 1780263 Island ADARB2 82.7 6.31E-05 0.031 
cg07959070 22 50026188 S_Shore C22orf34 24.4 6.31E-05 0.031 
cg07103201 17 20171047 
 
SPECC1 -29.3 6.32E-05 0.031 
cg03802185 7 101927846 N_Shore SH2B2 -72.3 6.33E-05 0.031 
cg19648306 2 179184854 
 
OSBPL6 -30.0 6.34E-05 0.031 
cg00122679 10 125673028 
 
NA -37.2 6.34E-05 0.031 
cg13131034 6 7590591 Island SNRNP48 1388.0 6.37E-05 0.031 
cg09914444 1 46972183 
 
DMBX1 -55.4 6.38E-05 0.031 
cg16230060 5 80530213 
 
CKMT2 -94.6 6.42E-05 0.031 
cg12885302 10 129979348 
 
NA -23.7 6.44E-05 0.031 
cg21918313 2 73496203 Island FBXO41 37.0 6.44E-05 0.031 
cg01011367 10 124798692 
 
ACADSB -46.5 6.46E-05 0.031 
cg18576206 22 44392384 S_Shore PARVB -44.9 6.55E-05 0.031 
cg06532880 5 176731545 Island PRELID1 294.4 6.55E-05 0.031 
cg01604601 2 69846936 
 
AAK1 -46.1 6.56E-05 0.031 
cg14774440 8 37730745 
 
RAB11FIP1 -29.8 6.56E-05 0.031 
cg09977847 2 217070953 
 
XRCC5 -47.6 6.56E-05 0.031 
cg02284273 10 14051679 N_Shelf FRMD4A 42.5 6.57E-05 0.031 
cg01033001 14 94637734 
 
PPP4R4 35.2 6.57E-05 0.031 
cg20116800 17 74258224 N_Shore UBALD2 -32.5 6.59E-05 0.031 
cg26453169 5 57787167 N_Shelf GAPT -32.0 6.59E-05 0.031 
cg12104246 6 24718589 
 
C6orf62 53.9 6.59E-05 0.031 
cg03479289 11 33563377 
 
KIAA1549L -73.0 6.60E-05 0.031 
cg12315466 2 233923814 N_Shore INPP5D -101.1 6.60E-05 0.031 
cg02138124 8 37901697 
 
EIF4EBP1 41.8 6.61E-05 0.031 
cg08854586 13 34094789 
 
STARD13 34.0 6.62E-05 0.031 
cg12119858 12 7023195 N_Shore ENO2 54.0 6.63E-05 0.031 
cg16836678 11 76836460 
 
MYO7A -51.5 6.64E-05 0.031 
cg17707487 13 114261869 S_Shore TFDP1 -46.8 6.65E-05 0.031 
cg20943461 17 76126886 N_Shore TMC8 -33.0 6.65E-05 0.031 
cg25332502 18 74832372 S_Shore MBP -89.8 6.66E-05 0.031 
cg19761273 17 80232096 S_Shore CSNK1D 91.1 6.69E-05 0.031 
cg13850871 9 139583773 S_Shore AGPAT2 -41.4 6.69E-05 0.031 
cg04125371 15 48937213 N_Shore FBN1 957.0 6.70E-05 0.031 
cg00231274 7 1263233 Island NA -49.1 6.70E-05 0.031 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg11589536 3 46250518 
 
CCR1 -73.5 6.71E-05 0.031 
cg09137125 10 7486981 
 
NA -49.5 6.75E-05 0.031 
cg04535945 5 137781554 
 
REEP2 -95.6 6.78E-05 0.031 
cg13972706 6 144671686 
 
UTRN -23.5 6.78E-05 0.031 
cg23374992 2 136872067 N_Shore CXCR4 -33.5 6.80E-05 0.031 
cg10126903 16 29675214 N_Shelf SPN -54.1 6.80E-05 0.031 
cg09624565 22 37256900 
 
NCF4 -41.8 6.81E-05 0.031 
cg11787176 14 96643191 
 
NA 41.3 6.82E-05 0.031 
cg13121428 14 76446161 N_Shelf TGFB3 34.9 6.82E-05 0.031 
cg01111041 6 32121055 
 
PPT2 45.4 6.85E-05 0.031 
cg00974864 1 161601053 N_Shore FCGR3B -74.8 6.85E-05 0.031 
cg19118972 3 184323327 S_Shore NA -73.4 6.85E-05 0.031 
cg07721547 22 42475119 N_Shore SMDT1 65.8 6.88E-05 0.031 
cg18766033 5 73729290 
 
NA -40.2 6.88E-05 0.031 
cg23129452 X 48542179 
 
WAS -44.7 6.88E-05 0.031 
cg16017420 12 1642879 S_Shelf NA -52.6 6.89E-05 0.031 
cg18835472 6 26546056 
 
HMGN4 -45.4 6.90E-05 0.031 
cg16960675 3 58626434 
 
FAM3D 335.7 6.91E-05 0.031 
cg01997629 1 209929622 
 
TRAF3IP3 -54.3 6.92E-05 0.031 
cg05703096 16 66887291 
 
CA7 -36.6 6.96E-05 0.032 
cg26967723 5 169617918 
 
NA -78.2 6.97E-05 0.032 
cg16362481 2 128413009 S_Shelf LIMS2 -64.3 6.98E-05 0.032 
cg03514239 1 153329781 
 
S100A9 -82.3 6.99E-05 0.032 
cg05897963 19 30157918 S_Shore PLEKHF1 46.5 7.01E-05 0.032 
cg08659179 5 27038707 
 
CDH9 76.3 7.04E-05 0.032 
cg00620452 3 32147645 N_Shore GPD1L 54.0 7.05E-05 0.032 
cg01250001 8 103758088 
 
NA 23.7 7.07E-05 0.032 
cg19590858 14 35009852 S_Shore EAPP -63.7 7.08E-05 0.032 
cg07389611 17 59540267 S_Shore TBX4 -38.5 7.09E-05 0.032 
cg20674521 22 38850521 N_Shore KCNJ4 -45.4 7.09E-05 0.032 
cg06508867 16 87814178 S_Shore NA -51.4 7.11E-05 0.032 
cg07631435 11 114043903 
 
ZBTB16 -39.2 7.15E-05 0.032 
cg01479396 17 7529693 N_Shore SAT2 -58.7 7.16E-05 0.032 
cg21877005 1 109242103 
 
PRPF38B -63.6 7.17E-05 0.032 
cg15965716 1 164688315 
 
PBX1 27.6 7.18E-05 0.032 
cg08952844 2 88313351 N_Shelf NA -65.1 7.22E-05 0.032 
cg02671382 1 120457856 
 
NOTCH2 56.3 7.25E-05 0.032 
cg23682913 1 2080710 N_Shore PRKCZ -57.1 7.25E-05 0.032 
cg26360402 14 105973994 
 
NA -45.2 7.25E-05 0.032 
cg26154999 2 225266346 
 
FAM124B -38.4 7.30E-05 0.032 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg13320202 3 63899097 S_Shore ATXN7 41.5 7.35E-05 0.032 
cg01991752 14 101014148 S_Shore BEGAIN -44.9 7.35E-05 0.032 
cg01120874 9 133811816 N_Shore FIBCD1 -46.8 7.37E-05 0.032 
cg13279083 4 110128090 
 
COL25A1 42.1 7.39E-05 0.032 
cg25864762 7 1850388 
 
NA 40.6 7.41E-05 0.032 
cg13394491 5 15737401 
 
FBXL7 38.2 7.42E-05 0.032 
cg26215869 14 73384273 S_Shore NA -40.3 7.44E-05 0.032 
cg09307264 17 4902281 
 
KIF1C 46.4 7.44E-05 0.032 
cg08802053 5 92932045 S_Shore MIR548AO -51.2 7.45E-05 0.032 
cg11783014 6 149285854 
 
LOC100128176 -81.3 7.52E-05 0.033 
cg02861504 1 207144367 
 
FCAMR -58.5 7.53E-05 0.033 
cg27294164 1 36585141 
 
NA 31.9 7.54E-05 0.033 
cg10732094 19 45957466 S_Shelf NA -52.8 7.57E-05 0.033 
cg25524052 4 182795806 
 
NA -112.9 7.58E-05 0.033 
cg23530268 17 74925720 Island MGAT5B -21.5 7.59E-05 0.033 
cg04681525 9 132145577 N_Shelf NA -74.1 7.59E-05 0.033 
cg03342032 13 94725495 
 
GPC6 26.9 7.61E-05 0.033 
cg26915370 7 134575524 
 
CALD1 24.3 7.61E-05 0.033 
cg03857553 22 29976613 N_Shore NIPSNAP1 25.2 7.62E-05 0.033 
cg04086097 7 128580792 S_Shelf IRF5 -37.7 7.67E-05 0.033 
cg23501051 11 19736912 S_Shore LOC100126784 24.3 7.69E-05 0.033 
cg25975856 3 19930780 
 
EFHB 72.3 7.69E-05 0.033 
cg26938118 18 56059556 S_Shore NEDD4L 53.8 7.70E-05 0.033 
cg21252523 7 27254071 
 
NA -58.3 7.70E-05 0.033 
cg07595602 1 240783371 
 
NA 35.3 7.72E-05 0.033 
cg24902557 14 105715464 Island BRF1 171.5 7.73E-05 0.033 
cg25983531 7 36765142 
 
AOAH -25.7 7.73E-05 0.033 
cg26889953 15 22915992 
 
CYFIP1 -37.9 7.73E-05 0.033 
cg13819552 9 95799870 Island NA -45.7 7.74E-05 0.033 
cg00258809 3 72704324 
 
NA 155.6 7.74E-05 0.033 
cg09580822 10 130834003 
 
NA -33.1 7.77E-05 0.033 
cg22694635 19 36362894 N_Shelf APLP1 -71.0 7.78E-05 0.033 
cg07031070 6 28543670 
 
SCAND3 -64.5 7.79E-05 0.033 
cg09372486 19 31845489 Island NA -52.6 7.86E-05 0.033 
cg03315764 1 29448425 S_Shore TMEM200B 192.5 7.86E-05 0.033 
cg16217908 3 111809470 S_Shelf C3orf52 -29.0 7.86E-05 0.033 
cg13857210 9 138999217 
 
NA -39.7 7.88E-05 0.033 
cg05654164 1 85725892 S_Shore C1orf52 39.4 7.89E-05 0.033 
cg17050616 22 50585229 
 
MOV10L1 36.4 7.92E-05 0.033 
cg10763594 2 218258333 
 
DIRC3 24.8 7.93E-05 0.033 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg05212260 17 39791766 
 
KRT42P 38.5 7.97E-05 0.033 
cg15417654 3 187959138 
 
LPP 46.5 7.98E-05 0.033 
cg14515803 14 100120874 S_Shore HHIPL1 22.5 8.01E-05 0.033 
cg04718447 16 85518989 N_Shore NA -54.5 8.02E-05 0.033 
cg22787468 17 27309113 N_Shelf SEZ6 -77.1 8.04E-05 0.033 
cg04467549 17 79921715 S_Shore NOTUM -67.4 8.05E-05 0.033 
cg23517605 6 3228365 Island TUBB2B 67.7 8.06E-05 0.033 
cg14188712 13 31942544 
 
NA -69.5 8.07E-05 0.033 
cg03838168 X 48433876 S_Shore RBM3 73.8 8.09E-05 0.033 
cg00471059 5 179562620 N_Shore RASGEF1C -96.1 8.12E-05 0.033 
cg22609908 12 858759 N_Shelf WNK1 -27.7 8.12E-05 0.033 
cg17675088 5 93013224 
 
FAM172A 30.1 8.13E-05 0.033 
cg26258213 10 127220321 
 
NA 25.2 8.13E-05 0.033 
cg04913246 14 99658630 
 
BCL11B 113.4 8.13E-05 0.033 
cg13725803 13 51640297 
 
GUCY1B2 -71.1 8.14E-05 0.033 
cg03841081 3 150967799 
 
P2RY14 -73.8 8.14E-05 0.033 
cg16706749 15 74222816 S_Shelf LOXL1-AS1 54.5 8.16E-05 0.033 
cg26158133 5 72824251 
 
NA -23.6 8.17E-05 0.033 
cg19186380 12 54427029 Island HOXC5 48.1 8.19E-05 0.033 
cg17975379 6 4893429 
 
CDYL -50.9 8.23E-05 0.033 
cg26371957 12 739280 
 
NINJ2 -18.0 8.24E-05 0.033 
cg27306802 1 3510561 N_Shore MEGF6 -26.4 8.26E-05 0.033 
cg01921323 7 153881192 
 
DPP6 40.4 8.27E-05 0.033 
cg05752118 11 2920564 N_Shelf SLC22A18 -73.5 8.29E-05 0.033 
cg18479249 6 19180718 
 
NA 34.8 8.37E-05 0.033 
cg14371731 10 81003175 Island ZMIZ1 55.5 8.39E-05 0.033 
cg07051833 12 93808395 
 
UBE2N -41.3 8.40E-05 0.033 
cg24872300 19 607586 N_Shelf HCN2 -52.2 8.41E-05 0.033 
cg01102073 3 128204813 N_Shore GATA2 49.4 8.42E-05 0.033 
cg06958766 14 76446087 N_Shelf TGFB3 27.8 8.43E-05 0.033 
cg18809126 3 11623526 
 
VGLL4 36.9 8.44E-05 0.033 
cg25228625 17 8127373 S_Shore LINC00324 37.3 8.48E-05 0.034 
cg25600256 4 127837396 
 
NA 75.2 8.50E-05 0.034 
cg10154597 10 134910271 N_Shore GPR123 26.9 8.51E-05 0.034 
cg14688905 12 51403056 
 
SLC11A2 -64.3 8.56E-05 0.034 
cg23013850 2 225266304 
 
FAM124B -33.6 8.58E-05 0.034 
cg02083676 3 127311156 S_Shore TPRA1 -66.3 8.59E-05 0.034 
cg11147094 15 88420438 
 
NTRK3 -97.9 8.61E-05 0.034 
cg07699546 1 201790194 
 
NAV1 -45.1 8.62E-05 0.034 
cg13826666 9 136600241 
 
SARDH -52.6 8.63E-05 0.034 
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cg11569159 12 115172959 N_Shore NA -38.3 8.64E-05 0.034 
cg20379671 22 39320879 N_Shelf NA 31.7 8.66E-05 0.034 
cg17974247 18 77336267 Island NA 25.1 8.67E-05 0.034 
cg12158889 2 84663044 
 
SUCLG1 66.0 8.68E-05 0.034 
cg09424308 4 7046094 N_Shore TADA2B 39.4 8.69E-05 0.034 
cg04267345 14 24835104 S_Shore NFATC4 393.2 8.69E-05 0.034 
cg25432518 7 1894300 N_Shore MAD1L1 -68.3 8.69E-05 0.034 
cg18624544 14 21567646 
 
ZNF219 25.0 8.72E-05 0.034 
cg06690535 3 196352142 S_Shore NA -41.7 8.72E-05 0.034 
cg14015015 6 35327915 Island PPARD 38.5 8.73E-05 0.034 
cg12378878 13 50700606 
 
DLEU2 -41.4 8.73E-05 0.034 
cg05533539 17 44104521 
 
MAPT -54.3 8.74E-05 0.034 
cg21734175 12 121107042 
 
NA 34.5 8.76E-05 0.034 
cg02169391 7 130126176 Island MEST -44.0 8.77E-05 0.034 
cg25520910 2 114576197 
 
NA 33.4 8.77E-05 0.034 
cg20098854 8 898407 
 
ERICH1-AS1 -39.5 8.81E-05 0.034 
cg10825315 14 81425912 
 
TSHR -42.3 8.81E-05 0.034 
cg08564172 5 73833812 
 
NA -21.6 8.82E-05 0.034 
cg26488183 15 75195105 
 
FAM219B -70.7 8.83E-05 0.034 
cg02497428 16 21665138 N_Shelf IGSF6 -48.4 8.83E-05 0.034 
cg07571344 20 1472071 
 
SIRPB2 -37.8 8.84E-05 0.034 
cg24425149 13 75991251 
 
TBC1D4 -36.8 8.85E-05 0.034 
cg05714729 18 33234096 
 
GALNT1 -58.5 8.86E-05 0.034 
cg07276534 3 193534580 
 
NA 36.6 8.88E-05 0.034 
cg11870455 3 187491295 
 
NA -40.3 8.94E-05 0.034 
cg07617207 2 161920006 
 
NA 31.9 8.95E-05 0.034 
cg24782497 19 18385409 
 
KIAA1683 -65.5 8.96E-05 0.034 
cg05494008 8 145579285 S_Shore TMEM249 -63.7 8.98E-05 0.034 
cg15739581 2 166626783 
 
GALNT3 -73.6 9.00E-05 0.034 
cg11795276 12 54454252 Island FLJ12825 -35.2 9.02E-05 0.034 
cg22904401 5 92947872 
 
MIR548AO 55.7 9.03E-05 0.034 
cg23668195 2 62805851 Island NA 21.0 9.05E-05 0.034 
cg23476456 X 110039192 
 
CHRDL1 73.4 9.05E-05 0.034 
cg04179148 14 94858339 
 
SERPINA1 -69.9 9.07E-05 0.034 
cg23850913 6 15505452 
 
JARID2 47.7 9.07E-05 0.034 
cg14510967 11 2321803 
 
C11orf21 -54.0 9.08E-05 0.034 
cg18343862 11 10590003 
 
LYVE1 -59.8 9.10E-05 0.034 
cg24607398 3 37033625 N_Shore EPM2AIP1 31.2 9.12E-05 0.034 
cg18046677 19 49220142 N_Shelf MAMSTR 36.1 9.13E-05 0.034 
cg14138312 9 6869699 
 
KDM4C -141.8 9.14E-05 0.034 
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cg02863169 2 45173548 S_Shore SIX3 -92.9 9.16E-05 0.034 
cg11300147 12 7596703 S_Shelf CD163L1 -25.4 9.21E-05 0.034 
cg10283690 1 245027135 
 
HNRNPU 1783.5 9.25E-05 0.034 
cg19716542 1 52302074 Island MIR761 -235.1 9.25E-05 0.034 
cg09197279 2 196966508 
 
NA 42.9 9.25E-05 0.034 
cg09683440 16 83869927 
 
NA -22.7 9.27E-05 0.034 
cg12081303 1 161039681 
 
ARHGAP30 -59.2 9.27E-05 0.034 
cg01416295 1 156710278 N_Shore MRPL24 172.9 9.31E-05 0.034 
cg18662080 13 29057716 
 
FLT1 41.0 9.32E-05 0.034 
cg12080566 2 75798232 
 
EVA1A 68.7 9.38E-05 0.034 
cg19832184 20 33578069 
 
MIR499A -107.8 9.47E-05 0.034 
cg21910709 5 893665 S_Shore TRIP13 35.5 9.48E-05 0.034 
cg11697038 1 27931284 S_Shore AHDC1 42.0 9.48E-05 0.034 
cg06389605 6 168147420 
 
NA -95.8 9.49E-05 0.034 
cg09976669 11 9738663 
 
SWAP70 -25.6 9.49E-05 0.034 
cg24361808 22 46477834 
 
MIRLET7BHG 47.5 9.51E-05 0.034 
cg09076077 20 58630315 N_Shelf C20orf197 -49.7 9.51E-05 0.034 
cg07517739 10 132364391 N_Shore NA 24.2 9.52E-05 0.034 
cg25487405 22 46473039 
 
NA 39.9 9.54E-05 0.034 
cg01636910 1 85740751 N_Shore LOC646626 -22.2 9.57E-05 0.035 
cg12646804 5 2008188 Island NA 37.6 9.62E-05 0.035 
cg19998150 10 14051838 
 
FRMD4A 50.3 9.63E-05 0.035 
cg03977385 16 48468609 
 
NA -35.1 9.65E-05 0.035 
cg23379806 10 14650660 S_Shelf FAM107B -53.7 9.65E-05 0.035 
cg02217815 22 36890079 N_Shelf FOXRED2 -37.2 9.67E-05 0.035 
cg08354401 5 177824353 S_Shore COL23A1 48.9 9.69E-05 0.035 
cg20316779 1 225997649 Island EPHX1 696.4 9.70E-05 0.035 
cg12926693 6 36665611 
 
RAB44 -50.2 9.72E-05 0.035 
cg26863600 19 2616921 S_Shelf GNG7 -25.1 9.72E-05 0.035 
cg07431973 14 52142383 
 
FRMD6 30.3 9.78E-05 0.035 
cg24087669 5 5419515 N_Shelf KIAA0947 43.6 9.79E-05 0.035 
cg13134916 12 25707564 
 
IFLTD1 -58.9 9.80E-05 0.035 
cg22325580 8 1899943 
 
ARHGEF10 -71.3 9.81E-05 0.035 
cg08433504 15 39872071 N_Shore THBS1 57.7 9.84E-05 0.035 
cg03389926 2 42651266 
 
NA 26.4 9.85E-05 0.035 
cg14527344 6 28554680 N_Shore SCAND3 48.5 9.85E-05 0.035 
cg01117339 11 73737124 
 
NA -50.9 9.86E-05 0.035 
cg03891346 11 121970725 
 
MIR125B1 25.2 9.91E-05 0.035 
cg19925518 10 90851787 
 
NA -26.4 9.91E-05 0.035 
cg08817540 3 108020727 
 
HHLA2 -28.4 9.92E-05 0.035 
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cg25226226 17 47591494 S_Shore NGFR 55.5 9.93E-05 0.035 
cg27542466 15 90728004 Island SEMA4B 58.0 9.93E-05 0.035 
cg25569396 6 11382769 N_Shelf NEDD9 -48.0 9.95E-05 0.035 
cg13338454 4 77659228 
 
SHROOM3 23.9 9.95E-05 0.035 
cg11882304 5 159456907 
 
TTC1 46.1 9.96E-05 0.035 
cg24089887 13 74899532 
 
NA 33.9 9.96E-05 0.035 
cg14909495 7 150549472 
 
AOC1 -57.5 9.98E-05 0.035 
cg06059409 11 73036247 
 
ARHGEF17 46.4 0.0001 0.035 
cg00504782 1 111037272 
 
NA -44.0 0.0001 0.035 
cg05667818 7 116786870 
 
ST7-AS2 -58.9 0.0001 0.035 
cg06898214 22 50585400 
 
MOV10L1 24.4 0.0001 0.035 
cg02691685 19 55851042 Island SUV420H2 2330.9 0.000101 0.035 
cg19801705 5 180542156 Island NA 187.5 0.000101 0.035 
cg15953461 14 77489763 N_Shelf NA 33.9 0.000101 0.035 
cg04233230 1 155910958 
 
RXFP4 -68.9 0.000101 0.035 
cg13039082 11 77123331 S_Shore PAK1 32.9 0.000101 0.035 
cg00107982 22 37813098 N_Shelf ELFN2 -21.1 0.000102 0.035 
cg00283535 8 124749564 
 
ANXA13 35.4 0.000102 0.035 
cg04206724 16 11027999 
 
DEXI -181.9 0.000102 0.035 
cg03739609 6 31555016 
 
LST1 -66.1 0.000103 0.035 
cg05499338 16 81517665 
 
CMIP -109.7 0.000103 0.035 
cg15358372 10 71108752 
 
HK1 -26.8 0.000103 0.035 
cg08550394 16 4013659 N_Shore ADCY9 -44.0 0.000103 0.035 
cg08914797 11 126870648 S_Shore KIRREL3 339.8 0.000103 0.035 
cg13019306 5 145155873 
 
PRELID2 32.1 0.000103 0.035 
cg20927119 7 149999961 
 
ACTR3C -42.2 0.000104 0.035 
cg00453717 11 74344629 
 
POLD3 -105.8 0.000104 0.035 
cg13594542 9 138850547 N_Shelf UBAC1 -57.7 0.000104 0.035 
cg03398002 1 15272082 
 
KAZN 28.5 0.000104 0.035 
cg10959668 3 195897912 
 
NA -60.2 0.000104 0.035 
cg20701531 2 121583695 
 
GLI2 41.5 0.000105 0.035 
cg26124860 3 42918681 N_Shelf CYP8B1 -95.7 0.000105 0.035 
cg10871721 21 46235052 N_Shore SUMO3 -52.3 0.000105 0.035 
cg15234627 13 33837178 
 
STARD13 -55.5 0.000105 0.036 
cg02026204 22 30663007 
 
OSM -39.6 0.000105 0.036 
cg13247967 11 123487358 
 
GRAMD1B 30.3 0.000106 0.036 
cg14779327 7 137931748 
 
NA 70.9 0.000106 0.036 
cg13705284 3 58523313 
 
ACOX2 31.5 0.000106 0.036 
cg16734981 11 109259766 
 
NA -21.8 0.000106 0.036 
cg25210609 1 19642293 S_Shelf PQLC2 -71.2 0.000106 0.036 
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cg17074396 22 49843754 Island NA 85.5 0.000106 0.036 
cg04972244 16 57117433 
 
NLRC5 -73.5 0.000107 0.036 
cg21616142 22 28076037 S_Shore NA -71.4 0.000107 0.036 
cg04890406 3 48647370 Island UQCRC1 126.6 0.000107 0.036 
cg05923857 10 114911615 
 
TCF7L2 -41.2 0.000107 0.036 
cg24674220 20 62251901 
 
GMEB2 80.5 0.000107 0.036 
cg09999348 2 46398848 
 
PRKCE 45.0 0.000107 0.036 
cg15806306 11 2893385 S_Shelf KCNQ1DN -50.6 0.000108 0.036 
cg26053480 7 25898758 Island NA -45.6 0.000108 0.036 
cg03277819 12 772529 
 
NINJ2 26.0 0.000108 0.036 
cg08310008 12 52836644 
 
NA 54.4 0.000108 0.036 
cg02978220 1 108337960 
 
VAV3 -83.8 0.000108 0.036 
cg02935298 22 43036734 
 
ATP5L2 -62.6 0.000108 0.036 
cg26363555 11 121973044 
 
MIR125B1 27.8 0.000109 0.036 
cg03313654 16 863510 Island PRR25 129.0 0.000109 0.036 
cg10277646 2 129079038 N_Shore HS6ST1 -98.6 0.000109 0.036 
cg24149590 14 75867231 
 
NA -47.2 0.000109 0.036 
cg09146459 6 32921200 
 
HLA-DMA -31.1 0.00011 0.036 
cg06218186 7 99691644 
 
MIR106B 50.1 0.00011 0.036 
cg26545040 19 994110 Island WDR18 36.5 0.00011 0.036 
cg23666844 7 151137882 S_Shore CRYGN 67.0 0.00011 0.036 
cg16302816 11 16834800 
 
PLEKHA7 -50.7 0.00011 0.036 
cg19760965 3 194868843 
 
XXYLT1-AS2 -58.2 0.000111 0.036 
cg10781468 6 168778312 
 
NA 36.7 0.000111 0.036 
cg04381249 20 61404888 S_Shore LINC00659 36.5 0.000111 0.036 
cg16129800 11 2920414 N_Shelf SLC22A18 -55.8 0.000111 0.036 
cg24475272 4 140432613 
 
SETD7 -34.8 0.000111 0.036 
cg20271057 3 16974160 
 
PLCL2 -56.9 0.000111 0.036 
cg05619785 6 32078574 
 
TNXB 31.7 0.000112 0.036 
cg00343906 1 1696692 
 
NADK -94.8 0.000112 0.036 
cg17828057 8 42037527 
 
PLAT -45.5 0.000112 0.036 
cg17182817 10 112624555 
 
NA -25.3 0.000112 0.036 
cg07684519 12 29303184 S_Shore FAR2 -65.9 0.000112 0.036 
cg23787937 12 29303160 S_Shore FAR2 -49.0 0.000112 0.036 
cg08160072 2 40009501 S_Shelf THUMPD2 -43.9 0.000112 0.036 
cg11141696 1 161700167 S_Shelf NA -39.7 0.000113 0.036 
cg19947463 7 1113237 
 
C7orf50 -31.9 0.000113 0.036 
cg14613786 18 48255506 N_Shore MAPK4 -72.0 0.000113 0.036 
cg24394336 1 17962705 
 
ARHGEF10L -55.8 0.000113 0.036 
cg12929160 13 77030645 
 
NA -43.1 0.000113 0.036 
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cg18710162 17 33390808 
 
RFFL -30.3 0.000113 0.036 
cg12666279 2 115918745 Island LOC389023 -197.8 0.000113 0.036 
cg09289820 6 30421275 S_Shore NA -50.0 0.000114 0.036 
cg07046426 2 237623903 
 
NA -27.0 0.000114 0.036 
cg12049550 1 65035261 
 
CACHD1 -65.5 0.000114 0.036 
cg00790255 3 194032074 N_Shore LINC00887 54.8 0.000114 0.036 
cg13577075 12 123444414 Island ABCB9 -233.5 0.000114 0.036 
cg10087754 7 2678263 
 
TTYH3 49.1 0.000114 0.036 
cg12661092 10 98861029 
 
LOC100505540 -78.3 0.000114 0.036 
cg02574844 11 5959923 
 
NA -23.5 0.000115 0.036 
cg26830558 11 69874845 
 
NA -69.0 0.000115 0.036 
cg17012513 X 2984799 
 
ARSF 43.0 0.000115 0.036 
cg00975624 3 159646501 
 
NA -45.0 0.000115 0.036 
cg17869960 6 12718530 
 
PHACTR1 21.9 0.000115 0.036 
cg18320356 12 10103812 
 
CLEC12A -38.2 0.000115 0.036 
cg10405075 16 79463964 
 
NA 33.9 0.000115 0.036 
cg03116466 7 2116512 Island MAD1L1 -73.2 0.000116 0.036 
cg12751042 12 12874288 N_Shelf CDKN1B -24.5 0.000116 0.036 
cg14347914 9 96706239 N_Shore NA -51.0 0.000116 0.036 
cg02713951 22 46516291 N_Shelf NA 42.2 0.000116 0.036 
cg02224021 19 836716 Island PRTN3 -54.4 0.000116 0.036 
cg00644351 10 121271840 
 
RGS10 -42.4 0.000116 0.036 
cg07984358 10 24704829 
 
KIAA1217 37.2 0.000117 0.036 
cg10783294 12 679668 S_Shore NINJ2 49.2 0.000117 0.036 
cg27009704 5 118367693 
 
NA -87.5 0.000117 0.036 
cg15414034 19 10196462 N_Shore C19orf66 45.9 0.000117 0.036 
cg03924115 9 133768966 
 
QRFP -40.7 0.000118 0.036 
cg02874658 12 52265308 S_Shelf NA -110.5 0.000118 0.036 
cg07207490 11 118492463 
 
PHLDB1 21.9 0.000118 0.036 
cg03190661 17 76126702 N_Shore TMC8 -29.6 0.000118 0.036 
cg26769927 16 29674972 N_Shore SPN -66.9 0.000118 0.036 
cg26100303 3 114099712 
 
ZBTB20 30.3 0.000118 0.036 
cg14734668 10 20864693 
 
NA -33.3 0.000118 0.036 
cg21240684 2 3526841 S_Shelf ADI1 40.7 0.000119 0.037 
cg06663317 16 56641101 N_Shore MT2A 47.6 0.000119 0.037 
cg23139609 6 105901342 
 
NA -31.1 0.000119 0.037 
cg02993722 1 6698457 
 
DNAJC11 37.1 0.00012 0.037 
cg04337358 14 98489522 
 
NA -25.8 0.00012 0.037 
cg10132694 19 54876752 
 
LAIR1 -41.5 0.00012 0.037 
cg11772801 14 51711237 S_Shelf TMX1 -56.7 0.00012 0.037 
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cg05689208 8 49496391 
 
NA 41.6 0.000121 0.037 
cg06495586 4 54424787 
 
LNX1 -27.9 0.000121 0.037 
cg05874270 1 2559893 Island MMEL1 56.8 0.000121 0.037 
cg07114627 1 110155839 
 
GNAT2 -58.0 0.000121 0.037 
cg17973038 8 99395068 
 
NA 44.3 0.000121 0.037 
cg24691042 5 171708977 N_Shore UBTD2 23.8 0.000121 0.037 
cg16813662 13 100650387 Island NA -50.0 0.000122 0.037 
cg00353571 19 49238653 Island RASIP1 53.0 0.000122 0.037 
cg06789856 17 77133777 N_Shore RBFOX3 36.5 0.000122 0.037 
cg05568930 11 75522399 N_Shelf UVRAG -62.1 0.000122 0.037 
cg21870662 17 2241570 S_Shore SGSM2 92.8 0.000122 0.037 
cg20706196 1 109242775 
 
PRPF38B -35.0 0.000122 0.037 
cg10512278 16 68027839 S_Shore DPEP2 -65.6 0.000123 0.037 
cg12004276 11 33913586 
 
LMO2 -65.9 0.000123 0.037 
cg06335008 2 99552109 N_Shore KIAA1211L 103.5 0.000123 0.037 
cg13071185 11 860134 S_Shore TSPAN4 27.4 0.000123 0.037 
cg14502319 12 125167409 
 
NA -60.8 0.000123 0.037 
cg15432485 12 2039878 
 
LINC00940 -59.3 0.000123 0.037 
cg01585860 6 75922610 
 
NA -60.1 0.000123 0.037 
cg20897136 10 74034667 Island DDIT4 53.3 0.000124 0.037 
cg07993586 7 157204960 N_Shore DNAJB6 -157.4 0.000124 0.037 
cg22148297 13 99910587 
 
GPR18 -43.3 0.000124 0.037 
cg23526586 12 105917092 
 
NA 31.1 0.000124 0.037 
cg27285720 1 89664782 
 
GBP4 -21.5 0.000124 0.037 
cg13149147 2 105757726 N_Shelf NA -52.3 0.000125 0.037 
cg11691844 11 85460604 
 
SYTL2 -53.9 0.000125 0.037 
cg15600966 6 31602257 S_Shelf PRRC2A 89.9 0.000125 0.037 
cg15605124 1 3230250 
 
PRDM16 37.8 0.000125 0.037 
cg08993690 4 124621838 
 
LOC285419 26.7 0.000125 0.037 
cg09603024 20 48599292 Island SNAI1 176.7 0.000125 0.037 
cg07310671 16 85253980 
 
NA 40.2 0.000125 0.037 
cg14271729 14 57858383 S_Shore NAA30 56.4 0.000125 0.037 
cg14772955 1 36024404 S_Shore NCDN 61.7 0.000125 0.037 
cg24034453 17 17597825 Island RAI1 171.0 0.000125 0.037 
cg27452278 8 102178508 
 
NA -84.5 0.000126 0.037 
cg02395819 12 108237572 Island NA 72.6 0.000126 0.037 
cg27540367 19 41848134 
 
TGFB1 -58.9 0.000126 0.037 
cg06871560 15 52944233 
 
FAM214A 64.1 0.000126 0.037 
cg24733384 14 35516283 S_Shore FAM177A1 49.4 0.000126 0.037 
cg19579652 10 433089 
 
DIP2C 27.2 0.000126 0.037 
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cg13817037 9 36100589 
 
RECK 38.7 0.000126 0.037 
cg16588947 12 131498749 
 
GPR133 -131.2 0.000127 0.037 
cg04509542 11 29358540 
 
NA 35.5 0.000127 0.037 
cg02124699 17 30590156 N_Shelf RHBDL3 62.8 0.000127 0.037 
cg15719339 21 17960584 
 
MIR125B2 35.5 0.000127 0.037 
cg22911867 11 126173548 Island DCPS 64.3 0.000127 0.037 
cg20978380 12 125001165 N_Shore NCOR2 33.3 0.000127 0.037 
cg26984593 10 14051636 
 
FRMD4A 44.9 0.000127 0.037 
cg16129526 14 69968273 
 
PLEKHD1 35.5 0.000127 0.037 
cg18275620 6 110591226 
 
METTL24 30.8 0.000127 0.037 
cg13043454 2 48980605 N_Shelf LHCGR -70.1 0.000127 0.037 
cg13728131 11 19799633 S_Shore NAV2 56.8 0.000128 0.037 
cg20535781 12 133465013 S_Shore CHFR 49.4 0.000128 0.037 
cg15382933 11 33745399 
 
CD59 -35.8 0.000128 0.037 
cg22487204 1 156435421 
 
MEF2D 88.4 0.000128 0.037 
cg15674813 2 238608549 
 
LRRFIP1 -51.6 0.000128 0.037 
cg12042264 20 44448693 N_Shelf NA -59.4 0.000128 0.037 
cg15339981 12 2942368 
 
NRIP2 39.9 0.000128 0.037 
cg11410920 20 43997025 
 
SYS1-DBNDD2 -66.9 0.000128 0.037 
cg21031128 8 21771278 S_Shore DOK2 -47.8 0.000129 0.037 
cg19102740 6 33860642 
 
LOC100507584 -79.6 0.000129 0.037 
cg14608454 9 140106083 N_Shore NDOR1 -119.3 0.000129 0.037 
cg26814335 8 6584320 
 
AGPAT5 -79.8 0.000129 0.037 
cg05756918 7 27253707 Island NA -47.8 0.000129 0.037 
cg25204955 10 72254314 
 
PALD1 -48.3 0.00013 0.037 
cg25742037 11 2171694 
 
IGF2 36.0 0.00013 0.037 
cg00136477 1 22970339 N_Shelf C1QC -54.4 0.00013 0.037 
cg02771464 22 19108494 N_Shore DGCR2 33.0 0.000131 0.037 
cg03715057 6 164009761 
 
NA -95.8 0.000131 0.037 
cg14944269 14 65439602 S_Shore RAB15 45.4 0.000131 0.037 
cg06673130 4 778924 Island LOC100129917 -44.0 0.000131 0.037 
cg04615460 12 115125098 Island TBX3 -37.0 0.000131 0.037 
cg07484220 16 136809 
 
NPRL3 26.8 0.000131 0.037 
cg15215077 6 119561839 
 
MAN1A1 -40.2 0.000131 0.037 
cg09888840 11 57252371 S_Shore SLC43A1 -78.4 0.000131 0.037 
cg05125838 3 48601585 
 
UCN2 -64.6 0.000131 0.037 
cg21268658 1 43998294 S_Shore PTPRF 32.7 0.000132 0.037 
cg11480762 10 73103395 
 
SLC29A3 -68.2 0.000132 0.037 
cg03690812 12 111875483 
 
SH2B3 -81.0 0.000132 0.037 
cg18333339 3 112885856 
 
NA 40.0 0.000132 0.037 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg17113856 6 32120895 N_Shore PPT2 32.5 0.000132 0.037 
cg20087093 7 27142799 N_Shore HOXA2 -22.6 0.000132 0.037 
cg08183317 13 114261934 S_Shore TFDP1 -54.9 0.000133 0.037 
cg13344587 10 63723919 
 
ARID5B 41.7 0.000133 0.037 
cg25685359 22 46473721 
 
NA 53.4 0.000133 0.037 
cg24250588 1 43203008 N_Shore CLDN19 -33.5 0.000133 0.037 
cg05227055 16 89105031 N_Shelf NA 145.3 0.000134 0.037 
cg01191154 22 37593672 N_Shore NA 35.6 0.000134 0.037 
cg18351781 19 4950888 Island UHRF1 -64.8 0.000134 0.037 
cg21785723 1 6551782 S_Shore PLEKHG5 -62.3 0.000134 0.037 
cg14272084 14 61685564 
 
NA -32.2 0.000134 0.037 
cg03301498 19 39889222 N_Shelf MED29 -61.8 0.000134 0.037 
cg23753807 17 1090291 
 
ABR 35.5 0.000134 0.037 
cg15514896 1 229074115 
 
NA -34.1 0.000134 0.037 
cg23723486 7 101361745 
 
NA -45.4 0.000134 0.037 
cg19460792 15 47676823 
 
SEMA6D 35.9 0.000135 0.037 
cg05861512 14 94442960 
 
ASB2 -34.0 0.000135 0.037 
cg03247944 12 3472883 N_Shelf NA -34.5 0.000135 0.037 
cg06545464 6 32299649 
 
C6orf10 -87.0 0.000135 0.037 
cg06064964 20 62199181 N_Shore HELZ2 -43.7 0.000135 0.037 
cg19771173 1 204296545 
 
PLEKHA6 -41.5 0.000136 0.037 
cg27308445 5 149699675 
 
NA 25.5 0.000136 0.037 
cg08981777 19 48497737 
 
ELSPBP1 28.1 0.000136 0.037 
cg13695585 6 30853014 S_Shore DDR1 34.1 0.000136 0.037 
cg07489413 11 2321937 
 
C11orf21 -43.1 0.000136 0.037 
cg20668644 17 38347603 Island RAPGEFL1 1195.5 0.000137 0.037 
cg17147917 8 119809044 
 
NA 52.5 0.000137 0.037 
cg03755794 5 156390431 
 
TIMD4 -71.9 0.000137 0.037 
cg06366374 6 6543659 N_Shelf LY86-AS1 -48.8 0.000137 0.037 
cg04880487 11 68436821 N_Shore NA -63.8 0.000137 0.037 
cg25501422 2 121108133 S_Shore INHBB -63.4 0.000138 0.037 
cg20454518 12 133135463 Island FBRSL1 -45.1 0.000138 0.037 
cg01372551 7 98050564 
 
NA 57.3 0.000138 0.037 
cg06332304 10 126782397 
 
CTBP2 33.6 0.000138 0.037 
cg16260126 10 4892269 
 
NA -29.3 0.000138 0.037 
cg04318619 17 1090300 
 
ABR 29.1 0.000138 0.037 
cg21023831 2 218769784 
 
TNS1 -51.8 0.000138 0.038 
cg06158944 4 99182422 Island RAP1GDS1 731.6 0.000139 0.038 
cg07110356 17 56355431 Island MPO -58.6 0.000139 0.038 
cg08995327 16 66070379 
 
NA -34.4 0.000139 0.038 
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cg19299755 11 116706051 N_Shore APOA1 -32.5 0.00014 0.038 
cg15010140 2 128644922 S_Shore AMMECR1L 39.4 0.00014 0.038 
cg01289343 13 114814401 Island RASA3 -44.6 0.00014 0.038 
cg26591391 7 117644097 
 
NA -36.3 0.00014 0.038 
cg17742416 2 25499619 N_Shore DNMT3A -53.5 0.00014 0.038 
cg13511576 6 31634890 S_Shore GPANK1 63.2 0.00014 0.038 
cg06108383 6 32120899 N_Shore PPT2 31.2 0.00014 0.038 
cg10996589 12 125017134 
 
NCOR2 27.7 0.00014 0.038 
cg06372522 X 118374789 S_Shelf PGRMC1 29.7 0.00014 0.038 
cg01102307 1 9340416 
 
NA 56.5 0.000141 0.038 
cg26948226 2 192365744 
 
NA 26.7 0.000141 0.038 
cg01458495 3 48310544 
 
ZNF589 25.7 0.000141 0.038 
cg25950638 15 70451935 
 
NA -67.6 0.000141 0.038 
cg13408086 9 140221397 S_Shelf EXD3 -63.7 0.000142 0.038 
cg15096829 1 202092005 
 
GPR37L1 37.3 0.000142 0.038 
cg26741350 19 33462235 N_Shore CEP89 55.3 0.000142 0.038 
cg17661220 20 3693179 
 
NA -56.6 0.000142 0.038 
cg15721134 10 133806677 
 
NA -71.1 0.000142 0.038 
cg16061668 11 70257149 N_Shore CTTN -64.4 0.000143 0.038 
cg22337438 19 54327437 
 
NLRP12 -45.8 0.000143 0.038 
cg15059548 7 47344634 
 
TNS3 -41.6 0.000143 0.038 
cg11185291 9 139744617 Island PHPT1 46.2 0.000143 0.038 
cg10671830 4 7652103 
 
SORCS2 -46.2 0.000143 0.038 
cg09062708 1 61649907 
 
NFIA 33.3 0.000144 0.038 
cg13344855 19 11300651 N_Shelf KANK2 35.4 0.000144 0.038 
cg09358422 1 1023247 Island C1orf159 26.3 0.000144 0.038 
cg23554164 8 118960159 
 
EXT1 55.1 0.000144 0.038 
cg22249566 X 16737422 N_Shore SYAP1 119.6 0.000144 0.038 
cg04204669 11 2193742 
 
MIR4686 -56.6 0.000144 0.038 
cg21218848 9 139604168 N_Shelf FAM69B -157.0 0.000144 0.038 
cg26917745 7 30939723 
 
NA -30.8 0.000145 0.038 
cg18333220 2 75655854 
 
NA -55.3 0.000145 0.038 
cg13939462 6 36843324 S_Shore PPIL1 37.0 0.000145 0.038 
cg16744996 14 70168865 
 
KIAA0247 -23.4 0.000145 0.038 
cg24038762 1 87817476 
 
NA 49.2 0.000145 0.038 
cg05149343 7 25897590 N_Shore NA -40.8 0.000145 0.038 
cg24149237 11 117687628 
 
NA -51.4 0.000146 0.038 
cg23440155 1 47264601 
 
CYP4B1 41.7 0.000146 0.038 
cg09540612 20 62492233 N_Shore ABHD16B -49.5 0.000146 0.038 
cg19187121 15 101628653 N_Shore NA -35.9 0.000146 0.038 
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cg10147479 4 185872977 Island NA -100.7 0.000146 0.038 
cg11941929 18 12429120 N_Shelf SLMO1 -50.2 0.000146 0.038 
cg13483727 18 615471 
 
CLUL1 -69.5 0.000146 0.038 
cg24096540 17 12695725 S_Shelf ARHGAP44 -112.9 0.000146 0.038 
cg11404380 4 41215359 N_Shore APBB2 90.2 0.000146 0.038 
cg03565868 11 47400146 S_Shore SPI1 -47.0 0.000146 0.038 
cg06471380 2 240878436 Island MIR4786 -56.0 0.000146 0.038 
cg01643712 11 112112572 
 
NA 35.6 0.000147 0.038 
cg06481660 6 6824580 
 
NA -117.5 0.000147 0.038 
cg25302015 19 18713816 N_Shelf CRLF1 -72.3 0.000147 0.038 
cg16360668 1 19265059 
 
IFFO2 -44.6 0.000147 0.038 
cg02647628 7 114053988 
 
FOXP2 34.0 0.000147 0.038 
cg16266227 1 202129204 
 
PTPN7 -41.5 0.000147 0.038 
cg03601229 17 73748344 N_Shore ITGB4 -58.1 0.000147 0.038 
cg15366423 18 48089684 S_Shelf MAPK4 -76.5 0.000147 0.038 
cg13521229 19 51013630 N_Shore JOSD2 55.9 0.000147 0.038 
cg08043565 11 12308645 
 
MICALCL 25.0 0.000148 0.038 
cg20367923 6 169624501 S_Shore THBS2 43.5 0.000148 0.038 
cg06959773 7 76033795 S_Shelf SRCRB4D -62.7 0.000148 0.038 
cg22867608 10 64573356 Island EGR2 27.2 0.000148 0.038 
cg13348574 17 207478 S_Shore RPH3AL 46.4 0.000148 0.038 
cg10129493 19 51728586 
 
CD33 -66.2 0.000149 0.038 
cg08545136 17 76775543 N_Shore CYTH1 -54.1 0.000149 0.038 
cg01040259 17 73314451 
 
GRB2 -54.2 0.000149 0.038 
cg25752703 3 128710390 N_Shelf KIAA1257 -42.9 0.000149 0.038 
cg12176605 3 40518138 N_Shore ZNF619 -23.9 0.00015 0.038 
cg01938023 5 138855699 
 
TMEM173 -82.6 0.00015 0.038 
cg04483936 15 57668247 N_Shore CGNL1 -55.4 0.00015 0.038 
cg08610987 1 157972005 
 
KIRREL 25.5 0.00015 0.038 
cg06523948 16 56640947 N_Shore MT2A 36.7 0.00015 0.038 
cg07588216 20 25204045 
 
ENTPD6 84.9 0.000151 0.038 
cg12223090 17 80128788 
 
CCDC57 -84.3 0.000151 0.038 
cg06834507 1 200876957 N_Shelf C1orf106 -57.5 0.000151 0.038 
cg02665037 12 54362496 S_Shore HOTAIR -40.6 0.000151 0.038 
cg25141611 13 113422162 S_Shore ATP11A -57.6 0.000151 0.038 
cg11740845 17 8638742 
 
CCDC42 -58.6 0.000152 0.038 
cg00136547 6 56507796 
 
DST 22.7 0.000152 0.038 
cg22275857 22 38198963 N_Shore H1F0 187.7 0.000152 0.038 
cg04141129 12 32530696 
 
BICD1 -110.7 0.000152 0.038 
cg21746459 9 104160900 Island MRPL50 562.7 0.000153 0.038 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg24129356 6 32920735 
 
HLA-DMA -31.3 0.000153 0.038 
cg08165083 1 10589400 
 
PEX14 -35.7 0.000153 0.038 
cg11363168 8 38470662 
 
NA 39.0 0.000153 0.038 
cg10141022 7 140624905 Island BRAF -465.7 0.000154 0.038 
cg19269039 1 111743200 N_Shelf DENND2D -55.7 0.000154 0.038 
cg09820180 6 140168822 
 
LOC100132735 34.6 0.000154 0.038 
cg09760574 20 34605662 
 
CNBD2 30.8 0.000154 0.038 
cg23497683 2 100759159 
 
AFF3 -35.3 0.000154 0.038 
cg10454879 8 602158 S_Shore NA -28.9 0.000154 0.038 
cg12871835 6 134639417 S_Shore SGK1 93.2 0.000155 0.038 
cg21714809 11 72463184 Island ARAP1 88.2 0.000155 0.038 
cg01710147 1 207233419 
 
PFKFB2 37.6 0.000155 0.038 
cg13670898 14 56792319 
 
NA 25.2 0.000155 0.038 
cg19122948 17 80207982 N_Shore CSNK1D 78.4 0.000155 0.038 
cg04103052 2 1203162 
 
SNTG2 56.0 0.000155 0.038 
cg03191919 3 196134040 
 
UBXN7 28.4 0.000156 0.039 
cg16923982 2 233369610 S_Shore NA -44.3 0.000156 0.039 
cg24523322 1 1023281 Island C1orf159 24.5 0.000156 0.039 
cg27185501 11 12562492 
 
NA 27.9 0.000157 0.039 
cg20061364 6 160582602 
 
NA -88.6 0.000157 0.039 
cg08967456 16 3114948 
 
IL32 -63.2 0.000157 0.039 
cg27182923 3 123129387 
 
ADCY5 -80.8 0.000157 0.039 
cg05628702 20 35491052 Island SOGA1 30.7 0.000157 0.039 
cg05584759 12 57869421 Island ARHGAP9 47.1 0.000157 0.039 
cg11525052 11 2321955 
 
C11orf21 -59.3 0.000157 0.039 
cg08165784 12 107297238 
 
NA 134.2 0.000158 0.039 
cg16637458 13 113585948 
 
NA 29.8 0.000158 0.039 
cg26574754 13 108870827 Island ABHD13 838.7 0.000158 0.039 
cg06655952 5 80364036 
 
RASGRF2 -30.0 0.000158 0.039 
cg00206233 21 44011158 S_Shore NA -33.3 0.000159 0.039 
cg09918657 16 14397207 S_Shore MIR193B -30.6 0.000159 0.039 
cg17470397 3 193308169 N_Shelf OPA1 -90.7 0.000159 0.039 
cg07648709 11 73043675 
 
ARHGEF17 27.0 0.000159 0.039 
cg26951839 5 77801011 
 
LHFPL2 36.6 0.000159 0.039 
cg27206665 7 107822217 
 
NRCAM -28.5 0.000159 0.039 
cg14478255 2 1425035 
 
TPO 43.4 0.00016 0.039 
cg14965694 14 102226416 N_Shore PPP2R5C 31.7 0.00016 0.039 
cg11810998 1 212819593 
 
NA -37.9 0.000161 0.039 
cg06639585 6 36236936 
 
PNPLA1 -72.2 0.000161 0.039 
cg11674933 1 36948313 
 
CSF3R -42.9 0.000161 0.039 
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cg03551062 16 88041289 S_Shore BANP -30.2 0.000161 0.039 
cg23919433 17 79830196 S_Shore ARHGDIA 620.3 0.000161 0.039 
cg03390187 11 65256983 
 
NA 39.3 0.000161 0.039 
cg01314252 3 9943828 
 
IL17RE -55.7 0.000162 0.039 
cg13101705 1 183248593 
 
NMNAT2 -37.3 0.000162 0.039 
cg09182750 15 99979346 
 
NA -40.7 0.000162 0.039 
cg07889201 20 2490030 S_Shore ZNF343 70.5 0.000162 0.039 
cg03225093 5 2008713 S_Shore NA 35.3 0.000162 0.039 
cg11062056 12 52249852 
 
NA 46.2 0.000162 0.039 
cg16340152 8 81789991 S_Shelf ZNF704 -35.7 0.000163 0.039 
cg04028450 8 23201488 
 
LOC100507156 36.5 0.000163 0.039 
cg27631256 9 117692745 
 
TNFSF8 -37.5 0.000163 0.039 
cg06219695 16 434256 S_Shore LOC100134368 -50.4 0.000163 0.039 
cg14421700 17 77755965 N_Shelf CBX2 -39.8 0.000164 0.039 
cg13523819 3 69915449 
 
MITF 38.8 0.000164 0.039 
cg25466245 1 223407095 
 
SUSD4 30.5 0.000164 0.039 
cg05694749 11 92616492 Island FAT3 -97.7 0.000164 0.039 
cg10215604 19 15375418 
 
BRD4 30.4 0.000165 0.039 
cg04921244 17 72096219 
 
NA 114.5 0.000165 0.039 
cg09889997 1 7692321 
 
CAMTA1 -51.0 0.000165 0.039 
cg23829395 12 46796953 
 
NA 43.8 0.000165 0.039 
cg16548254 2 27601342 Island ZNF513 47.3 0.000166 0.039 
cg04541607 22 27013978 
 
CRYBB1 -51.7 0.000166 0.039 
cg01582947 7 149156500 N_Shore ZNF777 57.7 0.000166 0.039 
cg27372422 19 41086247 S_Shelf SHKBP1 -65.6 0.000166 0.039 
cg03519711 1 86046512 Island CYR61 2238.5 0.000167 0.039 
cg01923089 12 49627746 N_Shore NA -49.4 0.000167 0.039 
cg02035102 7 23603991 
 
NA 51.9 0.000167 0.039 
cg06011086 8 61823275 S_Shore NA -66.2 0.000167 0.039 
cg25785639 6 33385083 N_Shore CUTA 427.4 0.000167 0.039 
cg09247486 1 61437380 
 
NA 40.2 0.000167 0.039 
cg22575540 2 27505625 
 
TRIM54 -58.0 0.000167 0.039 
cg02865595 1 36771714 N_Shore SH3D21 23.6 0.000167 0.039 
cg09714789 13 113422497 N_Shelf ATP11A -42.9 0.000167 0.039 
cg01241390 5 80596277 N_Shore LOC100131067 32.1 0.000168 0.039 
cg03328673 13 22687730 
 
NA -45.0 0.000168 0.039 
cg03892601 7 148036314 N_Shore CNTNAP2 55.0 0.000168 0.039 
cg01621764 19 8809175 S_Shore ACTL9 33.2 0.000168 0.039 
cg25214914 1 155910523 
 
RXFP4 -50.1 0.000169 0.040 
cg09012411 1 95167783 
 
NA -31.0 0.000169 0.040 
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cg26678516 12 107078680 
 
LOC100505978 -90.0 0.000169 0.040 
cg18162583 6 85484717 Island NA -44.6 0.00017 0.040 
cg22393213 2 237478526 S_Shore ACKR3 241.8 0.00017 0.040 
cg12492900 12 132551078 
 
EP400 -25.7 0.00017 0.040 
cg04785902 6 22878214 
 
NA 23.4 0.00017 0.040 
cg11978048 8 63951797 Island GGH 2569.2 0.00017 0.040 
cg13105234 4 1550473 N_Shelf NA 37.5 0.00017 0.040 
cg04856896 1 32665450 N_Shore CCDC28B 39.9 0.000171 0.040 
cg21582831 3 47029458 
 
NBEAL2 -35.5 0.000171 0.040 
cg11526866 1 20813614 S_Shore CAMK2N1 42.8 0.000171 0.040 
cg12165022 19 3785573 Island MATK 102.6 0.000171 0.040 
cg03994959 13 108866993 N_Shore LIG4 23.5 0.000171 0.040 
cg09338875 16 4818532 N_Shore ZNF500 244.3 0.000171 0.040 
cg27213549 10 44102591 S_Shore ZNF485 32.9 0.000171 0.040 
cg11847992 5 95590917 
 
NA 33.2 0.000171 0.040 
cg03681335 2 108903965 
 
SULT1C2 -77.4 0.000172 0.040 
cg05380759 3 45579354 
 
LARS2 -61.1 0.000172 0.040 
cg12554857 4 95264019 
 
HPGDS -50.6 0.000172 0.040 
cg19188632 2 3702481 S_Shelf ALLC -49.5 0.000172 0.040 
cg15490070 1 203148132 
 
MYBPH -50.4 0.000172 0.040 
cg04364339 10 91087703 
 
IFIT3 207.8 0.000172 0.040 
cg04567334 10 73408185 
 
CDH23 71.3 0.000172 0.040 
cg05643373 19 49220422 N_Shelf MAMSTR 94.5 0.000173 0.040 
cg25132782 15 84047082 N_Shore NA -37.5 0.000173 0.040 
cg22337624 16 72126421 N_Shore TXNL4B 29.2 0.000173 0.040 
cg26165660 12 76363767 
 
NA -57.2 0.000174 0.040 
cg00141308 22 44725065 N_Shore NA -42.1 0.000174 0.040 
cg24467535 4 100244604 
 
ADH1B -27.8 0.000174 0.040 
cg16749930 11 71709978 
 
IL18BP -29.9 0.000174 0.040 
cg16438525 3 52517742 N_Shelf NISCH 25.9 0.000174 0.040 
cg19198913 2 129495073 Island NA -63.7 0.000175 0.040 
cg07986469 10 129795003 
 
PTPRE 42.0 0.000175 0.040 
cg12228319 18 34916814 Island CELF4 -125.7 0.000175 0.040 
cg04497992 16 616212 S_Shore NHLRC4 36.2 0.000175 0.040 
cg23051123 1 226132841 
 
LEFTY2 -46.3 0.000175 0.040 
cg17433678 10 3135764 
 
PFKP -68.4 0.000175 0.040 
cg01165355 3 64225108 
 
NA 49.6 0.000175 0.040 
cg02385661 19 13215729 S_Shore LYL1 -30.7 0.000175 0.040 
cg18154954 19 39055500 Island RYR1 -41.9 0.000176 0.040 
cg22873892 15 49447651 S_Shore COPS2 526.3 0.000176 0.040 
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cg17008473 2 38356469 
 
CYP1B1-AS1 -78.8 0.000176 0.040 
cg04774469 14 21562632 S_Shore ZNF219 40.9 0.000176 0.040 
cg00830492 7 47432311 
 
TNS3 51.4 0.000176 0.040 
cg02108015 2 161777404 
 
NA 34.5 0.000177 0.040 
cg00048381 1 154587507 
 
ADAR 20.9 0.000177 0.040 
cg02886838 14 64576663 
 
SYNE2 -32.3 0.000177 0.040 
cg07675031 11 47399893 Island SPI1 -47.0 0.000177 0.040 
cg25817351 10 79977519 
 
NA -80.4 0.000177 0.040 
cg25574761 12 122688279 Island B3GNT4 69.4 0.000177 0.040 
cg12004641 2 218750749 
 
TNS1 -45.6 0.000177 0.040 
cg01012082 8 71025759 
 
NCOA2 35.0 0.000177 0.040 
cg02124724 21 46875142 N_Shore COL18A1 41.4 0.000177 0.040 
cg09335647 7 147097440 
 
CNTNAP2 33.4 0.000177 0.040 
cg14556677 9 127054428 
 
NEK6 -46.4 0.000177 0.040 
cg17353900 17 10101010 N_Shore GAS7 57.3 0.000178 0.040 
cg10533990 11 71846733 
 
FOLR3 -45.2 0.000178 0.040 
cg26358105 5 156247415 
 
NA -63.4 0.000178 0.040 
cg25325322 2 85073715 
 
TRABD2A -56.7 0.000178 0.040 
cg24948743 8 6481608 
 
MCPH1 -33.4 0.000179 0.040 
cg23697410 10 71336363 N_Shore NEUROG3 66.2 0.000179 0.040 
cg15125438 12 113684389 
 
TPCN1 44.3 0.000179 0.040 
cg10414208 17 74669923 S_Shore NA 56.1 0.00018 0.040 
cg07138115 8 26370349 N_Shore PNMA2 54.9 0.00018 0.040 
cg16792302 2 172945058 Island METAP1D -16.7 0.00018 0.040 
cg27655512 11 2287421 N_Shelf ASCL2 -33.6 0.00018 0.040 
cg11591485 3 124839640 
 
SLC12A8 41.0 0.000181 0.040 
cg18875357 14 105391263 
 
PLD4 -49.8 0.000181 0.040 
cg19015961 10 90712748 
 
ACTA2 49.7 0.000181 0.040 
cg18568534 14 23240117 S_Shelf OXA1L 74.9 0.000181 0.040 
cg22241045 4 54363911 
 
LNX1-AS1 22.5 0.000182 0.040 
cg17027260 2 109892050 
 
SH3RF3 -24.5 0.000182 0.040 
cg25790133 4 2627014 
 
FAM193A 23.4 0.000182 0.040 
cg13666041 14 69442697 N_Shore ACTN1 19.7 0.000182 0.040 
cg15841728 1 114642507 
 
SYT6 -42.4 0.000182 0.040 
cg04553793 2 25193837 N_Shore DNAJC27 35.4 0.000182 0.040 
cg08379738 19 6477033 Island DENND1C 39.5 0.000182 0.040 
cg06821075 10 99933209 
 
R3HCC1L -109.8 0.000182 0.040 
cg00369811 6 37673597 Island NA -81.7 0.000183 0.040 
cg15569052 4 2814122 
 
SH3BP2 -19.9 0.000183 0.040 
cg01702055 6 13303065 
 
NA -35.4 0.000183 0.040 
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cg01026796 5 54602543 N_Shore DHX29 32.3 0.000183 0.040 
cg11277156 3 139066791 S_Shelf MRPS22 65.7 0.000183 0.040 
cg24514275 8 42037170 
 
PLAT -42.9 0.000183 0.040 
cg01383082 8 11323474 N_Shore FAM167A 26.8 0.000184 0.040 
cg19179572 17 80377872 S_Shore OGFOD3 -57.0 0.000184 0.040 
cg01012026 7 229388 N_Shore FAM20C 38.9 0.000184 0.040 
cg08061524 22 46472568 
 
NA 23.7 0.000184 0.040 
cg07261920 5 156885069 N_Shore NIPAL4 -61.4 0.000184 0.040 
cg16842214 3 42727160 Island KLHL40 -48.8 0.000184 0.040 
cg09406921 8 37636099 
 
PROSC 50.0 0.000185 0.040 
cg27334740 16 85215660 
 
NA -73.1 0.000185 0.040 
cg06167221 18 77336130 Island NA 19.6 0.000185 0.040 
cg11823624 7 150778724 Island FASTK 60.5 0.000185 0.040 
cg15726700 3 196370254 S_Shelf NRROS -47.5 0.000186 0.040 
cg00600617 6 107221887 
 
LOC100422737 28.6 0.000186 0.040 
cg20149168 1 68512807 Island DIRAS3 -68.7 0.000186 0.040 
cg04023434 1 183778265 S_Shelf RGL1 -98.9 0.000186 0.040 
cg00712762 1 36351470 S_Shore AGO1 81.8 0.000186 0.040 
cg21031035 13 110279787 
 
NA -57.5 0.000186 0.040 
cg00036871 2 220436894 S_Shore INHA 63.8 0.000186 0.040 
cg25927215 6 34677450 
 
NA 32.2 0.000186 0.040 
cg23713900 18 615496 
 
CLUL1 -45.3 0.000187 0.040 
cg27080986 4 8396300 
 
ACOX3 31.6 0.000187 0.040 
cg25134859 5 171340543 
 
FBXW11 -19.5 0.000187 0.040 
cg24941342 11 95093809 
 
NA -28.0 0.000187 0.040 
cg27160007 19 41225374 S_Shelf ITPKC 35.9 0.000187 0.040 
cg08442088 7 44085357 S_Shore DBNL -81.1 0.000187 0.040 
cg20992708 4 5637894 
 
EVC2 -39.3 0.000187 0.040 
cg05254651 4 3705147 
 
NA 36.7 0.000187 0.040 
cg17934470 5 49959703 N_Shelf PARP8 -26.6 0.000188 0.040 
cg15035143 17 56408688 
 
MIR142 -48.3 0.000188 0.040 
cg04985661 6 12717192 
 
PHACTR1 28.9 0.000188 0.040 
cg08642285 15 68498589 
 
CALML4 -31.4 0.000188 0.040 
cg26401673 3 43431343 
 
ANO10 -22.2 0.000188 0.040 
cg09256413 1 72566690 
 
NEGR1 -30.7 0.000188 0.040 
cg25261361 8 145057101 
 
PARP10 74.0 0.000189 0.040 
cg21680307 6 170398618 N_Shelf NA -79.8 0.000189 0.040 
cg06023841 7 73308204 
 
NA 38.5 0.000189 0.040 
cg22387253 15 61310104 
 
RORA 48.8 0.000189 0.040 
cg25090051 20 57414059 N_Shore GNAS -69.1 0.00019 0.040 
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cg19956836 11 57241448 N_Shelf RTN4RL2 -48.0 0.00019 0.040 
cg23715045 11 124621944 
 
VSIG2 40.9 0.00019 0.040 
cg17261120 11 12578707 
 
NA 34.5 0.00019 0.040 
cg14590912 9 135905092 N_Shore GTF3C5 41.9 0.000191 0.040 
cg12157364 11 121612857 
 
NA 20.7 0.000191 0.040 
cg07579839 4 2933748 Island MFSD10 -32.4 0.000191 0.040 
cg00192882 17 19291120 
 
MFAP4 32.3 0.000191 0.040 
cg03668763 11 9549286 
 
ZNF143 45.1 0.000191 0.040 
cg14527564 7 100875556 Island CLDN15 37.1 0.000191 0.040 
cg08480068 16 29674959 N_Shore SPN -59.5 0.000191 0.040 
cg02914427 16 29674184 N_Shore SPN -46.0 0.000191 0.040 
cg20744756 1 95201495 
 
NA 19.9 0.000192 0.040 
cg00415011 8 142046261 
 
NA -34.2 0.000192 0.040 
cg21587837 6 31525894 
 
NFKBIL1 -48.1 0.000192 0.040 
cg23686831 15 93653310 S_Shore NA -38.0 0.000192 0.040 
cg10492657 6 4854374 
 
CDYL 44.3 0.000193 0.040 
cg24627789 8 1338463 N_Shelf NA 31.3 0.000193 0.040 
cg16008138 17 60885892 S_Shore 10-Mar 46.6 0.000193 0.040 
cg03039218 17 43025639 S_Shore KIF18B 113.6 0.000193 0.040 
cg17075096 10 124623239 
 
FAM24B-CUZD1 -89.0 0.000193 0.041 
cg19064258 16 22826117 Island HS3ST2 92.6 0.000194 0.041 
cg03116035 4 170897498 
 
LOC100506085 -61.3 0.000194 0.041 
cg15240455 2 162480821 
 
SLC4A10 88.0 0.000194 0.041 
cg07898087 4 17060364 
 
NA 21.4 0.000195 0.041 
cg23273465 2 36588933 S_Shelf CRIM1 28.3 0.000195 0.041 
cg01206915 10 74856003 Island P4HA1 502.1 0.000195 0.041 
cg17446719 1 16302584 Island ZBTB17 1355.4 0.000195 0.041 
cg14395761 17 81018559 S_Shelf NA -60.3 0.000195 0.041 
cg26195829 14 61122155 N_Shore NA -30.8 0.000195 0.041 
cg03149130 9 93404977 Island DIRAS2 115.7 0.000195 0.041 
cg11854777 2 131597644 S_Shelf NA -81.4 0.000195 0.041 
cg08272572 19 35953646 
 
NA -27.7 0.000195 0.041 
cg15545878 11 111782607 
 
CRYAB 38.3 0.000195 0.041 
cg25453154 10 81203244 N_Shore ZCCHC24 59.4 0.000196 0.041 
cg20147326 11 33913538 
 
LMO2 -81.7 0.000196 0.041 
cg23890469 10 88715317 
 
MMRN2 -46.7 0.000196 0.041 
cg00263619 12 94727462 
 
CCDC41 43.9 0.000197 0.041 
cg01368217 10 127836603 
 
ADAM12 21.4 0.000197 0.041 
cg26906998 17 17108846 Island PLD6 38.4 0.000197 0.041 
cg22502382 12 32701732 
 
FGD4 82.0 0.000197 0.041 
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cg00400041 5 180284090 N_Shelf ZFP62 -96.8 0.000197 0.041 
cg17716663 19 45978434 S_Shelf FOSB -27.8 0.000197 0.041 
cg22794775 4 106114477 
 
TET2 -93.2 0.000197 0.041 
cg12284382 22 35940438 S_Shelf RASD2 -31.1 0.000197 0.041 
cg11510557 12 132312857 Island MMP17 349.5 0.000197 0.041 
cg02604304 7 64451414 
 
ZNF117 -74.9 0.000197 0.041 
cg06867863 2 66159330 
 
NA -33.9 0.000197 0.041 
cg25440680 4 77226417 N_Shore STBD1 -61.7 0.000197 0.041 
cg21167761 11 77903617 N_Shelf USP35 29.3 0.000198 0.041 
cg01641371 17 26712092 Island SARM1 -47.6 0.000198 0.041 
cg02334109 15 26044050 
 
ATP10A -44.3 0.000198 0.041 
cg26740109 18 77585428 N_Shore NA -72.9 0.000198 0.041 
cg07177917 1 10724490 N_Shore CASZ1 61.3 0.000199 0.041 
cg07707505 1 12185435 
 
TNFRSF8 -34.3 0.000199 0.041 
cg27278729 11 61666595 
 
RAB3IL1 -63.2 0.000199 0.041 
cg02138358 17 56358318 S_Shore MPO -65.7 0.000199 0.041 
cg15128679 5 134476728 
 
LOC100996485 -47.8 0.000199 0.041 
cg24377826 10 126376113 
 
FAM53B -47.3 0.000199 0.041 
cg19190519 11 123175740 S_Shelf NA -89.9 0.0002 0.041 
cg05313153 8 119122430 N_Shore EXT1 133.9 0.0002 0.041 
cg10011495 22 46516475 N_Shore NA 24.6 0.0002 0.041 
cg16744741 4 82126025 
 
PRKG2 -47.4 0.0002 0.041 
cg01796676 15 73680284 
 
NA -70.7 0.0002 0.041 
cg18746336 3 128216122 Island GATA2 27.6 0.0002 0.041 
cg12416304 2 134884764 
 
MIR3679 -51.0 0.000201 0.041 
cg07834743 5 5139610 Island ADAMTS16 90.8 0.000201 0.041 
cg17189778 X 153169823 
 
AVPR2 -54.0 0.000201 0.041 
cg13486600 1 22977618 S_Shelf C1QB -117.5 0.000201 0.041 
cg17216243 2 170627694 S_Shelf NA -30.0 0.000201 0.041 
cg05143345 14 23447408 N_Shelf AJUBA 33.4 0.000201 0.041 
cg00446046 3 187686918 
 
NA -32.1 0.000202 0.041 
cg14622819 4 76944817 
 
CXCL10 -37.9 0.000202 0.041 
cg01844235 22 23487969 Island RAB36 53.0 0.000202 0.041 
cg22332722 18 25754857 N_Shore CDH2 -40.7 0.000202 0.041 
cg03106245 11 47399980 Island SPI1 -64.0 0.000202 0.041 
cg19675731 1 202129192 
 
PTPN7 -41.6 0.000203 0.041 
cg25654652 8 22423633 Island SORBS3 73.1 0.000203 0.041 
cg22110896 17 59533081 Island TBX4 -39.3 0.000203 0.041 
cg20577613 17 57409092 Island YPEL2 1551.3 0.000203 0.041 
cg11637721 11 65486928 N_Shore RNASEH2C 36.1 0.000203 0.041 
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cg10007927 6 32095148 N_Shelf ATF6B 70.3 0.000203 0.041 
cg27208925 16 85937106 
 
IRF8 -50.5 0.000204 0.041 
cg09699056 17 79503642 Island FSCN2 -24.5 0.000204 0.041 
cg07183637 6 31940692 S_Shore DOM3Z 43.7 0.000204 0.041 
cg24788483 10 114911652 
 
TCF7L2 -41.7 0.000205 0.041 
cg01477933 12 122922107 
 
NA 34.7 0.000205 0.041 
cg03137071 8 49496369 
 
NA 41.6 0.000205 0.041 
cg18801806 11 118869385 S_Shore CCDC84 50.7 0.000205 0.041 
cg03335246 4 4860431 N_Shore MSX1 -41.4 0.000205 0.041 
cg00112685 19 11591190 Island ELAVL3 60.0 0.000205 0.041 
cg18236464 1 176528783 
 
PAPPA2 -30.3 0.000206 0.041 
cg07641643 12 123234584 N_Shelf DENR 38.7 0.000206 0.041 
cg04605980 12 117471700 
 
NA 42.1 0.000206 0.041 
cg27482619 10 30818479 
 
NA -58.1 0.000207 0.041 
cg23006227 4 174423637 S_Shore NA -22.0 0.000207 0.041 
cg15059065 19 17354961 N_Shore NR2F6 46.2 0.000207 0.041 
cg23114262 10 135086817 N_Shelf ADAM8 -36.1 0.000207 0.041 
cg11523350 11 117171073 
 
BACE1 29.2 0.000208 0.041 
cg09632271 4 68441222 
 
STAP1 -23.9 0.000209 0.041 
cg23827488 6 24908452 N_Shelf FAM65B -33.2 0.000209 0.041 
cg17054708 3 13679636 S_Shore FBLN2 -53.4 0.000209 0.041 
cg15990632 1 157983193 
 
KIRREL 44.2 0.000209 0.041 
cg13829419 6 143167279 
 
HIVEP2 50.0 0.00021 0.041 
cg14285050 1 40778294 N_Shelf COL9A2 -59.3 0.00021 0.041 
cg04022194 4 8317995 
 
NA 84.0 0.00021 0.041 
cg02533173 19 15391124 
 
BRD4 33.6 0.00021 0.041 
cg01357222 6 137619143 
 
NA -31.7 0.00021 0.041 
cg16310003 12 122297080 
 
HPD 40.5 0.00021 0.041 
cg25581039 17 7350881 S_Shelf CHRNB1 -84.5 0.000211 0.041 
cg11859982 7 127907529 N_Shelf NA 41.5 0.000211 0.041 
cg11700584 14 50088544 S_Shore MGAT2 71.5 0.000212 0.041 
cg03049917 15 88752391 
 
NTRK3 -93.5 0.000212 0.041 
cg09376835 8 131347294 
 
ASAP1 -41.6 0.000212 0.041 
cg00733683 19 1244464 S_Shore ATP5D 40.2 0.000212 0.041 
cg06638023 19 59030102 N_Shore ZBTB45 89.0 0.000212 0.041 
cg13146517 11 560935 Island RASSF7 103.1 0.000213 0.041 
cg12414070 12 117627133 N_Shore FBXO21 45.7 0.000213 0.041 
cg13506158 3 191048377 S_Shore UTS2B 28.0 0.000213 0.041 
cg06358171 1 54822008 Island SSBP3 -45.1 0.000213 0.041 
cg15988010 4 166033722 Island TMEM192 659.6 0.000213 0.041 
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cg16337763 11 11438208 
 
GALNT18 -36.3 0.000213 0.041 
cg10413136 4 8207119 
 
SH3TC1 -45.4 0.000213 0.041 
cg14413904 10 62423377 
 
ANK3 -40.6 0.000213 0.041 
cg13407335 17 7832852 Island KCNAB3 30.7 0.000214 0.041 
cg15705865 2 900218 
 
NA -19.5 0.000214 0.041 
cg00465073 18 48252314 N_Shelf MAPK4 -69.9 0.000214 0.041 
cg03036373 14 37051902 N_Shore NKX2-8 114.4 0.000214 0.041 
cg21090033 3 196065357 
 
TM4SF19-
TCTEX1D2 -36.7 0.000214 0.041 
cg01473602 12 77257301 
 
CSRP2 26.0 0.000214 0.041 
cg04826345 13 22615334 
 
NA -68.5 0.000214 0.041 
cg27145098 16 29206563 
 
NA 25.4 0.000214 0.042 
cg05241536 10 121298236 N_Shelf RGS10 -62.5 0.000215 0.042 
cg24757778 10 60616392 
 
NA 36.8 0.000215 0.042 
cg19513727 12 110708125 
 
NA 40.3 0.000215 0.042 
cg22339338 1 159891638 N_Shelf TAGLN2 -29.7 0.000215 0.042 
cg11000707 6 42988922 N_Shore RRP36 45.3 0.000215 0.042 
cg27366072 12 12222913 
 
BCL2L14 -67.7 0.000215 0.042 
cg01956472 6 33968002 
 
MIR1275 -84.2 0.000216 0.042 
cg22235407 15 66209223 
 
MEGF11 38.9 0.000216 0.042 
cg01071159 2 129492198 N_Shelf NA -53.1 0.000216 0.042 
cg13855715 2 177430491 
 
NA -82.1 0.000216 0.042 
cg24847230 17 46986807 S_Shore UBE2Z 64.6 0.000217 0.042 
cg23647768 11 1054538 N_Shore NA 43.5 0.000217 0.042 
cg10640072 8 99985888 Island NA -41.9 0.000217 0.042 
cg14395885 9 130700923 S_Shore DPM2 22.9 0.000217 0.042 
cg24910112 8 37657824 S_Shore GPR124 32.7 0.000218 0.042 
cg24540710 17 48262937 
 
COL1A1 57.1 0.000218 0.042 
cg26686361 16 85964073 
 
NA -35.5 0.000218 0.042 
cg20931951 1 12508122 
 
VPS13D 33.3 0.000218 0.042 
cg17500228 5 448790 
 
EXOC3 -34.0 0.000218 0.042 
cg10420527 11 68138505 
 
LRP5 -31.2 0.000218 0.042 
cg02869653 22 39352432 
 
APOBEC3A_B -449.9 0.000218 0.042 
cg12123728 14 65457053 S_Shelf FNTB -59.0 0.000218 0.042 
cg14737287 11 130340832 N_Shelf ADAMTS15 -126.3 0.000218 0.042 
cg27134322 8 1900778 
 
ARHGEF10 -53.0 0.000219 0.042 
cg09307704 8 140277097 
 
NA 81.3 0.000219 0.042 
cg05868813 13 26594483 
 
ATP8A2 -25.7 0.000219 0.042 
cg20065005 1 16712408 
 
SZRD1 -72.1 0.000219 0.042 
cg21191255 11 698760 S_Shelf DEAF1 57.1 0.00022 0.042 
cg08989290 16 615782 Island NHLRC4 28.0 0.00022 0.042 
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cg21953058 15 41309253 
 
INO80 -34.6 0.00022 0.042 
cg26972614 11 71710885 
 
IL18BP 33.6 0.00022 0.042 
cg20580294 10 7486967 
 
NA -82.2 0.00022 0.042 
cg04494750 7 100304693 S_Shore POP7 37.2 0.00022 0.042 
cg09434536 15 70614790 
 
NA -80.4 0.00022 0.042 
cg05563033 13 101174060 
 
PCCA -330.9 0.000221 0.042 
cg04947052 2 128430937 N_Shore LIMS2 -21.9 0.000221 0.042 
cg20240860 11 44087423 N_Shore ACCS 112.4 0.000221 0.042 
cg00880290 19 14550999 N_Shore PKN1 -21.4 0.000221 0.042 
cg01742905 11 88071023 Island CTSC 696.8 0.000221 0.042 
cg19769147 14 105860954 N_Shelf TEX22 -37.0 0.000221 0.042 
cg08922603 4 4763690 
 
NA -177.2 0.000222 0.042 
cg00524561 12 125197665 
 
NA -22.8 0.000222 0.042 
cg09740468 6 3025325 
 
HTATSF1P2 -21.6 0.000222 0.042 
cg21337881 17 5138645 
 
SCIMP -55.2 0.000222 0.042 
cg09309261 12 113906999 N_Shore LHX5 74.4 0.000222 0.042 
cg13074682 15 40113167 
 
GPR176 -51.2 0.000222 0.042 
cg14218233 1 230276786 
 
GALNT2 -72.8 0.000222 0.042 
cg24094775 6 41704688 S_Shore TFEB 76.0 0.000223 0.042 
cg04880990 12 52887566 
 
KRT6A -50.7 0.000223 0.042 
cg09243909 16 53871485 
 
FTO 30.8 0.000223 0.042 
cg13576330 5 92943267 S_Shelf MIR548AO -34.0 0.000224 0.042 
cg12319143 10 134726771 N_Shelf TTC40 -27.7 0.000224 0.042 
cg12532266 5 132201652 N_Shore UQCRQ 26.2 0.000224 0.042 
cg04883269 3 127144483 
 
NA -73.6 0.000224 0.042 
cg09603795 10 75256221 S_Shore PPP3CB 43.0 0.000224 0.042 
cg08575883 10 3291355 
 
NA 37.5 0.000224 0.042 
cg14524724 5 173054985 
 
NA 31.1 0.000224 0.042 
cg02756056 6 32813582 S_Shore PSMB8 -43.8 0.000225 0.042 
cg09524658 3 129272656 
 
NA -14.6 0.000225 0.042 
cg01209296 20 62435316 S_Shore ZBTB46 -42.8 0.000225 0.042 
cg17951588 2 239951254 
 
NA -146.6 0.000225 0.042 
cg09235217 2 232263030 Island B3GNT7 -172.3 0.000225 0.042 
cg26974880 16 50308058 
 
NA -48.7 0.000226 0.042 
cg06879786 2 218847598 S_Shelf NA -87.6 0.000226 0.042 
cg02679503 2 42794680 N_Shore MTA3 22.4 0.000226 0.042 
cg24553170 1 49243472 S_Shore BEND5 32.3 0.000227 0.042 
cg27436940 17 43047115 N_Shore C1QL1 -32.0 0.000227 0.042 
cg21781157 20 47874111 
 
ZNFX1 -56.0 0.000227 0.042 
cg08120210 15 66682733 S_Shelf MAP2K1 -18.9 0.000227 0.042 
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cg20211629 18 48352490 
 
MRO -42.9 0.000227 0.042 
cg27507261 17 5403053 N_Shore LOC728392 38.1 0.000227 0.042 
cg18124162 13 109616351 
 
MYO16 -84.0 0.000227 0.042 
cg02424715 14 75893680 N_Shore JDP2 -46.5 0.000228 0.042 
cg16659773 6 4352453 
 
NA 40.2 0.000228 0.042 
cg15693483 7 1102177 N_Shelf C7orf50 -69.6 0.000228 0.042 
cg18263969 17 76970864 
 
LGALS3BP 48.5 0.000228 0.042 
cg02956248 6 32120901 N_Shore PPT2 45.2 0.000229 0.042 
cg24847621 6 30122565 
 
TRIM10 25.7 0.000229 0.042 
cg19680631 6 170478454 S_Shelf NA -101.1 0.000229 0.042 
cg06629120 3 197181773 N_Shore NA -45.1 0.000229 0.042 
cg01768328 17 1634018 N_Shelf WDR81 73.4 0.00023 0.042 
cg06885823 5 82675005 
 
NA -63.0 0.00023 0.042 
cg07576135 15 42694403 
 
CAPN3 -57.3 0.000231 0.042 
cg07636338 19 46214108 N_Shore FBXO46 37.0 0.000231 0.042 
cg15817960 12 54409599 S_Shore HOXC4 -30.7 0.000231 0.042 
cg20748065 7 75583421 
 
POR -35.7 0.000231 0.042 
cg16577789 14 94186558 
 
PRIMA1 -59.4 0.000231 0.042 
cg06354695 1 212643521 
 
NA 25.2 0.000231 0.042 
cg13152501 7 98626398 
 
SMURF1 -46.6 0.000231 0.042 
cg17718899 13 22773018 
 
NA 24.6 0.000231 0.042 
cg01226614 13 44947593 Island SERP2 39.4 0.000232 0.042 
cg24200165 13 111658907 
 
NA 51.7 0.000232 0.042 
cg14972827 6 17045947 
 
NA 31.0 0.000232 0.042 
cg12689803 12 119519948 
 
SRRM4 27.8 0.000232 0.042 
cg01045337 16 374988 Island AXIN1 -25.2 0.000232 0.042 
cg19874640 5 134527449 S_Shore LOC100996485 -89.1 0.000233 0.042 
cg17379666 17 71304784 N_Shelf CDC42EP4 28.0 0.000233 0.042 
cg25600446 8 145728543 N_Shore GPT 41.2 0.000233 0.042 
cg18615369 13 52701033 N_Shore NEK5 -57.4 0.000233 0.042 
cg16549994 22 36854045 S_Shelf NA 60.2 0.000233 0.042 
cg14086822 1 2724609 
 
NA 38.4 0.000234 0.042 
cg16577665 1 119702694 
 
NA 35.3 0.000234 0.042 
cg05469614 16 3142818 S_Shelf ZSCAN10 58.1 0.000234 0.042 
cg00489485 16 84341364 
 
WFDC1 -99.1 0.000235 0.042 
cg01123186 17 36514710 
 
SOCS7 29.7 0.000235 0.042 
cg22758834 7 95222104 N_Shelf PDK4 -16.6 0.000235 0.042 
cg02240622 15 40601467 
 
PLCB2 -54.7 0.000235 0.042 
cg02926868 11 66374763 
 
NA 23.3 0.000235 0.042 
cg22878535 17 78431627 S_Shelf NA -60.6 0.000235 0.042 
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Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg09794469 7 5391393 Island TNRC18 22.2 0.000236 0.042 
cg11105029 20 2362041 
 
TGM6 81.9 0.000236 0.042 
cg06126421 6 30720080 
 
NA 23.5 0.000236 0.042 
cg13314778 3 70889448 
 
NA -30.7 0.000236 0.042 
cg04760574 10 101989519 Island CHUK 305.4 0.000236 0.042 
cg19379721 19 19737143 N_Shore LPAR2 -104.8 0.000236 0.042 
cg00728848 6 13483832 N_Shelf GFOD1 -34.2 0.000237 0.042 
cg27129590 12 116351979 N_Shelf NA -63.9 0.000238 0.042 
cg14135809 9 140502926 S_Shelf ARRDC1 -45.4 0.000238 0.042 
cg00726046 20 43161260 S_Shore PKIG 43.5 0.000238 0.042 
cg11381282 13 20763366 N_Shelf GJB2 -61.1 0.000238 0.042 
cg03388575 7 1765158 
 
ELFN1 46.1 0.000238 0.043 
cg08734931 10 14051649 
 
FRMD4A 37.4 0.000238 0.043 
cg22969108 12 15983280 
 
NA 32.1 0.000239 0.043 
cg08447387 8 131369596 N_Shore ASAP1 48.9 0.000239 0.043 
cg23089425 8 19034837 
 
NA 32.2 0.000239 0.043 
cg14177325 17 1541763 S_Shelf SCARF1 -95.9 0.000239 0.043 
cg24716167 10 134545286 
 
INPP5A -87.0 0.00024 0.043 
cg21969792 4 1594995 N_Shore NA 36.4 0.00024 0.043 
cg13027206 14 91866325 
 
CCDC88C -58.3 0.00024 0.043 
cg25450034 X 129806493 
 
ENOX2 51.7 0.000241 0.043 
cg01353907 12 131438283 
 
GPR133 18.2 0.000241 0.043 
cg08651590 2 65543410 S_Shelf SPRED2 26.7 0.000241 0.043 
cg05002190 19 2926196 N_Shore NA 54.3 0.000241 0.043 
cg21017569 17 7832769 Island KCNAB3 43.9 0.000241 0.043 
cg08949143 13 30947713 
 
LINC00426 -67.1 0.000241 0.043 
cg00537673 6 43141823 N_Shore SRF 39.0 0.000241 0.043 
cg23922724 11 76474735 
 
NA 30.9 0.000241 0.043 
cg25813942 18 2843518 N_Shelf EMILIN2 -55.1 0.000241 0.043 
cg08572757 12 125582465 S_Shelf AACS -36.8 0.000242 0.043 
cg16346422 11 2920819 N_Shelf SLC22A18 -29.3 0.000242 0.043 
cg20450689 18 77586147 Island NA -24.0 0.000242 0.043 
cg11643457 12 80904153 
 
PTPRQ 45.8 0.000242 0.043 
cg16652392 1 1826227 S_Shelf GNB1 37.2 0.000242 0.043 
cg07889826 3 50127152 Island RBM5 339.6 0.000243 0.043 
cg18009496 5 1883940 Island IRX4 533.7 0.000243 0.043 
cg08215318 16 86016387 
 
NA -41.8 0.000243 0.043 
cg04586023 22 50690380 S_Shore HDAC10 -51.6 0.000244 0.043 
cg23502883 15 93959149 
 
NA -70.3 0.000245 0.043 
cg25103895 10 64565642 Island ADO 33.2 0.000245 0.043 
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cg21188037 7 45018658 
 
MYO1G -50.5 0.000245 0.043 
cg23251761 1 9750061 Island PIK3CD 30.1 0.000245 0.043 
cg06796779 3 128204927 N_Shore GATA2 41.9 0.000246 0.043 
cg20510285 6 11263797 
 
NEDD9 69.5 0.000246 0.043 
cg02932355 8 102184648 
 
NA 29.1 0.000246 0.043 
cg26217572 13 27540240 
 
NA 44.7 0.000247 0.043 
cg12974599 22 46770195 N_Shore CELSR1 -25.7 0.000247 0.043 
cg14365457 9 124029877 
 
GSN -68.4 0.000247 0.043 
cg01138020 17 4337094 
 
SPNS3 -34.0 0.000247 0.043 
cg10504436 22 24180492 Island DERL3 -39.0 0.000247 0.043 
cg08599824 7 67189164 
 
NA -85.1 0.000247 0.043 
cg14072027 17 15301904 
 
NA -27.7 0.000248 0.043 
cg17796461 15 31685823 Island NA -50.8 0.000248 0.043 
cg26083045 3 8560168 
 
LMCD1 -77.7 0.000248 0.043 
cg17111087 1 167407514 N_Shore CD247 -53.9 0.000248 0.043 
cg21477232 2 227994951 
 
COL4A4 -80.7 0.000248 0.043 
cg20522104 11 83251615 
 
DLG2 -45.6 0.000248 0.043 
cg02363766 5 2008270 Island NA 32.0 0.000248 0.043 
cg14699867 12 106994421 
 
RFX4 -290.5 0.000248 0.043 
cg23694605 11 120044146 S_Shelf NA 44.8 0.000248 0.043 
cg07554664 16 68431982 
 
SMPD3 66.0 0.000249 0.043 
cg01329756 17 80346912 Island NA -52.0 0.000249 0.043 
cg26340968 19 3798367 N_Shelf MATK -35.7 0.000249 0.043 
cg00184457 8 8946301 
 
NA -24.2 0.000249 0.043 
cg13084345 1 36948733 
 
CSF3R -58.9 0.000249 0.043 
cg12217560 13 24144900 
 
TNFRSF19 18.2 0.00025 0.043 
cg26933869 1 19218007 
 
ALDH4A1 -59.3 0.00025 0.043 
cg02452552 5 150618048 
 
NA 23.2 0.00025 0.043 
cg11386011 6 32121156 N_Shore PPT2 26.2 0.00025 0.043 
cg05323324 3 194120023 S_Shore GP5 -23.5 0.00025 0.043 
cg20442379 10 60024634 N_Shelf IPMK -32.4 0.00025 0.043 
cg05641529 4 100242957 
 
ADH1B -21.1 0.000251 0.043 
cg09920804 8 42053994 
 
PLAT 45.5 0.000251 0.043 
cg11361344 2 220361467 Island GMPPA -20.8 0.000251 0.043 
cg21400549 1 212588848 
 
TMEM206 -78.1 0.000251 0.043 
cg16846069 12 6462681 S_Shore SCNN1A -43.5 0.000251 0.043 
cg18516365 10 111721749 
 
ADD3-AS1 53.1 0.000252 0.043 
cg27462969 1 67896192 Island SERBP1 191.6 0.000252 0.043 
cg25349990 1 229294380 
 
NA -35.9 0.000252 0.043 
cg00931520 16 1231484 S_Shore CACNA1H 55.6 0.000252 0.043 
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cg10929387 3 52864659 
 
ITIH4 30.6 0.000252 0.043 
cg07924703 8 22423020 Island SORBS3 112.5 0.000253 0.043 
cg04821959 12 106900710 
 
POLR3B -61.1 0.000253 0.043 
cg19802165 5 134370033 Island PITX1 2312.2 0.000253 0.043 
cg22213622 12 22090730 N_Shelf ABCC9 -52.1 0.000254 0.043 
cg03750034 8 94430696 
 
LINC00535 -113.5 0.000254 0.043 
cg24295653 3 61237884 S_Shore FHIT 52.5 0.000255 0.043 
cg04172497 11 59382296 N_Shore OSBP 83.2 0.000255 0.043 
cg09449150 11 129731815 
 
NA 53.8 0.000255 0.044 
cg05754058 7 41094211 
 
NA -42.0 0.000256 0.044 
cg26146988 14 102034601 S_Shelf NA 36.9 0.000256 0.044 
cg07120544 8 93076082 
 
RUNX1T1 31.1 0.000256 0.044 
cg21012737 14 105393171 
 
PLD4 -46.2 0.000256 0.044 
cg08749735 17 16488023 S_Shore NA 55.6 0.000256 0.044 
cg03421236 16 49486155 
 
NA -29.6 0.000257 0.044 
cg21871050 13 24269500 Island NA -96.1 0.000257 0.044 
cg19522050 10 101281275 Island NA 54.1 0.000257 0.044 
cg03978682 5 53411773 
 
ARL15 -61.7 0.000257 0.044 
cg26588061 10 12086036 S_Shore UPF2 -67.4 0.000257 0.044 
cg11841649 5 131989505 N_Shelf IL13 23.3 0.000257 0.044 
cg03845683 11 64933489 
 
SPDYC 32.3 0.000257 0.044 
cg03730946 19 6475456 Island DENND1C 45.7 0.000258 0.044 
cg20425130 3 183273245 
 
KLHL6 -26.6 0.000258 0.044 
cg02793854 16 67867809 Island CENPT 487.9 0.000258 0.044 
cg16668176 19 5308893 
 
PTPRS 26.7 0.000258 0.044 
cg00830419 2 20371971 
 
NA 26.7 0.000259 0.044 
cg06968164 13 45629698 
 
NA 54.8 0.000259 0.044 
cg27141517 15 66923526 
 
NA -62.7 0.000259 0.044 
cg09739398 11 47416886 S_Shore NA -24.9 0.000259 0.044 
cg11723077 6 158508188 S_Shore SYNJ2 -39.1 0.000259 0.044 
cg16810559 3 64090850 
 
PRICKLE2-AS2 31.3 0.000259 0.044 
cg19192626 17 38708638 
 
NA 27.8 0.000259 0.044 
cg17541674 19 51296949 S_Shore ACPT 48.1 0.00026 0.044 
cg26219182 1 32687590 Island TMEM234 479.8 0.00026 0.044 
cg16418183 16 51360402 
 
NA 39.5 0.00026 0.044 
cg09634176 6 100037332 Island NA 206.3 0.00026 0.044 
cg12958561 4 26460878 
 
NA 42.3 0.00026 0.044 
cg00451635 16 10675030 S_Shore EMP2 55.1 0.00026 0.044 
cg04917208 16 70680104 
 
IL34 44.6 0.00026 0.044 
cg04329382 22 46480891 N_Shore MIRLET7BHG 39.1 0.000261 0.044 
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cg07708453 1 14032034 
 
PRDM2 -139.0 0.000261 0.044 
cg00387090 1 201615401 N_Shore NAV1 -27.1 0.000261 0.044 
cg11277662 8 143408047 Island TSNARE1 -56.8 0.000261 0.044 
cg07778315 12 133380627 S_Shore GOLGA3 48.1 0.000261 0.044 
cg20005057 12 10364834 N_Shore GABARAPL1 105.8 0.000262 0.044 
cg16472369 17 4618322 S_Shelf ARRB2 -49.3 0.000262 0.044 
cg03473377 10 33568029 
 
NRP1 -59.7 0.000262 0.044 
cg10436257 16 30959496 Island ORAI3 32.2 0.000262 0.044 
cg15200801 19 48999042 N_Shore LMTK3 -48.0 0.000262 0.044 
cg06988336 16 89922397 S_Shore SPIRE2 -47.2 0.000263 0.044 
cg23193059 11 116706090 N_Shore APOA1 -19.4 0.000263 0.044 
cg15348869 12 119418004 N_Shore SRRM4 274.0 0.000263 0.044 
cg09315878 1 1152580 Island TNFRSF4 -25.3 0.000263 0.044 
cg27447296 2 27994265 N_Shore MRPL33 95.4 0.000263 0.044 
cg16759783 18 77746937 N_Shore TXNL4A 37.4 0.000263 0.044 
cg03654841 16 88615609 
 
NA 142.4 0.000263 0.044 
cg13966557 4 184908884 
 
STOX2 25.1 0.000264 0.044 
cg26785896 12 58013354 Island SLC26A10 -40.5 0.000264 0.044 
cg09447621 11 134254646 S_Shore B3GAT1 -37.3 0.000265 0.044 
cg18506124 19 35629603 N_Shelf FXYD1 33.5 0.000265 0.044 
cg14311559 12 7060257 
 
PTPN6 -49.8 0.000265 0.044 
cg02258139 7 97841513 N_Shore BHLHA15 -99.3 0.000266 0.044 
cg10990081 3 3168142 N_Shore TRNT1 27.4 0.000266 0.044 
cg11287077 5 158590712 
 
RNF145 48.2 0.000267 0.044 
cg08204162 8 22785567 
 
PEBP4 35.1 0.000267 0.044 
cg02059317 16 89024511 
 
CBFA2T3 -55.8 0.000267 0.044 
cg20267775 1 171623695 
 
MYOC 35.7 0.000267 0.044 
cg14935646 7 27215464 S_Shore HOXA10 -30.2 0.000267 0.044 
cg27584146 1 46599915 S_Shore PIK3R3 -51.4 0.000268 0.044 
cg14088811 11 47399994 Island SPI1 -50.3 0.000268 0.044 
cg21550219 5 135394043 
 
TGFBI 33.5 0.000268 0.044 
cg16144864 1 177244231 
 
FAM5B 37.3 0.000268 0.044 
cg02845870 11 85524670 S_Shelf SYTL2 -72.9 0.000268 0.044 
cg23152742 12 132920884 N_Shore NA 28.1 0.000268 0.044 
cg03574571 19 35820181 
 
CD22 -69.5 0.000268 0.044 
cg18589526 7 138575872 
 
KIAA1549 49.7 0.000269 0.044 
cg23704627 22 39152758 S_Shore SUN2 -41.2 0.000269 0.044 
cg27175943 16 85334190 
 
NA -58.1 0.000269 0.044 
cg05227215 5 139057496 S_Shore CXXC5 31.3 0.000269 0.044 
cg02699829 19 13216355 S_Shore LYL1 -46.2 0.000269 0.044 
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cg09350536 14 23236725 S_Shore OXA1L 165.8 0.000269 0.044 
cg04330176 10 105619211 S_Shelf SH3PXD2A 40.7 0.000269 0.044 
cg10223234 6 31926205 N_Shore SKIV2L 47.0 0.000269 0.044 
cg18498263 14 91034963 
 
TTC7B 21.9 0.00027 0.044 
cg21325802 7 16948307 
 
NA -43.2 0.00027 0.044 
cg21643095 11 105009375 
 
CARD18 68.6 0.00027 0.044 
cg04333785 10 31446813 
 
NA 35.2 0.00027 0.044 
cg18269493 1 8772984 
 
RERE -33.5 0.00027 0.044 
cg17451138 12 124155880 Island TCTN2 401.4 0.000271 0.044 
cg13460556 15 89709638 
 
ABHD2 -15.5 0.000271 0.044 
cg26604895 5 89842121 
 
NA 40.3 0.000271 0.044 
cg22776771 X 107976903 N_Shore IRS4 44.2 0.000271 0.044 
cg21531685 3 73672063 N_Shore PDZRN3 29.1 0.000271 0.044 
cg14805932 2 241401799 Island GPC1 -133.3 0.000271 0.044 
cg26633373 19 54377836 S_Shore MYADM -34.8 0.000271 0.044 
cg14938313 11 70028676 
 
ANO1 -63.7 0.000271 0.044 
cg22986569 5 2659008 
 
NA 30.8 0.000272 0.044 
cg04204526 1 2980937 S_Shore LINC00982 53.3 0.000272 0.044 
cg10191684 8 22423014 Island SORBS3 139.5 0.000272 0.044 
cg06764092 1 159796658 
 
SLAMF8 -32.1 0.000272 0.044 
cg06766636 6 116598395 N_Shelf TSPYL1 42.5 0.000273 0.044 
cg02807984 11 722258 S_Shore EPS8L2 -35.2 0.000273 0.044 
cg03732020 11 47282968 
 
NR1H3 -32.8 0.000273 0.044 
cg14213992 19 40503358 S_Shore ZNF546 143.5 0.000273 0.044 
cg09806318 6 1383064 Island NA -62.3 0.000274 0.044 
cg16717713 14 100069657 Island CCDC85C -27.4 0.000274 0.044 
cg07888661 10 73759402 
 
CHST3 58.8 0.000274 0.044 
cg23033749 7 116610238 
 
ST7 -62.4 0.000275 0.044 
cg06750038 16 87425101 N_Shore FBXO31 41.3 0.000275 0.044 
cg11328127 11 415441 N_Shore SIGIRR -27.1 0.000275 0.044 
cg21110337 12 113671028 
 
TPCN1 -32.1 0.000275 0.044 
cg03678274 1 236017128 
 
MIR1537 -29.3 0.000276 0.044 
cg05798429 6 31743928 
 
VWA7 -62.2 0.000276 0.044 
cg26011438 17 1964730 S_Shelf SMG6 69.5 0.000276 0.044 
cg23685650 14 56045894 N_Shore KTN1-AS1 34.8 0.000277 0.044 
cg02776658 19 35800589 N_Shore MAG 22.8 0.000277 0.044 
cg02807008 19 1910258 N_Shore SCAMP4 30.5 0.000277 0.044 
cg03772108 7 116889900 
 
NA -79.4 0.000277 0.044 
cg03543648 22 42319809 N_Shelf TNFRSF13C -112.9 0.000277 0.044 
cg03781727 7 22007540 
 
NA -23.9 0.000277 0.044 
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cg14685146 17 42088751 N_Shelf TMEM101 22.8 0.000277 0.044 
cg05283597 3 52812410 
 
ITIH1 -37.6 0.000277 0.044 
cg26504229 21 45149038 Island PDXK 32.6 0.000278 0.044 
cg23334306 14 33945217 
 
NPAS3 -55.4 0.000278 0.044 
cg00580562 10 21789124 Island C10orf114 -19.8 0.000278 0.044 
cg14211332 1 117255389 
 
NA -53.6 0.000278 0.044 
cg00083659 22 37404577 
 
TEX33 -22.6 0.000279 0.044 
cg07978738 10 116298339 
 
ABLIM1 -55.3 0.000279 0.044 
cg01247127 20 1538366 
 
SIRPD 52.5 0.000279 0.044 
cg21599100 11 2920437 N_Shelf SLC22A18 -74.9 0.000279 0.044 
cg06812840 17 7492524 Island SOX15 73.7 0.00028 0.044 
cg24761567 6 40687984 
 
NA -52.1 0.00028 0.044 
cg06638568 6 163730822 
 
PACRG -37.6 0.00028 0.044 
cg21301505 1 159796629 
 
SLAMF8 -28.9 0.00028 0.044 
cg07175797 16 50317656 
 
ADCY7 -50.6 0.00028 0.044 
cg13084335 11 111782670 
 
CRYAB 40.3 0.00028 0.044 
cg00255726 8 21769114 N_Shore DOK2 -61.7 0.000281 0.044 
cg08578641 9 34457440 Island FAM219A 31.0 0.000281 0.044 
cg03736235 19 1071622 Island HMHA1 38.7 0.000281 0.044 
cg24997703 14 105969175 S_Shelf NA 70.5 0.000281 0.044 
cg27477250 19 12841735 N_Shelf C19orf43 71.7 0.000282 0.044 
cg16674248 22 46664402 S_Shore TTC38 30.1 0.000282 0.044 
cg23889967 10 131568313 
 
NA -72.9 0.000282 0.044 
cg11064966 5 32506514 
 
NA 82.6 0.000282 0.044 
cg24848189 11 44338968 S_Shore NA -57.4 0.000282 0.044 
cg02893604 14 23512805 
 
PSMB11 84.7 0.000282 0.044 
cg07092212 11 46382544 
 
DGKZ -34.1 0.000282 0.044 
cg14765414 13 113652335 N_Shelf MCF2L -45.5 0.000282 0.044 
cg24492778 15 57414740 
 
TCF12 -38.9 0.000283 0.044 
cg10472067 20 35402298 Island DSN1 766.4 0.000283 0.044 
cg25523538 10 28031957 Island MKX 539.0 0.000283 0.044 
cg17153426 22 24640743 
 
GGT5 33.1 0.000284 0.044 
cg22541400 17 9840728 
 
GAS7 39.4 0.000284 0.044 
cg20165746 8 8870185 
 
ERI1 -43.7 0.000284 0.044 
cg04697299 2 200849634 
 
NA 33.6 0.000284 0.044 
cg12484113 1 27898757 N_Shelf AHDC1 44.5 0.000284 0.044 
cg24139443 17 74131549 N_Shelf NA 43.4 0.000284 0.044 
cg01942776 14 30920008 
 
NA 20.6 0.000284 0.044 
cg06081306 17 37760830 N_Shore NEUROD2 104.4 0.000285 0.044 
cg14292572 12 67665055 S_Shore CAND1 21.5 0.000285 0.044 
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cg18544564 2 189839120 
 
COL3A1 31.2 0.000285 0.044 
cg01775245 8 6452110 
 
MCPH1 42.0 0.000285 0.044 
cg16874347 2 86450216 
 
REEP1 39.4 0.000285 0.044 
cg09107438 12 56819060 
 
TIMELESS -22.8 0.000285 0.044 
cg20471783 12 50157085 
 
TMBIM6 -37.0 0.000285 0.044 
cg06169276 11 71164262 Island NADSYN1 1026.1 0.000286 0.044 
cg23502162 2 189839015 
 
COL3A1 35.6 0.000286 0.044 
cg00450164 1 209930127 
 
TRAF3IP3 -31.2 0.000286 0.044 
cg21228270 9 133871033 
 
NA -29.0 0.000286 0.044 
cg06566994 3 44596384 N_Shore ZKSCAN7 27.5 0.000286 0.044 
cg24850296 12 25707569 
 
IFLTD1 -58.0 0.000286 0.044 
cg17745697 2 38138126 
 
NA -60.6 0.000286 0.044 
cg02674693 11 45109122 
 
NA 37.3 0.000287 0.044 
cg08251901 12 15114904 
 
ARHGDIB -18.5 0.000287 0.044 
cg23709430 17 3977501 
 
ZZEF1 -64.8 0.000287 0.044 
cg13895322 12 6877740 S_Shore PTMS 27.5 0.000287 0.044 
cg17244340 6 36973448 
 
FGD2 -35.1 0.000287 0.044 
cg24710179 11 642975 N_Shore NA -83.1 0.000288 0.044 
cg02063520 6 102516590 
 
GRIK2 28.7 0.000288 0.044 
cg13509421 12 110476821 
 
ANKRD13A 28.8 0.000288 0.044 
cg18113826 6 31583942 N_Shelf AIF1 -59.4 0.000288 0.044 
cg18502630 9 139871955 N_Shore PTGDS 47.9 0.000288 0.044 
cg16689434 16 90089547 S_Shore GAS8 32.2 0.000288 0.044 
cg25618198 13 26423104 
 
ATP8A2 47.0 0.000289 0.045 
cg12617080 1 156509844 
 
IQGAP3 -67.4 0.000289 0.045 
cg11842502 6 111862202 
 
TRAF3IP2-AS1 -34.3 0.00029 0.045 
cg12012524 19 1268008 Island CIRBP 43.0 0.00029 0.045 
cg20136855 1 12233852 
 
TNFRSF1B -26.2 0.00029 0.045 
cg02086790 16 375327 Island AXIN1 -50.6 0.00029 0.045 
cg21939215 11 60738995 
 
CD6 -51.1 0.00029 0.045 
cg02659854 13 24824078 
 
SPATA13-AS1 -52.7 0.00029 0.045 
cg07137429 10 100093476 
 
NA -47.4 0.000291 0.045 
cg23627149 1 193155273 
 
B3GALT2 24.1 0.000291 0.045 
cg02405503 15 68871738 Island CORO2B -133.1 0.000291 0.045 
cg13038847 22 28073997 Island NA -54.1 0.000291 0.045 
cg09761367 1 25360712 
 
NA -30.3 0.000291 0.045 
cg23972298 1 32665582 N_Shore CCDC28B 31.6 0.000291 0.045 
cg22774605 6 47247047 
 
TNFRSF21 -18.7 0.000292 0.045 
cg06548416 1 24438703 
 
MYOM3 89.0 0.000292 0.045 
cg04202957 2 207023158 N_Shore NDUFS1 69.0 0.000293 0.045 
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cg02881939 2 43860690 N_Shelf PLEKHH2 103.0 0.000293 0.045 
cg20309061 15 42693555 
 
CAPN3 -44.5 0.000293 0.045 
cg06319579 17 8127196 S_Shore LINC00324 42.8 0.000293 0.045 
cg16532400 7 150217056 
 
GIMAP7 -35.0 0.000293 0.045 
cg06618298 5 16913076 
 
MYO10 31.2 0.000293 0.045 
cg26675485 16 67968879 N_Shore PSMB10 44.2 0.000295 0.045 
cg04332442 22 46770063 N_Shore CELSR1 -24.5 0.000295 0.045 
cg01357846 2 79252794 
 
REG3G 31.3 0.000295 0.045 
cg00955682 5 138677338 Island PAIP2 1162.9 0.000295 0.045 
cg08380252 19 35530254 N_Shore HPN -26.9 0.000295 0.045 
cg23586138 2 27719544 S_Shore GCKR -47.9 0.000296 0.045 
cg16389209 10 63809121 
 
ARID5B 40.0 0.000296 0.045 
cg09795027 17 74006440 S_Shore EVPL -50.1 0.000296 0.045 
cg02481950 16 21665002 
 
IGSF6 -52.3 0.000296 0.045 
cg14679668 8 102130344 
 
NA -23.1 0.000296 0.045 
cg20332354 12 91451819 
 
KERA 25.8 0.000297 0.045 
cg12282777 15 74203067 
 
NA -77.2 0.000297 0.045 
cg22908922 14 105855008 S_Shelf PACS2 -59.0 0.000297 0.045 
cg05453924 13 24079390 
 
NA 26.9 0.000297 0.045 
cg09594075 17 1358505 N_Shore CRK 74.9 0.000297 0.045 
cg09618904 20 34026478 S_Shelf GDF5 27.8 0.000297 0.045 
cg16562342 1 109783503 
 
NA 36.2 0.000298 0.045 
cg13629388 6 170687780 S_Shore FAM120B -30.9 0.000298 0.045 
cg17285709 2 220300242 Island SPEG -56.4 0.000298 0.045 
cg01210113 16 11352835 S_Shelf SOCS1 -42.4 0.000298 0.045 
cg12133423 8 1094575 N_Shore NA -43.0 0.000298 0.045 
cg03700135 17 707059 N_Shore NXN 42.0 0.000299 0.045 
cg05671385 11 104915759 
 
CARD16 -32.8 0.000299 0.045 
cg04221624 10 72274527 
 
PALD1 -38.9 0.000299 0.045 
cg17687962 19 51358244 
 
KLK3 -52.7 0.000299 0.045 
cg03529043 6 31021134 
 
HCG22 -45.4 0.000299 0.045 
cg07777703 17 40811829 S_Shore TUBG2 86.7 0.000299 0.045 
cg24448340 1 179921042 N_Shelf CEP350 -78.1 0.000299 0.045 
cg03545548 3 167320581 
 
WDR49 -32.5 0.0003 0.045 
cg13423054 3 160192028 
 
NA 51.3 0.0003 0.045 
cg26564172 1 183728338 
 
RGL1 46.0 0.0003 0.045 
cg26433582 11 68848232 N_Shore TPCN2 -56.0 0.0003 0.045 
cg05999377 X 152712061 S_Shore TREX2 -69.9 0.0003 0.045 
cg06677151 10 616959 
 
DIP2C 24.3 0.0003 0.045 
cg15815084 17 54912870 S_Shore DGKE -19.1 0.0003 0.045 
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cg16699540 3 156793711 
 
NA -29.1 0.000301 0.045 
cg17222164 17 43339476 Island SPATA32 68.1 0.000301 0.045 
cg11538810 22 46481727 N_Shore MIRLET7BHG 49.5 0.000302 0.045 
cg07148896 1 11119225 Island SRM 43.0 0.000302 0.045 
cg08639762 1 201437298 N_Shore PHLDA3 32.5 0.000302 0.045 
cg04818845 1 6580167 
 
PLEKHG5 52.1 0.000302 0.045 
cg25199283 1 38099265 N_Shore RSPO1 -61.7 0.000302 0.045 
cg25623459 11 1861344 
 
TNNI2 -34.4 0.000302 0.045 
cg10544324 3 53915957 Island ACTR8 158.7 0.000302 0.045 
cg22113926 17 28566331 S_Shelf SLC6A4 -83.4 0.000302 0.045 
cg04664126 6 28554262 N_Shore SCAND3 22.7 0.000302 0.045 
cg04822621 5 169724656 
 
LCP2 -23.1 0.000302 0.045 
cg13029400 3 141087190 
 
ZBTB38 57.3 0.000302 0.045 
cg21311067 19 4916983 S_Shore UHRF1 -44.2 0.000303 0.045 
cg25765104 1 167601275 S_Shore RCSD1 -52.3 0.000303 0.045 
cg21306988 13 108867134 Island LIG4 27.2 0.000303 0.045 
cg02370667 16 84029511 Island NECAB2 -35.3 0.000303 0.045 
cg17297216 15 99194474 Island IGF1R 64.0 0.000303 0.045 
cg16064425 14 101111348 
 
NA -38.4 0.000303 0.045 
cg27487796 7 28973253 
 
NA 22.3 0.000303 0.045 
cg13216022 15 51631687 N_Shelf CYP19A1 -29.1 0.000304 0.045 
cg19011001 14 93539613 
 
ITPK1 -41.0 0.000304 0.045 
cg08370546 7 56160770 
 
PHKG1 41.9 0.000304 0.045 
cg12656307 1 2349734 S_Shelf NA 72.0 0.000305 0.045 
cg11338389 11 63742044 Island COX8A 1119.0 0.000305 0.045 
cg18213495 6 17985408 N_Shelf KIF13A 61.3 0.000305 0.045 
cg11234013 11 27646797 
 
LINC00678 -22.5 0.000306 0.045 
cg04233521 1 27743080 
 
WASF2 -44.7 0.000306 0.045 
cg07263492 8 99835768 N_Shore STK3 -50.3 0.000306 0.045 
cg27366766 17 56565286 Island HSF5 -37.8 0.000307 0.045 
cg06419959 9 140354043 Island NSMF 323.0 0.000307 0.045 
cg04112866 2 105925965 
 
TGFBRAP1 -43.4 0.000307 0.045 
cg03467087 6 158448134 
 
SYNJ2 -25.4 0.000308 0.045 
cg03293883 6 86124742 
 
NA -35.7 0.000308 0.045 
cg03001305 17 40439492 N_Shore STAT5A -42.5 0.000308 0.045 
cg20531872 3 196440087 S_Shore PIGX 87.0 0.000308 0.045 
cg02185248 17 78748494 
 
RPTOR -54.4 0.000309 0.045 
cg14045814 2 219267341 S_Shore MIR26B 45.1 0.000309 0.045 
cg06592027 5 38445220 
 
EGFLAM 24.6 0.000309 0.045 
cg23433370 12 27396894 N_Shore STK38L -41.3 0.000309 0.045 
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cg11002208 2 241562650 Island GPR35 -36.5 0.000309 0.045 
cg05185634 14 24804750 S_Shore ADCY4 -91.2 0.00031 0.045 
cg20306842 7 28475265 
 
CREB5 -74.7 0.00031 0.045 
cg16499834 12 131355834 N_Shore RAN 32.3 0.00031 0.045 
cg23992426 11 47870622 S_Shore NUP160 119.3 0.00031 0.045 
cg15529532 10 15077470 
 
NA -41.4 0.00031 0.045 
cg19357849 19 8071093 
 
ELAVL1 107.1 0.00031 0.045 
cg24566261 6 30854164 S_Shore DDR1 50.5 0.00031 0.045 
cg04442631 22 36593144 
 
APOL4 -19.5 0.000311 0.045 
cg22613905 2 240039481 
 
HDAC4 -66.7 0.000311 0.045 
cg18081338 6 17212963 
 
NA 34.3 0.000312 0.045 
cg04869379 13 109610256 
 
MYO16 24.0 0.000312 0.045 
cg11999571 8 25442428 
 
NA 28.1 0.000312 0.045 
cg15658306 6 41168972 
 
TREML2 -42.9 0.000312 0.045 
cg07766743 8 27348001 N_Shore EPHX2 26.8 0.000312 0.045 
cg22073869 13 98866089 
 
FARP1 46.7 0.000312 0.045 
cg25243775 22 45903119 S_Shelf FBLN1 67.3 0.000312 0.045 
cg21579294 13 113997499 
 
GRTP1 -53.7 0.000313 0.045 
cg26780138 16 477087 S_Shore RAB11FIP3 131.8 0.000313 0.045 
cg05266786 10 49742271 
 
ARHGAP22 26.8 0.000314 0.045 
cg26792089 16 28518200 
 
IL27 -55.7 0.000314 0.045 
cg22260478 6 132272790 S_Shore CTGF 47.4 0.000315 0.045 
cg27395391 6 16375082 
 
ATXN1 25.3 0.000315 0.045 
cg07630327 5 131008111 
 
FNIP1 19.4 0.000315 0.045 
cg01367328 7 162351 S_Shelf NA -43.1 0.000315 0.045 
cg10726475 3 149375252 Island WWTR1 277.3 0.000315 0.045 
cg22935317 14 23447078 N_Shelf AJUBA 33.7 0.000315 0.045 
cg04432599 17 4835608 
 
GP1BA -32.8 0.000315 0.045 
cg05616355 11 124480990 
 
PANX3 38.9 0.000316 0.045 
cg20538986 17 19295550 
 
NA 41.9 0.000316 0.045 
cg18230356 X 135045624 
 
MMGT1 95.8 0.000316 0.045 
cg02102684 16 4421445 N_Shore VASN 32.5 0.000316 0.045 
cg12136883 4 120613606 
 
NA 38.2 0.000317 0.046 
cg16706099 11 100590197 
 
ARHGAP42 39.3 0.000317 0.046 
cg10464462 17 33417059 S_Shore RFFL -29.7 0.000317 0.046 
cg06591011 4 111086137 
 
ELOVL6 -35.4 0.000318 0.046 
cg17166282 13 103249241 Island TPP2 7684.0 0.000318 0.046 
cg05802141 16 29911556 Island ASPHD1 3807.1 0.000318 0.046 
cg10919177 3 44519663 S_Shore ZNF445 35.2 0.000318 0.046 
cg00071391 4 126560514 
 
NA 23.7 0.000319 0.046 
137 
 
Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg17736336 5 148788401 
 
MIR143HG 40.4 0.000319 0.046 
cg10592592 10 74034663 Island DDIT4 45.2 0.000319 0.046 
cg24525952 7 2127830 
 
MAD1L1 -50.4 0.00032 0.046 
cg00137016 19 52675231 S_Shore ZNF836 40.5 0.00032 0.046 
cg17426905 7 50612053 
 
DDC 75.4 0.00032 0.046 
cg09852607 3 128205200 N_Shore GATA2 29.7 0.00032 0.046 
cg00917031 9 123477533 S_Shore MEGF9 46.2 0.000321 0.046 
cg26608486 16 88482341 
 
NA -80.0 0.000321 0.046 
cg22898924 19 4903952 
 
ARRDC5 -52.7 0.000321 0.046 
cg01595717 9 140586201 N_Shore EHMT1 -31.9 0.000321 0.046 
cg10299128 4 82796846 
 
NA -31.3 0.000321 0.046 
cg05885577 10 104597359 
 
CYP17A1 39.1 0.000321 0.046 
cg07212541 15 101442710 
 
ALDH1A3 31.3 0.000322 0.046 
cg12708109 1 168397916 
 
NA 37.4 0.000322 0.046 
cg20942867 1 27426144 
 
SLC9A1 35.3 0.000322 0.046 
cg04661001 19 19217217 N_Shelf SLC25A42 50.4 0.000322 0.046 
cg04441857 10 14701815 
 
FAM107B -51.0 0.000323 0.046 
cg23121335 11 67784489 
 
ALDH3B1 136.9 0.000323 0.046 
cg16582803 2 219763642 S_Shore NA 40.3 0.000323 0.046 
cg24699699 1 93258316 
 
EVI5 -27.6 0.000324 0.046 
cg02551095 15 33597346 
 
NA -45.1 0.000324 0.046 
cg23484159 14 74184843 N_Shore PNMA1 44.2 0.000324 0.046 
cg05420143 2 210286628 N_Shore MAP2 36.2 0.000325 0.046 
cg01715248 9 93953608 N_Shore NA -65.5 0.000325 0.046 
cg08343834 17 15168658 S_Shelf PMP22 22.7 0.000325 0.046 
cg01063509 1 20502234 
 
PLA2G2C 36.5 0.000325 0.046 
cg15484406 14 94461913 
 
LINC00521 34.4 0.000325 0.046 
cg16013543 1 154300241 N_Shore ATP8B2 -45.7 0.000326 0.046 
cg02072940 6 31656126 
 
ABHD16A 71.1 0.000326 0.046 
cg26337914 7 157461081 
 
PTPRN2 -59.7 0.000326 0.046 
cg11934819 20 1472078 
 
SIRPB2 -36.5 0.000326 0.046 
cg07975680 10 73225789 
 
CDH23 -37.0 0.000326 0.046 
cg12545949 6 71571446 
 
B3GAT2 -84.8 0.000326 0.046 
cg04656451 20 5626258 
 
NA -27.6 0.000327 0.046 
cg25503381 15 39871923 N_Shore THBS1 46.0 0.000327 0.046 
cg26022064 7 98739782 N_Shore SMURF1 37.0 0.000327 0.046 
cg24063856 17 43863303 S_Shore CRHR1 -23.6 0.000328 0.046 
cg00193668 9 35814283 N_Shore HINT2 50.5 0.000328 0.046 
cg02839593 16 66934539 
 
NA 43.0 0.000328 0.046 
cg08428819 10 123924042 S_Shore TACC2 -53.7 0.000328 0.046 
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cg17372758 10 73976798 S_Shore ASCC1 25.9 0.000328 0.046 
cg23359665 6 32120907 N_Shore PPT2 52.7 0.000328 0.046 
cg16151795 11 1918450 
 
NA -50.9 0.000329 0.046 
cg24484905 1 58530146 
 
DAB1 -153.6 0.000329 0.046 
cg12635120 12 121345228 S_Shelf SPPL3 21.7 0.000329 0.046 
cg00054706 2 68289972 
 
C1D 597.8 0.000329 0.046 
cg13284470 2 69001115 
 
ARHGAP25 -30.9 0.000329 0.046 
cg15621731 19 5074616 Island KDM4B -51.2 0.000329 0.046 
cg25143508 1 203449947 
 
PRELP 49.3 0.000329 0.046 
cg20731384 10 134993392 S_Shore KNDC1 -44.4 0.00033 0.046 
cg02945192 19 1038140 N_Shore ABCA7 -50.6 0.00033 0.046 
cg17603988 7 56160766 
 
PHKG1 30.6 0.00033 0.046 
cg04237436 11 35808688 
 
TRIM44 53.6 0.00033 0.046 
cg09763644 1 207103660 
 
PIGR -32.7 0.00033 0.046 
cg04682967 22 37608626 
 
SSTR3 69.2 0.000331 0.046 
cg03208902 16 3265467 
 
OR1F2P -33.7 0.000331 0.046 
cg24724587 1 86044103 S_Shore DDAH1 39.6 0.000331 0.046 
cg00502509 7 1956121 
 
MAD1L1 -37.2 0.000331 0.046 
cg20969822 19 41787138 
 
HNRNPUL1 36.1 0.000331 0.046 
cg07682037 11 63974153 N_Shore FERMT3 -52.0 0.000332 0.046 
cg08947774 4 169644750 
 
PALLD -31.8 0.000332 0.046 
cg03498081 16 80061357 
 
NA -34.2 0.000332 0.046 
cg12950181 5 93447648 S_Shore FAM172A 47.6 0.000332 0.046 
cg21957813 11 44638520 
 
CD82 43.8 0.000332 0.046 
cg24742298 17 27309486 N_Shelf SEZ6 -22.3 0.000332 0.046 
cg13475578 12 99548550 
 
ANKS1B 44.1 0.000332 0.046 
cg17329202 13 113807930 S_Shore NA 38.4 0.000332 0.046 
cg17845532 19 3786643 Island MATK 47.6 0.000333 0.046 
cg02054776 1 165326345 S_Shore LMX1A -35.4 0.000333 0.046 
cg24342094 1 112047496 
 
ADORA3 -120.6 0.000333 0.046 
cg02149069 12 6649733 Island IFFO1 -34.0 0.000334 0.046 
cg14781394 19 16441457 S_Shelf NA -38.1 0.000334 0.046 
cg06760507 1 161168145 N_Shelf ADAMTS4 40.6 0.000334 0.046 
cg18003659 2 175629267 
 
CHRNA1 48.4 0.000334 0.046 
cg27425413 6 4974439 
 
NA 28.4 0.000334 0.046 
cg09106231 1 207455715 
 
NA -34.0 0.000335 0.046 
cg13689831 1 227175077 
 
ADCK3 -43.5 0.000335 0.046 
cg19211853 13 79968216 
 
RBM26 -28.1 0.000335 0.046 
cg12054981 8 42037387 
 
PLAT -28.3 0.000335 0.046 
cg00679520 12 63133578 
 
PPM1H 23.6 0.000335 0.046 
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cg25963980 11 35442225 S_Shore SLC1A2 -29.4 0.000336 0.046 
cg21578596 6 32906460 
 
HLA-DMB -43.8 0.000336 0.046 
cg09773238 11 113424208 
 
NA 23.1 0.000336 0.046 
cg09990481 10 90712684 
 
ACTA2 46.0 0.000336 0.046 
cg02866149 20 35405989 S_Shelf DSN1 57.4 0.000336 0.046 
cg24777399 2 109855574 
 
SH3RF3 -41.7 0.000337 0.046 
cg00849854 17 17780937 
 
TOM1L2 35.3 0.000337 0.046 
cg10548978 10 72545053 
 
TBATA -69.8 0.000337 0.046 
cg04132891 3 112351647 
 
CCDC80 38.8 0.000337 0.046 
cg17674726 2 231743193 
 
ITM2C -57.7 0.000337 0.046 
cg01638225 4 1202930 N_Shore SPON2 40.1 0.000337 0.046 
cg04079779 16 2256121 S_Shore MLST8 72.6 0.000337 0.046 
cg13930766 9 122577345 
 
NA -57.1 0.000337 0.046 
ch.6.169008488F 6 169266563 
 
NA -36.1 0.000337 0.046 
cg17893934 10 858817 S_Shelf LARP4B 51.5 0.000337 0.046 
cg06556244 7 143089459 
 
EPHA1 57.2 0.000338 0.046 
cg21667244 13 111281324 S_Shelf CARKD 43.9 0.000338 0.046 
cg19749538 4 78114867 
 
NA -43.5 0.000338 0.046 
cg23950714 5 176935364 S_Shelf DOK3 -35.1 0.000338 0.046 
cg06901890 9 132803508 N_Shore FNBP1 -54.1 0.000338 0.046 
cg24129177 12 132076442 
 
NA 55.3 0.000338 0.046 
cg15620114 10 91296457 S_Shore SLC16A12 -100.8 0.000339 0.046 
cg24590430 10 99097076 S_Shelf FRAT2 36.5 0.000339 0.046 
cg15907473 13 95253641 N_Shore GPR180 46.3 0.000339 0.046 
cg07096238 2 66589902 
 
MIR4778 -34.4 0.00034 0.046 
cg09398762 13 107571965 S_Shore NA -19.6 0.00034 0.046 
cg11736942 14 105054436 N_Shore C14orf180 -74.3 0.00034 0.046 
cg26078436 11 5265992 
 
HBBP1 26.2 0.000341 0.046 
cg25940517 12 113645509 
 
IQCD -39.7 0.000341 0.046 
cg17601785 5 71475111 
 
MAP1B 29.9 0.000341 0.046 
cg20511815 7 5537036 N_Shelf MIR589 -48.7 0.000341 0.046 
cg06126593 16 20910405 N_Shore LYRM1 48.8 0.000342 0.046 
cg14700104 5 139527250 S_Shore NA 75.9 0.000342 0.046 
cg21964800 11 63272764 
 
LGALS12 -27.3 0.000342 0.046 
cg20873136 2 129037710 
 
HS6ST1 -46.6 0.000343 0.046 
cg05146756 9 21558871 N_Shore MIR31HG -29.8 0.000344 0.046 
cg09823760 12 131484594 
 
GPR133 55.1 0.000344 0.046 
cg22210337 11 2322808 
 
C11orf21 -43.3 0.000344 0.046 
cg25877009 8 142288517 
 
NA -80.5 0.000344 0.046 
cg02927747 18 60381593 N_Shore PHLPP1 -31.3 0.000344 0.046 
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cg10710218 1 55012989 
 
ACOT11 -59.6 0.000344 0.046 
cg14299883 12 80447038 
 
NA 73.0 0.000345 0.046 
cg23586792 2 200423026 
 
NA 98.1 0.000345 0.046 
cg00040749 2 62556079 
 
NA -57.9 0.000345 0.046 
cg10370574 19 1840461 
 
REXO1 -39.9 0.000345 0.046 
cg07007807 12 117176115 Island RNFT2 1516.8 0.000345 0.046 
cg20345915 10 121296042 
 
RGS10 -37.1 0.000346 0.046 
cg13578303 19 49838698 N_Shelf CD37 -53.4 0.000346 0.046 
cg00787013 10 125665208 
 
NA 63.6 0.000346 0.046 
cg09130190 11 32115439 S_Shelf RCN1 51.1 0.000346 0.046 
cg02395812 14 105955879 N_Shore C14orf80 43.9 0.000346 0.046 
cg23537932 10 121172463 
 
GRK5 41.5 0.000346 0.046 
cg15549251 15 40426006 
 
NA -73.1 0.000347 0.047 
cg24754956 19 1729851 S_Shelf NA 44.1 0.000347 0.047 
cg19874726 14 61114476 Island SIX1 -29.6 0.000348 0.047 
cg11100309 12 57637268 Island NDUFA4L2 63.8 0.000348 0.047 
cg01389728 10 6620572 N_Shore PRKCQ -19.1 0.000348 0.047 
cg07897701 7 150549370 
 
AOC1 -58.5 0.000349 0.047 
cg15155441 11 57005981 
 
APLNR -83.2 0.000349 0.047 
cg06147863 11 47400113 S_Shore SPI1 -27.8 0.000349 0.047 
cg11953516 2 27719501 S_Shore GCKR -45.1 0.000349 0.047 
cg22180580 6 138867046 
 
NHSL1 37.3 0.000349 0.047 
cg04822278 12 125023878 S_Shore NCOR2 21.1 0.000349 0.047 
cg05289022 2 98377864 
 
TMEM131 -79.0 0.00035 0.047 
cg14533068 6 158507953 Island SYNJ2 -66.8 0.00035 0.047 
cg11854227 3 121714109 S_Shore ILDR1 -39.1 0.000351 0.047 
cg25727029 15 89482453 
 
NA -54.0 0.000351 0.047 
cg11370814 2 242927418 N_Shore NA -38.6 0.000352 0.047 
cg25816696 2 239427974 
 
LOC151171 65.8 0.000352 0.047 
cg10421194 2 43133914 
 
NA 27.6 0.000352 0.047 
cg27520905 7 153999655 N_Shelf DPP6 24.8 0.000353 0.047 
cg01209642 6 170581355 S_Shore NA -53.4 0.000353 0.047 
cg14189441 10 30971547 
 
NA 40.9 0.000353 0.047 
cg12633817 7 1117479 N_Shelf C7orf50 -32.8 0.000353 0.047 
cg23081604 12 130824224 S_Shore PIWIL1 44.2 0.000353 0.047 
cg15034267 22 39106452 S_Shelf GTPBP1 -52.5 0.000353 0.047 
cg13600632 9 129169002 
 
NRON 43.2 0.000353 0.047 
cg06596943 6 901264 
 
NA 25.6 0.000353 0.047 
cg13637552 11 1534712 N_Shelf MOB2 -51.4 0.000354 0.047 
cg09317128 4 56265301 S_Shelf TMEM165 39.9 0.000354 0.047 
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cg15969901 6 36810478 S_Shore CPNE5 -39.2 0.000354 0.047 
cg23618218 12 51474138 N_Shelf CSRNP2 41.6 0.000354 0.047 
cg13945880 5 171008055 
 
NA 55.4 0.000354 0.047 
cg17372408 8 143427750 N_Shore TSNARE1 39.8 0.000354 0.047 
cg17319795 14 93170808 
 
LGMN -54.3 0.000355 0.047 
cg00486259 4 152096720 
 
SH3D19 27.9 0.000355 0.047 
cg04012600 1 109850126 
 
MYBPHL -39.8 0.000355 0.047 
cg15241074 2 12860614 S_Shore TRIB2 42.1 0.000355 0.047 
cg08951051 16 4993543 
 
NA 44.8 0.000356 0.047 
cg00664697 16 80061290 
 
NA -42.2 0.000356 0.047 
cg23878494 11 63687937 S_Shore RCOR2 46.5 0.000356 0.047 
cg14324675 6 31554848 
 
LST1 -61.8 0.000356 0.047 
cg04121415 3 38325566 
 
NA 29.7 0.000357 0.047 
cg22844229 12 58013475 Island SLC26A10 -34.7 0.000357 0.047 
cg26312337 2 25170414 
 
DNAJC27 32.9 0.000357 0.047 
cg00732378 16 55021073 
 
NA -44.9 0.000357 0.047 
cg27078890 11 128457459 
 
ETS1 48.6 0.000357 0.047 
cg19408626 1 12189773 
 
TNFRSF8 -52.6 0.000358 0.047 
cg23054840 10 45920485 N_Shelf ALOX5 -32.7 0.000358 0.047 
cg12871285 17 76713379 
 
CYTH1 26.0 0.000358 0.047 
cg20625523 2 64893849 
 
NA -40.2 0.000358 0.047 
cg01372366 11 48041783 
 
PTPRJ -50.4 0.000358 0.047 
cg11028624 11 13983793 N_Shore SPON1 -41.5 0.000359 0.047 
cg20198611 6 33163689 S_Shelf COL11A2 53.0 0.000359 0.047 
cg14443726 9 129468049 N_Shore NA 153.3 0.000359 0.047 
cg20594303 10 60680256 
 
NA 62.5 0.00036 0.047 
cg27554551 16 4421486 N_Shore VASN 34.8 0.00036 0.047 
cg03716908 5 81149002 
 
NA 41.5 0.00036 0.047 
cg24962576 3 42745362 
 
HHATL -70.4 0.000361 0.047 
cg19214300 16 56709503 N_Shore MT1IP -41.4 0.000362 0.047 
cg27350483 17 58822074 
 
BCAS3 36.2 0.000362 0.047 
cg27368523 2 113544348 
 
IL1A -51.6 0.000362 0.047 
cg01401037 3 185839955 
 
NA 33.3 0.000362 0.047 
cg19961151 5 68207879 
 
NA 30.0 0.000363 0.047 
cg06489606 17 80251697 S_Shore NA 49.9 0.000363 0.047 
cg01386185 3 15935423 
 
NA 47.1 0.000363 0.047 
cg03330678 17 75316233 
 
9-Sep 35.2 0.000363 0.047 
cg06898168 7 5447353 
 
TNRC18 41.1 0.000363 0.047 
cg22479403 5 151328842 
 
NA 35.2 0.000363 0.047 
cg16277944 5 169068404 S_Shelf DOCK2 27.2 0.000364 0.047 
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cg16903025 8 124549553 N_Shelf FBXO32 45.3 0.000364 0.047 
cg24795614 2 44973115 
 
CAMKMT -30.2 0.000364 0.047 
cg06635832 5 154654216 
 
NA -23.6 0.000364 0.047 
cg17441062 11 88242604 S_Shore GRM5-AS1 -34.3 0.000364 0.047 
cg17518965 19 3178955 Island S1PR4 -51.5 0.000364 0.047 
cg20976581 17 34080240 
 
GAS2L2 70.7 0.000366 0.047 
cg02857726 3 149088388 
 
TM4SF1 -29.4 0.000366 0.047 
cg05944877 16 24197863 
 
PRKCB 51.9 0.000366 0.047 
cg17973773 8 27695870 S_Shore PBK 43.1 0.000366 0.047 
cg22365240 2 105374995 
 
LOC284998 31.2 0.000366 0.047 
cg05590274 11 113262625 S_Shelf ANKK1 -32.4 0.000366 0.047 
cg03925411 3 35986831 
 
NA -180.9 0.000367 0.047 
cg16227748 2 232186992 
 
ARMC9 -29.1 0.000367 0.047 
cg16974893 3 156799514 
 
LINC00880 62.2 0.000367 0.047 
cg02434051 19 54848878 
 
LILRA4 38.1 0.000368 0.047 
cg12808347 2 11622001 Island NA -54.9 0.000368 0.047 
cg10809783 6 148784879 
 
SASH1 -65.6 0.000368 0.047 
cg19618297 13 112760313 Island NA 124.0 0.000368 0.047 
cg12492496 19 18271859 Island PIK3R2 34.1 0.000368 0.047 
cg08790487 5 179135308 
 
CANX -46.7 0.000368 0.047 
cg03980424 10 3526723 
 
NA -22.4 0.000368 0.047 
cg12947138 5 71475303 
 
MAP1B 24.2 0.000368 0.047 
cg27352123 5 92353980 
 
NA 56.3 0.000368 0.047 
cg16667251 2 54697181 
 
SPTBN1 -30.3 0.000368 0.047 
cg19272266 8 38125865 N_Shore PPAPDC1B 32.6 0.000368 0.047 
cg11580525 11 118022923 N_Shore SCN4B 38.3 0.000369 0.047 
cg00447208 17 76126301 N_Shore TMC8 -42.1 0.000369 0.047 
cg06051662 X 153096786 S_Shore PDZD4 26.7 0.000369 0.047 
cg03642503 17 76899257 S_Shore LOC100653515 59.7 0.000369 0.047 
cg05245794 8 119884332 
 
NA -78.3 0.000369 0.047 
cg21060429 7 2280360 N_Shore FTSJ2 -131.5 0.000369 0.047 
cg13247398 11 46366840 N_Shore DGKZ -51.1 0.000369 0.047 
cg11247497 4 183756392 
 
NA -61.0 0.00037 0.047 
cg00869668 17 1549012 S_Shore SCARF1 -30.7 0.00037 0.047 
cg22353096 2 100851666 
 
LOC150577 -24.7 0.00037 0.047 
cg14311134 19 7414062 
 
NA -35.1 0.00037 0.047 
cg13599613 9 130524902 
 
SH2D3C -16.5 0.000371 0.047 
cg25736482 19 54677232 
 
TMC4 -42.0 0.000371 0.047 
cg26037142 6 32097481 N_Shore FKBPL 28.2 0.000371 0.047 
cg20033981 13 41590153 
 
ELF1 -29.7 0.000371 0.047 
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cg19980148 14 39639590 Island TRAPPC6B 946.9 0.000372 0.047 
cg23386659 19 840950 N_Shelf PRTN3 -50.0 0.000372 0.047 
cg23722096 7 127347748 
 
SND1 29.6 0.000372 0.047 
cg17178748 13 43594122 N_Shelf DNAJC15 38.1 0.000373 0.047 
cg27269488 3 191048411 S_Shore UTS2B 34.2 0.000373 0.047 
cg08087655 11 122073541 
 
MIR100HG 42.8 0.000373 0.047 
cg14478589 9 124086862 
 
GSN -52.6 0.000373 0.047 
cg14549256 4 2627142 
 
FAM193A 32.6 0.000373 0.047 
cg24947456 12 57441432 
 
MYO1A -48.4 0.000373 0.047 
cg21133433 4 169991796 
 
NA 30.4 0.000374 0.047 
cg07734926 6 28832358 S_Shore LOC401242 34.7 0.000374 0.047 
cg26583078 4 186877778 
 
SORBS2 25.8 0.000374 0.047 
cg07620928 10 92689909 
 
NA 34.6 0.000374 0.048 
cg04812726 5 171875049 
 
SH3PXD2B 45.6 0.000375 0.048 
cg18784903 7 1337353 Island NA 29.4 0.000375 0.048 
cg14017402 2 86225602 
 
NA 31.5 0.000375 0.048 
cg20545409 11 87423941 
 
NA -32.3 0.000376 0.048 
cg21773297 8 2049910 S_Shelf MYOM2 -25.2 0.000376 0.048 
cg17460386 1 207095668 
 
FAIM3 -36.0 0.000376 0.048 
cg01396774 2 218299024 
 
DIRC3 152.5 0.000376 0.048 
cg12159992 12 102059490 
 
MYBPC1 -24.3 0.000377 0.048 
cg09262974 15 38478762 
 
NA -90.9 0.000377 0.048 
cg02307664 2 134586281 
 
NA 50.3 0.000377 0.048 
cg02625536 20 47749901 
 
STAU1 72.7 0.000377 0.048 
cg11460364 2 162931397 S_Shore DPP4 -36.4 0.000377 0.048 
cg10516359 11 45827763 S_Shore SLC35C1 57.6 0.000377 0.048 
cg17243643 12 56114269 S_Shelf RDH5 22.9 0.000378 0.048 
cg19251656 1 100000372 
 
NA -21.0 0.000378 0.048 
cg08595656 4 17723733 
 
FAM184B 54.7 0.000378 0.048 
cg23976723 4 185872645 N_Shore NA -166.8 0.000378 0.048 
cg18069290 12 58013539 Island SLC26A10 -38.7 0.000379 0.048 
cg04514998 11 108680123 
 
DDX10 -41.4 0.000379 0.048 
cg19256813 12 117627286 N_Shore FBXO21 34.0 0.000379 0.048 
cg15616915 2 219266163 S_Shore MIR26B 41.0 0.000379 0.048 
cg14163484 2 97359926 
 
FER1L5 -63.3 0.00038 0.048 
cg18786643 1 117129532 
 
IGSF3 -40.2 0.00038 0.048 
cg25746394 19 45450501 
 
APOC2 -70.5 0.00038 0.048 
cg20901787 17 79936477 S_Shore ASPSCR1 58.0 0.00038 0.048 
cg02768671 6 169470822 
 
NA 45.8 0.00038 0.048 
cg13925432 9 110398260 N_Shore NA -48.7 0.000381 0.048 
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cg15922176 10 134096798 S_Shore STK32C 45.0 0.000381 0.048 
cg16371538 1 37940813 S_Shore ZC3H12A 60.3 0.000381 0.048 
cg09218250 3 9943848 
 
IL17RE -43.1 0.000381 0.048 
cg25550753 2 47205281 
 
TTC7A -42.0 0.000382 0.048 
cg26466234 10 124264224 
 
HTRA1 40.1 0.000383 0.048 
cg18824446 15 89154058 
 
MIR7-2 -23.1 0.000383 0.048 
cg15234197 11 68924956 Island NA 34.0 0.000383 0.048 
cg22631555 10 23216637 
 
ARMC3 89.7 0.000384 0.048 
cg19005210 6 41168960 
 
TREML2 -59.8 0.000384 0.048 
cg26723624 4 53700940 
 
NA -120.0 0.000384 0.048 
cg27391982 13 76957970 
 
NA 17.0 0.000385 0.048 
cg13573928 4 169754534 Island PALLD 38.2 0.000385 0.048 
cg05947761 7 1734325 
 
NA 69.8 0.000385 0.048 
cg26199631 2 239924551 
 
NA 31.5 0.000385 0.048 
cg17554875 5 179520998 S_Shelf NA -43.3 0.000385 0.048 
cg02016178 16 3628416 
 
NLRC3 -40.9 0.000386 0.048 
cg20444218 11 73024037 S_Shelf ARHGEF17 58.3 0.000386 0.048 
cg25666403 22 30662994 
 
OSM -39.8 0.000387 0.048 
cg27534957 2 174265733 
 
NA -27.1 0.000387 0.048 
cg02878966 X 24692176 
 
PCYT1B -51.1 0.000387 0.048 
cg09356916 4 23791473 
 
NA 25.7 0.000387 0.048 
cg06395232 12 15105654 
 
ARHGDIB -43.8 0.000387 0.048 
cg21484586 19 35531859 Island HPN -46.6 0.000388 0.048 
cg09936919 2 19249137 
 
NA 47.7 0.000388 0.048 
cg03939352 1 162346594 
 
C1orf111 -103.1 0.000389 0.048 
cg24088042 3 126327440 
 
TXNRD3NB 38.9 0.000389 0.048 
cg17976873 14 23352295 N_Shelf REM2 59.8 0.00039 0.048 
cg02818170 19 3336941 
 
NA 36.8 0.00039 0.048 
cg14426428 6 106961936 S_Shore AIM1 -26.7 0.00039 0.048 
cg18997124 6 31740268 
 
VWA7 -38.1 0.000391 0.048 
cg03389133 22 37608611 
 
SSTR3 56.4 0.000391 0.048 
cg00244001 10 126336805 
 
FAM53B -64.6 0.000391 0.048 
cg20866090 3 188537167 
 
LPP -62.8 0.000392 0.048 
cg22801799 8 134072526 
 
SLA -53.7 0.000392 0.048 
cg21184454 X 19765879 
 
SH3KBP1 -46.4 0.000392 0.048 
cg10371643 13 109807836 
 
MYO16 -34.1 0.000392 0.048 
cg14260643 7 99277394 
 
CYP3A5 28.7 0.000392 0.048 
cg07646714 11 34378884 Island ABTB2 -920.3 0.000392 0.048 
cg00852595 12 99548437 
 
ANKS1B 26.7 0.000393 0.048 
cg03333377 11 93277841 S_Shore SMCO4 -19.0 0.000393 0.048 
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cg19351638 X 153170390 
 
AVPR2 -69.7 0.000393 0.048 
cg26536240 16 89509760 
 
ANKRD11 26.3 0.000393 0.048 
cg14070162 17 40575582 S_Shore PTRF 90.0 0.000394 0.048 
cg19175386 12 115134496 N_Shore NA -35.3 0.000394 0.048 
cg02543462 2 113885116 
 
IL1RN -52.4 0.000394 0.048 
cg15049549 3 48732213 
 
IP6K2 24.1 0.000394 0.048 
cg08590069 8 101118899 S_Shore RGS22 -40.5 0.000395 0.048 
cg24475517 2 118737667 
 
CCDC93 -56.8 0.000395 0.048 
cg02367723 1 46378857 
 
MAST2 29.2 0.000395 0.048 
cg24290574 3 148583152 
 
CPA3 -29.5 0.000395 0.048 
cg21946299 3 12329166 Island PPARG 102.0 0.000395 0.048 
cg05007997 2 219246985 
 
SLC11A1 -55.4 0.000395 0.048 
cg02124912 1 202091933 
 
GPR37L1 33.3 0.000395 0.048 
cg16339434 11 2286788 N_Shelf NA -23.7 0.000396 0.048 
cg21902474 5 150396984 N_Shelf GPX3 -34.1 0.000396 0.048 
cg17875922 6 37045823 
 
NA 53.3 0.000396 0.048 
cg04886849 10 118997146 N_Shelf SLC18A2 -47.3 0.000397 0.049 
cg09472600 1 183537770 
 
NCF2 -15.9 0.000398 0.049 
cg07053114 10 129794994 
 
PTPRE 29.9 0.000398 0.049 
cg15426626 12 132984261 Island NA 47.2 0.000398 0.049 
cg10493436 1 161168957 N_Shelf ADAMTS4 27.8 0.000398 0.049 
cg08882904 19 13233291 S_Shelf NACC1 51.3 0.000398 0.049 
cg04536829 3 127771995 S_Shore SEC61A1 107.5 0.000399 0.049 
cg19747945 6 42946146 N_Shore PEX6 31.0 0.000399 0.049 
cg04522671 5 139144055 Island NA -73.0 0.000399 0.049 
cg03779374 3 114343825 
 
ZBTB20 -32.0 0.000399 0.049 
cg06961205 6 6623143 
 
LY86-AS1 34.0 0.0004 0.049 
cg19089617 2 42154188 
 
NA -40.4 0.0004 0.049 
cg23262488 2 112468472 
 
NA -42.8 0.0004 0.049 
cg09624923 10 33244211 N_Shelf ITGB1 28.1 0.0004 0.049 
cg13017813 14 77491023 N_Shore IRF2BPL 26.9 0.000401 0.049 
cg18229071 19 2695245 
 
GNG7 -82.2 0.000401 0.049 
cg14630206 11 77121864 N_Shore PAK1 -41.2 0.000401 0.049 
cg18908499 1 247712237 
 
GCSAML -36.9 0.000401 0.049 
cg10927968 11 1807333 
 
NA -41.7 0.000401 0.049 
cg23840053 4 15940541 
 
FGFBP1 -30.1 0.000402 0.049 
cg00694357 1 154976647 S_Shore ZBTB7B 406.2 0.000402 0.049 
cg17311022 3 119379792 
 
POPDC2 30.2 0.000402 0.049 
cg05626128 1 19251115 
 
IFFO2 -89.3 0.000402 0.049 
cg15985132 11 130642799 
 
NA 16.7 0.000403 0.049 
146 
 
Table A1. 2,573 BMI-Associated Methylation Sites in the Normal Breast Study, adjusting for age, race, 
and alcohol use 
Probe CHR MAPINFO Location* Gene Coeff p-value q-value 
cg05034363 7 75443193 
 
CCL24 -41.9 0.000403 0.049 
cg02358862 16 30197211 S_Shore CORO1A -46.8 0.000403 0.049 
cg07691897 11 112000518 
 
NA -36.0 0.000404 0.049 
cg17232217 4 1203104 Island SPON2 45.4 0.000404 0.049 
cg23068939 1 112016586 
 
C1orf162 -18.0 0.000404 0.049 
cg10082662 11 47282094 
 
NR1H3 -74.6 0.000405 0.049 
cg13615971 15 92392821 N_Shelf SLCO3A1 -72.3 0.000405 0.049 
cg24134261 2 33661362 
 
RASGRP3 -24.4 0.000405 0.049 
cg01747518 14 103994927 N_Shore TRMT61A 31.2 0.000405 0.049 
cg16904686 1 47133294 N_Shore ATPAF1 47.5 0.000405 0.049 
cg08450965 21 46677779 Island NA 69.9 0.000405 0.049 
cg03593014 10 98977821 
 
ARHGAP19-SLIT1 -23.7 0.000406 0.049 
cg10987682 2 23509827 
 
NA 38.9 0.000406 0.049 
cg11525210 5 149445234 
 
CSF1R -63.7 0.000407 0.049 
cg09715059 6 32223336 
 
NA 70.8 0.000407 0.049 
cg17550495 4 39364570 N_Shelf RFC1 27.6 0.000407 0.049 
cg05206657 15 70328301 S_Shore NA -57.5 0.000408 0.049 
cg13987606 1 160002698 S_Shore PIGM 22.3 0.000408 0.049 
cg01790438 5 10332117 N_Shore NA 42.4 0.000409 0.049 
cg01269718 18 13869025 Island NA 240.2 0.000409 0.049 
cg13505631 9 127018840 N_Shore NEK6 -37.4 0.000409 0.049 
cg25343227 22 42353589 N_Shore LINC00634 49.6 0.000409 0.049 
cg25076039 5 169128937 
 
DOCK2 32.5 0.000409 0.049 
cg26058884 6 30579440 
 
PPP1R10 23.3 0.000409 0.049 
cg21720385 19 4455239 N_Shelf UBXN6 38.8 0.00041 0.049 
cg16399624 10 134553188 N_Shore INPP5A -68.4 0.00041 0.049 
cg23687971 20 32262772 N_Shore NECAB3 131.2 0.00041 0.049 
cg26246740 10 49893026 
 
WDFY4 -61.7 0.00041 0.049 
cg02179700 10 3336162 
 
NA 27.2 0.00041 0.049 
cg18558108 8 131439096 
 
ASAP1 -84.2 0.00041 0.049 
cg10905593 10 102027479 Island CWF19L1 449.1 0.000411 0.049 
cg23965459 14 104647094 S_Shore KIF26A 34.1 0.000411 0.049 
cg20714328 5 79331850 S_Shore THBS4 -43.8 0.000411 0.049 
cg15890075 17 18011923 
 
MYO15A 67.3 0.000411 0.049 
cg14916108 12 2027993 
 
CACNA2D4 -58.4 0.000411 0.049 
cg07702311 11 128646953 
 
FLI1 29.1 0.000411 0.049 
cg15083578 3 44450272 
 
TCAIM -67.2 0.000412 0.049 
cg01085165 16 4426401 
 
VASN 33.1 0.000412 0.049 
cg10964627 3 65985404 
 
MAGI1 -42.4 0.000412 0.049 
cg09288273 5 156886816 N_Shore NIPAL4 -46.9 0.000412 0.049 
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cg03044513 11 116706153 N_Shore APOA1 -25.3 0.000412 0.049 
cg09354037 6 32813531 S_Shore PSMB8 -43.1 0.000413 0.049 
cg10283036 12 111853088 N_Shelf SH2B3 -74.5 0.000413 0.049 
cg02713832 11 60772559 N_Shelf CD6 25.2 0.000413 0.049 
cg27438980 15 99195143 S_Shore IGF1R 20.0 0.000413 0.049 
cg00861207 4 8098270 N_Shore ABLIM2 -67.9 0.000413 0.049 
cg01912298 17 4872499 S_Shore SPAG7 35.1 0.000414 0.049 
cg15135286 2 33359281 
 
LTBP1 25.0 0.000414 0.049 
cg17653203 4 2933715 Island MFSD10 -23.9 0.000414 0.049 
cg16007497 4 74713356 
 
NA -41.2 0.000414 0.049 
cg09530438 10 106095350 N_Shelf ITPRIP -72.7 0.000414 0.049 
cg23304605 14 91866373 
 
CCDC88C -39.6 0.000414 0.049 
cg01256232 14 40337190 
 
NA 26.0 0.000414 0.049 
cg05825700 8 99440522 S_Shore KCNS2 -89.5 0.000414 0.049 
cg03298716 6 168196351 N_Shore C6orf123 -55.1 0.000415 0.049 
cg22066894 11 126581972 
 
KIRREL3 -26.7 0.000415 0.049 
cg14171527 21 44473840 Island CBS -48.3 0.000416 0.049 
cg14301190 16 31159704 Island PRSS36 49.1 0.000416 0.049 
cg23225508 17 62500377 N_Shore DDX5 35.9 0.000417 0.049 
cg14729344 10 121129753 
 
GRK5 -31.8 0.000417 0.049 
cg04926904 10 14529831 
 
NA 42.2 0.000418 0.049 
cg02792168 10 101281924 Island NA 48.3 0.000418 0.049 
cg11077392 11 19719446 
 
NAV2 47.7 0.000418 0.049 
cg09470638 19 15121509 N_Shore CCDC105 38.0 0.000418 0.049 
cg17499826 19 46284986 S_Shore DMPK 44.7 0.000418 0.049 
cg02804819 19 49238364 N_Shore RASIP1 40.2 0.000418 0.049 
cg08721931 2 110874344 S_Shore MALL -46.0 0.000419 0.049 
cg14164816 1 91483823 N_Shelf ZNF644 -24.5 0.000419 0.049 
cg17644856 2 10687962 
 
NA -41.7 0.000419 0.049 
cg18397730 6 52439185 N_Shelf TRAM2 36.9 0.000419 0.049 
cg02950701 10 35656925 
 
CCNY 32.8 0.000419 0.049 
cg12424867 1 19752812 
 
CAPZB 38.3 0.000419 0.049 
cg20156545 21 28335020 N_Shelf ADAMTS5 26.5 0.000419 0.049 
cg27250037 20 35471692 S_Shelf SOGA1 -38.3 0.00042 0.049 
cg21236860 7 66766855 N_Shore PMS2P4 24.0 0.00042 0.049 
cg23406509 17 31479452 
 
ASIC2 -52.4 0.00042 0.049 
cg23943268 13 33589621 N_Shore KL -30.8 0.00042 0.049 
cg12423658 13 111318555 
 
CARS2 -66.5 0.000421 0.049 
cg14288403 1 28503368 
 
PTAFR -48.9 0.000421 0.049 
cg23035241 5 142594147 
 
ARHGAP26 -79.6 0.000421 0.049 
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cg02431531 16 59244939 
 
NA 27.7 0.000422 0.049 
cg14671926 6 169930772 
 
WDR27 43.1 0.000422 0.049 
cg17056607 17 72709096 
 
CD300LF -45.3 0.000422 0.049 
cg11182257 10 118652981 
 
KIAA1598 -28.5 0.000422 0.049 
cg18750833 2 71358451 S_Shore MPHOSPH10 24.9 0.000423 0.049 
cg10111629 1 113067124 
 
ST7L 36.9 0.000423 0.049 
cg27157050 22 42563204 
 
TCF20 89.4 0.000424 0.049 
cg18336453 6 43082296 
 
PTK7 48.8 0.000424 0.049 
cg14622443 17 60886038 S_Shore 10-Mar 41.7 0.000424 0.049 
cg20525037 3 64203257 
 
PRICKLE2 82.8 0.000424 0.049 
cg16671238 13 20987145 N_Shore CRYL1 -61.6 0.000424 0.049 
cg01430385 10 1033349 N_Shore GTPBP4 34.2 0.000425 0.049 
cg14654385 11 63973006 N_Shore FERMT3 -67.0 0.000425 0.049 
cg16346032 1 180100912 
 
NA -26.0 0.000425 0.049 
cg11147471 12 125087686 
 
NA -36.9 0.000425 0.049 
cg03732056 8 21771059 S_Shore DOK2 -21.6 0.000425 0.049 
cg03763077 2 74231297 S_Shore NA 31.6 0.000425 0.049 
cg06096446 6 158744008 
 
TULP4 -132.0 0.000425 0.049 
cg19797956 4 879432 S_Shore GAK 98.1 0.000426 0.049 
cg06015525 12 57872123 S_Shore ARHGAP9 -51.1 0.000426 0.049 
cg27097846 12 53443485 S_Shore TENC1 46.8 0.000426 0.049 
cg13721589 17 17716006 Island MIR33B 25.2 0.000426 0.049 
cg07873154 6 30122544 
 
TRIM10 27.0 0.000426 0.049 
cg12544957 13 60587190 
 
DIAPH3 268.5 0.000426 0.049 
cg11812748 1 246733057 S_Shelf CNST -27.6 0.000426 0.049 
cg23275958 17 75503249 
 
NA -58.8 0.000426 0.049 
cg10098221 4 53523482 N_Shore USP46 26.0 0.000426 0.049 
cg14520957 1 154179856 
 
C1orf189 95.5 0.000427 0.049 
cg13611006 17 45983023 
 
SP2 39.1 0.000427 0.049 
cg00496026 10 102766610 Island LZTS2 63.5 0.000427 0.049 
cg15615645 10 104543040 
 
WBP1L 33.6 0.000427 0.049 
cg19251564 6 166418922 N_Shelf NA 33.2 0.000428 0.049 
cg20124551 11 120439522 S_Shelf NA -49.4 0.000428 0.049 
cg25064052 4 166216151 
 
KLHL2 -32.4 0.000428 0.049 
cg09118048 7 2048663 S_Shelf MAD1L1 -95.6 0.000428 0.049 
cg12655251 1 53992565 
 
GLIS1 73.0 0.000428 0.049 
cg15568628 1 59529453 
 
NA -21.3 0.000429 0.049 
cg25924688 15 72977851 N_Shore HIGD2B 19.9 0.000429 0.049 
cg25093045 4 5990638 
 
NA 33.7 0.000429 0.049 
cg20144984 1 38604476 
 
NA 32.2 0.00043 0.049 
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cg12397205 11 1244002 N_Shelf MUC5B 38.7 0.00043 0.049 
cg27138390 X 147279853 
 
NA 48.3 0.00043 0.049 
cg10085474 4 1221935 Island CTBP1 -49.4 0.00043 0.049 
cg00336149 3 53700195 
 
CACNA1D -31.7 0.00043 0.049 
cg11961813 17 40995546 
 
AOC2 151.1 0.000431 0.049 
cg13327134 12 53618407 S_Shelf RARG 38.7 0.000431 0.049 
cg12687767 20 19870109 
 
RIN2 49.1 0.000431 0.049 
cg25291551 11 46402666 Island MDK 2287.8 0.000431 0.049 
cg01132064 11 46382562 
 
DGKZ -35.4 0.000431 0.049 
cg11707445 1 156889964 N_Shore LRRC71 74.4 0.000431 0.049 
cg07062388 6 70507787 S_Shore LMBRD1 58.9 0.000431 0.049 
cg18854666 2 219247055 
 
SLC11A1 -51.9 0.000431 0.049 
cg00748218 11 19372553 
 
NAV2 43.3 0.000432 0.049 
cg26696162 6 151709522 N_Shore ZBTB2 -64.4 0.000432 0.049 
cg26683005 19 48752990 
 
CARD8 -33.6 0.000432 0.049 
cg19476186 20 3869959 Island PANK2 1266.6 0.000433 0.049 
cg18397726 14 93395464 
 
CHGA -96.1 0.000433 0.049 
cg18797590 4 15480643 
 
CC2D2A 23.3 0.000433 0.049 
cg27052183 11 66411986 S_Shore RBM4 37.2 0.000433 0.049 
cg11953913 5 139562873 
 
CYSTM1 -42.8 0.000433 0.049 
cg18066206 22 46459890 S_Shore NA 22.1 0.000433 0.049 
cg14647287 4 6927183 S_Shore TBC1D14 -56.3 0.000434 0.049 
cg11219614 8 49984776 
 
C8orf22 30.7 0.000434 0.049 
cg12086464 4 2814064 
 
SH3BP2 -18.6 0.000434 0.049 
cg24644436 10 135202906 N_Shore MTG1 -27.9 0.000434 0.049 
cg17342247 17 3540594 S_Shore CTNS 90.3 0.000434 0.049 
cg26892635 16 3253043 
 
OR1F1 109.8 0.000434 0.049 
cg15202213 11 641042 S_Shore DRD4 -40.9 0.000434 0.049 
cg13830300 17 41822900 
 
NA -18.8 0.000434 0.049 
cg13577072 11 2715286 
 
KCNQ1OT1 67.3 0.000434 0.049 
cg08698854 7 134575306 
 
CALD1 16.3 0.000435 0.049 
cg22791932 16 88537374 Island MIR5189 -80.5 0.000435 0.049 
cg19731612 5 176559334 Island NSD1 83.9 0.000435 0.049 
cg06881695 6 30168773 
 
TRIM26 -33.9 0.000435 0.049 
cg12193327 2 31454631 N_Shelf EHD3 -37.3 0.000435 0.049 
cg22696167 15 96864283 N_Shore NR2F2 -45.5 0.000436 0.049 
cg15648896 15 39542877 
 
C15orf54 -34.3 0.000436 0.049 
cg04735908 14 23538430 
 
ACIN1 293.9 0.000436 0.049 
cg06314111 12 58119915 Island AGAP2-AS1 42.2 0.000437 0.049 
cg01292625 10 88157172 N_Shelf NA -81.6 0.000437 0.049 
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cg19856273 1 46668472 N_Shore LURAP1 26.4 0.000437 0.049 
cg01873886 14 54419825 N_Shore BMP4 127.3 0.000437 0.049 
cg17271561 19 52839334 N_Shore ZNF610 313.7 0.000437 0.049 
cg18418655 X 70331557 
 
IL2RG -46.6 0.000438 0.049 
cg26959945 7 20233217 
 
MACC1 -17.9 0.000438 0.049 
cg10864791 13 22178445 Island MICU2 411.6 0.000438 0.049 
cg05293299 3 29374128 
 
RBMS3 21.1 0.000438 0.049 
cg04764597 10 63510947 
 
C10orf107 -63.9 0.000438 0.049 
cg25745746 1 20617452 
 
VWA5B1 -40.7 0.000438 0.049 
cg03032798 2 221298903 
 
NA -38.1 0.000439 0.049 
cg07187855 6 30854161 S_Shore DDR1 43.9 0.000439 0.049 
cg14884929 17 46657656 N_Shore MIR10A -37.4 0.000439 0.049 
cg25649895 17 48356195 
 
TMEM92 -63.9 0.000439 0.049 
cg23929682 11 2321842 
 
C11orf21 -41.3 0.000439 0.049 
cg05519002 11 8104458 S_Shore TUB 41.8 0.000439 0.049 
cg20305578 8 1908301 
 
NA -39.7 0.000439 0.049 
cg05608790 7 69427388 
 
AUTS2 -38.3 0.00044 0.049 
cg01122304 4 2845576 Island ADD1 659.8 0.000441 0.049 
cg07685357 11 121971954 
 
MIR125B1 29.9 0.000441 0.049 
cg02086820 16 88698611 N_Shore NA -91.5 0.000441 0.049 
cg24159636 6 18043467 
 
NA 33.4 0.000441 0.049 
cg19755003 22 46489736 
 
MIR3619 40.3 0.000441 0.049 
cg23729881 3 13057184 
 
IQSEC1 -34.6 0.000441 0.049 
cg05894801 6 155850469 
 
NA -17.7 0.000441 0.049 
cg26250461 5 19734126 
 
CDH18 76.7 0.000441 0.049 
cg10782218 17 61518489 S_Shelf CYB561 -55.3 0.000441 0.049 
cg23965588 11 71699167 
 
RNF121 26.0 0.000441 0.049 
cg04071967 17 53511321 
 
NA -32.2 0.000442 0.049 
cg14517126 15 41923323 
 
NA -39.0 0.000442 0.049 
cg07099073 6 44593284 
 
NA 46.3 0.000442 0.049 
cg04468671 12 132337407 S_Shelf NA -56.8 0.000442 0.049 
cg02919122 3 112109797 
 
NA 135.5 0.000443 0.049 
cg04561571 12 93834146 N_Shore UBE2N 36.0 0.000443 0.049 
cg11599981 19 6475902 Island DENND1C 43.9 0.000443 0.049 
cg00593773 18 77336201 Island NA 19.3 0.000444 0.050 
cg19984681 3 64479957 
 
NA -45.4 0.000444 0.050 
cg03306368 6 99396091 S_Shore FBXL4 72.1 0.000444 0.050 
cg25113360 11 120530355 
 
GRIK4 -38.5 0.000444 0.050 
cg23000806 8 48854968 
 
PRKDC 19.8 0.000444 0.050 
cg02271790 6 10381196 N_Shore NA -21.8 0.000445 0.050 
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cg14596589 5 1107148 N_Shore SLC12A7 -74.9 0.000445 0.050 
cg20759486 6 30951225 
 
MUC21 -65.2 0.000445 0.050 
cg05612839 16 85768907 
 
C16orf74 -49.6 0.000445 0.050 
cg17398233 2 136876887 Island CXCR4 1596.2 0.000445 0.050 
cg03569637 12 47609357 
 
PCED1B -45.3 0.000445 0.050 
cg08275633 1 11751631 Island MAD2L2 281.8 0.000446 0.050 
cg03437770 16 12442738 
 
SNX29 -41.7 0.000446 0.050 
cg03872934 6 33151135 
 
COL11A2 -28.6 0.000446 0.050 
cg03485217 4 10686300 
 
CLNK -45.3 0.000446 0.050 
cg12103569 12 132258560 
 
SFSWAP -42.1 0.000447 0.050 
cg25488990 12 65668614 N_Shelf MSRB3 -44.9 0.000447 0.050 
cg19339179 4 113324678 
 
ALPK1 35.9 0.000447 0.050 
cg27091343 6 30130226 
 
TRIM15 -37.8 0.000447 0.050 
cg20343063 11 57089744 N_Shore TNKS1BP1 21.4 0.000448 0.050 
cg25110757 14 95065642 
 
NA 71.0 0.000448 0.050 
cg24509919 1 168230886 
 
NA 36.8 0.000448 0.050 
cg04561731 1 54869371 N_Shore SSBP3 37.1 0.000449 0.050 
cg00907204 7 92461971 N_Shore CDK6 79.9 0.000449 0.050 
cg10570158 11 19546133 
 
NAV2-AS4 24.6 0.000449 0.050 
cg26525025 12 52521183 
 
NA -37.0 0.000449 0.050 
cg24144893 1 45480507 S_Shelf UROD 127.1 0.00045 0.050 
cg26279216 10 131506261 
 
MGMT 20.2 0.00045 0.050 
cg19714332 13 80058898 S_Shelf NDFIP2-AS1 -36.5 0.000451 0.050 
cg11264392 19 15564092 Island WIZ 59.7 0.000451 0.050 
cg02228160 5 143192067 
 
HMHB1 -32.7 0.000452 0.050 
cg00002426 3 57743543 S_Shore SLMAP 23.0 0.000452 0.050 
cg18493214 6 17764205 
 
KIF13A -63.9 0.000452 0.050 
cg23176340 15 89154196 
 
MIR7-2 -21.3 0.000452 0.050 
cg04388657 9 127623377 N_Shore RPL35 24.0 0.000452 0.050 
cg02780017 11 64981227 
 
SLC22A20 -40.6 0.000453 0.050 
cg18935453 11 68167030 
 
LRP5 33.0 0.000453 0.050 
cg08882341 6 166470330 
 
NA 25.7 0.000453 0.050 
cg05935800 1 226023590 
 
EPHX1 35.4 0.000453 0.050 
cg11648522 1 15272238 
 
KAZN 40.8 0.000454 0.050 
cg25858160 20 55499436 N_Shore NA -47.7 0.000454 0.050 
cg04601383 19 6713459 S_Shelf C3 -88.5 0.000454 0.050 
cg17753974 1 201622519 S_Shelf NAV1 -35.2 0.000454 0.050 
cg13397898 9 133768931 
 
QRFP -29.2 0.000454 0.050 
cg15220969 21 44819112 Island NA -48.5 0.000454 0.050 
cg08870914 17 15281288 
 
NA 22.4 0.000454 0.050 
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cg08755743 3 128205418 N_Shore GATA2 55.0 0.000454 0.050 
cg05497216 16 89408076 N_Shore ANKRD11 58.1 0.000454 0.050 
cg13092738 8 124498970 
 
NA 52.2 0.000455 0.050 
cg13914531 7 128579876 S_Shore IRF5 -46.9 0.000455 0.050 
cg12706938 19 1566839 Island MEX3D 34.1 0.000455 0.050 
cg01206970 19 49621187 N_Shore C19orf73 -66.2 0.000455 0.050 
cg14519356 7 83097669 
 
SEMA3E -52.5 0.000455 0.050 
cg21814870 4 62383240 Island LPHN3 -37.1 0.000456 0.050 
cg23595304 11 46879516 
 
LRP4-AS1 -32.3 0.000456 0.050 
cg12166018 15 72564196 N_Shore PARP6 41.0 0.000456 0.050 
cg13745692 3 60065489 
 
FHIT 38.5 0.000456 0.050 
cg02773868 6 30522774 N_Shore PRR3 64.9 0.000457 0.050 
cg08575819 6 31740291 
 
VWA7 -48.9 0.000457 0.050 
cg24709951 17 73033009 S_Shore NA -17.9 0.000457 0.050 
cg08133755 11 19792080 
 
NAV2 31.3 0.000457 0.050 
*N_Shore = North shore; N_Shelf = North shelf; S_Shore = South shore; S_Shelf = South shelf; Blank 
indicates genomic location not in or near CpG Island 
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ID 
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1D-myo-inositol Hexakisphosphate 
Biosynthesis II (Mammalian) 
6 18 
0.01 
ITPKC,ITPK1,INPP5A,IPMK,INPP5D,SYNJ2 
Acute Myeloid Leukemia Signaling 14 73 
0.02 
BRAF,EIF4EBP1,SPI1,PIK3CG,STAT5A,PIK3CD,MAP2K1,CSF1R,PIK3R2,TCF7L2
,PIK3R3,CSF3R,TCF7,GRB2 
Acute Phase Response Signaling 21 161 
0.00 
TNFRSF11B,APOA1,C1R,PIK3CD,NGFR,IL1A,SOCS7,TRAF6,TNFRSF1B,PIK3R2,
CHUK,ITIH4,SOCS1,SERPINA1,OSM,PIK3CG,MAP2K1,IL1RN,PIK3R3,C3,GRB2 
Aldosterone Signaling in Epithelial Cells 23 147 
0.01 
PRKCE,DNAJB13,CRYAB,ASIC2,PLCD4,PLCL2,DNAJC11,PLCB2,PIK3CD,DNAJ
B6,PRKCZ,PIK3R2,SGK1,DNAJC27,PRKCQ,SLC9A1,SCNN1A,ASIC1,PRKCB,PIK
3CG,MAP2K1,DNAJC15,PIK3R3 
Altered T Cell and B Cell Signaling in 
Rheumatoid Arthritis 
7 54 
0.02 
TNFRSF13C,HLA-DMA,TGFB1,CD79B,IL1A,IL1RN,FCER1G 
Angiopoietin Signaling 10 63 0.03 PIK3CG,STAT5A,PIK3CD,DOK2,CHUK,PIK3R2,PAK1,CRK,PIK3R3,GRB2 
Antiproliferative Role of Somatostatin 
Receptor 2 
10 58 
0.02 
PIK3CG,CDKN1B,PIK3CD,PTPN6,BRAF,MAP2K1,GNG7,GNB1,PIK3R2,PIK3R3 
Atherosclerosis Signaling 17 114 
0.00 
COL3A1,CXCR4,PLA2G4E,APOA1,COL1A1,PLA2G2C,SERPINA1,COL18A1,ITG
B2,APOC2,TGFB1,IL1A,COL11A2,IL1RN,ALOX5,LYZ,ITGA4 
B Cell Receptor Signaling 22 149 
0.04 
CD79B,PIK3CD,VAV2,PIK3R2,PRKCQ,GAB1,PPP3CB,ETS1,PRKCB,NFATC4,CH
UK,VAV3,SYNJ2,CD22,PIK3CG,PTPN6,MAP2K1,CD79A,CREB5,PIK3R3,INPP5D,
GRB2 
Calcium-induced T Lymphocyte 
Apoptosis 
11 53 
0.03 
HDAC1,HLA-
DMA,PRKCE,PRKCB,MEF2D,PRKCZ,CD247,PRKCQ,FCER1G,PPP3CB,HLA-
DMB 
CCR3 Signaling in Eosinophils 18 112 
0.02 
PRKCE,PRKCB,PLA2G4E,PAK1,PIK3CG,GNAS,CCL24,PLCB2,PIK3CD,MAP2K1,
LIMK2,PRKCZ,MYLK,GNG7,GNB1,PIK3R2,PRKCQ,PIK3R3 
CD28 Signaling in T Helper Cells 17 106 
0.01 
NFATC4,CHUK,LCP2,CD247,PAK1,PIK3CG,HLA-
DMA,PTPN6,PIK3CD,MAP2K1,PIK3R2,PRKCQ,PIK3R3,PPP3CB,FCER1G,HLA-
DMB,GRB2 
Cell Cycle: G1/S Checkpoint Regulation 12 60 
0.03 
HDAC1,HDAC4,CDKN1B,TGFB3,CCND2,TGFB1,TFDP1,CCND3,CDK6,E2F5,SM
AD3,HDAC10 
Chronic Myeloid Leukemia Signaling 21 88 
0.00 
HDAC4,CDKN1B,TGFB3,CHUK,CTBP1,CDK6,E2F5,SMAD3,CTBP2,HDAC10,HD
AC1,PIK3CG,STAT5A,PIK3CD,TGFB1,MAP2K1,TFDP1,PIK3R2,CRK,PIK3R3,GR
B2 
Complement System 5 32 0.02 CD59,C1QB,C1R,C3,C1QC 
CXCR4 Signaling 25 149 
0.01 
PRKCE,CXCR4,DIRAS3,ADCY7,PAK1,PXN,PLCB2,PIK3CD,GNA12,PRKCZ,ADC
Y5,PIK3R2,CRK,PRKCQ,PRKCB,ADCY9,ADCY4,PIK3CG,GNAS,MAP2K1,GNAT
1
5
3
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2,GNG7,GNB1,FNBP1,PIK3R3 
Dendritic Cell Maturation 17 74 
0.00 
CHUK,DDR1,COL3A1,PLCL2,HLA-
DMA,NGFR,IRF8,TRAF6,FSCN2,COL11A2,IL32,TNFRSF1B,CREB5,PIK3R2,IL1R
N,FCGR3B,FCER1G 
D-myo-inositol (134)-trisphosphate 
Biosynthesis 
6 18 
0.02 
INPP5D,ITPKC,MINPP1,INPP5A,IPMK,SYNJ2 
Eicosanoid Signaling 8 60 0.01 HPGDS,PLA2G4E,ALOX5AP,PLA2G2C,TBXAS1,ALOX5,DPEP2,PTGDS 
Endothelin-1 Signaling 28 165 
0.00 
ECE1,PLD4,PRKCE,PLA2G4E,PLCD4,ADCY7,PLCL2,PLA2G2C,PLCB2,PIK3CD,
GNA12,CASP2,PRKCZ,ADCY5,PIK3R2,PLD6,PRKCQ,GAB1,MAPK4,BRAF,PRKC
B,ADCY9,ADCY4,PIK3CG,GNAS,GNAT2,PIK3R3,GRB2 
Erythropoietin Signaling 13 66 
0.01 
PRKCE,PRKCB,SOCS1,PIK3CG,STAT5A,PTPN6,PIK3CD,MAP2K1,PRKCZ,PIK3R
2,PRKCQ,PIK3R3,GRB2 
FAK Signaling 16 82 
0.02 
ACTA2,TNS1,ARHGAP26,PAK1,PXN,PIK3CG,ASAP1,PIK3CD,CAPN3,MAP2K1,I
TGB1,PIK3R2,CRK,PIK3R3,GRB2,ITGA4 
Fc Epsilon RI Signaling 19 105 
0.00 
PRKCE,IL13,PRKCB,LCP2,VAV3,PLA2G4E,SYNJ2,PIK3CG,PIK3CD,VAV2,MAP2
K1,PRKCZ,PIK3R2,PRKCQ,GAB1,PIK3R3,INPP5D,FCER1G,GRB2 
FcγReceptor-mediated Phagocytosis in 
Macrophages and Monocytes 
18 90 
0.00 
PLD4,PRKCE,ACTA2,PRKCB,LCP2,VAV3,PAK1,PXN,PIK3CG,VAV2,PRKCZ,NC
K2,PIK3R2,CRK,PRKCQ,PLD6,PIK3R3,INPP5D 
FcγRIIB Signaling in B Lymphocytes 8 40 0.02 PIK3CG,PIK3CD,CD79B,CD79A,PIK3R2,PIK3R3,INPP5D,GRB2 
fMLP Signaling in Neutrophils 16 102 
0.05 
PRKCE,PRKCB,NFATC4,NCF2,PIK3CG,GNAS,PLCB2,PIK3CD,MAP2K1,PRKCZ,
GNG7,GNB1,PIK3R2,PRKCQ,PIK3R3,PPP3CB 
Gap Junction Signaling 24 149 
0.03 
PRKCE,ACTA2,PLCD4,CSNK1D,ADCY7,PLCL2,PRKG2,PLCB2,PIK3CD,BGLAP,
PRKCZ,ADCY5,PIK3R2,PRKCQ,PPP3CB,TUBB2B,PRKCB,ADCY9,ADCY4,PIK3
CG,GNAS,MAP2K1,PIK3R3,GRB2 
Gα12/13 Signaling 16 113 
0.04 
CHUK,MEF2D,VAV3,CDH8,CDH9,PXN,CDH18,PIK3CG,LPAR2,PIK3CD,GNA12,
VAV2,MAP2K1,PIK3R2,PIK3R3,CDH2 
Granulocyte Adhesion and Diapedesis 15 154 
0.03 
CXCL10,CXCR4,TNFRSF11B,ITGB2,NGFR,CLDN15,IL1A,ITGB1,TNFRSF1B,CSF
3R,MMP17,CCL24,CLDN19,IL1RN,ITGA4 
Growth Hormone Signaling 15 65 
0.01 
PRKCE,PRKCB,IGF2,SOCS1,SRF,PIK3CG,STAT5A,PTPN6,PIK3CD,IGF1R,PRKC
Z,SOCS7,PIK3R2,PRKCQ,PIK3R3 
HER-2 Signaling in Breast Cancer 15 75 
0.03 
CDKN1B,PRKCE,PRKCB,CDK6,ITGB2,PIK3CG,PIK3CD,ITGB4,PRKCZ,ITGB1,PI
K3R2,PRKCQ,PIK3R3,ITGB7,GRB2 
HGF Signaling 17 96 
0.02 
PRKCE,ETS1,PRKCB,PAK1,RAP1A,PXN,PIK3CG,PIK3CD,MAP2K1,ELF1,PRKCZ
,MET,PIK3R2,PRKCQ,GAB1,PIK3R3,GRB2 
iCOS-iCOSL Signaling in T Helper 
Cells 
15 95 
0.03 
NFATC4,CHUK,LCP2,CD247,PIK3CG,HLA-
DMA,PIK3CD,PIK3R2,PRKCQ,PIK3R3,INPP5D,FCER1G,PPP3CB,HLA-
DMB,GRB2 
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Ingenuity Systems Pathway Analysis 
ID 
Count Size p-value Gene Symbol 
IL-2 Signaling 8 51 0.04 PIK3CG,STAT5A,PIK3CD,MAP2K1,PIK3R2,SOCS1,PIK3R3,GRB2 
IL-3 Signaling 15 69 
0.00 
PRKCE,PRKCB,PAK1,PIK3CG,STAT5A,PTPN6,PIK3CD,MAP2K1,PRKCZ,PIK3R2
,PRKCQ,PIK3R3,INPP5D,PPP3CB,GRB2 
IL-4 Signaling 12 67 
0.04 
NFATC4,SYNJ2,SOCS1,PIK3CG,HLA-
DMA,PTPN6,PIK3CD,PIK3R2,PIK3R3,INPP5D,HLA-DMB,GRB2 
IL-6 Signaling 17 110 
0.00 
CHUK,CYP19A1,TNFRSF11B,COL1A1,SOCS1,SRF,PIK3CG,PIK3CD,NGFR,MAP2
K1,IL1A,TRAF6,TNFRSF1B,PIK3R2,IL1RN,PIK3R3,GRB2 
IL-8 Signaling 30 177 
0.00 
PLD4,PRKCE,ARRB2,DIRAS3,ITGB2,NCF2,FLT1,PLCB2,PIK3CD,GNA12,PRKCZ
,TRAF6,PIK3R2,MPO,PLD6,PRKCQ,CCND2,BRAF,PRKCB,EIF4EBP1,CHUK,CCN
D3,PIK3CG,GNAS,MAP2K1,LIMK2,GNG7,GNB1,FNBP1,PIK3R3 
Insulin Receptor Signaling 21 122 
0.04 
SCNN1A,RPTOR,ASIC1,EIF4EBP1,ASIC2,SYNJ2,PPP1R10,TRIP10,SH2B2,PIK3C
G,PIK3CD,PTPRF,MAP2K1,PRKCZ,PIK3R2,SGK1,CRK,GAB1,PIK3R3,INPP5D,G
RB2 
Integrin Signaling 30 188 
0.01 
TSPAN4,ACTA2,DIRAS3,ARHGAP26,PAK1,ACTN1,ITGB2,RAP1A,PXN,PARVB,
ASAP1,CAPN3,PIK3CD,ITGB1,PIK3R2,CRK,NEDD9,ITGA2B,BRAF,CTTN,PIK3C
G,MAP2K1,ITGB4,MYLK,NCK2,FNBP1,PIK3R3,ITGB7,ITGA4,GRB2 
Intrinsic Prothrombin Activation 
Pathway 
5 26 
0.04 
COL11A2,COL1A1,COL18A1,COL3A1,KLK3 
JAK/Stat Signaling 10 67 0.04 SOCS1,PIK3CG,STAT5A,PTPN6,PIK3CD,MAP2K1,SOCS7,PIK3R2,PIK3R3,GRB2 
Leptin Signaling in Obesity 14 72 
0.03 
ADCY9,ADCY4,PLCD4,ADCY7,PLCL2,PIK3CG,GNAS,PLCB2,PIK3CD,MAP2K1,
ADCY5,PIK3R2,PIK3R3,GRB2 
Leukocyte Extravasation Signaling 28 181 
0.01 
CD44,PRKCE,ACTA2,CXCR4,NCF4,ACTN1,ITGB2,RAP1A,NCF2,PXN,PIK3CD,C
LDN15,VAV2,PRKCZ,SPN,ITGB1,PIK3R2,CRK,PRKCQ,ARHGAP9,PRKCB,VAV3
,CTTN,MMP17,PIK3CG,CLDN19,PIK3R3,ITGA4 
LPS/IL-1 Mediated Inhibition of RXR 
Function 
23 196 
0.01 
ALDH4A1,XPO1,ALDH3B1,CYP3A5,TNFRSF11B,HS6ST1,ALDH1A3,NGFR,IL1A
,ACOX2,TRAF6,ACSL1,TNFRSF1B,HS3ST2,MGMT,ACSL6,SULT1C2,NR1H3,AP
OC2,CHST3,ACOX3,IL1RN,ABCB9 
LPS-stimulated MAPK Signaling 12 71 
0.03 
PRKCE,PRKCB,CHUK,PAK1,SRF,PIK3CG,PIK3CD,MAP2K1,PRKCZ,PIK3R2,PRK
CQ,PIK3R3 
LXR/RXR Activation 13 115 
0.04 
NR1H3,ITIH4,TNFRSF11B,APOA1,SERPINA1,APOC2,NGFR,IL1A,NCOR2,TNFR
SF1B,IL1RN,C3,LYZ 
Macropinocytosis Signaling 15 66 
0.00 
PRKCE,PRKCB,PAK1,ITGB2,PIK3CG,PIK3CD,ITGB4,PRKCZ,MET,ITGB1,CSF1R
,PIK3R2,PRKCQ,PIK3R3,ITGB7 
Melanocyte Development and 
Pigmentation Signaling 
16 82 
0.02 
ADCY9,ADCY4,ADCY7,SH2B2,MITF,PIK3CG,GNAS,PTPN6,PIK3CD,MAP2K1,A
DCY5,CREB5,PIK3R2,CRK,PIK3R3,GRB2 
MSP-RON Signaling Pathway 8 43 0.02 PIK3CG,PIK3CD,ACTA2,PRKCZ,KLK3,PIK3R2,PIK3R3,ITGB2 
Natural Killer Cell Signaling 18 68 0.00 PRKCE,PRKCB,SH3BP2,LCP2,VAV3,SYNJ2,PAK1,PTPN6,PIK3CD,VAV2,MAP2K
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Ingenuity Systems Pathway Analysis 
ID 
Count Size p-value Gene Symbol 
1,PRKCZ,PRKCQ,FCGR3B,PIK3R3,INPP5D,FCER1G,GRB2 
NF-κB Activation by Viruses 12 71 
0.05 
PRKCE,PRKCB,CHUK,ITGB2,PIK3CG,PIK3CD,PRKCZ,ITGB1,PIK3R2,PRKCQ,PI
K3R3,ITGA4 
NF-κB Signaling 25 155 
0.01 
BMP4,DDR1,SIGIRR,TNFRSF11B,FLT1,PIK3CD,NGFR,TGFBR3,IGF1R,IL1A,PRK
CZ,TRAF6,TNFRSF1B,NTRK3,PIK3R2,PRKCQ,BRAF,PRKCB,CHUK,HDAC1,PIK
3CG,IL1RN,UBE2N,PIK3R3,FCER1G 
P2Y Purigenic Receptor Signaling 
Pathway 
21 117 
0.03 
PRKCE,PRKCB,ADCY9,ADCY4,PLCD4,ADCY7,PLCL2,PIK3CG,GNAS,PLCB2,PI
K3CD,MAP2K1,PRKCZ,ADCY5,GNG7,GNB1,CREB5,PIK3R2,PRKCQ,PIK3R3,IT
GA2B 
Paxillin Signaling 17 96 
0.01 
ACTA2,PAK1,ACTN1,ITGB2,PXN,PIK3CG,PIK3CD,ITGB4,ITGB1,NCK2,PIK3R2,
CRK,PIK3R3,ITGB7,ITGA2B,GRB2,ITGA4 
Phospholipase C Signaling 37 216 
0.00 
PRKCE,PLD4,CD79B,MEF2D,LCP2,PLA2G4E,DIRAS3,ADCY7,RAP1A,PLCB2,PR
KCZ,ADCY5,ITGB1,ARHGEF17,PLD6,PRKCQ,PPP3CB,ARHGEF10,HDAC4,PRK
CB,ADCY9,NFATC4,ADCY4,CD247,ARHGEF12,HDAC10,HDAC1,GNAS,MAP2K
1,GNG7,GNB1,FNBP1,CD79A,CREB5,FCER1G,GRB2,ITGA4 
Phospholipases 8 55 0.01 PLD4,PLCB2,PLA2G4E,PLCD4,PLA2G2C,PLCL2,PLD6,CCR1 
PI3K Signaling in B Lymphocytes 20 119 
0.02 
ATF6B,CD79B,PRKCB,NFATC4,CHUK,VAV3,PLCD4,SH2B2,PLCL2,PIK3CG,PLC
B2,PIK3CD,VAV2,MAP2K1,PRKCZ,CD79A,PIK3R2,INPP5D,PPP3CB,C3 
PKCθ¸ Signaling in T Lymphocytes 16 106 
0.04 
NFATC4,CHUK,LCP2,VAV3,CD247,PIK3CG,HLA-
DMA,PIK3CD,VAV2,PIK3R2,PRKCQ,PIK3R3,PPP3CB,FCER1G,HLA-DMB,GRB2 
PPAR Signaling 14 84 
0.02 
PPARD,PPARG,CHUK,NR1H3,TNFRSF11B,STAT5A,NGFR,MAP2K1,IL1A,NCOR
2,TRAF6,TNFRSF1B,IL1RN,GRB2 
Production of Nitric Oxide and Reactive 
Oxygen Species in Macrophages 
29 172 
0.00 
PRKCE,DIRAS3,NCF4,PPP1R10,TNFRSF11B,APOA1,RAP1A,NCF2,PIK3CD,NGF
R,PRKCZ,TNFRSF1B,PIK3R2,MPO,PRKCQ,LYZ,HOXA10,PRKCB,CHUK,PPP2R5
C,SERPINA1,SPI1,PIK3CG,APOC2,PTPN6,MAP2K1,IRF8,FNBP1,PIK3R3 
Prolactin Signaling 14 73 
0.02 
PRKCE,PRKCB,SOCS1,PIK3CG,STAT5A,PIK3CD,MAP2K1,PRKCZ,SOCS7,PIK3R
2,PRKCQ,PIK3R3,TCF7,GRB2 
PTEN Signaling 22 111 
0.02 
MAGI1,CDKN1B,CHUK,DDR1,SYNJ2,MAST2,FLT1,PIK3CG,PIK3CD,NGFR,MAP
2K1,TGFBR3,IGF1R,PRKCZ,ITGB1,NTRK3,PIK3R2,MAGI2,PIK3R3,INPP5D,ITG
A4,GRB2 
Pyridoxal 5'-phosphate Salvage Pathway 13 58 
0.01 
PRKCE,BRAF,MAP2K1,LIMK2,PKN1,DMPK,CSNK1D,PAK1,SGK1,GRK5,PDXK,
PRKCQ,CDK6 
RAR Activation 29 168 
0.01 
PRKCE,NRIP2,SORBS3,DHRS7C,RARG,ADCY7,ALDH1A3,PIK3CD,TGFB1,NSD1
,PRKCZ,ADCY5,PIK3R2,ZBTB16,PRKCQ,TGFB3,PRKCB,ADCY9,ADCY4,SMAD
3,PIK3CG,GNAS,STAT5A,RDH5,MAP2K1,NCOR2,NR2F2,NR2F6,PIK3R3 
Renal Cell Carcinoma Signaling 13 68 
0.00 
ETS1,PAK1,RAP1A,PIK3CG,PIK3CD,TGFB1,MAP2K1,MET,PIK3R2,CRK,GAB1,P
IK3R3,GRB2 
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ID 
Count Size p-value Gene Symbol 
RhoGDI Signaling 26 165 
0.02 
CD44,ACTA2,DIRAS3,PAK1,CDH18,GNA12,DGKZ,ITGB1,ARHGEF17,ARHGAP9
,ARHGDIA,CDH2,ARHGEF10,ARHGEF12,CDH8,CDH9,GNAS,WASF2,LIMK2,GN
AT2,GDI2,GNG7,GNB1,FNBP1,ITGA4,ARHGDIB 
Role of Cytokines in Mediating 
Communication between Immune Cells 
5 33 
0.00 
IL1RN,IL13,TGFB1,IL27,IL1A 
Role of NFAT in Cardiac Hypertrophy 29 174 
0.03 
PRKCE,MEF2D,PLCD4,ADCY7,PLCL2,PLCB2,PIK3CD,TGFB1,IGF1R,PRKCZ,AD
CY5,PIK3R2,PRKCQ,PPP3CB,HDAC4,TGFB3,PRKCB,NFATC4,ADCY9,ADCY4,H
DAC10,HDAC1,PIK3CG,GNAS,MAP2K1,GNG7,GNB1,PIK3R3,GRB2 
Role of NFAT in Regulation of the 
Immune Response 
27 158 
0.00 
CD79B,MEF2D,LCP2,XPO1,CSNK1D,HLA-
DMA,PLCB2,PIK3CD,GNA12,PIK3R2,PRKCQ,FCGR3B,PPP3CB,HLA-
DMB,NFATC4,CHUK,CD247,PIK3CG,GNAS,MAP2K1,GNAT2,GNG7,GNB1,CD79
A,PIK3R3,FCER1G,GRB2 
Role of Osteoblasts Osteoclasts and 
Chondrocytes in Rheumatoid Arthritis 
29 209 
0.03 
BMP4,TNFRSF11B,AXIN1,PIK3CD,NGFR,TGFB1,GSN,IL1A,BGLAP,TRAF6,CSF1
R,ITGB1,TNFRSF1B,ADAMTS5,PIK3R2,TCF7L2,PPP3CB,SMURF1,ADAMTS4,NF
ATC4,CHUK,ACP5,COL1A1,BMP7,LRP5,PIK3CG,IL1RN,PIK3R3,TCF7 
Role of Pattern Recognition Receptors in 
Recognition of Bacteria and Viruses 
13 85 
0.02 
PRKCE,PRKCB,NOD2,C1QB,C1QC,PIK3CG,PIK3CD,PRKCZ,TRAF6,PIK3R2,PRK
CQ,PIK3R3,C3 
Semaphorin Signaling in Neurons 9 51 0.04 LIMK2,MET,DPYSL2,DIRAS3,ITGB1,FNBP1,ARHGEF12,PAK1,NRP1 
Signaling by Rho Family GTPases 33 219 
0.03 
ACTA2,DIAPH3,CDC42EP4,DIRAS3,PAK1,NCF2,CDH18,PIK3CD,GNA12,PRKCZ,
ITGB1,PIK3R2,ARHGEF17,SLC9A1,CDH2,ARHGEF10,ARHGEF12,CDH8,CDH9,S
EPT9,PIK3CG,GNAS,MAP2K1,LIMK2,GNAT2,PKN1,MYLK,GNG7,GNB1,FNBP1,
CYFIP1,PIK3R3,ITGA4 
Sphingosine-1-phosphate Signaling 18 108 
0.01 
ADCY9,ADCY4,S1PR4,DIRAS3,PLCD4,ADCY7,PLCL2,PIK3CG,GNAS,PLCB2,PI
K3CD,GNA12,CASP2,ADCY5,FNBP1,PIK3R2,PIK3R3,SMPD3 
Superpathway of D-myo-inositol (145)-
trisphosphate Metabolism 
6 23 
0.04 
ITPKC,MINPP1,INPP5A,IPMK,INPP5D,SYNJ2 
Superpathway of Inositol Phosphate 
Compounds 
27 175 
0.00 
PLD4,IPMK,PPM1H,PLCD4,ITPK1,MINPP1,IP6K2,PLCB2,PIK3CD,PPP1R16B,PAL
D1,TNS3,PIK3R2,CCR1,ACP5,PTPRJ,SYNJ2,INPP5A,EPHX2,PTPN7,PIK3CG,ITPK
C,PTPN6,PTPRF,ATP1A1,PIK3R3,INPP5D 
T Cell Receptor Signaling 15 90 
0.01 
NFATC4,CHUK,LCP2,VAV3,CD247,PTPN7,PIK3CG,PIK3CD,VAV2,MAP2K1,PIK
3R2,PRKCQ,PIK3R3,PPP3CB,GRB2 
T Helper Cell Differentiation 6 41 0.04 IL13,IL10RA,TNFRSF1B,TNFRSF11B,FCER1G,HLA-DMB 
Tec Kinase Signaling 24 144 
0.01 
PRKCE,ACTA2,DIRAS3,PAK1,PIK3CD,GNA12,VAV2,PRKCZ,ITGB1,PIK3R2,PR
KCQ,TNFRSF21,PRKCB,VAV3,PIK3CG,GNAS,STAT5A,GNAT2,GNG7,GNB1,FN
BP1,PIK3R3,FCER1G,ITGA4 
Thrombopoietin Signaling 11 55 
0.02 
PIK3CG,STAT5A,PRKCE,PIK3CD,MAP2K1,PRKCB,PRKCZ,PIK3R2,PRKCQ,PIK3
R3,GRB2 
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Type II Diabetes Mellitus Signaling 19 109 
0.01 
ACSL6,PRKCE,PRKCB,PPARG,CHUK,TNFRSF11B,SOCS1,SH2B2,PIK3CG,PIK3C
D,NGFR,PRKCZ,SOCS7,ACSL1,TNFRSF1B,PIK3R2,PRKCQ,PIK3R3,SMPD3 
UVB-Induced MAPK Signaling 10 50 
0.03 
PIK3CG,PRKCE,PIK3CD,MAP2K1,PRKCB,EIF4EBP1,PRKCZ,PIK3R2,PRKCQ,PIK
3R3 
VEGF Family Ligand-Receptor 
Interactions 
14 75 
0.01 
PRKCE,PRKCB,PLA2G4E,FLT1,PIK3CG,PIK3CD,MAP2K1,PRKCZ,PIK3R2,PRKC
Q,PIK3R3,NRP1,NRP2,GRB2 
Virus Entry via Endocytic Pathways 15 88 
0.05 
PRKCE,ACTA2,PRKCB,ITGB2,PIK3CG,PIK3CD,ITGB4,PRKCZ,ITGB1,PIK3R2,FL
NB,PRKCQ,PIK3R3,ITGB7,ITGA4 
1D-myo-inositol Hexakisphosphate 
Biosynthesis II (Mammalian) 
6 18 
0.01 
ITPKC,ITPK1,INPP5A,IPMK,INPP5D,SYNJ2 
Acute Myeloid Leukemia Signaling 14 73 
0.02 
BRAF,EIF4EBP1,SPI1,PIK3CG,STAT5A,PIK3CD,MAP2K1,CSF1R,PIK3R2,TCF7L2
,PIK3R3,CSF3R,TCF7,GRB2 
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Table A.3. BMI-Associated Methylation Sites Correlated* with Gene Expression in the Normal Breast Study 
Probe CHR MAPINFO Gene Location** 
Regression 
Coefficient 
Regression 
p-value 
Regression 
q-value 
Correlation 
Coefficient 
cg13674705 1 184829177 FAM129A 
 
-101.28 8.3E-07 0.01 0.34 
cg01440934 1 47051752 MKNK1 
 
-94.28 1.6E-06 0.02 -0.34 
cg00407944 9 139424152 NOTCH1 N_Shore -53.82 3.4E-06 0.02 -0.32 
cg11967765 7 2774195 GNA12 N_Shore -57.05 3.5E-06 0.02 -0.32 
cg11967765 7 2774195 GNA12 N_Shore -57.05 3.5E-06 0.02 -0.32 
cg03458695 10 78163703 C10orf11 
 
-87.01 3.5E-06 0.02 -0.43 
cg13071208 8 145686887 CYHR1 N_Shore 44.69 4.4E-06 0.02 -0.31 
cg08202836 3 196373751 NRROS 
 
-37.86 4.6E-06 0.02 -0.32 
cg10499974 3 46244099 CCR1 
 
-59.50 4.6E-06 0.02 -0.51 
cg24527008 5 177870233 COL23A1 
 
-52.60 4.7E-06 0.02 0.34 
cg27571769 4 185704063 ACSL1 
 
-42.30 5.1E-06 0.02 -0.31 
cg25346117 1 116923256 ATP1A1 
 
-95.44 5.4E-06 0.02 0.36 
cg18418051 5 32734970 NPR3 
 
-57.90 7.0E-06 0.02 -0.35 
cg18418051 5 32734970 NPR3 
 
-57.90 7.0E-06 0.02 -0.35 
cg10145584 11 117860269 IL10RA S_Shelf -75.48 7.0E-06 0.02 -0.32 
cg17207512 6 11382553 NEDD9 
 
-54.54 9.3E-06 0.02 -0.34 
cg16250868 7 3710628 SDK1 
 
-23.00 9.9E-06 0.02 -0.32 
cg03886558 12 57869490 ARHGAP9 Island 48.72 1.2E-05 0.02 0.41 
cg00471696 2 173955214 ZAK 
 
46.53 1.3E-05 0.02 0.31 
cg07113653 6 13428657 GFOD1 
 
-47.94 1.3E-05 0.02 -0.36 
cg11297046 19 49657000 HRC S_Shore -57.81 1.5E-05 0.02 -0.36 
cg20049422 15 26044289 ATP10A 
 
-41.95 1.5E-05 0.02 -0.51 
cg13549277 12 6659520 IFFO1 S_Shore -57.03 1.7E-05 0.02 -0.40 
cg16903174 2 9468351 ASAP2 
 
-44.57 1.8E-05 0.02 -0.38 
cg10058766 1 12186079 TNFRSF8 
 
-38.62 1.8E-05 0.02 -0.31 
cg23854567 12 120694893 PXN 
 
43.29 1.8E-05 0.02 0.36 
cg15757292 11 119994008 TRIM29 
 
-61.91 1.8E-05 0.02 0.31 
cg24413778 13 110977981 COL4A2 
 
-45.81 2.2E-05 0.02 -0.35 
cg02933639 4 8207325 SH3TC1 
 
-60.35 3.0E-05 0.03 -0.40 
cg06787669 7 45018789 MYO1G 
 
-49.76 3.2E-05 0.03 -0.48 
cg14669515 1 9386821 SPSB1 
 
47.05 3.3E-05 0.03 0.53 
cg14669515 1 9386821 SPSB1 
 
47.05 3.3E-05 0.03 0.53 
cg04217515 21 46325853 ITGB2 S_Shore -50.83 3.4E-05 0.03 -0.40 
cg01457077 2 239228573 TRAF3IP1 N_Shore 80.94 3.4E-05 0.03 0.32 
cg06385449 11 63974123 FERMT3 N_Shore -64.54 3.4E-05 0.03 -0.33 
cg10271819 7 139426030 HIPK2 
 
-51.72 3.6E-05 0.03 -0.34 
cg06942450 20 57583520 CTSZ S_Shore -78.87 3.8E-05 0.03 -0.35 
cg04516672 10 126411663 FAM53B 
 
-28.89 4.0E-05 0.03 -0.30 
cg17184477 15 67360705 SMAD3 S_Shore 51.27 4.2E-05 0.03 0.31 
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cg13795831 20 57582706 CTSZ S_Shore -45.40 4.3E-05 0.03 -0.42 
cg21271945 1 2080081 PRKCZ N_Shelf -39.49 4.3E-05 0.03 0.43 
cg00539174 20 57583434 CTSZ S_Shore -66.21 4.9E-05 0.03 -0.39 
cg01721313 3 169751609 GPR160 N_Shelf -86.69 4.9E-05 0.03 0.32 
cg11433866 12 115126908 TBX3 S_Shore -67.22 4.9E-05 0.03 0.46 
cg20306863 1 3593812 TP73 
 
-63.16 5.0E-05 0.03 -0.32 
cg20682563 5 133460874 TCF7 
 
36.85 5.1E-05 0.03 -0.41 
cg18315380 7 1095666 GPR146 N_Shore -42.60 5.4E-05 0.03 -0.45 
cg06579738 11 111165311 C11orf93 N_Shelf 28.52 5.6E-05 0.03 -0.36 
cg17013990 1 161091682 NIT1 S_Shelf -51.66 5.6E-05 0.03 0.36 
cg10163050 X 153637650 DNASE1L1 N_Shelf -71.77 5.7E-05 0.03 -0.30 
cg02794695 8 134072611 SLA 
 
-56.42 5.8E-05 0.03 -0.30 
cg09676376 12 54779077 ZNF385A 
 
-68.91 6.0E-05 0.03 -0.36 
cg00520380 22 31643997 LIMK2 
 
64.92 6.1E-05 0.03 -0.40 
cg01578632 16 69958298 WWP2 
 
27.27 6.1E-05 0.03 -0.30 
cg07103201 17 20171047 SPECC1 
 
-29.26 6.3E-05 0.03 -0.43 
cg07103201 17 20171047 SPECC1 
 
-29.26 6.3E-05 0.03 -0.43 
cg18576206 22 44392384 PARVB Island -44.87 6.6E-05 0.03 -0.41 
cg11589536 3 46250518 CCR1 
 
-73.55 6.7E-05 0.03 -0.51 
cg03514239 1 153329781 S100A9 
 
-82.31 7.0E-05 0.03 -0.37 
cg00620452 3 32147645 GPD1L N_Shore 54.04 7.1E-05 0.03 -0.31 
cg02671382 1 120457856 NOTCH2 
 
56.33 7.3E-05 0.03 0.32 
cg23682913 1 2080710 PRKCZ N_Shore -57.15 7.3E-05 0.03 0.54 
cg13279083 4 110128090 COL25A1 
 
42.08 7.4E-05 0.03 0.37 
cg03342032 13 94725495 GPC6 
 
26.89 7.6E-05 0.03 0.35 
cg03857553 22 29976613 NIPSNAP1 N_Shore 25.23 7.6E-05 0.03 -0.37 
cg26938118 18 56059556 NEDD4L 
 
53.84 7.7E-05 0.03 -0.38 
cg22609908 12 858759 WNK1 N_Shelf -27.75 8.1E-05 0.03 -0.37 
cg26371957 12 739280 NINJ2 
 
-18.04 8.2E-05 0.03 -0.33 
cg18809126 3 11623526 VGLL4 
 
36.88 8.4E-05 0.03 -0.35 
cg23013850 2 225266304 FAM124B 
 
-33.56 8.6E-05 0.03 -0.31 
cg13826666 9 136600241 SARDH 
 
-52.61 8.6E-05 0.03 0.35 
cg11300147 12 7596703 CD163L1 S_Shelf -25.39 9.2E-05 0.03 -0.44 
cg12080566 2 75798232 EVA1A 
 
68.68 9.4E-05 0.03 -0.30 
cg08354401 5 177824353 COL23A1 S_Shore 48.88 9.7E-05 0.03 -0.35 
cg26863600 19 2616921 GNG7 S_Shelf -25.10 9.7E-05 0.03 0.44 
cg07431973 14 52142383 FRMD6 
 
30.26 9.8E-05 0.03 -0.36 
cg03277819 12 772529 NINJ2 
 
25.96 1.1E-04 0.04 0.40 
cg16129800 11 2920414 SLC22A18 N_Shelf -55.76 1.1E-04 0.04 0.35 
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cg20271057 3 16974160 PLCL2 
 
-56.89 1.1E-04 0.04 -0.30 
cg23787937 12 29303160 FAR2 S_Shore -48.96 1.1E-04 0.04 -0.47 
cg08160072 2 40009501 THUMPD2 S_Shelf -43.91 1.1E-04 0.04 0.41 
cg17869960 6 12718530 PHACTR1 
 
21.89 1.1E-04 0.04 0.42 
cg07984358 10 24704829 KIAA1217 
 
37.20 1.2E-04 0.04 -0.32 
cg10783294 12 679668 NINJ2 S_Shore 49.23 1.2E-04 0.04 0.38 
cg06663317 16 56641101 MT2A N_Shore 47.59 1.2E-04 0.04 0.40 
cg00353571 19 49238653 RASIP1 Island 52.99 1.2E-04 0.04 0.36 
cg21870662 17 2241570 SGSM2 S_Shore 92.81 1.2E-04 0.04 -0.31 
cg13071185 11 860134 TSPAN4 S_Shore 27.39 1.2E-04 0.04 0.40 
cg13728131 11 19799633 NAV2 S_Shore 56.77 1.3E-04 0.04 -0.46 
cg13728131 11 19799633 NAV2 S_Shore 56.77 1.3E-04 0.04 -0.46 
cg15674813 2 238608549 LRRFIP1 
 
-51.62 1.3E-04 0.04 -0.36 
cg21031128 8 21771278 DOK2 S_Shore -47.83 1.3E-04 0.04 -0.31 
cg02771464 22 19108494 DGCR2 N_Shore 33.01 1.3E-04 0.04 -0.35 
cg14944269 14 65439602 RAB15 S_Shore 45.45 1.3E-04 0.04 -0.32 
cg04615460 12 115125098 TBX3 Island -37.00 1.3E-04 0.04 0.53 
cg03690812 12 111875483 SH2B3 
 
-80.96 1.3E-04 0.04 -0.34 
cg21785723 1 6551782 PLEKHG5 S_Shore -62.29 1.3E-04 0.04 -0.41 
cg19771173 1 204296545 PLEKHA6 
 
-41.54 1.4E-04 0.04 0.45 
cg13695585 6 30853014 DDR1 S_Shore 34.11 1.4E-04 0.04 -0.51 
cg20454518 12 133135463 FBRSL1 Island -45.09 1.4E-04 0.04 0.32 
cg06332304 10 126782397 CTBP2 
 
33.62 1.4E-04 0.04 -0.33 
cg01458495 3 48310544 ZNF589 
 
25.69 1.4E-04 0.04 -0.33 
cg22337438 19 54327437 NLRP12 
 
-45.84 1.4E-04 0.04 -0.60 
cg09358422 1 1023247 C1orf159 Island 26.32 1.4E-04 0.04 -0.38 
cg06959773 7 76033795 SRCRB4D S_Shelf -62.65 1.5E-04 0.04 -0.43 
cg22867608 10 64573356 EGR2 Island 27.21 1.5E-04 0.04 -0.30 
cg10129493 19 51728586 CD33 
 
-66.19 1.5E-04 0.04 -0.45 
cg25752703 3 128710390 KIAA1257 N_Shelf -42.90 1.5E-04 0.04 0.39 
cg04483936 15 57668247 CGNL1 N_Shore -55.35 1.5E-04 0.04 0.38 
cg25141611 13 113422162 ATP11A S_Shore -57.56 1.5E-04 0.04 -0.36 
cg00136547 6 56507796 DST 
 
22.70 1.5E-04 0.04 -0.31 
cg23497683 2 100759159 AFF3 
 
-35.31 1.5E-04 0.04 0.34 
cg24523322 1 1023281 C1orf159 Island 24.49 1.6E-04 0.04 -0.39 
cg05584759 12 57869421 ARHGAP9 Island 47.13 1.6E-04 0.04 0.35 
cg13101705 1 183248593 NMNAT2 
 
-37.29 1.6E-04 0.04 -0.33 
cg04541607 22 27013978 CRYBB1 
 
-51.73 1.7E-04 0.04 -0.32 
cg02865595 1 36771714 SH3D21 N_Shore 23.57 1.7E-04 0.04 -0.39 
162 
 
Table A.3. BMI-Associated Methylation Sites Correlated* with Gene Expression in the Normal Breast Study 
Probe CHR MAPINFO Gene Location** 
Regression 
Coefficient 
Regression 
p-value 
Regression 
q-value 
Correlation 
Coefficient 
cg16438525 3 52517742 NISCH N_Shelf 25.88 1.7E-04 0.04 -0.31 
cg12004641 2 218750749 TNS1 
 
-45.57 1.8E-04 0.04 -0.32 
cg19015961 10 90712748 ACTA2 
 
49.70 1.8E-04 0.04 -0.31 
cg13666041 14 69442697 ACTN1 N_Shore 19.68 1.8E-04 0.04 -0.31 
cg15726700 3 196370254 NRROS S_Shelf -47.52 1.9E-04 0.04 -0.39 
cg20149168 1 68512807 DIRAS3 Island -68.65 1.9E-04 0.04 0.35 
cg23715045 11 124621944 VSIG2 
 
40.89 1.9E-04 0.04 -0.50 
cg14590912 9 135905092 GTF3C5 N_Shore 41.90 1.9E-04 0.04 -0.38 
cg15545878 11 111782607 CRYAB 
 
38.35 2.0E-04 0.04 0.35 
cg02334109 15 26044050 ATP10A 
 
-44.29 2.0E-04 0.04 -0.56 
cg05143345 14 23447408 AJUBA N_Shelf 33.44 2.0E-04 0.04 -0.44 
cg01844235 22 23487969 RAB36 Island 53.00 2.0E-04 0.04 -0.49 
cg03335246 4 4860431 MSX1 N_Shore -41.42 2.1E-04 0.04 -0.35 
cg14285050 1 40778294 COL9A2 N_Shelf -59.25 2.1E-04 0.04 0.46 
cg11700584 14 50088544 MGAT2 S_Shore 71.47 2.1E-04 0.04 0.33 
cg12414070 12 117627133 FBXO21 N_Shore 45.75 2.1E-04 0.04 -0.38 
cg10413136 4 8207119 SH3TC1 
 
-45.45 2.1E-04 0.04 -0.41 
cg14413904 10 62423377 ANK3 
 
-40.59 2.1E-04 0.04 0.46 
cg12532266 5 132201652 UQCRQ N_Shore 26.24 2.2E-04 0.04 0.50 
cg24553170 1 49243472 BEND5 S_Shore 32.27 2.3E-04 0.04 -0.37 
cg08120210 15 66682733 MAP2K1 S_Shelf -18.88 2.3E-04 0.04 -0.32 
cg02424715 14 75893680 JDP2 N_Shore -46.46 2.3E-04 0.04 -0.41 
cg01226614 13 44947593 SERP2 Island 39.38 2.3E-04 0.04 -0.36 
cg01123186 17 36514710 SOCS7 
 
29.70 2.3E-04 0.04 -0.42 
cg00728848 6 13483832 GFOD1 N_Shelf -34.24 2.4E-04 0.04 -0.39 
cg08651590 2 65543410 SPRED2 S_Shelf 26.70 2.4E-04 0.04 -0.32 
cg21188037 7 45018658 MYO1G 
 
-50.49 2.5E-04 0.04 -0.51 
cg12974599 22 46770195 CELSR1 N_Shore -25.70 2.5E-04 0.04 0.39 
cg14365457 9 124029877 GSN 
 
-68.45 2.5E-04 0.04 -0.32 
cg26083045 3 8560168 LMCD1 
 
-77.73 2.5E-04 0.04 -0.44 
cg26933869 1 19218007 ALDH4A1 
 
-59.26 2.5E-04 0.04 -0.52 
cg26933869 1 19218007 ALDH4A1 
 
-59.26 2.5E-04 0.04 -0.52 
cg09920804 8 42053994 PLAT 
 
45.46 2.5E-04 0.04 -0.42 
cg16846069 12 6462681 SCNN1A 
 
-43.50 2.5E-04 0.04 0.31 
cg03730946 19 6475456 DENND1C Island 45.65 2.6E-04 0.04 0.38 
cg20425130 3 183273245 KLHL6 
 
-26.58 2.6E-04 0.04 -0.37 
cg20425130 3 183273245 KLHL6 
 
-26.58 2.6E-04 0.04 -0.37 
cg00387090 1 201615401 NAV1 N_Shore -27.05 2.6E-04 0.04 -0.40 
cg03473377 10 33568029 NRP1 
 
-59.67 2.6E-04 0.04 -0.45 
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cg03473377 10 33568029 NRP1 
 
-59.67 2.6E-04 0.04 -0.45 
cg09447621 11 134254646 B3GAT1 S_Shore -37.30 2.7E-04 0.04 0.48 
cg02059317 16 89024511 CBFA2T3 
 
-55.76 2.7E-04 0.04 -0.33 
cg02845870 11 85524670 SYTL2 S_Shelf -72.93 2.7E-04 0.04 0.46 
cg18498263 14 91034963 TTC7B 
 
21.86 2.7E-04 0.04 0.39 
cg26633373 19 54377836 MYADM S_Shore -34.82 2.7E-04 0.04 -0.34 
cg02807984 11 722258 EPS8L2 S_Shore -35.25 2.7E-04 0.04 0.34 
cg23033749 7 116610238 ST7 
 
-62.42 2.7E-04 0.04 -0.31 
cg21110337 12 113671028 TPCN1 
 
-32.05 2.8E-04 0.04 0.31 
cg14685146 17 42088751 TMEM101 N_Shelf 22.75 2.8E-04 0.04 -0.44 
cg00580562 10 21789124 C10orf114 Island -19.85 2.8E-04 0.04 -0.31 
cg07175797 16 50317656 ADCY7 
 
-50.60 2.8E-04 0.04 -0.45 
cg00255726 8 21769114 DOK2 N_Shore -61.71 2.8E-04 0.04 -0.35 
cg08578641 9 34457440 FAM219A Island 30.97 2.8E-04 0.04 0.36 
cg12484113 1 27898757 AHDC1 N_Shelf 44.49 2.8E-04 0.04 -0.46 
cg17244340 6 36973448 FGD2 
 
-35.14 2.9E-04 0.04 -0.40 
cg13509421 12 110476821 ANKRD13A 28.80 2.9E-04 0.04 -0.33 
cg18113826 6 31583942 AIF1 N_Shelf -59.35 2.9E-04 0.04 -0.39 
cg04332442 22 46770063 CELSR1 N_Shore -24.54 2.9E-04 0.04 0.47 
cg22908922 14 105855008 PACS2 S_Shelf -59.04 3.0E-04 0.04 -0.33 
cg25623459 11 1861344 TNNI2 
 
-34.35 3.0E-04 0.04 0.32 
cg04822621 5 169724656 LCP2 
 
-23.09 3.0E-04 0.04 -0.49 
cg17297216 15 99194474 IGF1R Island 63.97 3.0E-04 0.04 -0.38 
cg19011001 14 93539613 ITPK1 
 
-41.00 3.0E-04 0.04 -0.43 
cg24566261 6 30854164 DDR1 S_Shore 50.51 3.1E-04 0.05 -0.49 
cg21579294 13 113997499 GRTP1 
 
-53.68 3.1E-04 0.05 0.36 
cg05266786 10 49742271 ARHGAP22 26.81 3.1E-04 0.05 0.35 
cg22935317 14 23447078 AJUBA N_Shelf 33.70 3.2E-04 0.05 -0.44 
cg01595717 9 140586201 EHMT1 N_Shore -31.87 3.2E-04 0.05 0.40 
cg01595717 9 140586201 EHMT1 N_Shore -31.87 3.2E-04 0.05 0.40 
cg08343834 17 15168658 PMP22 S_Shelf 22.71 3.3E-04 0.05 0.38 
cg21957813 11 44638520 CD82 
 
43.78 3.3E-04 0.05 -0.42 
cg09990481 10 90712684 ACTA2 
 
46.02 3.4E-04 0.05 -0.34 
cg17674726 2 231743193 ITM2C 
 
-57.71 3.4E-04 0.05 0.42 
cg13578303 19 49838698 CD37 N_Shelf -53.42 3.5E-04 0.05 -0.31 
cg02395812 14 105955879 C14orf80 N_Shore 43.95 3.5E-04 0.05 0.38 
cg15155441 11 57005981 APLNR 
 
-83.20 3.5E-04 0.05 -0.35 
cg12871285 17 76713379 CYTH1 
 
25.99 3.6E-04 0.05 0.31 
cg16277944 5 169068404 DOCK2 S_Shelf 27.20 3.6E-04 0.05 0.32 
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cg02434051 19 54848878 LILRA4 
 
38.06 3.7E-04 0.05 0.30 
cg19272266 8 38125865 PPAPDC1B N_Shore 32.56 3.7E-04 0.05 -0.59 
cg24947456 12 57441432 MYO1A 
 
-48.43 3.7E-04 0.05 -0.37 
cg26583078 4 186877778 SORBS2 
 
25.78 3.7E-04 0.05 -0.33 
cg04812726 5 171875049 SH3PXD2B 
 
45.58 3.7E-04 0.05 -0.30 
cg17460386 1 207095668 FAIM3 
 
-36.02 3.8E-04 0.05 -0.45 
cg17243643 12 56114269 RDH5 S_Shelf 22.85 3.8E-04 0.05 0.37 
cg18069290 12 58013539 SLC26A10 Island -38.73 3.8E-04 0.05 0.30 
cg19256813 12 117627286 FBXO21 N_Shore 33.99 3.8E-04 0.05 -0.50 
cg25550753 2 47205281 TTC7A 
 
-41.95 3.8E-04 0.05 -0.36 
cg14260643 7 99277394 CYP3A5 
 
28.67 3.9E-04 0.05 0.40 
cg03333377 11 93277841 SMCO4 S_Shore -18.99 3.9E-04 0.05 0.36 
cg26536240 16 89509760 ANKRD11 
 
26.32 3.9E-04 0.05 -0.33 
cg15049549 3 48732213 IP6K2 
 
24.13 3.9E-04 0.05 -0.37 
cg09472600 1 183537770 NCF2 
 
-15.93 4.0E-04 0.05 -0.40 
cg19747945 6 42946146 PEX6 N_Shore 30.97 4.0E-04 0.05 -0.32 
cg03779374 3 114343825 ZBTB20 
 
-32.01 4.0E-04 0.05 -0.32 
cg17311022 3 119379792 POPDC2 
 
30.24 4.0E-04 0.05 -0.32 
cg25076039 5 169128937 DOCK2 
 
32.47 4.1E-04 0.05 0.34 
cg07702311 11 128646953 FLI1 
 
29.10 4.1E-04 0.05 0.34 
cg00861207 4 8098270 ABLIM2 N_Shore -67.94 4.1E-04 0.05 -0.33 
cg14729344 10 121129753 GRK5 
 
-31.82 4.2E-04 0.05 -0.32 
cg11077392 11 19719446 NAV2 
 
47.68 4.2E-04 0.05 -0.46 
cg11077392 11 19719446 NAV2 
 
47.68 4.2E-04 0.05 -0.46 
cg02804819 19 49238364 RASIP1 N_Shore 40.25 4.2E-04 0.05 0.36 
cg14671926 6 169930772 WDR27 
 
43.07 4.2E-04 0.05 -0.36 
cg18750833 2 71358451 
MPHOSPH1
0 S_Shore 24.88 4.2E-04 0.05 -0.37 
cg16671238 13 20987145 CRYL1 N_Shore -61.58 4.2E-04 0.05 -0.41 
cg14654385 11 63973006 FERMT3 N_Shore -66.98 4.2E-04 0.05 -0.30 
cg03732056 8 21771059 DOK2 S_Shore -21.58 4.3E-04 0.05 -0.31 
cg06015525 12 57872123 ARHGAP9 S_Shore -51.06 4.3E-04 0.05 -0.33 
cg25064052 4 166216151 KLHL2 
 
-32.36 4.3E-04 0.05 0.35 
cg00748218 11 19372553 NAV2 
 
43.34 4.3E-04 0.05 -0.44 
cg00748218 11 19372553 NAV2 
 
43.34 4.3E-04 0.05 -0.44 
cg11953913 5 139562873 CYSTM1 
 
-42.83 4.3E-04 0.05 -0.40 
cg14647287 4 6927183 TBC1D14 S_Shore -56.31 4.3E-04 0.05 0.30 
cg12193327 2 31454631 EHD3 N_Shelf -37.28 4.4E-04 0.05 0.34 
cg26959945 7 20233217 MACC1 
 
-17.89 4.4E-04 0.05 0.33 
cg07187855 6 30854161 DDR1 S_Shore 43.86 4.4E-04 0.05 -0.44 
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cg04388657 9 127623377 RPL35 N_Shore 24.02 4.5E-04 0.05 -0.44 
cg17753974 1 201622519 NAV1 S_Shelf -35.25 4.5E-04 0.05 -0.35 
cg08133755 11 19792080 NAV2 
 
31.34 4.6E-04 0.05 -0.45 
cg08133755 11 19792080 NAV2 
 
31.34 4.6E-04 0.05 -0.45 
*A correlation coefficient of ≤ -0.30 or ≥ 0.30 was the cut-off for determining which CpG sites were correlated with gene 
expression; **N_Shore = North shore; N_Shelf = North shelf; S_Shore = South shore; S_Shelf = South shelf; blank = not in or 
near CpG island 
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Table A.4. Probes Associated with BMI in Gene Expression Data in 
the Normal Breast Study 
Probe Gene Coefficient p-value q-value 
A_24_P475349 RAB6B 0.049 2.69E-06 0.01 
A_23_P114903 HSPA6 0.066 2.53E-05 0.04 
A_23_P132956 UCHL1 0.082 2.95E-05 0.04 
A_23_P165136 LRRC25 0.067 5.72E-05 0.04 
A_23_P44674 CRIP1 0.045 6.97E-05 0.04 
A_23_P63390 FCGR1B 0.079 7.09E-05 0.04 
A_24_P416177 ADCY7 0.051 7.19E-05 0.04 
A_23_P69154 FAM198A 0.056 9.25E-05 0.05 
A_23_P157875 FCN1 0.081 1.02E-04 0.05 
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Table A.5. 174 BMI-associated methylation sites (FDR<0.05) in the Normal Breast Study, 
adjusting for tissue type, age, race, and alcohol use 
Probe CHR MAPINFO Gene Coefficient p-value q-value 
cg01044662 2 75938360 GCFC2 58.98 1.27E-07 0.02 
cg01440934 1 47051752 MKNK1 -93.27 4.08E-07 0.02 
cg05612654 6 2375895 LOC100508120 -88.63 4.48E-07 0.02 
cg09667606 6 1.59E+08 SYNJ2 -44.26 4.74E-07 0.02 
cg12924510 18 514363 NA -74.22 2.93E-07 0.02 
cg13673563 14 21738473 HNRNPC -75.20 4.38E-07 0.02 
cg17190781 6 40387783 LRFN2 -143.73 4.06E-07 0.02 
cg21988461 4 88008667 AFF1 -66.71 4.45E-07 0.02 
cg15028995 19 46628119 IGFL3 -119.26 5.43E-07 0.02 
cg03886558 12 57869490 ARHGAP9 52.65 9.05E-07 0.02 
cg16551670 5 1.07E+08 NA -40.15 9.12E-07 0.02 
cg22216196 19 15564105 WIZ 51.24 9.20E-07 0.02 
cg26050975 5 1.79E+08 MGAT4B -81.76 7.37E-07 0.02 
cg20810975 17 42467199 ITGA2B -77.88 1.01E-06 0.02 
cg02609279 2 1.82E+08 ITGA4 -51.78 1.60E-06 0.03 
cg08468577 11 2973342 NAP1L4 -78.37 1.82E-06 0.03 
cg18334681 6 1.32E+08 ENPP3 -31.83 1.66E-06 0.03 
cg25346117 1 1.17E+08 ATP1A1 -96.72 1.78E-06 0.03 
cg01048752 8 10001523 MSRA -119.27 2.39E-06 0.03 
cg04147906 17 26373775 NLK -66.67 4.25E-06 0.03 
cg04681525 9 1.32E+08 NA -84.42 3.66E-06 0.03 
cg06034527 15 96912955 NA -43.49 3.86E-06 0.03 
cg06107293 15 22915986 CYFIP1 -48.82 3.17E-06 0.03 
cg07788061 19 13207239 NFIX -91.39 3.96E-06 0.03 
cg13674705 1 1.85E+08 FAM129A -104.32 3.43E-06 0.03 
cg14724298 4 54424764 LNX1 -42.14 3.62E-06 0.03 
cg18445108 17 5138259 SCIMP -74.12 3.69E-06 0.03 
cg18857467 1 32787489 HDAC1 -35.35 2.78E-06 0.03 
cg21218183 1 92760687 RPAP2 -29.95 4.24E-06 0.03 
cg21241317 6 32122736 LOC100507547 151.87 4.20E-06 0.03 
cg22438522 4 646293 PDE6B -135.91 3.16E-06 0.03 
cg22573003 X 15402648 FIGF 56.78 2.60E-06 0.03 
cg22727965 7 25898770 NA -71.35 2.21E-06 0.03 
cg23252243 2 26987820 SLC35F6 46.56 3.98E-06 0.03 
cg24165086 11 64705980 GPHA2 -116.29 3.00E-06 0.03 
cg24640390 10 71336969 NEUROG3 53.54 4.25E-06 0.03 
cg26272443 19 41083341 SHKBP1 107.17 3.69E-06 0.03 
cg26972389 5 1.69E+08 FAM196B 67.52 3.93E-06 0.03 
cg00309582 20 55841925 BMP7 437.49 4.49E-06 0.03 
cg05287480 7 27176127 HOXA-AS3 62.19 4.47E-06 0.03 
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Table A.5. 174 BMI-associated methylation sites (FDR<0.05) in the Normal Breast Study, 
adjusting for tissue type, age, race, and alcohol use 
Probe CHR MAPINFO Gene Coefficient p-value q-value 
cg00027232 2 85547231 TGOLN2 -78.62 7.30E-06 0.04 
cg00045118 8 93076177 RUNX1T1 49.28 7.45E-06 0.04 
cg01652190 22 50026171 C22orf34 32.05 6.14E-06 0.04 
cg03458695 10 78163703 C10orf11 -84.88 5.31E-06 0.04 
cg10499974 3 46244099 CCR1 -58.85 6.83E-06 0.04 
cg10767045 10 89264128 MINPP1 38.55 6.98E-06 0.04 
cg13580767 12 50135122 TMBIM6 754.30 7.34E-06 0.04 
cg14855124 1 9180023 GPR157 -67.51 6.96E-06 0.04 
cg16515974 6 31695064 DDAH2 -93.42 5.82E-06 0.04 
cg16721359 8 98610787 NA -69.12 5.92E-06 0.04 
cg17852032 6 1.58E+08 ZDHHC14 -61.09 6.33E-06 0.04 
cg17969683 8 24151514 ADAM28 -48.48 6.32E-06 0.04 
cg20487608 6 15288126 JARID2 -66.02 7.49E-06 0.04 
cg21500909 19 41870640 B9D2 -44.80 6.42E-06 0.04 
cg22190361 2 1.75E+08 NA -31.88 5.69E-06 0.04 
cg23159337 3 1.93E+08 ATP13A4 75.02 6.77E-06 0.04 
cg24833674 1 1.67E+08 ILDR2 -59.33 6.15E-06 0.04 
cg26894297 1 23754550 TCEA3 -121.66 7.16E-06 0.04 
cg13423554 1 42317463 HIVEP3 -30.93 8.05E-06 0.04 
cg21067465 11 86304288 ME3 -44.00 8.05E-06 0.04 
cg22717593 19 45647012 PPP1R37 -86.79 8.01E-06 0.04 
cg00478874 6 33396235 SYNGAP1 154.86 8.82E-06 0.04 
cg00667525 19 18699118 C19orf60 46.30 8.93E-06 0.04 
cg02382221 4 86682649 ARHGAP24 -112.61 8.51E-06 0.04 
cg20382493 13 1.15E+08 RASA3 45.97 9.16E-06 0.04 
cg22460123 12 52638294 KRT7 -37.48 9.01E-06 0.04 
cg22595920 1 9716050 C1orf200 -78.35 9.10E-06 0.04 
cg02737379 3 1.19E+08 POPDC2 29.08 9.79E-06 0.04 
cg03814063 22 50025915 C22orf34 46.87 9.85E-06 0.04 
cg05587400 10 5817943 GDI2 -50.71 9.81E-06 0.04 
cg00017461 22 30663316 OSM -56.79 1.09E-05 0.04 
cg01033299 12 53601015 ITGB7 -43.36 1.18E-05 0.04 
cg01534527 3 38003247 CTDSPL -46.85 1.15E-05 0.04 
cg03198066 2 1.59E+08 CCDC148 -62.32 1.09E-05 0.04 
cg03874653 3 1.23E+08 MYLK 36.47 1.18E-05 0.04 
cg04042106 11 65628736 MUS81 262.54 1.18E-05 0.04 
cg09167779 5 1.13E+08 MCC 37.18 1.16E-05 0.04 
cg11494437 3 15678564 BTD -48.72 1.20E-05 0.04 
cg11649821 1 1859438 NA -61.32 1.09E-05 0.04 
cg13071208 8 1.46E+08 CYHR1 42.78 1.10E-05 0.04 
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Table A.5. 174 BMI-associated methylation sites (FDR<0.05) in the Normal Breast Study, 
adjusting for tissue type, age, race, and alcohol use 
Probe CHR MAPINFO Gene Coefficient p-value q-value 
cg19502709 5 1.7E+08 KCNMB1 -30.87 1.08E-05 0.04 
cg24637417 12 51636921 DAZAP2 -70.44 1.19E-05 0.04 
cg26697477 16 1836234 NUBP2 73.59 1.14E-05 0.04 
cg27574973 7 78218446 MAGI2 -105.40 1.17E-05 0.04 
cg23357708 19 8580509 ZNF414 -67.86 1.23E-05 0.04 
cg00348762 16 56228114 DKFZP434H168 65.97 1.30E-05 0.04 
cg01816936 12 1.24E+08 PITPNM2 -53.67 1.25E-05 0.04 
cg04090347 21 44061597 NA 40.89 1.32E-05 0.04 
cg06427816 17 1090326 ABR 35.65 1.32E-05 0.04 
cg06955979 14 1.01E+08 NA 59.04 1.28E-05 0.04 
cg08840913 2 24139933 ATAD2B -58.06 1.36E-05 0.04 
cg09250458 16 1139916 C1QTNF8 43.50 1.34E-05 0.04 
cg10145584 11 1.18E+08 IL10RA -72.42 1.34E-05 0.04 
cg16298927 6 1.7E+08 LINC00574 28.02 1.35E-05 0.04 
cg04188920 10 3138534 PFKP -47.47 1.40E-05 0.05 
cg24870729 1 62102363 NA -50.38 1.41E-05 0.05 
cg23343486 17 75449911 SEPT9 -67.62 1.44E-05 0.05 
cg06928741 6 31691430 C6orf25 -68.95 1.47E-05 0.05 
cg14188712 13 31942544 NA -77.38 1.47E-05 0.05 
cg08202836 3 1.96E+08 NRROS -35.63 1.51E-05 0.05 
cg13688889 9 1.01E+08 NA -42.98 1.52E-05 0.05 
cg24546683 1 2.42E+08 NA 29.86 1.50E-05 0.05 
cg01986263 20 58659848 NA -62.32 1.55E-05 0.05 
cg06389605 6 1.68E+08 NA -101.99 1.58E-05 0.05 
cg12405520 11 1.26E+08 NA 47.58 1.56E-05 0.05 
cg12967050 19 36233297 IGFLR1 -82.28 1.60E-05 0.05 
cg26732720 11 64392533 NRXN2 -60.64 1.60E-05 0.05 
cg18993949 4 15481269 CC2D2A 34.02 1.62E-05 0.05 
cg10274453 13 43378116 NA -33.18 1.65E-05 0.05 
cg24013213 13 51640142 GUCY1B2 -40.02 1.67E-05 0.05 
cg00407944 9 1.39E+08 NOTCH1 -50.91 2.02E-05 0.05 
cg00451054 8 77913321 PEX2 47.60 1.96E-05 0.05 
cg01825818 2 1.32E+08 NA -67.59 2.17E-05 0.05 
cg02338840 2 2.08E+08 NA -83.40 1.88E-05 0.05 
cg02455383 22 27014116 CRYBB1 -65.75 1.84E-05 0.05 
cg02492873 2 25193821 DNAJC27 40.43 2.30E-05 0.05 
cg02596994 12 1.22E+08 HPD 49.06 2.28E-05 0.05 
cg03069267 9 1.35E+08 NA 52.40 1.95E-05 0.05 
cg03089651 1 1.61E+08 ARHGAP30 -55.94 1.84E-05 0.05 
cg04217515 21 46325853 ITGB2 -48.97 2.00E-05 0.05 
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Table A.5. 174 BMI-associated methylation sites (FDR<0.05) in the Normal Breast Study, 
adjusting for tissue type, age, race, and alcohol use 
Probe CHR MAPINFO Gene Coefficient p-value q-value 
cg05120113 3 33140160 GLB1 -134.06 2.33E-05 0.05 
cg05711445 7 1.4E+08 TBXAS1 -39.24 1.96E-05 0.05 
cg06110286 8 1.46E+08 GPT 68.09 1.81E-05 0.05 
cg06112654 10 35505599 NA -43.73 1.76E-05 0.05 
cg08813888 2 662396 NA -52.15 2.26E-05 0.05 
cg10324998 1 92338262 TGFBR3 62.90 2.14E-05 0.05 
cg10666916 6 33872206 NA -73.54 2.22E-05 0.05 
cg10825315 14 81425912 TSHR -46.71 2.10E-05 0.05 
cg10864791 13 22178445 MICU2 470.02 2.19E-05 0.05 
cg11574092 2 2.41E+08 MIR149 -58.41 2.02E-05 0.05 
cg12097896 8 26471364 DPYSL2 -86.90 2.34E-05 0.05 
cg12446613 5 1.59E+08 NA -68.91 2.21E-05 0.05 
cg13549277 12 6659520 IFFO1 -55.57 2.21E-05 0.05 
cg14080050 9 33159025 B4GALT1 -46.31 2.30E-05 0.05 
cg14225168 9 1.39E+08 NOTCH1 -55.44 1.91E-05 0.05 
cg14575356 6 1.3E+08 ARHGAP18 -51.87 1.81E-05 0.05 
cg15818008 11 1.12E+08 C11orf34 -40.27 2.19E-05 0.05 
cg17210664 10 61297420 NA 41.22 2.27E-05 0.05 
cg18637901 4 3247372 MSANTD1 -113.92 2.06E-05 0.05 
cg22718308 15 42308160 PLA2G4E -173.10 1.96E-05 0.05 
cg23301925 14 91294322 NA 60.17 2.32E-05 0.05 
cg24020157 10 43697521 RASGEF1A -58.67 2.01E-05 0.05 
cg24394336 1 17962705 ARHGEF10L -59.47 2.13E-05 0.05 
cg24428218 10 1.26E+08 NA -27.00 2.13E-05 0.05 
cg24527008 5 1.78E+08 COL23A1 -49.43 2.07E-05 0.05 
cg25789721 3 10370264 ATP2B2 61.11 2.11E-05 0.05 
cg25992874 7 1.43E+08 CASP2 -85.97 1.83E-05 0.05 
cg26011014 1 40783003 COL9A2 317.17 2.29E-05 0.05 
cg26504421 17 71339361 SDK2 62.36 1.80E-05 0.05 
cg26787020 1 1.75E+08 CACYBP 40.34 2.11E-05 0.05 
cg27050111 16 8738240 METTL22 -48.25 2.29E-05 0.05 
cg27571769 4 1.86E+08 ACSL1 -40.72 1.86E-05 0.05 
cg14146966 2 61757674 XPO1 40.52 2.36E-05 0.05 
cg23854567 12 1.21E+08 PXN 43.07 2.42E-05 0.05 
cg01034993 15 68992751 CORO2B -46.93 2.44E-05 0.05 
cg05596664 3 1.71E+08 TNIK 384.62 2.49E-05 0.05 
cg15694146 1 27823372 NA 52.70 2.51E-05 0.05 
cg15757292 11 1.2E+08 TRIM29 -59.31 2.52E-05 0.05 
cg23238058 6 7042879 NA -37.90 2.52E-05 0.05 
cg12006375 13 51640315 GUCY1B2 -68.15 2.53E-05 0.05 
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Table A.5. 174 BMI-associated methylation sites (FDR<0.05) in the Normal Breast Study, 
adjusting for tissue type, age, race, and alcohol use 
Probe CHR MAPINFO Gene Coefficient p-value q-value 
cg01209566 8 1.26E+08 LINC00964 53.24 2.58E-05 0.05 
cg06261052 10 13545875 BEND7 -77.66 2.68E-05 0.05 
cg11967765 7 2774195 GNA12 -53.14 2.59E-05 0.05 
cg12332776 10 71336241 NEUROG3 63.43 2.61E-05 0.05 
cg14007090 20 60915009 LAMA5 -79.79 2.68E-05 0.05 
cg15335334 17 73642547 SMIM6 -43.79 2.63E-05 0.05 
cg16377679 5 58388744 PDE4D 34.13 2.67E-05 0.05 
cg20609803 1 1.61E+08 FCER1G -64.10 2.68E-05 0.05 
cg25299676 7 1.16E+08 MET 110.89 2.60E-05 0.05 
cg08526959 2 25149334 NA -84.28 2.72E-05 0.05 
cg11010552 5 1.31E+08 ACSL6 -90.06 2.75E-05 0.05 
cg19960420 10 1.01E+08 NA 35.51 2.75E-05 0.05 
cg15998505 1 1.53E+08 NA 72.54 2.77E-05 0.05 
cg01052699 4 1.71E+08 NA 48.48 2.81E-05 0.05 
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Table A.6. Genes overlapping with BMI-associated genes from published studies 
Genes Overlapping with Creighton et al. 
 
Genes Overlapping with Sun et al. 
ADI1 TIMM8A  ABCC9 MPP2 
ARHGEF12 VPS13D  AGAP2-AS1 NACC1 
ATXN7 ZNF143  ARRDC1 NLGN2 
CCDC93 
 
 C1orf106 NPR3 
CDH18 
 
 CACNA1C NXN 
CEP350 
 
 CCDC28B PCYT1B 
CTBP2 
 
 CCDC80 PEX6 
CYP3A5 
 
 CD6 PIK3R2 
DDX5 
 
 CD82 PMP22 
DIP2C 
 
 CKMT2 PPP1R10 
DRD4 
 
 CNTNAP2 PRICKLE2 
DYNC1H1 
 
 COL11A2 PRKCZ 
EPM2AIP1 
 
 COL23A1 PRRC2A 
FBLN1 
 
 COL9A2 PTAFR 
FBXO21 
 
 CTBP2 RARG 
FOXJ3 
 
 CYP4B1 RDH5 
GPD1L 
 
 DDC RGS22 
HDAC4 
 
 DEAF1 SARDH 
HK2 
 
 EFHB SCAND3 
INPP5A 
 
 EHD3 SDK2 
JARID2 
 
 ERC2 SETD7 
LPP 
 
 FBN1 SLC12A8 
MCF2L 
 
 FBXO46 SLC25A20 
MUM1 
 
 GNG7 SNTG2 
MYBPH 
 
 GPR35 SPIRE2 
NEDD4L 
 
 GSN TBX3 
NEDD9 
 
 H1F0 TCF7 
NTRK3 
 
 HPN TMEM145 
PPP2R5C 
 
 HS6ST1 ZAK 
PROSC 
 
 IDNK  
PRPF38B 
 
 IGSF3  
RBM3 
 
 IL32  
RBM4 
 
 ITM2C  
RBM5 
 
 JDP2  
SEC14L1 
 
 KDM4C  
SP2 
 
 LMCD1  
SPN 
 
 LRFN2  
SPRED2 
 
 MAPK4  
TCF12 
 
 MDK  
 Table A.7. Correlation between BMI-associated methylation sites (overall and among ER-positive tumors identified in the Carolina Breast Cancer 
Study) and gene expression in 581 breast tumors from The Cancer Genome Atlas (TCGA)  
Gene ID CHR 
450K Probe 
ID 
450K Build 36 
Location GG Probe ID 
Closest GG Build 
36 Location 
450k bp Distance 
from GG Probe Correlation p-value 
ABO 9 cg13506600 135140182 ABO_E110_F 135140341 159 -0.3278 <0.0001 
ARHGDIB 12 cg10925082 15005970 ARHGDIB_P148_R 15005977 7 -0.5470 <0.0001 
ARHGDIB 12 cg15450139 15005977 ARHGDIB_P148_R 15005977 Direct Match -0.5521 <0.0001 
ARHGDIB 12 cg00512404 15005999 ARHGDIB_P148_R 15005977 22 -0.5038 <0.0001 
BMPR1A 10 cg17776353 88506400 BMPR1A_E88_F 88506464 64 -0.0723 0.0817 
BTK X cg03791917 100527943 BTK_P105_F 100527943 168 -0.2481 <0.0001 
CHI3L2 1 cg01440333 111571634 CHI3L2_P226_F 111571578 56 -0.6998 <0.0001 
DNMT3B 20 cg25803642 30813413 DNMT3B_P352_R 30813500 87 -0.0327 0.4321 
ERCC6 10 cg04550285 50417799 ERCC6_P698_R 50417776 23 0.1170 0.0047 
FZD9 7 cg20692569 72486417 FZD9_E458_F 72486503 86 -0.5516 <0.0001 
IGFBP6 12 cg07927839 51777750 IGFBP6_E47_F 51777750 Direct Match -0.0236 0.5706 
PKD2 4 cg22426627 89147505 PKD2_P336_R 89147508 3 -0.1318 0.0015 
PKD2 4 cg07577579 89147519 PKD2_P336_R 89147508 11 -0.1876 <0.0001 
PLAGL1 6 cg00702231 144371166 PLAGL1_E68_R 144371178 12 -0.2017 <0.0001 
PLAGL1 6 cg12757684 144371178 PLAGL1_E68_R 144371178 Direct Match -0.2253 <0.0001 
RIPK4 21 cg11719297 42060152 RIPK4_E166_F 42060152 Direct Match -0.4475 <0.0001 
SEZ6L 22 cg16605942 24895137 SEZ6L_P299_F 24895181 44 -0.2321 <0.0001 
SH3BP2 4 cg07991621 2790277 SH3BP2_E18_F 2790357 80 0.1250 0.0025 
SH3BP2 4 cg01710886 2789505 SH3BP2_P771_R 2789568 63 0.1532 0.0002 
SH3BP2 4 cg10745272 2789568 SH3BP2_P771_R 2789568 Direct Match 0.1868 <0.0001 
SNURF 15 cg18506672 22751345 SNURF_P78_F 22751150 128 -0.5066 <0.0001 
SPI1 11 cg07675031 47356469 SPI1_E205_F 47356469 Direct Match -0.4957 <0.0001 
TDGF1 3 cg20941258 46593672 TDGF1_P428_R 46593789 117 -0.1437 0.0016 
         
         
         
         
1
7
3
 
 Table A.7. Correlation between BMI-associated methylation sites (overall and among ER-positive tumors identified in the Carolina Breast Cancer 
Study) and gene expression in 581 breast tumors from The Cancer Genome Atlas (TCGA)  
Gene ID CHR 
450K Probe 
ID 
450K Build 36 
Location GG Probe ID 
Closest GG Build 
36 Location 
450k bp Distance 
from GG Probe Correlation p-value 
TSG101 11 cg19225095 18505285 TSG101_P257_R 18505322 37 -0.2835 <0.0001 
XIST X cg11717280 72989343 Xist_seq_80_S95_R 72989296 Direct Match -0.5489 <0.0001 
Note: The TCGA data determined methylation in breast tumors using the Illumina HumanMethylation 450 Beadchip panel while the present study used the 
Illumina GoldenGate Cacner I Panel. Only seven of the BMI-associated probes in the present study matched directly with probes in the 450 Beadchip panel 
(labeled as Direct Match in the table). The remaining BMI-associated probes were within 200 base pairs, either up or downstream, of a 450 Beadchip probe. 
CHR = Chromosome; GG = Illumina GoldenGate Cancer Panel I; TCGA = The Cancer Genome Atlas; Bold text represents a significant, inverse correlation 
(correlation coefficent ≤ -0.20) 
1
7
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APPENDIX B. FIGURES 
 
Selection Bias in the Normal Breast Study 
 
 
    
                               
     
 
Figure B.1. In the directed acyclic graph above, there is potential for selection bias based on the 
NBS study design. Women with high BMI are more likely than low BMI women to participate in 
the study because they are more likely to undergo reduction mammoplasty. Women with breast 
tumors or at high risk of breast cancer are also more likely to participate. The selection of these 
groups of women can result in collider stratification bias if having a tumor or being at high risk 
of breast cancer is associated with gene methylation. This could lead to a biased pathway 
between BMI and gene methylation which could result in bias away from the null for some gene 
sites (that is, it could induce a spurious association). This potential bias is largely an artifact of 
having a selection criterion (reduction mammoplasty) that is directly associated with the 
exposure of interest (BMI). However, there were no significant associations between tissue 
source and gene methylation in the results (false discovery rate q-value <0.05), alleviating some 
concern about selection bias. 
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